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Abstract
The treatment of infections with HIV or HCV is challenging. Thus,
novel drugs and new computational approaches that support the
selection of therapies are required. This work presents methods that
support therapy selection as well as methods that advance novel
antiviral treatments.
geno2pheno[ngs-freq] identifies drug resistance from HIV-1
or HCV samples that were subjected to next-generation sequencing
by interpreting their sequences either via support vector machines
or a rules-based approach. geno2pheno[coreceptor-hiv2] deter-
mines the coreceptor that is used for viral cell entry by analyzing a
segment of the HIV-2 surface protein with a support vector machine.
openPrimeR is capable of finding optimal combinations of primers
for multiplex polymerase chain reaction by solving a set cover prob-
lem and accessing a new logistic regression model for determining
amplification events arising from polymerase chain reaction.
geno2pheno[ngs-freq] and geno2pheno[coreceptor-
hiv2] enable the personalization of antiviral treatments and support
clinical decision making. The application of openPrimeR on human
immunoglobulin sequences has resulted in novel primer sets that
improve the isolation of broadly neutralizing antibodies against
HIV-1. The methods that were developed in this work thus constitute
important contributions towards improving the prevention and
treatment of viral infectious diseases.
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Zusammenfassung
Die Behandlung von HIV- oder HCV-Infektionen ist herausfordernd.
Daher werden neue Wirkstoffe, sowie neue computerbasierte Ver-
fahren benötigt, welche die Therapie verbessern. In dieser Arbeit
wurden Methoden zur Unterstützung der Therapieauswahl entwick-
elt, aber auch solche, welche neuartige Therapien vorantreiben.
geno2pheno[ngs-freq] bestimmt, ob Resistenzen gegen Medika-
mente vorliegen, indem es Hochdurchsatzsequenzierungsdaten von
HIV-1 oder HCV Proben mittels Support Vector Machines oder einem
regelbasierten Ansatz interpretiert. geno2pheno[coreceptor-
hiv2] bestimmt den HIV-2 Korezeptorgebrauch dadurch, dass es
einen Abschnitt des viralen Oberflächenproteins mit einer Support
Vector Machine analysiert. openPrimeR kann optimale Kombi-
nationen von Primern für die Multiplex-Polymerasekettenreaktion
finden, indem es ein Mengenüberdeckungsproblem löst und auf
ein neues logistisches Regressionsmodell für die Vorhersage von
Amplifizierungsereignissen zurückgreift.
geno2pheno[ngs-freq] und geno2pheno[coreceptor-
hiv2] ermöglichen die Personalisierung antiviraler Therapien und
unterstützen die klinische Entscheidungsfindung. Durch den Ein-
satz von openPrimeR auf humanen Immunoglobulinsequenzen
konnten Primersätze generiert werden, welche die Isolierung von
breit neutralisierenden Antikörpern gegen HIV-1 verbessern. Die
in dieser Arbeit entwickelten Methoden leisten somit einen wichti-
gen Beitrag zur Verbesserung der Prävention und Therapie viraler
Infektionskrankheiten.
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Introduction
In 2017, there were more than 36 million people living with human
immunodeficiency virus (HIV)1. If left untreated, persons in the final
stage of infection develop acquired immunodeficiency syndrome
(AIDS), which is lethal. In the year 2017 alone, just below 1 million
people died due to AIDS-related causes2. In order to reduce the dis-
ease burden of HIV infection3, it is necessary to reinforce our efforts
in preventing, diagnosing, and treating the infection. Antiretroviral
treatment is important for two reasons. First, effective treatments
enable HIV-positive persons to live long and healthy lives rather
than succumbing to the infection4. Second, since infected persons
with durably suppressed viral loads5 cannot transmit the infection6,
successful treatments also prevent further transmissions7. The aim of
this dissertation is the development of novel computational methods
that can improve treatment and prevention of viral infections. The
developed approaches fall into two categories. The first category com-
prises approaches that can guide the selection of antiviral treatments
and the second category deals with approaches that can advance the
development of novel antiviral agents.
Treatment decisions are typically informed by sequencing of the
viral genome, which allows for inferences about the properties of the
virus. A common application of sequencing is the genotypic identifi-
cation of viral drug resistance. Human immunodeficiency virus type
1 (HIV-1) drug resistance testing is crucial because it can allow for
the selection of effective antiretroviral drugs even when resistance
mutations are detected8. Although HIV is the most prominent virus
for which drug resistance is a concern, there are also other prevalent
viral infections such as the hepatitis C virus (HCV)9, where drug
resistance is an issue10. Thus, this dissertation is not only concerned
with drug resistance of the HIV-1 but also of HCV. The identifica-
tion of drug resistance can be informed by expert opinions. In order
to determine which mutations are associated with drug resistance,
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11 Predictive models that are based on
machine learning are called statistical
models in the following.
12 HIV coreceptor usage can also be
considered a resistance phenotype as
the use of a certain coreceptor may
preclude the use of available coreceptor
antagonists.
13 Pillai et al. 2003; Jensen et al. 2003;
Lengauer et al. 2007; Pfeifer and
Lengauer 2012; Thielen and Lengauer
2012
14 HIV-2 drug resistance was not
investigated in this work due to the
scarcity of the data. However, a rules-
based approach is available in form of
the HIV2-EU resistance interpretation
engine, which can be accessed via
HIV-GRADE.
15 An antibody is called autologous
if it targets only autologous viruses,
that is, viruses found in the host
where the antibody emerged. An
antibody is called heterologous if it can
inhibit heterologous viruses, that is,
variants that are not present in the
viral population found in the host that
generated the antibody.
physicians and virologists regularly form panels to discuss evidence
from the literature and to exchange their personal experiences. These
meetings give rise to rules-based approaches, which rely on expertly
crafted sets of rules in order to identify whether a viral sequence is
associated with drug resistance or not.
The combination of increasing data availability and technolog-
ical innovation has ushered in another approach that is based on
supervised learning, a type of machine learning that is concerned
with learning from data in order to fit predictive models.11 Statistical
models for the identification of drug resistance have two advantages
over rules-based approaches. First, they can identify novel associ-
ations between viral genotype and resistance phenotype from the
data. Second, statistical models can be updated with little human
intervention. However, new prediction scenarios also require new
computational approaches. Predictive models that identify drug re-
sistance were previously only applicable to viral sequences obtained
through Sanger sequencing. Currently, next-generation sequencing
(NGS) is in the process of supplanting Sanger sequencing for the
purpose of drug resistance testing. In this work, a drug resistance
test for NGS samples from HIV-1 or HCV was developed, which
tackles two challenges. The first challenge involves processing the
thousands of reads that are generated by NGS. The second challenge
concerns the interpretation of drug resistance from NGS data. Since
resistance mutations may be found only in a small number of reads,
it is necessary to interpret drug resistance under consideration of the
read prevalence.
A further, HIV-specific problem that can inform treatment deci-
sions is the identification of coreceptor usage. Since HIV needs to
interact with a coreceptor before it can enter human immune cells,
drugs blocking the coreceptor — so-called coreceptor antagonists
— are used to prevent HIV cell entry. Because HIV can use different
types of coreceptors, it is necessary to identify which coreceptor is
used before prescribing coreceptor antagonists.12 Although several
models for identifying HIV-1 coreceptor usage are available13, human
immunodeficiency virus type 2 (HIV-2) has been overlooked for a
long time. Therefore, the provision of a model for identifying HIV-2
coreceptor usage was another aim of this dissertation.14 The main
challenge in this project was the selection of features and models that
afford high predictive accuracies.
Besides supporting the selection of antiviral treatments, this dis-
sertation also aims at advancing the development of novel antiviral
agents. Although the autologous immune response against HIV-1
infection is insufficient for controlling the infection, certain heterol-
ogous antibodies enable promising new treatment strategies.15 The
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isolation of novel antibodies hinges on our ability to amplify im-
munoglobulin transcripts using multiplex polymerase chain reaction
(mPCR). The success of mPCR critically depends on the used combi-
nation of primers, oligomers that are complementary to the template
sequences, which are required for polymerase attachment and elonga-
tion. Available sets of primers for the amplification of immunoglobu-
lin sequences may preclude the amplification of highly mutated HIV-
1-specific antibody sequences. Since established mPCR primer design
tools were found incapable of producing suitable primers, a further
aim of this work was to develop a new primer design approach for
the design of mPCR primers that improve the amplification of highly
mutated antibodies to HIV-1. An important aspect of this work was
to ensure that all of the germline immunoglobulin sequence variants
can be amplified using the designed primers. For this purpose, it was
necessary to develop optimization algorithms for selecting minimum
sets of primers maximizing the coverage of templates.
Outline
This dissertation is structured into four parts. Part I provides the
biological and methodological background via Chapters 2 and 3,
respectively. Chapter 2 introduces the virological and immunological
foundations of this work. This background chapter begins with an
introduction to viruses (Section 2.1) and host defense mechanisms
(Section 2.2). In the following sections, the characteristics of HIV
(Section 2.3) and HCV (Section 2.4) are described. The chapter con-
cludes with the molecular techniques that are essential for virological
research (Section 2.5).
In Chapter 3, I offer the methodological foundations of my work.
After providing an overview of machine learning (Section 3.1), I in-
troduce important concepts from supervised learning (Section 3.2),
various measures of predictive performance (Section 3.3), and mod-
els for prediction such as logistic regression and support vector
machines (Section 3.4). The unsupervised learning technique of clus-
tering is illustrated in terms of K-means and hierarchical clustering
(Section 3.5). Since significance tests are particularly useful for the
comparison of predictive approaches, I describe the principles of
statistical hypothesis testing (Section 3.6). At the end of the chapter
(Section 3.7), the reader is familiarized with optimization through lin-
ear programs, which are exemplified through the set cover problem.
Part II comprises the four original scientific contributions of this
dissertation, which are structured into Chapters 4, 5, 6, and 7. Chap-
ter 4 introduces geno2pheno[ngs-freq], a web service for the iden-
tification of drug resistance from NGS samples of HIV-1 or HCV.
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After an introduction to genotypic resistance testing (Section 4.1),
I describe the three main contributions of geno2pheno[ngs-freq]:
decoupling of data preprocessing and interpretation, provision of
access to the models of geno2pheno[resistance] and geno2pheno[hcv]
in the NGS setting, and improvement of model interpretability
(Section 4.2). The clinical usefulness of the developed approach is
exemplified through two cases studies (Section 4.3). The chapter
concludes with a critical discussion of the benefits and limitation of
using geno2pheno[ngs-freq] for the detection of drug resistance in
minor viral populations (Section 4.4).
Chapter 5 is concerned with the prediction of HIV-2 coreceptor
usage. The chapter begins with an overview of established genotypic
methods for the identification of HIV-1 and HIV-2 coreceptor usage
(Section 5.1). I then describe the development of a support vector
machine for the prediction of HIV-2 coreceptor usage (Section 5.2),
which has been made available in terms of geno2pheno[coreceptor-
hiv2], the first web service for this task (Section 5.3). The discussion
(Section 5.4) focuses on differences between the molecular markers of
HIV-1 and HIV-2 coreceptor usage and tries to explain the conflicting
results that were obtained from phenotypic coreceptor assays.
Chapter 6 describes the work that led to openPrimeR, a program
for evaluating and designing primer sets for mPCR. To establish the
background, I first describe requirements and established approaches
to mPCR primer design (Section 6.1). Next, I formulate methods for
the evaluation of primers (Section 6.2) and offer algorithms for the
design and selection of mPCR primers (Section 6.3). The usefulness
of openPrimeR is demonstrated through its application on human
immunoglobulin sequences (Section 6.4). The chapter concludes
with a discussion (Section 6.5), in which the obtained results are
interpreted and the limitations of openPrimeR are presented.
The molecular determinants of amplification events resulting
from polymerase chain reaction are examined in Chapter 7. Novel
polymerase chain reaction data were used to construct a logistic re-
gression model for the prediction of amplification events (Section 7.1).
The characteristics of successful amplification events are analyzed
and the favorable performance of the statistical model is shown (Sec-
tion 7.2). The discussion (Section 7.3) comprises a commentary on the
use of predictive models for primer design.
Part III contains Chapter 8 and Chapter 9, the final chapters of
the main matter. Chapter 8 discusses the relevance of the presented
approaches and indicates possibilities for future work. Chapter 9
provides the outlook.
The appendix can be found in Part IV. It includes Chapters A, B,
and C. Chapter A provides supplemental information. Chapter B lists
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the scientific contributions that I made during my doctoral phase.
Chapter C summarizes the results of running plagiarism detection
software on this dissertation. The back matter comprises several




This work is at the junction of life and computer sciences. For the
appreciation of the developed methods, it is important to have a firm
grasp of concepts from several fields. Chapter 2 intends to familiarize
the reader with the most important virological and immunological
concepts. Chapter 3 introduces concepts from machine learning,
statistics, and optimization.

Nature is not human-hearted.
Lao Tzu
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Virological and Immunological Foundations
2008 was the first year in which noncommunicable diseases caused
more deaths than infectious diseases1 and, in 2013, UNAIDS reported
a 33% reduction in new HIV infections compared to 20012. These
data signify the progress that has been made in the prevention,
diagnosis, and treatment of viral infectious diseases. Still, viral
infections remain a major source of disease burden. In 2016, there
were more than 35 million HIV-infected people worldwide and 1
million people died of AIDS-related diseases that year alone3. HIV
and AIDS are particularly prevalent in developing countries: In 2016,
7% of East and Southern African adults were infected with HIV and
just under half a million people in this region died of AIDS-related
illnesses that year4. Moreover, despite years of efforts, there is still
no vaccine against HIV5. Additionally, since public health efforts
have focused on the containment of the HIV epidemic, other viral
infections have been overlooked. For example, the number of HCV-
related deaths increased from 0.89 million in 1990 to 1.45 million in
2013
6.
HIV and HCV share commonalities with respect to disease pro-
gression and treatment. Both infections can remain without symp-
toms for several years but when symptoms appear, they are often
life-threatening and acquired damage may be irreversible. The timely
diagnosis of HIV or HCV infection is therefore particularly important.
Once diagnosed, infections with these viruses can be treated with
a diverse arsenal of potent drugs. A major difference between HIV
and HCV infection is that HIV infection is cleared neither sponta-
neously nor through treatment because the HIV provirus persists in
reservoirs of host cells that can be reactivated at any point in time.
Thus, HIV-infected persons have to submit to life-long treatments,
while HCV-infected persons clear the infection either spontaneously
or through an antiviral treatment that typically last twelve weeks.
Since drug resistance can impair the treatment of an HIV or HCV
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translational machinery (Schulz et al.,
2017).
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infection, drug resistance testing is relevant in two ways. First, since
resistant viral strains can be transmitted, selection of the initial
treatment can be guided by the identification of drug resistance.
Second, in case of treatment failure due to the emergence of resistant
variants during therapy, a new treatment can be selected on the basis
of drug resistance testing.
The purpose of this chapter is to summarize the current body of
knowledge on HIV and HCV, with a focus on the aspects that are
relevant for their treatment and prevention. In order to appreciate the
commonalities of viral infections, an introduction to viruses and viral
pathogenesis is provided in Section 2.1. Since defense mechanisms
of the host immune system are involved in the prevention and patho-
genesis of viral infections, Section 2.2 describes the components of
the immune system with a focus on the adaptive immune response.
Note that the information provided in the aforementioned sections is
based on Flint (2004) if not stated otherwise. Section 2.3 introduces
HIV and deals with the treatment-relevant aspects of drug resistance,
viral coreceptor usage, and the antibody response. The properties
of HCV and the consequences of HCV infection are discussed in
Section 2.4. The chapter concludes with Section 2.5, which introduces
molecular techniques that are crucial for the investigation of viruses
and host immune responses such as phenotypic methods for the
determination of coreceptor usage and drug resistance, sequencing,
and polymerase chain reaction (PCR).
2.1 Viruses and Viral Pathogenesis
Viruses are small obligate parasites (i.e. are dependent on a living
host organism for reproduction). Lacking the energy-generating and
biosynthetic systems that are required for independent existence,
viruses are simpler than even the smallest microorganisms. With
diameters as small as 100 nm, they are typically much smaller than
other pathogens such as bacteria whose diameters are on the µm
scale (Figure 2.1).7
Viral genomes are composed of either deoxyribonucleic acid
(DNA) or ribonucleic acid (RNA). All viruses share a replication
cycle consisting of three stages. In the first stage, the viral genome is
replicated in an appropriate host cell and viral proteins are expressed
through the cellular translation machinery. Second, newly synthe-
sized viral proteins assemble to form progeny virions that bud from
the host cell. Third, progeny viruses infect new cells by entering an
appropriate cell and releasing their genome into the cytoplasm.
Viral Pathogenesis Viral infection is associated with cellular damage8.
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Figure contributed to LibreTexts by OpenStax, licensed under CC BY-NC-SA.
Figure 2.1: Size of viruses.
9 Laurent-Crawford et al. 1991
Figure 2.2: Formation of mult-
inucleated giant cells during
herpes simplex virus infection.
Adapted from Wikipedia, licensed
under CC BY 3.0.
10 Note that cell death is not to the
advantage of the virus but merely a
side effect of viral proliferation.
11 Rodriguez et al. 1983
We can distinguish damage that is a direct consequence of viral
infection (direct damage) and self-inflicted damage resulting from
the immune response (indirect damage). Direct damage is often the
result of cytopathic effects (structural changes in infected cells, see
Figure 2.2 for an example), which are associated with apoptosis9.
By hijacking (reprogramming) infected cells, viral infection can
impede essential cellular processes such as translation, synthesis
of DNA and RNA, as well as vesicular transport. Alterations in
these processes can lead to the autolytic digestion of infected cells
by increasing membrane permeability10. Although less common,
direct damage can also be a consequence of noncytolytic effects. For
example, lymphocytic choriomeningitis virus is a noncytolytic virus
that infects cells in the pituitary gland. The pathogenicity of the virus
is solely based on reducing the production of growth hormone in
infected cells, which can be fatal for the host11.
The pathology of viruses is largely based on indirect damage that
results from the immune response of the host, for example through
immunopathological lesions. These lesions can be caused by CD8+
cells, CD4+ cells, and B cells. CD8+ cells can cause lesions due to
secretion of perforin, their major cytolytic protein. CD4+ cells can
damage cells by recruiting other cells of the immune system such
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as macrophages or neutrophils, which induce cell lysis and cause
inflammations. B cells can cause pathological effects when extensive
viral replication occurs in sites that are inaccessible to the immune
system or when the immune response is unable to clear the infection.
2.2 Defense Mechanisms against Viruses
There are several layers of defense mechanisms against viral infec-
tions. Before a person can become infected by a virus, it needs to
overcome the physical and chemical defense mechanisms of the hu-
man body. Only once the virus is inside the body does the innate
immune response commence (Section 2.2.1). When the innate im-
mune response cannot contain the infection, the adaptive immune
response (Section 2.2.2) begins to develop specific B and T cells (Sec-
tion 2.2.3). If the adaptive immune response is successful, it will
produce antibodies (Section 2.2.4) that are capable of eliminating the
pathogen (Section 2.2.5).
2.2.1 Components of the Immune System
The primary defense mechanisms against viruses comprise physical
and chemical barriers such as the skin. These barriers are assisted by
surface-cleansing mechanisms such as blinking (eyelids), swallowing
(throat), and the flow of mucus (mucosal system). If intact, the skin
is virtually impervious to viral infections as it consists of keratinized
cells that are continually shed. Thus, regions of the human body that
are not covered by skin such as the respiratory or urogenital tract
are at greatest risk of infection. Once a virus breaches the primary
defense mechanisms, the immune system begins to intervene.
The immune system relies on innate (non-specific) and adaptive
(specific) components. The innate immune system represents the first
line of defense as it immediately targets any type of pathogen. The
following components are major contributors to the innate immune
system: interferons, protein activators that stimulate the immune
system; the complement system, a collection of serum proteins that
is capable of destroying infected cells as well as pathogens; natural
killer (NK) cells, cytolytic lymphocytes that recognize and destroy
infected cells; neutrophils, phagocytic granulocytes that migrate to
sites of infection during (acute) inflammations; and macrophages,
phagocytes that eliminate pathogens during (chronic) inflammations.
The following sections provide more details on the adaptive
immune response.
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12 In humans, MHC receptors are
encoded through the human leukocyte
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2.2.2 Overview of the Adaptive Immune System
The adaptive immune response can be differentiated into the hu-
moral and cell-mediated response. The humoral response involves
serum and lymph proteins, while the cell-mediated response requires
the action of effector cells. An important characteristic of the adaptive
immune system is its ability to discern infected from uninfected cells.
This function is facilitated by the major histocompatibility complex
(MHC) molecules that are present on the surfaces of cells12.
Binding of antigens by B-cell and T-cell receptors triggers a cas-
cade of reactions, which involves the production of cytokines, the
differentiation of immune cells, the production of antibodies and,
eventually, the elimination of the pathogen or pathogen-infected
cell. Upon initial infection, it usually takes days or weeks until the
adaptive response becomes fully active. However, if a pathogen has
been previously encountered, the adaptive response can occur within
hours even if the previous infection has been months or years in the
past. For this purpose, a subset of lymphocytes called memory cells
is maintained after each encounter with a foreign antigen.
The following section sheds light on the cells that are essential for
the adaptive immune response.
2.2.3 Cells of the Adaptive Immune System
Figure reproduced from The Adaptive Immune Response: B-lymphocytes
and Antibodies by Rice University, licensed under CC BY 4.0.
Figure 2.3: B cell activation.
The adaptive immune response is initiated by the interplay of
lymphocytes and antigen-presenting cells (APCs). Lymphocytes are
white blood cells that circulate in the blood and the lymphatic sys-
tem, often settling in the lymphoid organs that are present through-
out the body. Lymph nodes are the centers at which antigen presen-
tation takes place. Almost all cells are APCs because they present
endogenous antigens via major histocompatibility complex class I
(MHC I). The subset of APCs that performs exogenous antigen pre-
sentation through major histocompatibility complex class II (MHC II)
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makes up the set of professional APCs. These cells ingest extracellu-
lar proteins either via endocytosis (e.g. dendritic cells) or via surface
antibodies (e.g. B cells). The major classes of lymphocytes are B cells
and T cells.
B Cells B cells originate in the bone marrow and travel to lymph
and lymphoid organs where they are activated by binding their
specific antigens. Interaction of MHC II with the T-cell receptor of a T
helper cell leads to the secretion of T-cell cytokines that stimulate the
proliferation and differentiation of B cells into plasma and memory
B cells (Figure 2.3). While memory cells are long-lived and express
membrane-bound antibodies on their surface, plasma cells exist only
a few days and secrete antibodies instead of exposing them on their
membranes.
Over the course of an immune response, affinity maturation leads
to the development of B cells with increased affinities to antigens.
Affinity maturation occurs in the germinal centers of the secondary
lymphoid organs and encompasses two processes: somatic hypermu-
tation (SHM) and clonal expansion under affinity-based selection13.
SHM describes the development of mutations in the variable re-
gions of immunoglobulin genes, particularly in the complementarity-
determining regions (CDRs)14. During clonal expansion in the ger-
minal centers, B cells that have undergone SHM are competing for
resources such as antigen presented by dendritic cells as well as
proliferation/survival signals from T helper cells. As a result of
this competition, only B cells exhibiting receptors with high antigen
affinities are retained.
T Cells T-cell precursors are produced in the bone marrow and
mature in the thymus. The maturation process entails positive and
negative selection pressure. Positive selection pressure ensures the
proliferation of T cells that bind to the specific MHC molecules of the
individual, while negative selection pressure eliminates T cells that
recognize host peptides. Only approximately 1% to 2% of immature
T cells entering the thymus emerge as mature T cells. When the
T-cell receptors of a naive T cell interact with peptide fragments
presented by MHC, the T cell becomes activated and differentiates
into long-lived memory and short-lived effector T cells (e.g. helper
and cytotoxic cells, respectively).
Differentiation of naive T cells into effector T cells is determined
by their surface antigens, the cluster of differentiation (CD) markers.
CD4+ cells that interact with antigen presented through MHC II dif-
ferentiate into T helper (Th) cells, while CD8+ cells that interact with
antigens presented by MHC I differentiate into cytotoxic T lympho-
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cytes (CTLs). These types of cells perform contrasting functions. Th
cells produce growth factors and cytokines that stimulate the recruit-
ment of specific lymphocytes. CTLs recognize antigens presented via
MHC I receptors and subsequently destroy the peptide-presenting
cell.
There are two types of Th cells: Th1 and Th2 cells. These helper
cells release different types of cytokines that influence the activation
and proliferation of specific immune cells. Th1 cells promote the cell-
mediated proinflammatory response as they enable CTLs to mature.
Th2 cells increase the antibody response by stimulating the matura-
tion of immature B cells and resting macrophages. Additionally, they
reduce the inflammatory response by producing specific interleukins.
The two types of Th cells act like a seesaw — the cytokines produced
by one class tend to suppress the generation of cytokines from the
other class.


















Figure 2.4: Structure of an an-
tibody. The variable regions
of the heavy (blue) and light
(red) chains are indicated by VH
and VL, respectively. The corre-
sponding constant regions are
indicated by CH and CL. The
geometric inlets at the end of
the variable chains indicate the
complementarity-determining
regions.
Antibodies (immunoglobulins) are glycoproteins with Y-shaped
structures (Figure 2.4) that provide a link between the adaptive and
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16 The antigen binding site of an anti-
body is also called paratope.
17 A primary immune response occurs
when the immune system encounters
an antigen for the first time.
18 Klasse 2014
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20 Lu et al. 2017
21 Trkola 2014; Platt et al. 2012
innate components of the immune system15. Each antibody consists
of two heavy and two light polypeptide chains whose segments can
be differentiated into constant and variable regions. The glycosy-
lated constant regions interact with the host immune system and
are highly conserved. The variable regions, on the other hand, are
involved in antigen recognition and are typically highly mutated.
The two functional components of an antibody can be localized
with respect to the central disulfide bonds that make up the hinge
region. The constant region that lies on one side of the hinge region
is termed the fragment crystallizable (Fc) region. The region that lies
on the other side of the hinge region is called the fragment antigen-
binding (Fab) region because each arm of Fab contains three CDRs16.
Due to their involvement in antigen binding, the CDRs of Fab, are
particularly adapted to the molecular structure of the antigen that is
recognized by the antibody.
There are five classes of immunoglobulins: IgA, IgG, IgD, IgE,
and IgM. They are defined by their characteristic heavy chain con-
stant regions (α, γ, δ, ε, and µ, respectively). Each antibody class is
associated with a specific range of functions. For example, IgG, IgA,
and IgM are often produced as a result of viral infections. While IgA
has a more localized role as it is important for mucosal immunity,
both IgG and IgM are associated with systemic immune responses.
IgG is the most abundant antibody and associated with memory
responses. IgM is the largest antibody and is involved in the primary
immune response17. Different classes of antibodies arise by switching,
that is, recombination of constant region genes during plasma cell
differentiation.
2.2.5 Neutralizing Antibodies
Neutralization describes the ability of an antibody to prevent the
cellular entry of pathogens18. Neutralization can only occur when
antibody has bound to a sufficient number of pathogen receptors
via the CDRs of Fab (Figure 2.5). Mechanisms that allow for neutral-
ization include steric hindrance, target dissociation, and promotion
of structural inflexibility in the pathogen’s surface proteins19. Neu-
tralization by itself can already prevent pathogenic effects20. For
example, an antibody targeting the viral cluster of differentiation
antigen 4 (CD4) binding site can prevent HIV cell entry by disrupting
the interaction between CD4 and glycoprotein 120 (gp120).
Since neutralization is a reversible process that does not elimi-
nate pathogens, controlling an infection also requires cell-mediated
effector functions on whose basis even non-neutralizing antibodies
can support the immune response21. The cell-dependent effector
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Figure reproduced with permission from Springer Nature (Trkola,
2014).
Figure 2.5: Mechanisms of an-
tibodies. Pathogens that have
been neutralized are prevented
from entering cells. Once a
pathogen has been bound by
antibodies, cell-dependent effec-
tor functions enable pathogen
elimination.
22 Forthal 2014
functions of antibodies (Figure 2.5) are complement-dependent cy-
totoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity
(ADCC)22.
CDC is mediated by the complement system. The interaction of Fc
with components of the complement system triggers the complement
cascade, which leads to the formation of the membrane attack com-
plex (MAC). Attachment of MAC to the cellular surface of an infected
cell results in cell lysis. ADCC is an instance of opsonization, a pro-
cess in which pathogens are marked for digestion by phagocytes. In
ADCC, pathogens are marked by antibodies. The interaction between
Fc and the Fcγ receptor of an effector cell such as an NK cell leads to
cell lysis through the release of cytotoxins.
2.3 Human Immunodeficiency Virus
HIV is a retrovirus that infects human immune cells and causes AIDS.
There are two types of HIV, HIV-1 and HIV-2, as introduced in Sec-
tion 2.3.1. HIV is a parasite whose structural constituents are of viral
and human origin (Section 2.3.2). In order to replicate, the virus must
hijack suitable host cells (Section 2.3.3). Through the use of different
cellular coreceptors, HIV can enter distinct subsets of human immune
cells (Section 2.3.4). The spread of HIV is mainly due to its high rate
of sexual transmission, while its lethality is due to AIDS, which devel-
ops when the infection is not treated (Section 2.3.5). A diverse arsenal
of potent antiretroviral agents is capable of controlling the infection
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(Section 2.3.6). Additionally, novel types of antibodies unlock new
treatment and prevention strategies (Section 2.3.7).
2.3.1 Introduction to HIV
HIV, which was discovered23 in 1984, is a lentivirus24 of group VI
that belongs to the Retroviridae family. It infects human immune cells
and is the cause of AIDS. HIV is classified into HIV-1 and HIV-2
based on genetic differences. There are two groups of HIV-1: group
M, which includes most HIV-1 isolates, and group O, which rep-
resents relatively rare outliers. There are at least seven group M
subtypes, which are associated with distinct geographic areas. For
example, subtype B (10% of global infections) is most common in Eu-
rope and North America, while subtype C (50% of global infections)
is prevalent in Southern Africa and India25.
While HIV-1 is a global epidemic, HIV-2 is mainly prevalent in
Western Africa as well as European countries with colonial ties to
these countries such as France and Portugal26. The smaller spread
of HIV-2 compared to HIV-1 is a consequence of its reduced infec-
tivity27, lower replicative capacity28, and increased susceptibility to
neutralization by the immune system29. With an estimated preva-
lence of one to two million cases in Western Africa alone 30, HIV-2 is
still a global health concern. HIV-2 is genetically diverse and there ex-
ist eight phylogenetic groups, named A-H. The phylogenetic groups
A and B are the most prevalent genotypes: They are causative of
almost all cases of clinical disease and are therefore considered the
epidemic groups of HIV-231. The other groups (C-H) are consid-
ered nonepidemic32 because viruses from these groups are rarely
transmitted between humans.
Note that, when the term HIV is used in the following, I refer to
properties that are shared by the two types of immunodeficiency
viruses.33
2.3.2 Structure and Genome Organization
HIV is a spherical virus with a diameter of roughly 145 nm34. It
contains two copies of positive single-stranded (ss) RNA. The genetic
information carried by the virus is enclosed by a conical capsid,
which consists of thousands of copies of the capsid protein p24. The
capsid encloses viral RNA bound to the nucleocapsid protein p7 as
well as the enzymes involved in viral replication: RT, PR, and IN.
The integrity of the virion is ensured by a matrix consisting of
p17 proteins that surrounds the capsid. The matrix is enclosed by
a membrane comprising two layers of host phospholipids that are
appropriated by the virus when budding from a cell. The viral
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Diagram of the HIV virion by Thomas Splettstoesser, licensed under
CC-BY-SA 4.0.
Figure 2.6: Structure of HIV.
35 Korber et al. 1998
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37 Malim and Bieniasz 2012
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39 Vicenzi and Poli 2013
membrane serves two purposes. It masks the virus from the immune
system and displays the envelope glycoprotein, which facilitates viral
cell entry.
Structure of the HIV-1 genome by Thomas Splettstoesser, licensed under CC-BY-SA 4.0.
Figure 2.7: The HIV-1 genome.
Genome Organization Due to the presence of insertions or deletions,
the length of the HIV genome can vary. The HIV-1 reference strain
HXB2 has a genome comprising 9 719 bases35. The HIV-1 genome
consists of nine genes that are grouped into three classes: genes en-
coding structural proteins (gag, pol, env), genes encoding regulatory
proteins (tat, rev)36, and genes for accessory proteins (nef, vpr, vif,
vpu)37. The length of the HIV-2 reference sequence SIVMM239 is
10 278 bases38. With respect to genome organization, the only differ-
ence between HIV-1 and HIV-2 is that HIV-2 codes for vpx instead of
vpu39. Since the genes that encode the structural proteins of HIV are
40
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particularly relevant for this work, they are described in more detail
in the following.
gag (group-specific antigen) encodes the precursor gag polypro-
tein. It consists of matrix (MA) protein p17, capsid (CA) protein p24,
spacer peptide 1 (SP1), nucleocapsid (NC) protein p7, spacer peptide
2 (SP2), and protein p6. pol (polymerase) codes for the HIV protease
(PR), the reverse transcriptase (RT), and the integrase (IN). env (en-
velope) codes for gp160 that is cleaved by a host protease within the
endoplasmatic reticulum (ER) in order to obtain the surface protein
gp120 and the transmembrane glycoprotein 41 (gp41).
Albeit structurally similar, the proteins of HIV-2 have different
identifiers than those of HIV-1 as they exhibit contrasting molecular
weights. For example, the HIV-2 precursor protein gp140 is processed
to obtain gp125 and gp36, which correspond to gp120 and gp41 in
HIV-140. In the following, the protein identifiers of HIV-1 are used
when referring to mechanisms that are shared between HIV-1 and
HIV-2. Otherwise, the respective protein identifiers for HIV-1 or
HIV-2 are used.
The next section summarizes the life cycle of HIV and indicates
the roles of the aforementioned viral and host proteins.
2.3.3 Life Cycle
The life cycle of HIV (Figure 2.8) begins with its entry into a human
CD4+ cell. HIV cell entry involves binding of the CD4 receptor,
coreceptor binding, and finally virus-cell fusion (Figure 2.9). The
interaction of cellular CD4 and viral gp120 leads to a conformational
change in the envelope protein that allows for binding a coreceptor
on the cellular surface. The tight binding afforded by the interactions
with CD4 and a coreceptor enables the fusion of viral and host
membrane via gp41.
Once the viral capsid has entered the cell, it dissolves and re-
leases the formerly enclosed RNA into the cell. Exploiting cellular
nucleotides, RT transcribes viral RNA to complementary deoxyri-
bonucleic acid (cDNA), which migrates to the nucleus where IN
catalyzes the integration of viral DNA into the host genome. Once vi-
ral DNA is integrated into the host genome, it is called proviral DNA,
or, in short, provirus. Next, cellular enzymes transcribe proviral DNA
into messenger RNA (mRNA) that is transported out of the nucleus
for translation in the ribosomes. After translation, the polypeptides
of the virus are cleaved by PR and a new virion is assembled. Dur-
ing budding of the newly assembled virion, PR cleaves the gag-pol
polyprotein at nine sites rendering each fragment into a functional
protein. This processing completes the viral life cycle, giving rise to
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Figure reproduced with permission from Springer Nature (Engelman and Cherepanov, 2012).
Figure 2.8: Life cycle of HIV.
Arrows indicate steps in the life
cycle, while red lines indicate
potential sites for inhibition.
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another infectious viral particle.
As illustrated by Figure 2.8, each step in the viral life cycle offers
unique opportunities for inhibiting viral replication. An overview of
mechanisms that can be exploited for antiretroviral therapy (ART)
is provided in Section 2.3.6. The next section sheds light on the
coreceptors that are used during HIV cell entry and introduces
how different variants of HIV can be differentiated based on their
coreceptor usage.
2.3.4 Coreceptor Usage
The figure was created by Delhalle et al. (2012) and is licensed under
CC-BY-SA 4.0.
Figure 2.9: The stages of HIV
cell entry. (A) Binding of the
CD4 receptor to the viral enve-
lope protein. (B) Opening of the
gp120 structure allows for the
interaction of the variable loops
with the cellular coreceptor. (C)
Binding of the coreceptor in-
creases proximity between HIV
and the cell. (D) Insertion of
the viral fusion peptide into the
cellular membrane. (E) Fusion
of viral and human membrane
allows for cell entry.
The coreceptors that are required for the cellular entry of HIV (Fig-
ure 2.9) are G-protein coupled receptors with a 7-transmembrane
structure that are located on human CD4+ cells. Their natural
ligands are chemokines, a group of cytokines that is involved in
chemotaxis (i.e. cellular movement). The four classes of chemokine
receptors (CXC, CC, CX3C, and XC) are defined by the chemokine
subfamilies with which they interact. The main coreceptors that
are used by HIV are the C-C chemokine receptor type 5 (CCR5), a
beta-chemokine receptor, and the C-X-C chemokine receptor type
4 (CXCR4), an alpha-chemokine receptor. While naive CD4+ cells
express mainly CXCR441, monocyte-derived macrophages express
higher quantities of CCR5 than CXCR442. On the basis of differen-
tial coreceptor expression, two types of viral strains can be identi-
fied: macrophage-tropic (M-tropic) and T-cell tropic (T-tropic) HIV.
While M-tropic strains typically use CCR5 and predominantly infect
macrophages and memory T-cells, T-tropic strains enter cells via
CXCR4 and predominantly infect naive CD4+ cells in addition to
macrophages.
In order to refer to specific types of coreceptor usage in this work,
an adjusted version of the notation that was established by Berger
et al. (1998) is used. According to this notation, a virus that can use
only CCR5 is called R5. If a virus can use CXCR4 but not CCR5, it is
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called X4. If a viral population can use both CCR5 and CXCR4, it is
called R5X4 or dual-tropic43. Since routinely used assays for tropism
determination (Section 2.5.1) cannot distinguish R5X4 viruses from
mixed populations of R5 and X4 variants, the term dual/mixed is used
in these cases. In this work, I use the term X4-capable to indicate the
presence of any virus capable of using CXCR4 (i.e. either an X4 virus,
an R5X4 virus, or a mixed population) and R5 for viruses that can
use only the CCR5 coreceptor.
HIV-1 Coreceptor Usage HIV-1 uses the CCR5 and CXCR4 corecep-
tors. In the initial stages of the infection, the CCR5 coreceptor is
predominantly used. A switch to the CXCR4 coreceptor is correlated
with disease progression44. Patients infected with X4-capable variants
exhibit increased viral loads45. The variable loop 3 (V3) of the surface
glycoprotein gp120 is the main molecular marker for the use of the
CXCR4 coreceptor46. The variable loop 1 (V1) and variable loop 2
(V2) regions have a minor influence on HIV-1 coreceptor usage47.
HIV-2 Coreceptor Usage Although in vitro experiments have demon-
strated that there are HIV-2 strains capable of infecting cells indepen-
dent of the CD4 receptor48, HIV-2 enters cells in vivo by first binding
to CD4 and then interacting with a coreceptor49. HIV-2 is known to
use a wide range of coreceptors in vitro50 but exhibits a limited core-
ceptor usage in vivo. As demonstrated by experiments with primary
blood mononuclear cells (PBMCs), HIV-2 predominantly uses CCR5
and CXCR451 — variants independent of CCR5 and CXCR4 are in-
frequent and have been described only in asymptomatic patients52.
The use of CXCR4 is often associated with broad coreceptor usage53,
which is particularly prevalent in late stage patients54. X4-capable
strains of HIV-2 are highly virulent, associated with progressed dis-
ease55, and are less susceptible to antibody neutralization than R5
strains56.
There are three loops on the HIV-2 surface glycoprotein (gp125)
that are important for coreceptor binding: V1, V2, and V3. Of these
loops, V3 has the greatest impact on coreceptor usage and has been
studied most extensively. It has been shown that specific substitu-
tions in V3 and an increased V3 net charge57 are associated with
X4-capability. With regard to the impact of V1 and V2 on HIV-2 core-
ceptor usage, the following is known. Changes in the V1 and V2 of
HIV-2 influence the usage of the CCR8 coreceptor58 and substitutions
at the base and the tip of V1/V2 affect CXCR4 usage59. Additionally,
insertions in the V1/V2 region seem to be associated with reduced
rates of disease progression60.
More information on the molecular markers of HIV-2 coreceptor
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usage are available in Chapter 5.
Natural Resistance to R5-tropic HIV Some individuals are carriers
of the CCR5∆32 mutation, a deletion of 32 base pairs (bp) in the
CCR5 gene. This deletion results in a premature stop codon. As a
consequence, expressed CCR5 coreceptors are non-functional. Both
heterozygous and homozygous carriers of the CCR5∆32 mutation
exhibit an increased protection against infection with HIV. While
heterozygosity has been shown to reduce the risk of HIV infection by
70% compared to individuals not carrying the mutation61, carriers of
the homozygous variant are nearly fully resistant against infection
with HIV62 as initial infection typically occurs through viruses using
CCR5. The CCR5∆32 mutation (either hetero- or homozygous) has
an average prevalence of 10% in Caucasians but is almost absent
in native African, Asian, and American Indian populations63. The
prevalence of the homozygous variant ranges between 1% and 2% in
Caucasian populations64.
Coreceptor Antagonists Coreceptor antagonists can impede HIV cell
entry by blocking the molecular interaction of coreceptors and vi-
ral surface proteins. Over the years, several compounds targeting
CCR5 have been developed, most notably maraviroc65, TAK-77966,
vicriviroc67, and aplaviroc68. However, the CCR5 antagonist mar-
aviroc is the only coreceptor antagonist that has obtained approval
by the federal drug administration (FDA) at the present time69. The
development of CXCR4 antagonists was less successful: none of
the researched compounds such as AMD310070, AMD07071, and
AMD345172 have obtained FDA approval.73
Use of Maraviroc Maraviroc is typically used in salvage treatments
of heavily treatment-experienced patients for which few other treat-
ment options remain. It has been intensively studied for treating
HIV-1-infected persons74 but less is known about its use in HIV-2
infection 75. The first successful application of maraviroc in an HIV-
2-infected patient was reported in 201076. In 2012, two independent
studies demonstrated the inhibitory effect of maraviroc in vitro77, and,
in the same year, the first long-term use of maraviroc was reported
in a salvage patient78. HIV can evade the drug pressure from mar-
aviroc by switching to the CXCR4 coreceptor. Additionally, HIV-1
can become resistant against maraviroc through an alanine insertion
(G310_P311insA) in V379. No similar resistance mutation has been
described for HIV-2 yet.
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Figure 2.10: Course of HIV
infection.
The major mode of HIV transmission is sexual intercourse. One
of the reasons why the sexual transmission of HIV is so efficient is
that semen-derived enhancer of viral infection (SEVI) drastically
increases the risk of sexual transmission80. Since the gut-associated
lymphoid tissue (GALT) contains the majority of T lymphocytes81,
HIV is most prevalent among men who have sex with men (MSM),
particularly those practicing receptive anal sex with frequently chang-
ing partners82. For example, in the United States, MSM make up
70% of all new HIV infections each year83. A comparatively small
risk group (10% of global infections) in which HIV is transmitted
via blood involves intravenous drug use (IVDU)84. In the past, out-
breaks of HIV also occurred in clinical settings85. For example, in
1988, 99 children were infected with HIV-1 in two Russian hospitals
due to blood-contaminated needles86. However, improved hygiene
standards and routine testing of blood products have rendered the
transmission of HIV in this context highly unlikely.
The course of HIV infection (Figure 2.10) can be separated into
three phases that are characterized by distinct viral loads (VLs) and
CD4 cell counts. In the acute phase, the virus rapidly replicates and
the VL reaches its peak. The majority of infected persons develops
acute retroviral syndrome (flu-like symptoms) roughly two weeks
after initial infection87. In the remainder of persons, the infection
remains asymptomatic88. Since antibodies against HIV appear four to
six weeks after infection89, antibody-based HIV tests are still negative
during acute infection. Therefore, the risk of HIV transmission
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Figure 2.11: Kaposi’s sarcoma is
a type of cancer that can mani-
fest via purple skin lesions.
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is particularly high during this brief stage of infection in which
diagnosis is not possible and VLs are high90.
The second stage is the asymptomatic (clinically latent) stage. In
this phase of the infection, HIV plasma VLs are low because replicat-
ing viruses are being concentrated in the lymphoid organs91. Without
treatment, the asymptomatic phase of HIV-1 infection culminates
in AIDS after roughly ten years of infection. AIDS is characterized
by a CD4 count less than 200 cells per mL of plasma or the acquisi-
tion of an AIDS-defining condition. AIDS-defining conditions are
opportunistic infections and and certain cancers such as Kaposi’s
sarcoma92, see Figure 2.11. An opportunistic infection is an infection
that is more frequent or more severe in immunocompromised per-
sons than in control patients. Examples for opportunistic infection
include pneumocystis pneumonia or tuberculosis. Without treatment,
people with AIDS typically survive only a few years.
The rate of CD4 depletion during the course of an HIV-2 infection
is distinctly slower in HIV-1 infection. Therefore, the clinically latent
phase can last for decades93. While HIV-1-infected persons without
detectable VLs are a rarity (< 1%)94, undetectable VLs were found in
about 40% of untreated HIV-2 infected persons in Western Africa95.
Despite the slower course of HIV-2 disease progression, infection
with HIV-2 eventually leads to AIDS if left untreated96.
2.3.6 Treatment of HIV Infection
An infection with HIV is treated through a combination of antiretro-
virals (ARVs) that interferes with distinct molecular events in the
viral life cycle. To understand the aims of antiretroviral treatment, I
first give an overview of markers for treatment success. Thereafter, I
describe how drug resistance emerges and why it is one of the main
challenges of HIV treatment. Finally, I give an overview of antiviral
agents against HIV infection and their use for the treatment of HIV-1
or HIV-2 infection.
Treatment Goals and Markers Treatment of HIV infection can be eval-
uated with respect to its virological, immunological, and clinical
success. The primary goal of treatment is the reduction of the VL
to an undetectable level (≤ 50 copies per mL). Since persons with
undetectable VLs are highly unlikely to transmit the virus97, reach-
ing undetectability is critical for the implementation of treatment as
prevention (TasP)98,99. Moreover, long periods of undetectable VLs
ensure immune reconstitution, which is measured in terms of the
CD4 cell count. HIV-infected persons with normal CD4 cell counts
(≥ 500 cells per mL) are typically in good health100. The main con-
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sideration for evaluating the clinical success of a treatment is the
absence of immunodeficiency symptoms 101 and the tolerability of
the treatment102. Based on these considerations, HIV treatment fail-

















Figure 2.12: Development of
drug resistance. If drug pres-
sure insufficiently inhibits viral
replication, resistant variants
emerge that can replicate even
under drug pressure. If drug
pressure subsides, reversions to
the wild type are possible.
Drug Resistance Similarly to almost all RNA viruses, HIV has a
polymerase that lacks proofreading ability103. The virus exhibits a
replication rate of roughly 1010 virions per day104,105 and a mutation
rate of 3.4× 10−5 per cycle106. Due to the high rate at which HIV can
mutate its genome, it can quickly adapt to changing conditions in the
host.
Viral evolution can even be accelerated by the host itself. Apolipopro-
tein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) is
a protein that can hypermutate the provirus, rendering it replication-
incompetent. However, mutations induced by APOBEC do not al-
ways prevent viral replication. The action of APOBEC may therefore
support viral escape from the immune response107 and lead to the
development of drug resistance108.
For these reasons, resistance mutations are quickly selected when
sub-inhibitory drug levels allow for viral replication in the presence
of drug, as illustrated in Figure 2.12. HIV drug resistance is one of
the major challenges of ART because strains carrying drug resistance
mutations are archived in the latent viral reservoir and can emerge at
a later point in time109. Thus, drug resistance mutations may persist
for an indefinite amount of time. Due to the threat that is posed by
drug resistant strains, resistance testing is recommended prior to
48
110 Hirsch et al. 2008
111 Nikolenko et al. 2005
112 Schauer et al. 2014
113 Huff 1991
114 Zeldin and Petruschke 2003
115 Gallant et al. 2013
116 Deeks 2014
117 Dorr et al. 2005
118 Matthews et al. 2004
119 Hare et al. 2011
120 Bruno and Jacobson 2010
121 Larder et al. 1996
initiating ART or in case of treatment failure110.
Drugs for Treating HIV Infection The arsenal of antiretroviral drugs
against HIV consists of more than 20 compounds (Figure 2.13). These
compounds can be differentiated into six classes: nucleoside reverse
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors (EIs),
integrase strand-transfer inhibitors (INSTIs), and antibody-based
treatments (Section 2.3.7).
Both NRTIs and NNRTIs prevent reverse transcription of viral
RNA. When viral RT incorporates an NRTI into newly synthesized
DNA, cDNA synthesis fails because strand elongation is prematurely
interrupted111. NNRTIs, on the other hand, allosterically inhibit RT
by binding to a hydrophobic pocket that induces conformational
changes in the active site of the enzyme112.
PIs interfere with the maturation of immature HIV particles that
have just budded from a host cell by preventing the action of viral
protease, which is responsible for cleaving the gag polyprotein113.
Viral particles whose PR has been inhibited remain immature (i.e.
non-infectious) because they lack critical structural components
such as the capsid or matrix proteins. PIs are typically combined
with boosters such as RTV114 or cobicistat115. Boosters improve the
bioavailability of PIs by reducing the metabolism of PIs through the
inhibition of cytochrome P450 3A, the main driver of PI metabolism
in the intestine and liver116.
EIs reduce viral replication by prevention of viral cell entry. There
are two types of EIs: attachment and fusion inhibitors. Attachment
inhibitors such as maraviroc compete for binding to the CCR5 core-
ceptor117, while fusion inhibitors such as enfuvirtide interact with the
transmembrane protein gp41118.
INSTIs prevent the integration of viral cDNA into the host
genome119. Finally, recently introduced treatments based on anti-
bodies such as ibalizumab120 allow for the neutralization of viral
particles and the subsequent elimination of infected cells through
functions of the immune system.
History of Antiretroviral Treatment The development of antiretroviral
treatments can be grouped into four phases. Until the early 1990s,
only NRTIs were available. In this period, treatments were monother-
apies consisting of a single NRTI or combinations of two NRTIs121.
Since these treatments used a single mechanism for inhibiting viral
replication, early treatment failure due to the emergence of drug
resistance was common.
The introduction of NNRTIs and PIs in the mid 1990s heralded
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Figure 2.13: Timeline of HIV
drugs.
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the era of highly active antiretroviral therapy (HAART). HAART crit-
ically improved treatment success122 by introducing triple therapies
consisting of three drugs from at least two different classes. With
the increasing number of available antiretroviral drugs, it became
challenging to select suitable drug combinations. Therefore, resis-
tance testing became an essential tool for the selection of effective,
personalized treatment regimens in the early 2000s123.
The advent of INSTIs at the end of the 2000s marked the inception
of an even more effective era of ART. Because INSTIs were much
more potent than previous drugs, they quickly became part of recom-
mended first-line treatments124. Treatments with INSTIs reduced VLs
quickly and proved to be very durable, giving rise to fewer resistance
mutations than other drugs125. Since effective therapies of HIV were
commonplace now, the term HAART was supplanted by ART.
Current Treatment Strategies The current era of ART is mainly con-
cerned with the simplification of treatments and the prevention of
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new infections. One aspect of treatment simplification is reducing the
pill burden. An increasing number of one-pill once a day regimens
is becoming available126. These drugs can critically improve patient
adherence, which is an important factor for treatment success127.
Another aspect of treatment simplification is the implementation of
dual rather than triple therapies for maintenance therapy. By relying
on fewer drugs, these treatments can reduce side effects, save costs,
and retain future treatment options128.
Regarding prevention, a major concern is the implementation of
pre-exposure prophylaxis (PrEP)129. After the effectiveness of PrEP
had been demonstrated by the PROUD130 and IPERGAY studies131,
the global availability of PrEP has been strongly recommended by the
World Health Organization132. In the future, long-acting, injectable
formulations could improve the effectiveness of PrEP even further133.
Moreover, TasP still plays a major role: A variety of tolerable and
robust treatments are currently under investigation134.
Treatment of HIV-1 Infection The guidelines for the treatment of
HIV-1 infection have changed considerably through the years. In
previous years, treatment was initiated only when the infection was
sufficiently severe (e.g. at a CD4 count less than 350 cells per mL).
However, recent studies such as the START trial have shown that
early therapy improves treatment outcomes and reduces the risk
of HIV transmission135. Therefore, recent European AIDS Clinical
Society (EACS) guidelines recommend that an infection with HIV-1
should be treated immediately irrespective of CD4 counts136. All
of the aforementioned antiretroviral drugs can be used for treating
HIV-1.
Treatment of HIV-2 Infection Since HIV-2 infection is characterized
by a slower disease progression than HIV-1 infection, treatment can
be initiated later (e.g. when the CD4 cell count reaches a value less
than 500 cells per mL137). However, since the immune reconstitution
of patients infected with HIV-2 is slower than in patients that are
infected with HIV-1138, treatment should not be started too late.
Available treatments for individuals infected with HIV-2 are limited
because the development of antiretrovirals is directed towards HIV-1
rather than HIV-2. Only few drugs that are effective against HIV-
1 can be used for treating HIV-2 infection. HIV-2 is intrinsically
resistant to NNRTIs139, to the fusion inhibitor enfuvirtide140, and
exhibits reduced susceptibility to PIs other than LPV, DRV, and
SQV141. Moreover, drug resistance can emerge particularly rapidly in
HIV-2-infected persons142.
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2.3.7 Neutralizing Antibodies and Treatment
Antibodies to HIV develop within the first few weeks of infection.
However, these early antibodies are non-neutralizing antibodies that
do not have a detectable effect on viremia143. Indeed, it usually takes
several months until neutralizing antibodys (NAbs) against envelope
glycoprotein (Env) are elicited via affinity maturation144.
The development of effective NAbs is hindered by the high muta-
tional rate of the surface glycoprotein and its defensive mechanisms.
For example, antibodies often develop against easily accessible
epitopes such as V1/V2/V3. These epitopes act as decoy epitopes
because HIV-1 can quickly escape neutralization by antibodies that
bind to these hypervariable regions145. Moreover, the presence of
the glycan shield146 often prevents the development of antibodies
against more conserved viral epitopes such as the CD4 binding site
(CD4bs)147.
The majority of persons (65%) develops antibodies that are effec-
tive against viral strains from a single HIV-1 clade148 but ineffective
against strains from other clades149. Broadly neutralizing antibod-
ies (bNAbs) can neutralize HIV-1 strains from several clades and
typically appear after two to three years post-seroconversion150.
According to Simek et al. (2009), an antibody exhibits broad neutral-
ization if its half maximal inhibitory concentration (IC50) titer151 is
at least 100 across at least four viral clades (Figure 2.14). Although
bNAbs are elicited in approximately 34% of HIV-1 infected individu-
als, merely 1% of HIV-1 infected persons produce antibodies that are
both broad and potent, with serum titers of at least 300 across four
viral clades152. These rare persons, who are decisive for researching
antibody responses, are called elite neutralizers.
The interaction between HIV-1 and the adaptive immune system
is an evolutionary arms race in which HIV-1 always outpaces the
immune response because emerging antibodies cannot prevent viral
escape153. Therefore autologous antibodies NAbs are ineffective in
vivo although they are effective against wild-type strains in vitro.
Despite their ability to broadly neutralize HIV-1, bNAbs also do not
alter the disease progression of HIV-1-infected persons154. Even elite
neutralizers progress towards AIDS if left untreated155, except in rare
cases156. While autologous antibodies cannot control HIV infection,
treatments with heterologous antibodies are being successfully used.
Overview of Broadly Neutralizing Antibodies The first generation of
bNAbs was identified in the early and mid 1990s. Although these an-
tibodies were not very potent, they revealed many potential antibody
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site159, glycans on gp120160, and the membrane proximal external
region (MPER) of gp41161. However, interest in bNAbs subsided in
the following years because it was thought that their low potency
rendered them ineligible for treatment purposes162.
Two developments invigorated research into bNAbs once again.
The development of single cell cloning techniques allowed for the
systematic screening of antibodies from elite neutralizers with respect
to both neutralization and breadth163. Moreover, the RV144 human
vaccine trial revealed that a reduced risk of infection was associated
with the presence of antibodies targeting the viral envelope spike164.
Thus, in the following years further bNAbs were isolated. The main
target sites of second-generation bNAbs are CD4bs165, the N160
glycan-dependent site associated with the V1/V2 loops166, the N332
glycan-dependent site at the base of V3167, and the MPER of gp41168.
Note that some persons elicit neutralization through multiple an-
tibodies targeting several epitopes on the envelope spike169, while
others rely on a single clonal antibody170.
Antibody-based Treatments Naturally emerging antibodies against
HIV cannot control the infection because viral evolution outpaces the
adaptive processes of the immune system. However, potent, heterolo-
gous antibodies that are administered as a part of antiviral treatment,
are capable of neutralizing HIV. The relevance of swift and potent
immune responses is underlined by studies in simians171, which
suggest that immunization can be achieved if antibody treatments are
started directly after infection172.
Treatments based on bNAbs are different from treatments that
rely on conventional ARVs with respect to toxicity, drug delivery,
frequency of treatment, and emergence of drug resistance. While
frequently used ARVs such as RTV and TDF are associated with
hepatoxicity173 and nephrotoxicity174, respectively, NAbs exhibit
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Figure 2.15: Envelope epitopes
targeted by antibodies against
HIV-1. The grey grid shows an
image of the envelope obtained
by cryo-electron microscopy.
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different side effects such as immune reconstitution inflammatory
syndrome (IRIS) or injection site reactions175. Thus, antibody-based
treatments may be well-suited for HIV-1-infected persons that are
prone to organ damage (e.g. those that are coinfected with HCV).
In contrast to conventional ART, which requires the daily oral
intake of drugs, antibody-based treatments require infusions176.
What first appears as a disadvantage is compensated by the long half-
life of antibodies, which enables less frequent dosing, for example
only every few weeks177. Moreover, since antibodies target different
epitopes than conventional ARVs, they are particularly useful for
patients exhibiting multi-class drug resistance to established drugs.
At the current point in time, there is only one FDA-approved
antibody, the CD4 binding site inhibitor ibalizumab178. The drug is
being used in combination with other ARVs in order to treat patients
exhibiting high levels of drug resistance179. A plethora of other
antibodies are currently under investigation in clinical studies. One
of the most promising bNAbs of the second generation is VRC01180,
a bNAb targeting the CD4bs. VRC01 is currently being investigated
in the antibody-mediated prevention study (AMP), a clinical trial
in phase 2b. Here, study participants receive infusions of VRC01
every 8 weeks and are followed for 22 months. The goal of this study
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is to determine whether periodic injections with VRC01 safely and
effectively protect high-risk persons from infection with HIV-1. If
VRC01 is shown to protect against HIV-1 infection, the drug may be
an interesting candidate for the use in PrEP.
In the future, combination therapies consisting of several antibod-
ies targeting distinct epitopes could reduce the risk of viral escape181.
The recent development of bispecific bNAbs182, which simultane-
ously target two distinct epitopes, may considerably improve the
robustness and effectiveness of antibody-based treatments. Finally,
improving our understanding of how potent bNAbs are elicited
could have profound ramifications for the development of an HIV-1
vaccine183.
2.4 Hepatitis C Virus
HCV infects human hepatocytes and is a leading cause of chronic
liver disease (Section 2.4.1). The HCV genome consists of structural
and non-structural proteins (Section 2.4.2). In contrast to HIV, HCV
does not integrate into the genome of host cells in order to replicate
(Section 2.4.3). HCV is highly prevalent and can cause lethal diseases
such as liver cirrhosis or hepatocellular carcinoma (Section 2.4.4). The
continual use of highly potent drugs over several weeks can typically
clear the infection (Section 2.4.5).
2.4.1 Introduction to HCV
HCV, which was discovered184 in 1989, is a group IV hepacivirus that
belongs to the family of Flaviviridae. HCV infects human hepatocytes
and is a leading cause of chronic liver disease, cirrhosis, and hepa-
tocellular carcinoma (HCC). It is also the most common indication
for liver transplantation in many countries185. There are approxi-
mately 170 million people living with chronic HCV infection. Each
year, 350 000 people die due to HCV-related causes186. In contrast to
hepatitis A and hepatitis B virus, there is no vaccine against HCV187.
HCV is genetically highly diverse. There are seven HCV genotypes
(designated as 1–7) that differ in their nucleotide sequence by at
least 30%188. HCV genotypes are further differentiated into subtypes
(designated by letters a, b, and so on) that exhibit a nucleotide diver-
gence of at least 20%. The globally most prevalent genotypes189 are
genotype 1 (46.2% of global and 70% of European infections190) and
genotype 3 (30.1% of global infections).
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Figure 2.16: HCV genome
organization.
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2.4.2 Structure and Genome Organization
The HCV virion consists of a nucleocapsid that is surrounded by a
host-derived membrane containing the glycoproteins E1 and E2. The
(+)ssRNA genome of HCV (Figure 2.16) has a length of about 9.6 kb
and is defined by a single open-reading frame that is translated into
a precursor polyprotein191. The polyprotein can be divided into two
regions: the 5’ region, which contains the structural proteins, and the
3’ region, which contains the non-structural proteins.
There are three structural proteins: C (core), E1, and E2. C is
involved in the nucleocapsid, while E1 and E2 form the surface
glycoproteins. The non-structural proteins of HCV are NS1, the
transmembrane protein NS2, the protease NS3, the protease cofactor
NS4A, the intracellular membrane protein NS4B, the viral replication
factor NS5A192, and the RNA polymerase NS5B. Research is focused
on the non-structural proteins NS3, NS5A, and NS5B because these
proteins are the target of direct-acting antivirals (DAAs).
2.4.3 Life Cycle
The life cycle of HCV (Figure 2.17) begins with its attachment to spe-
cific receptors on hepatocytes193. Thereafter, HCV is internalized and
the nucleocapsid is released into the cytoplasm where viral RNA is
uncoated. Positive-stranded viral RNA is used as a template for both
translation and generation of a complementary RNA intermediate.
The negative stranded RNA is used as the template for the synthesis
of additional positive RNA strands that are required to produce new
virions.
Using the internal ribosome entry site (IRES) (Figure 2.16), HCV
RNA directly recruits the cellular translation apparatus and initiates
the translation of viral proteins194. The precursor protein is then
processed by both host and viral proteases in order to obtain mature
viral proteins195. HCV replication occurs within the ER-membrane
bound replication complex, which contains replicating viral RNA and
non-structural proteins as well as cellular proteins196. After the virus
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Figure 2.17: The HCV life cycle.
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Figure 2.18: A person showing
symptoms of jaundice (high
bilirubin levels). Jaundice is
associated with diseases of the
liver.
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has been assembled in the ER, it is released from the cell197.
2.4.4 Transmission and Course of Infection
HCV is a blood-borne infection. Currently, the main route of in-
fection with HCV is IVDU198 although sexual contact with HIV-
1-positive persons or MSMs seems to be a contributing factor199.
However, there is almost no risk of sexual transmission in groups
of persons that neither belong to IVDU nor MSM200. In the past,
blood transfusions also played an important role. Nowadays, routine
screening of blood samples renders infection via blood products
highly unlikely (roughly 1 in 2 million)201. The high prevalence of
HCV infection can be explained by the following three factors. First,
HCV was as discovered as recently as 1989. Until then, HCV could
disseminate freely. Second, blood products were previously treated
less carefully than nowadays, which suggests that clinics could have
been a major driver of HCV spread. For example, the high preva-
lence of HCV in Egypt is largely due to a parenteral antischistosomal
therapy campaign (1960s to 1980s), in which unsterilized injection
material was reused202. Third, since HCV infection often remains
asymptomatic for many years, this increases the likelihood that a
person unknowingly transmits the infection during his lifetime.
Between 70% and 80% of HCV infections follow an asymptomatic
course203. The remainder of infections leads to clinical symptoms
(e.g. malaise, weakness, anorexia, or jaundice, see Figure 2.18) within
three to twelve weeks after infection. During the acute phase, con-
siderable hepatocyte necrosis takes place, which is evidenced by
exceedingly high levels of serum alanine aminotransferase. During
the first weeks of infection, HCV RNA levels peak at 105 to 107 inter-
national units (IU) per mL of blood204 Antibodies to HCV become
detectable one to three months after exposure.
HCV infection is considered to be chronic if HCV RNA persists
for at least six months after the onset of acute infection. The majority
of HCV infected persons (75% to 85%) cannot spontaneously clear
the infection205. HCV disease progression is measured in terms of
liver fibrosis, which is graded according to liver biopsy. Here, the
number of mononuclear inflammatory cells and the number of dead
or dying hepatocytes are considered. Liver cirrhosis describes the
advanced stage of fibrosis in which the function of the liver is lim-
ited (Figure 2.19). HCV infected persons can unknowingly develop
compensated cirrhosis, which is not associated with any symp-
toms. Decompensated cirrhosis, whose treatment necessitates a liver
transplant, is associated with life-threatening conditions including
bleeding varices206, ascites207, encephalopathy, or jaundice.208
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Figure 2.19: Comparison of a
normal and a cirrhotic liver.
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After ten years of HCV infection, the cumulative probability of
acquiring decompensated cirrhosis reaches approximately 30%. Once
decompensated cirrhosis is present, the 5-year survival drops to
50%. In cirrhotic patients, HCC develops at a rate of 1% to 4%. The
mean time to development of cirrhosis and HCC is 24 years and
27 years, respectively209. Note that HCV infection can also cause
extrahepatic disease manifestations, which typically occur in the form
of autoimmune disorders, most notably cryoglobulinemia210.211
2.4.5 Treatment of HCV Infection
The success of HCV treatment is measured in terms of the long-
lasting disappearance of HCV-RNA from serum, which is called
sustained virologic response (SVR). Previously, treatment of HCV
infection was based on the administration of interferon and rib-
avirin.212 For persons with acute symptomatic hepatitis C, an im-
mediate monotherapy with interferon could clear the infection in
90% of patients within 24 weeks213. The treatment of chronic infec-
tions, however, proved more challenging: combinations of interferon
and ribavirin attained SVR rates of only 50% after 24 or 48 weeks of
treatment214.
The way in which HCV infection is treated has changed drastically
since the arrival of DAAs in 2011. In contrast to interferon and
ribavirin, DAAs target specific steps in the HCV replication cycle in
a similar fashion as antiretroviral drugs against HIV. There are three
classes of DAAs available (Table 2.1): inhibitors of NS3, NS5A, and
NS5B.215 Modern treatments, which are based on these drugs, are
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Date Drug Genotype
NS3 Inhibitors
May 14, 2011 Bocprevir (BOC) 1
May 23rd, 2011 Telaprevir (TVR) 1
November 22, 2013 Simeprevir (SMV) 1,4
July 2014 Asunaprevir (ASV) 1
January 28, 2016 Grazoprevir (GZR) 1,4
July 22, 2016 Paritaprevir (PTV) 1,4
July 18, 2017 Voxilaprevir (VOX) Pangenotypic
August 3, 2017 Glecaprevir (GLE) Pangenotypic
NS5A Inhibitors
October 10, 2014 Ledipasvir (LDV) 1,4,5,6
July 24, 2015 Daclatasvir (DCV) 1,3
July 24, 2015 Ombitasvir (OBV) 1,4
January 28, 2016 Elbasvir (EBR) 1,4
June 28, 2016 Velpatasvir (VEL) Pangenotypic
August 3, 2017 Pibrentasvir (PIB) Pangenotypic
NS5B Inhibitors
December 6, 2013 Sofosbuvir (SOF) 1,2,3,4
July 22, 2016 Dasabuvir (DSV) 1
Table 2.1: Drugs for the treat-
ment of HCV infection. The
Genotype column indicates the
genotypes for which drugs
are approved and the Date col-
umn indicates the date of FDA
approval. Pangenotypic are ap-
proved for all HCV genotypes.
216 Holmes and Thompson 2015
217 Holmes and Thompson 2015
218 European Association for the Study
of the Liver 2018
219 Holmes and Thompson 2015
220 Rockstroh 2018
221 Pawlotsky 2011
222 Susser et al. 2011; Pawlotsky 2016
223 Yoshimi et al. 2015
224 European Association for the Study
of the Liver 2018
225 Puoti et al. 2018
226 Wang et al. 2018
all-oral since interferon infusions are no longer necessary216.
With the advent of DAAs, the required treatment duration was
reduced to 12 weeks and the rate of SVR was raised to 90% for
most patients217. However, because the first DAAs were effective
only against specific HCV genotypes218, the effectiveness of HCV
treatments such as SOF+LDV or GZR+EBR varied in dependence
on the genotype219. Recently introduced pangenotypic treatments
against HCV such as SOF+VEL or GLE+PIB are eligible for all HCV
genotypes and ensure SVR rates of at least 95%220.
Treatment failure with DAAs can be caused by the selection of
resistance-associated variants (RAVs)221. RAVs in NS3 and NS5A are
particularly problematic as they can persist for months222 or even
years after treatment cessation223, respectively. Currently, it is not rec-
ommended to perform systematic resistance testing prior to the initi-
ation of treatments in DAA-naive patients224. Initial drug resistance
testing is not recommended for three reasons. First, 99% of patients
without cirrhosis that are treated with current pangenotypic DAAs
reach SVR after twelve weeks225. Second, the presence of resistance-
associated substitutions (RASs) leads to treatment failure in only a
small fraction of patients226. Third, the clinical consequences of treat-
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ment failure are small because organ damage resulting from HCV
accumulates over several years; requiring an additional twelve weeks
to eliminate the infection is of little clinical consequence. Thus, drug
resistance testing is mostly used in case of treatment failure. Based
on the information of resistance testing, the treating clinician can
either select another treatment or continue the previous treatment for
an extended period of time. Of course, it is also important to monitor
the epidemiology of HCV drug resistance for surveillance purposes.
2.5 Molecular Techniques
This section introduces molecular techniques that are useful for
the study of viruses. Phenotypic methods for the identification of
HIV coreceptor usage (Section 2.5.1) are employed to investigate
the molecular characteristics of viruses using different coreceptors.
Results from phenotypic assays inform genotypic methods for the
identification of HIV coreceptor usage (Chapter 5), which are used to
guide the prescription of the CCR5 coreceptor antagonist maraviroc.
Phenotypic methods for the determination of HIV drug resistance
(Section 2.5.2) can offer insights into the mutations that confer re-
sistance. Viral genomes are routinely sequenced (Section 2.5.3) for
genotypic resistance testing (Chapter 4), in which viral genomes
are analyzed with respect to drug resistance mutations in order to
aid treatment selection. Polymerase chain reaction methods (Sec-
tion 2.5.4) are important for a multitude of biological techniques.
mPCR is particularly important for the elucidation of antiviral im-
mune responses (Chapter 6).
2.5.1 Phenotypic HIV Coreceptor Testing
Phenotypic approaches for the identification of HIV coreceptor usage
rely on assays that are based either on CD4+ cell lines or on primary
cells. The CD4+ cell lines are engineered such that they express only
certain coreceptors and elicit a specific signal upon viral infection.
Assays based on primary cells, on the other hand, are typically
evaluated according to the concentration of capsid antigen (p24 for
HIV-1 and p27 for HIV-2), which provides a surrogate marker for the
number of infected cells227.
Primary Cells vs Cell Lines Assays based on primary cells have a
higher agreement with in vivo coreceptor usage than assays based
on cell lines. Since engineered cell lines often express higher con-
centrations of CD4+ receptors and HIV coreceptors than naturally
occurring cells228, they are often hypersensitive to coreceptor usage.
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Assays that are based on such cell lines therefore typically yield a
greater number of false positive results (i.e. reporting a virus as X4-
capable although it is incapable of infecting a CD4 cell exhibiting
only the CXCR4 coreceptor in vivo). Still, assays based on cell lines
are more frequently used than assays based on primary cells because
they are standardized, less work-intensive, and are more suitable for
detecting coreceptors other than CCR5 or CXCR4.
Two Types of Assays There are two approaches for measuring core-
ceptor usage phenotypically. The first approach relies on comparing
the infection status of two types of cells that express different core-
ceptors. The second approach uses coreceptor antagonists to block
specific coreceptors and subsequently measures the infection status.
Assays based on U87 cells and GHOST (3) cells229 follow the first
approach, while assays based on TZM-bl cells230 follow the second
approach. PBMCs can be used for both approaches since PBMCs
with homozygous CCR5∆32 can be used for the first approach, while
conventional PBMCs can be used for the second approach231. In the
next paragraphs, I first deal with assays that follow the first approach
and then discuss assays pursuing the second strategy.
The Trofile assay is the standard assay for identifying HIV-1 core-
ceptor usage and relies on U87 cells232. In the first step, a replication-
defective pseudovirus carrying the envelope region of the target virus
is constructed via transfection233. The use of a pseudovirus prevents
multiple rounds of infection that could bias the results of the assay234.
Two types of U87 cells that provide different luminescent signals
upon infection are used. U87:CXCR4 expresses only CXCR4, while
U87:CCR5 expresses only CCR5. If a signal is measured only from
CCR5- or CXCR4-expressing cells, the virus is identified as R5 or X4,
respectively. Otherwise, if signals from both types of cells are found,
the virus is identified as dual/mixed. An improved version of the
original Trofile assay, the enhanced-sensitivity Trofile assay (ESTA),
was shown to obtain sensitivities of 100% for detecting envelope
sequences from X4-capable variants even at a prevalence of only
0.3%235.
Assays based on TZM-bl cells follow the second strategy since
TZM-bl cells exhibit both CCR5 and CXCR4 simultaneously. Upon
infection, these cells express firefly luciferase enzyme under the con-
trol of the HIV promoter such that HIV infection can be detected. By
blocking one of the coreceptors with excessive amounts of coreceptor
antagonists and then measuring luminescence, R5 and X4-capable
variants can be discriminated236.
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Interpretation of Results Interpreting the results of phenotypic assays
can be challenging. For example, the fluorescence readouts from
GHOST (3) cells should be compared to a control cell line expressing
only the CD4 receptor to account for background noise levels. If
no reference cell line is available, a threshold for discerning true
signal and noise has to be chosen judiciously. For TZM-bl cells, it
is necessary to interpret low levels of residual replication after the
application of coreceptor antagonists. Furthermore, care should
be taken when comparing results from assays relying on the use
of coreceptor antagonists because these assays may yield different
results for the same isolate in case that different types of coreceptor
antagonists were used (e.g. the CCR5 antagonists maraviroc and
TAK-779).
2.5.2 Phenotypic Resistance Testing
Phenotypic resistance testing relies on experimental monitoring of
the extent to which viral replication is inhibited at varying concentra-
tions of an antiretroviral drug237. If viral replication is suppressed at
relatively low drug concentrations, a viral strain is considered to be
susceptible to a drug. Otherwise, if relatively high drug concentra-
tions are required for inhibiting a viral strain, it is considered to be
resistant238.
Phenotypic assays determine drug resistance through an in vitro
binding assay. An advantage of phenotypic assays over genotypic
approaches (Chapter 4) is that they directly assess the efficiency with
which the drug binds to its target rather than searching for genomic
footprints that are indicative of resistance. Moreover, they measure
the effect of individual drugs rather than the resistance patterns of
multiple drugs, which is the case for genotypic approaches that rely
on clinical data239. However, since phenotypic tests are performed
in vitro, it is necessary to interpret their results carefully when these
tests are used for in vivo applications (e.g. guiding treatment choices).
Due to the accuracy of phenotypic measurements, they have formed
the basis for genotypic approaches for resistance testing such as
geno2pheno[resistance]240. Since phenotypic tests are time- and
cost-intensive, they are typically not applied in clinical settings
and are more relevant for basic research. For example, phenotypic
methods haven been used to identify the resensitizing effect of the
RT mutations M184V and L74V241 or to determine patterns of co-
occurring resistance mutations242.
There are two generations of phenotypic resistance tests. The first
generation is based on the cultivation of PBMCs243. Since phenotypic
resistance testing based on PBMCs infected with HIV-1 was found
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to be very time-consuming, new assays that can be performed in
8–10 days were developed. These PCR-based assays utilize recom-
binant viruses244 and are performed in the following way. After
amplifying the genomic regions of interest (typically PR, RT, or IN of
the pol gene) from viral plasma RNA through reverse transcription
polymerase chain reaction (RT-PCR), the corresponding segments
are inserted into a modified HIV-1 vector. Finally, drug resistance is
determined by measuring the IC50 as described in Section 2.5.2.
Antivirogram and PhenoSense Based on this second-generation ap-
proach, two commercial phenotypic assays were developed: the
Antivirogram assay (formerly Virco, later Janssen Pharmaceutica)245
and the PhenoSense assay (formerly ViroLogic, later Monogram
Biosciences)246. The Antivirogram assay requires at least 1000 HIV-1
RNA copies per mL and includes PR and the majority of RT (up to
codon 482). The PhenoSense assay requires at least 500 HIV-1 RNA
copies per mL and also considers protease cleavage sites in gag in
addition to PR. RT, however, is included only until codon 313247.
The PhenoSense assay performs only a single cycle of viral replica-
tion and captures the extent of replication with a luminescent marker.
This is achieved through a vector containing a defective env gene,
which ensures that budding virions are not replication-competent.
Antivirogram, on the other hand, compares the cytopathic effect of
HIV in the presence and absence of an ARV. Since this is a more
indirect marker that relies on multiple cycles of replication, the re-
sults that are produced by the Antivirogram assay are typically less
accurate than those of the PhenoSense assay.
The observed correlation between the PhenoSense and the Antivi-
rogram assay depends on the distribution of observed levels of resis-
tance in the study population. In one study where the samples had
either very low or very high levels of resistance, the assays agreed
well with a concordance of 91.5%248. Another study in which a large
number of samples showed intermediate levels of resistance reported
an agreement of only 36%249, which suggests that the Antivirogram
assay is less accurate for samples with intermediate resistance250.
Due to the greater commercial success of the PhenoSense assay, the
Antivirogram assay was discontinued in 2010.
Interpretation of Phenotypic Resistance Tests
In the following paragraphs, I summarize methods for the inter-
pretation of IC50 values obtained from phenotypic resistance tests.
For this purpose, I first introduce the notion of resistance factors




























Figure 2.20: Determination of
the resistance factor from a
dose-response curve. The blue
curve shows the inhibition of a
wild-type virus by an antiretro-
viral drug, while the orange
curve shows the inhibition of a
mutated virus. The IC50 is the
drug concentration at which
viral replication is inhibited by
50%.
251 The resistance factor is also called
fold change.
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interpretable levels of resistance.
The Resistance Factor The resistance factor (RF)251 is determined by
comparing the IC50 of a mutated viral strain (IC50MT) with the IC50




The interpretation of RF is straightforward. RF > 1 indicates a
relative increase in resistance, RF < 1 indicates a relative increase in
drug susceptibility, and RF = 1 indicates susceptibility at the level of
the wild-type strain.
The RF is limited in that it reflects only a single point along the
dose-response curve of a drug (Figure 2.20) and thereby discards
information that may be obtained from considering the shape of the
sigmoidal dose-response curve. Two drugs with the same RF may
behave very differently when varying their dose252. This means that
the IC50 underestimates the impact of HIV mutations that do not
change the RF but influence the slope of the dose-response curve.
Therefore, the use of measures other than the IC50 may be warranted
when interpreting drug resistance. For example, the instantaneous
inhibitory potential, which gives the log inhibition of single-round
infectivity at clinical concentrations, may be favorable because it
considers both slope and IC50253. Note that the approaches that are
discussed in the following use only the IC50.
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There are two challenges with respect to the RF. First, how to
compare RFs across drugs? Second, how to make RFs more inter-
pretable? The following paragraphs are concerned with answering
these questions.
Standardization of Resistance Factors Before answering the first ques-
tion, it is important to understand that RFs vary considerably de-
pending on the tested ARV. This is intuitively clear because RF is
defined relative to IC50WT. A drug whose IC50WT is low is gener-
ally associated with greater RFs than a drug whose IC50WT is high.
For example, the mean IC50 for subtype B isolates from untreated
HIV-1 infected persons is 0.01 µM for ZDV, while the correspond-
ing mean IC50 for TDF is 1.1 µM254. Hence, viral RFs relating to
different drugs should never be compared directly but only after
standardization to z-scores.
The approach of geno2pheno[resistance]255 uses the mean, µ, and
standard deviation, σ, from the normal distribution of RFs from
therapy-naive HIV-1 infected persons in order to compute the z-score





Relative to therapy-naive persons, zRF < 0 and zRF > 0 indicate
strains that are either more susceptible or less susceptible to a drug,
respectively.
Discretization of Resistance Factors In order to improve the inter-
pretability of the RF, it is necessary to find cutoffs that give rise to
meaningful, discrete levels of resistance. Drug resistance is typically
described using the SIR classification scheme, which considers three
levels of resistance: susceptible, intermediate, and resistant. These resis-
tance levels originate from bacterial resistance against antibiotics256.
They are formally described according to the ISO 20776-1:2006 stan-
dard257:
“Susceptible: A bacterial strain is said to be susceptible to a givenantibiotic when it is inhibited in vitro by a concentration of this drug
that is associated with a high likelihood of therapeutic success.
Intermediate: The sensitivity of a bacterial strain to a given antibiotic
is said to be intermediate when it is inhibited in vitro by a concen-
tration of this drug that is associated with an uncertain therapeutic
effect.
Resistant: A bacterial strain is said to be resistant to a given antibiotic
when it is inhibited in vitro by a concentration of this drug that is
associated with a high likelihood of therapeutic failure.
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”These classes of resistance are used correspondingly in the realm
of HIV. In clinical applications, where therapeutic drug dosing
schemes are used, susceptible corresponds to full activity, intermediate
to residual activity, and resistant to inactivity258.
It is possible to map from in vitro measurements of resistance
to levels of resistance by selecting cutoffs from the RF distribu-
tion. Initially, HIV resistance levels were determined by applying
technically-motivated cutoffs to the RFs obtained from phenotypic
tests259. However, these cutoffs were inaccurate because they did not
take drug-specific effects into account, which are important for two
reasons260. First, the susceptibility of HIV in treatment-naive persons
differs across drugs261,262. Second, the in vivo effect of drugs is mod-
erated by different metabolic pathways. PIs are a prime example for
this. When prescribed, these drugs are usually combined with boost-
ers that extend the half-life of these compounds263. As a consequence,
boosted PIs exhibit superior potency in vivo than suggested by in vitro
tests, which do not take boosting into account.
To circumvent these shortcomings, biologically-motivated cutoffs
were developed. These cutoffs are selected based on the RF distri-
bution of viral strains from therapy-naive patients. For example,
Harrigan et al. (2001) defined a biological cutoff for differentiating
susceptible and resistant strains at an RF defined by the distribution’s
mean plus two standard deviations. Although these cutoffs afforded
an improvement over the technical cutoffs, they did not necessarily
correlate well with treatment outcomes. Thus, clinically-motivated
cutoffs were developed. These cutoffs are derived by determining
the association between treatment outcomes and RF values. Initial
clinical cutoffs relied on experts who would associate RFs, which
were measured for specific drugs, with clinical outcomes. This ap-
proach was originally used by the geno2pheno[resistance] web server
but was subsequently discontinued because it is time-intensive, not
automatable, and subject to human biases. These problems were
solved by statistical approaches for finding clinical cutoffs264, which
are described in more detail in Section 4.1.2.
2.5.3 Sequencing of Viral Genomes
The application of genotypic methods for the identification of vi-
ral drug resistance (Section 4.1) requires prior sequencing of viral
genomes. Two approaches can be used for this purpose. Sanger se-
quencing has been the predominant sequencing method for the last
three decades but the more recently established NGS is currently
being widely adopted.
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Figure 2.21: Sequencing via the
Sanger method.
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Sanger Sequencing At the end of the 1970s, Sanger sequencing265,266
heralded the era of first-generation sequencing technologies267,268.
The approach by Sanger is based on the observation that DNA is
formed by incremental linkage of individual deoxyribose nucleoside
triphosphates (dNTPs), a reaction that is catalyzed by polymerase.
In contrast to dNTPs, didexobyribose nucleoside triphosphates
(ddNTPs) do not have the 3’ hydroxyl group that is required for
bonding with other dNTPs. The incorporation of a ddNTP into a
nascent nucleic acid terminates its synthesis by polymerase269, which
can be exploited for determining the sequence of a nucleic acid in the
following way.
In the approach proposed by Sanger in 1977, ddNTPs are radiola-
beled in order to differentiate the four types of nucleobases A, C, G,
and T. Given a template DNA whose sequence is to be determined,
four different reaction containers are set up. Each of the four prepara-
tion contains one of the four types of ddNTPs (either ddATP, ddCTP,
ddGTP, or ddTTP) as well as all types of dNTPs, primers, and poly-
merase. The labeled ddNTPs are present in lower concentrations
than the conventional dNTPs, which ensures that some synthesized
fragments can reach full length. Due to the presence of ddNTPs, each
of the four reactions generates thousands of nucleic acid fragments
with varying lengths, for which the terminal nucleotide is known. It
is possible to determine the sequence of nucleotides by performing
gel electrophoresis, which separates the fragments according to size.
By assigning each of the four reactions to a single lane in the gel, the
nucleotide sequence can be obtained by moving from the shortest
segment to the longest segment while noting the lane in which each
segment was found (Figure 2.21).
The original Sanger sequencing approach was further refined
throughout the years. One innovation was the substitution of ra-
diolabeling with fluorescent dyes. The assignment of one of four
fluorophores to each ddNTP gave rise to dye-terminator sequencing
in which a single preparation is used instead of four preparations.
This substantially decreased the extent of laboratory work and facili-
tated the automated computational analysis of gels270. Additionally,
the use of fluorescent dyes removed the need of adhering to strin-
gent safety protocols for handling radioactively labeled ddNTPs. By
replacing gel electrophoresis with capillary electrophoresis in later
years271, the throughput of Sanger sequencing was further increased.
Current commercial Sanger sequencing systems272 are extremely
accurate with overall accuracies as high as 99.999%273. The errors
that do occur are concentrated at the beginning and at the end of
the reads. Errors are more prevalent in the first 50 bases of reads
because smaller DNA fragments exhibit anomalies during gel elec-
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trophoresis.274 The end of the sequence is also subject to a higher
error rate due to the reduced electrophoretic mobility of long reads
and their relatively small number275. The maximal read length of
Sanger sequence is at about 750 bp276.
Sanger sequencing is suitable for the analysis of viral samples
from patients that may contain a viral population consisting of differ-
ent variants of the same viral species277. This is because individual
variants of the same viral species can be detected in the form of
overlapping peaks in the chromatogram. Since the level of detection
is limited by noise in the fluorescence signal, current industrial se-
quencers can detect population variants at a prevalence of 10% to
20%278.
Next-Generation Sequencing NGS279 is characterized by the massive
parallelization of the two steps of Sanger sequencing: synthesis
of DNA and determination of the sequence. The greater depth of
coverage afforded by NGS allows for the detection of variations
at low population prevalence (e.g. at 1% in a population)280. This,
however, comes at the cost of shorter reads281 and higher error rates
(at least 0.1%)282. In this section, I introduce the well-established
sequencing approach that was developed by Solexa and later refined
by Illumina, which is called the Solexa/Illumina approach in the
following.
Figure adapted from Anderson and Schrijver (2010), licensed under CC BY-NC-SA 3.0.
Figure 2.22: Chemistry of Illu-
mina/Solexa sequencingIn the approach by Solexa/Illumina, template DNA is amplified
in a process termed bridge PCR. Single-stranded template DNA is
added to a flow cell and immobilized by hybridization to anchor
molecules such that templates arch over to adjacent anchor oligonu-
cleotides during hybridization. By performing multiple rounds of
PCR, arching clusters, that is, clusters containing thousands of clonal
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nucleic acids are generated. About 50× 106 of such clusters are gener-
ated283. After denaturing the clusters, sequencing can take place.
Sequencing based on the approach of Solexa/Illumina is similar
to Sanger sequencing as it relies on the use of modified dNTPs284
(Figure 2.22). Each type of dNTP carries a specific dye as well as a
terminator for blocking the further polymerization of DNA. Once a
nucleotide has been incorporated, further elongation is possible only
after the terminator has been removed.
Sequencing is performed by iteratively cycling three steps. In the
first step, all four types of dNTPs are added simultaneously such
that the sequences are extended by a single nucleotide. In the second
step, incorporated nucleotides are interrogated using an optical
system that records the fluorescence signal. In the third step, the
terminators are removed and the fluorescent labels are cleaved and
degraded allowing for the next sequencing cycle to commence. Reads
from the Solexa/Illumina approach suffer from increasing rates of
errors at the end of the reads because nucleotides may be over- or
underincorporated or terminator removal may fail285.
The use of NGS poses two challenges. First NGS is computation-
ally demanding because it requires the processing of thousands of
short (e.g. 200 bp) reads. Second, NGS suffers from higher error
rates than Sanger sequencing, which need to be taken into account
when interpreting the results286. Despite these shortcomings, NGS is
advantageous over Sanger sequencing as it affords a higher through-
put at an improved resolution. A detailed account of the technical
requirements for processing NGS data is provided in Section 4.1.4.
2.5.4 Polymerase Chain Reaction
PCR is the fundamental method that is used for the amplification
and modification of DNA. PCR involves performing the following
steps in multiple cycles (Figure 2.23): denaturation, annealing, and
elongation. In the denaturation phase, double-stranded DNA is
turned into single-stranded DNA by applying high temperatures
(e.g. 95◦ C). Next, the temperature is reduced (e.g. to 50 ◦C) such that
complimentary oligomers (primers) can attach to the single-stranded
DNA. In the third step, the temperature is increased again (e.g. to
72
◦C). Then, polymerase attaches to the region where the primer
has bound and elongates the DNA segment to fully double-stranded
DNA. Each PCR cycle roughly doubles the amount of DNA. For
example, a single copy of DNA could be amplified to more than one
million copies in only 20 PCR cycles.
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Image reproduced with permission from Elsevier (Garibyan and
Avashia, 2013).
Figure 2.23: Steps involved in
polymerase chain reaction.
Multiplex Polymerase Chain Reaction In contrast to conventional PCR,
mPCR strives to amplify several template sequences simultaneously,
which typically requires the use of multiple primers. Primer design
for multiplex PCR is particularly challenging because the molecular
characteristics of mPCR need to be considered (Section 6.1.1) and
a combinatorial optimization problem has to be solved to find a
suitable set of primers (Section 6.3.3).
Quantitative PCR Quantitative polymerase chain reaction (qPCR),
which is also called real-time PCR, has the goal of measuring the
concentration of amplified DNA in real time. The principle approach
of qPCR is very similar to conventional PCR. In each cycle of PCR,
amplified templates are tagged using specific fluorophores, which
are excited with a beam of light. The emitted fluorescence is then
detected. By calculating the increase in fluorescence between cycles,
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it is possible to quantify the template species287. While conventional
PCR is used to amplify a genomic sequence for further experimental
investigation, qPCR is often an experimental end point. Since qPCR
is concerned with the quantification of nucleic acid sequences, primer
amplification rates should be uniform to ensure that the estimates of
qPCR are accurate.
To exemplify this point, let us consider the use of qPCR for study-
ing gene expression levels. Assume we are studying three genes, A,
B, and C, which have initial concentrations of cA = 1 nM, cB = 2
nM, and cC = 3 nM. If we perform 20 cycles of qPCR, 1 nM of DNA
could ideally be amplified to roughly 1 mM of DNA. If A, B, and
C have maximum amplification rates of ηA = ηB = ηC = 1, the
concentrations of the amplified templates would be c′A u 1 mM,
c′B u 2 mM, and c′C u 3 mM. Based on these results, we would
correctly conclude that C is the most prevalent transcript, followed
by B and C. Let us now assume that the amplification rates for A, B,
and C are different, for example, ηA = 1, ηB = 0.5, and ηC = 0.1.
In this case, each amplification cycle doubles the concentration of A
but only increases the concentrations of B and C by 50% and 10%,
respectively. Then, after performing qPCR, the concentrations would
be c′A = 1× 10−9 × 220 u 1 mM, c′B = 2× 10−9 × 1.520 u 6.6 µM, and
c′C = 3× 10−9 × 1.120 u 0.2 nM. Based on these results, we would
falsely conclude that A is the most prevalent transcript, followed by B
and C, merely because the amplification rates were different.
There are two quantities that are essential for qPCR. The threshold
cycle, Ct, measures the cycle at which the fluorescence signal be-
comes exponentially larger than the background noise. Based on the
Ct of a reference sequence, Ctref, it is possible to define the cycle de-
lay for the template of interest (denoted by OI), ∆CtOI = CtOI − Ctref.
The values of ∆Ct are typically greater than zero. Templates that are
amplified efficiently will have ∆Ct close to 0, while those that are
amplified poorly will have large values of ∆Ct.
To exemplify the cycle delay, let us consider the previous example
once again. Let us assume that Ct = 1µM such that CtA = 10,
CtB = 18, and CtC = 73. If we define Ctref := CtC, then ∆CtA =
CtA − CtA = 0, ∆CtB = CtB − CtA = 8, and ∆CtC = CtC − CtA = 63.
The cycle delays indicate that the amplification of B and C lag 8 and
63 cycles behind the amplification of A, respectively. The high value
of ∆CtC indicates that the amplification of C is exceedingly slow.

[T]ruth ... is much too
complicated to allow anything
but approximations ...
John von Neumann
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is called semi-supervised learning. In
semi-supervised learning, predictive
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The 2000s and 2010s signify periods in which machine learning has
brought about technological innovations in various areas such as
image recognition1, face recognition2, and gaming3. In the biomed-
ical field, machine learning was successfully used to improve the
treatment of diseases including diabetic retinopathy4, cancer5, and
those caused by viral infections6. Since machine learning techniques
form the methodological basis of this work, I first give an overview of
machine learning (Section 3.1) and thereafter introduce the core con-
cepts of supervised learning (Section 3.2). Measures for evaluating
the predictive performance of classifiers are covered in Section 3.3.
Since the supervised learning methods of support vector machines
and logistic regression are especially relevant, these models are in-
troduced in Section 3.4. The principles of clustering and significance
tests are briefly covered in Section 3.5 and 3.6, respectively. Finally,
an overview of optimization with linear programs is provided in
Section 3.7.
3.1 Overview of Machine Learning
Machine learning is a subfield of artificial intelligence that is con-
cerned with enabling computers to learn from data without explicit
programming. There are three machine learning scenarios: super-
vised, unsupervised, and reinforcement learning7. Supervised
learning requires the observation of input variables as well as cor-
responding outcomes. Its goal is to learn a generalized model that
is capable of accurately estimating the outcomes for new inputs. In
unsupervised learning, the outcomes are not available. Therefore,
unsupervised learning is not concerned with prediction but rather
with structuring related data according to their distribution. Applica-
tions of unsupervised learning include clustering and dimensionality
reduction. In clustering, the goal is to assign observations into dis-
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tinct groups, which represent their characteristics. Dimensionality
reduction is concerned with projecting data into spaces with reduced
dimensionality, while retaining as much information as possible.
Finally, reinforcement learning studies how an agent can learn
from interactions with the environment. Reinforcement learning is
different from both supervised and unsupervised learning because
it does not rely on a fixed learning data set but on exploration of
the environment, which produces non-deterministic outcomes. In
particular, reinforcement learning is different from active learning,
which refers to supervised learning problems in which the algorithm
can retrieve additional labels. This is because reinforcement learning
is not concerned with prediction8. For more information on reinforce-
ment learning, I refer the interested reader to the excellent book by
Sutton et al. (1998).
The following sections on machine learning are restricted to
supervised and unsupervised learning. Their content is based on
the books by Hastie et al. (2009) and Schölkopf and Smola (2001) if
not stated otherwise.
3.2 Supervised Learning
Supervised learning is concerned with the identification of predic-
tive models that are capable of accurately estimating the outcomes
for new measurements. These models are fitted using a training
data set containing measurements of features and their correspond-
ing outcomes. Section 3.2.1 introduces the relevant notation and
the two types of supervised learning tasks, regression and clas-
sification. Supervised learning can be seen as a form of function
estimation in which we want to minimize the expected prediction
error (Section 3.2.2). In order to reason about models for a specific
prediction task, it is useful to think about the bias-variance trade-
off (Section 3.2.3). The errors of a model can be determined on the
training data or on an independent test set (Section 3.2.4), giving rise
to estimates of the in-sample or the extra-sample error, respectively
(Section 3.2.5). To limit the complexity of a model, regularization
(Section 3.2.6) or feature selection can be performed (Section 3.2.7).
3.2.1 Preliminaries
Input data for supervised learning consist of pairs of features X
and outcomes Y. Features are represented by the feature matrix
X ∈ RN×p, where N indicates the number of observations and p
gives the number of features. The feature vector of the i-th sample
is denoted by xi ∈ Rp. In case of a regression task, the vector of
methodological foundations 75
outcomes is given by Y ∈ RN . In case of a classification task, the
set of possible outcomes, G, is discrete and the vector of outcomes
is denoted by Y ∈ GN . The outcome, G, can indicate categorical or
ordinal data.
The two types of learning scenarios can be illustrated by the
following example. Assume that we would like to predict the level
of precipitation, for example, given observations of temperature,
atmospheric pressure, humidity, and so on. When we are interested
in predicting the precipitation per square meter (i.e. a continuous
variable), this gives rise to a regression problem.
The same problem can be formulated as a classification task by
discretizing the outcome. For example, we could use the categorical
outcomes G = {−1, 1} where the two classes −1 and 1 represent
the states No Rain and Rain, respectively. Classification problems
that deal with two classes are particularly common and are called
binary classification tasks. A classifier based on ordinal outcomes
may consider the classes 0 (No Precipitation), 1 (Little Precipitation), 2
(Medium Precipitation), and 3 (High Precipitation). Note that there is
an ordering associated with the classes such that 0 < 1 < 2 < 3.
For example, the ordering indicates that class 1 is associated with a
smaller level of precipitation than class 3.
3.2.2 Supervised Learning as Function Estimation
Supervised learning is a form of function estimation, in which we
would like to obtain a function f (X) for predicting Y given X that
minimizes the risk, where risk is defined by the expected prediction
error. The expected prediction error can be estimated by defining
a loss function L(Y, f (X)), which determines the penalties that
are incurred when f (X) deviates from Y. Let X and Y be random
variables from the joint probability distribution, Pr(X, Y). Then, the
risk, R( f (X)), can be formally defined as the expectation over the
loss function:
R( f (X)) = E(L(Y, f (X)))
=
∫
L(Y, f (X))d Pr(X, Y) .
Since Pr(X, Y) is usually not known, the empirical risk needs to be
determined instead. The empirical risk relies only on the available,
discrete set of data and is defined as






L(Yi, f (Xi)) .
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9 A parametric model (e.g. logistic
regression) has a fixed number of
parameters. A non-parametric model
(e.g. nonlinear support vector machine),
on the other hand, can fit a variable
number of parameters.
An optimal prediction function can be found by minimizing the
empirical risk,
f (X)∗ = min
f (X)
Remp ( f (X)) .
The selected loss function critically influences the result of empir-
ical risk minimization. The set of eligible loss functions depends
on the type of the prediction task. For example, squared-error loss,
L( f (X), Y) = (Y− f (X))2, is often used for regression, while classifi-
cation often uses the zero-one loss,
L( f (X), Y) =
1 if Y 6= f (X)0 else .
3.2.3 The Bias-Variance Decomposition
Minimizing the empirical risk is a useful tool for learning prediction
functions. In order to select the best possible prediction function,
however, the expected risk should be minimized over several choices
of training sets T . This idea gives rise to the notion of the expected
prediction error, which can be decomposed into a term describing
the squared bias and a term describing the variance of the prediction
model. For example, the mean squared error (MSE) that results
from the prediction ŷ0 of the outcome y0 at the test point x0 can be
decomposed as
MSE(x0) = ET [y0 − ŷ0]2
= σ2ε + ET [ŷ0 − ET (ŷ0)]2 + [ET (ŷ0)− y0]2
= σ2ε + VarT (ŷ0) + Bias
2(ŷ0) .
The first term in the final equation, σ2ε , is the irreducible error. This
quantity describes the variance of the target around the mean. The
remaining two terms depend on the prediction model, which should
yield an appropriate trade-off between variance and bias. Variance
describes the extent to which the predictions of a model would vary
given different training data. Non-parametric models are prone to
greater variance, while parametric models typically have low vari-
ance.9 Bias represents the systematic deviation of model predictions
from the true outcomes. Parametric models, which typically have
strong assumptions, often have greater bias than non-parametric
models, which typically have few assumptions. For example, using
logistic regression on nonlinear data would incur greater bias than
the use of support vector regression, which can handle nonlinearity,
given an appropriate kernel function.
Minimizing both bias and variance simultaneously is impossible
because these quantities have opposing trends. For example, flexible
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models (e.g. nonlinear models) have low bias (due to weak assump-
tions) but high variance (due to many parameters), while stiff models
(e.g. linear models) have high bias (due to strong assumptions) but
low variance (due to few parameters).
The type of model that should be considered for a specific super-
vised learning task critically depends on the amount of data and its
distribution. For example, models with low bias and high variance
are often appropriate when N  p because the large number of train-
ing samples N may reduce the variance of the model.10 In a scenario
where the distribution of the data follows a certain probabilistic dis-
tribution, a model with high bias and low variance may be suitable.
For example, a linear model would make few systematic errors when
the squared errors largely follow a normal distribution.
3.2.4 Training and Test Errors
Figure reproduced with permission from Springer Series in
Statistics (Hastie et al., 2009).
Figure 3.1: Relationship be-
tween training and test error.
Models that are too complex
allow for low training errors
at the cost of high test errors.
Models that are too simple
exhibit similar, albeit relatively
high test and training errors.
Predictive errors can occur either when training (fitting) a model
(training error) or when the model is validated on an independent
test set (test error). The training error is the mean loss over the








where f̂ (xi) = ŷi indicates the prediction for the i-th sample. Models
should never be selected based on the training error alone due to
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the optimism of the training error. The training error is optimistic
because it is typically lower than the error that would be observed
if the model were applied on another data set (Figure 3.1). Instead,
the generalization error (test error) should be used. Given a fixed
training set T and samples of X and Y that are drawn from the
population distribution, the test error is defined as the expected loss,
ErrT = E[L(Y, f̂ (X))|T] .
The generalization error is also called extra-sample error because
X and Y do not necessarily coincide with the observations that are
contained in the training set T. A related measure is the expected
prediction error,
Err = E[L(Y, f̂ (x))] = E[ErrT ] ,
which averages out the randomness of selecting a specific training set
T. Ideally, model selection should be performed using the test error
because supervised models are fitted using a single training set, T. If
the test error cannot be determined, the expected prediction error can
be used instead.
3.2.5 Estimating Model Errors
In order to select a model based on the performance on the training
data alone, the in-sample error can be used. This measure penalizes
model complexity in order to compensate for the optimism of the
training error. The extra-sample error (test error), on the other hand,
requires that the model is evaluated on a separate data set. In the
following paragraphs, I first introduce methods for estimating the
in-sample error and then describe methods for estimating the extra-
sample error.
Estimating the In-Sample Error
In the following paragraphs, I present two approaches for estimating
the in-sample prediction error, the Cp statistic and the Akaike infor-










i , f̂ (xi))|T] ,
where Y0 indicates the observation of new responses for each of the
training points xi with i = 1, . . . , N. The optimism is defined as the
difference between in-sample error and training error err:
op = Errin − err .
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The value of op is typically positive because err underestimates
the error. The average optimism is the expected optimism over the
training set outcomes,
ω = Ey(op) .








where Cov(ŷi, yi) = E[(ŷi − E(ŷi))(yi − E(yi))] indicates the covariance
between the estimates, ŷi, and the observed outcomes, yi. Thus, the
expected optimism decreases when the number of observations N
increases or when yi has little influence on the estimate ŷi. For linear




Cov(ŷi, yi) = dσ2ε ,
where σε is the standard deviation of the additive error in Y =
f (X) + ε. So, given a linear model, the fluctuation in the predictions is
governed by the variance of the additive error σ2ε and the number of
model features d.
Since the estimate of the in-sample error can be decomposed into
ˆErrin = err + ω̂ ,
the in-sample error can be estimated by the Cp statistic,




For log-likelihood loss functions, the AIC11 can be used to estimate
the in-sample error. It is based on the following relationship, which
holds when N → ∞:







Here, Prθ̂(Y) is a family of densities for Y and θ̂ indicates the maximum-
likelihood estimate of the distribution parameters θ. The maximized






For the logistic regression model, the AIC is defined as









Figure 3.2: Hold-out validation.
Train Train Train TrainTest
Fold 1 Fold 2 Fold 3 Fold 4 Fold 5
Figure 3.3: Cross validation for
k = 5.
TrainTrain Train TrainTest




Fold I1 Fold I2 Fold I3 Fold I4 Fold I5
Figure 3.4: Nested cross valida-
tion for k = 5.
Estimating the Extra-Sample Error
The extra-sample error is estimated by evaluating the model on
data that was not used for training the model. In the following, I
present two approaches for estimating the extra-sample error. The
first approach directly estimates the generalization error, while the
second approach estimates the expected prediction error.
Estimating the Generalization Error The generalization error can
be estimated using hold-out validation. This entails splitting the
data into three parts: a training set, a validation set, and a test set
(Figure 3.2). The training set is used to fit the models. The validation
set is used to select the parameters at which the models perform
best. Finally, the test set is used to estimate the generalization error
associated with the chosen models. The data are typically split such
that 50% of the observations are used for training, while 25% of
observations are used for validation and testing, respectively. The
reason why models are selected on the validation set and not on the
test set is to prevent optimistic estimates of the test error. By selecting
model parameters on the independent validation set, the measured
error on the test set resembles the generalization error more closely.
Hold-out validation is easily implemented and requires a smaller
runtime than cross validation, which is described later. However,
hold-out validation is problematic for small data sets for which the
random assignment of observations to training, validation, and test
sets may critically influence the estimated predictive performance.
This is particularly the case if specific subsets of data exhibit distinct
feature distributions, which may require sampling strategies such as
stratified sampling.
Estimating the Expected Prediction Error The expected prediction
error can be estimated using methods such as the bootstrap or cross
validation (CV). These methods are particularly useful when few
data are available, in which case the generalization error cannot be
estimated well. In the following, I limit myself to describing CV.
In k-fold cross validation the data set is split into k folds. The i-th
of k rounds of CV entails training a model using the samples con-
tained in all folds except for the i-th fold and then determining the
predictive performance by applying the model on the observations
of the i-th fold (Figure 3.3). Because the assignment of observations
to folds is a random process, the estimates of the expected prediction
error may vary across CV runs. To reduce the impact of randomness,
several runs of CV are typically performed, after which the obtained
errors are averaged.
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In order to incorporate model selection into CV, one can deter-
mine the in-sample error using the training data or perform nested
cross validation (NCV). In NCV, two interlaced runs of CV are per-
formed (Figure 3.4). One round of NCV entails the following steps.
Having selected an outer CV fold for testing (k = 1 in Figure 3.4), an
inner CV run is performed using the data from all other outer folds.
Based on the results from this inner CV run, the parameters maxi-
mizing the predictive performance are selected. Subsequently, the
prediction error for a single fold is determined by training a model
with the selected parameters using the current outer training folds
and evaluating it on the currently selected outer fold for testing. The
expected prediction error can be obtained once the errors across all
outer folds have been determined.
3.2.6 Limiting Model Complexity via Regularization
Models with many parameters can easily be overtrained (overfitted).
A model is said to be overtrained if it has learned the peculiarities
of the training data. Complex models are particularly prone to
overfitting in which case they suffer from high variance and do not
generalize well. Overtraining can be curbed through regularization.
Regularization involves penalizing the model coefficients with a
regularization parameter, λ, which controls model complexity. For
least-squares loss, coefficients β̂ can be regularized by setting




















q is the regularization term. The choice of q defines
which regularization method is used. For q = 0, the total number of
coefficients is penalized. Therefore, q = 0 corresponds to best subset
selection, which is described later. Setting q = 1 or q = 2, on the
other hand, corresponds to the shrinkage methods of Lasso and ridge
regression, respectively. The difference between the two methods is
that Lasso regression uses an L1-norm, while ridge regression uses
an L2-norm. The L1-norm that is used in Lasso regression ensures
that the coefficients of some coefficients become zero.
3.2.7 Feature Selection
There are two situations in which it is useful to select a subset of
the available features. On the one hand, features can be selected
for model selection. In this case, feature selection mainly serves as
a means of limiting model complexity. On the other hand, feature
selection can be performed after a model has been trained. This
allows for the interpretation of the most salient model features.
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Feature Selection for Model Selection While regularization regulates
model complexity at the time the model is fit, model complexity can
also be reduced using feature selection. Feature selection determines
a subset of features that yields the best tradeoff between model
complexity and predictive performance. Suitable quantities for this
purpose include the Cp statistic and the AIC. Best-subset selection
trains a model for all 2p subsets of features and then selects the
model maximizing the chosen performance measure. This approach
already becomes infeasible at small values of p. For example, for
p = 20, one would have to fit 220 = 1 048 576 models. However, using
the leaps-and-bounds algorithm12, best subset selection can still be
performed for p as large as 40.
Due to the infeasibility of best subset selection for data sets with
many features, greedy subset selection is often performed. Greedy
subset selection can be performed either in the form of forward-
stepwise selection or in the form of backward-stepwise selection.
Here, I limit myself to describing the backward-selection procedure
because the procedure for forward-stepwise selection is analogous.
In backward-stepwise selection, we start with a full model, that is, a
model fitted using all p features. In each step of the procedure, the
least predictive feature according to a specific criterion is eliminated.
One way of selecting the least predictive feature is to consider the
feature whose coefficient has the smallest absolute z-score. For a





where µ and σ are the mean and standard deviation of the normal
distribution from which β was drawn. Once the least important
feature has been removed, the model is refit and additional variables
are eliminated until all coefficients have z-scores above a threshold.
Feature Selection for Model Interpretation In order to interpret the
impact of features from a model that relies on many features, it is
useful to limit the analysis to the most important features of the
model. The importance of the i-th feature can be quantified using
the value of the i-th model coefficient, βi. Let B = ∑
p
i=1 |βi| denote
the sum of absolute feature weights. If we order the coefficients by
decreasing absolute value, we obtain β(1), . . . , β(p) with |β(i−1)| ≥
|β(i)|, ∀i ∈ {2, . . . , p}. We can select the ratio r ∈ [0, 1] of features
with the greatest absolute weight in the following way. Let Bcut = rB
indicate the cutoff on the total absolute model weight with respect to
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Prediction/Reference Class +1 Class -1
Class +1 TP FP
Class -1 FN TN
Table 3.1: Structure of the con-
fusion matrix resulting from
the predictions of a binary
classifier.
r. Then, we set







and interpret only the features associated with the coefficients
β(1), . . . , β(k). Typically only those features making up at least 50% of
the total absolute model weight are considered (i.e. r ≥ 0.5). How-
ever, the specific choice of r depends on the distribution of the model
weights, as this influences the number of selected features. The pre-
sented approach is particularly suitable for regularized models. This
is because L2 regularization leads to sparse models, which have many
coefficients whose value is zero.
3.3 Measures of Predictive Performance
Regression and classification give rise to distinct measures of pre-
dictive performance. Since the machine learning models that were
developed in this work perform binary classification, I only deal
with performance measures for this task in the following. For binary
classification, the confusion matrix (Section 3.3.1) can be used to de-
rive performance measures for non-scoring (Section 3.3.2) or scoring
classifiers (Section 3.3.3).
3.3.1 The Confusion Matrix
All quantities that describe the predictive performance of classifica-
tion models can be derived from the confusion matrix. For a binary
classification task with a positive class, +1, and a negative class, −1,
the confusion matrix is a 2× 2 matrix that indicates the number of
times that a classifier correctly predicted the positive and the negative
class, as well as the number of times that it confused the positive
with the negative class, and vice versa (Table 3.1). The confusion ma-
trix gives rise to four quantities: the number of true positives (TPs),
which indicates how often the positive class was correctly predicted;
the number of false positives (FPs), which indicates how often the
positive class was falsely predicted; the number of false negatives
(FNs), which indicates how often the negative class was falsely pre-
dicted; and the number of true negatives (TNs), which indicates how
often the negative class was correctly predicted.
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3.3.2 Performance Measures for Non-Scoring Classifiers
A non-scoring classifier computes estimates of the class labels via
ŷ ∈ G. For example, for the prediction of precipitation, a non-scoring
classifier such as k-nearest neighbors may output ŷ ∈ {No Rain, Rain}.
For a non-scoring classifier, it is useful to summarize the entries in
the confusion matrix that results from the application of the model.
In the following, I introduce the most important quantities that
can be obtained from the confusion matrix such as the accuracy or
sensitivity and specificity.
Accuracy Accuracy captures the overall predictive performance of a




TP + TN + FP + FN
.
Accuracy is in the range [0, 1]. Well-performing classifiers have accu-
racies close to 100%. Note that accuracy is ill-suited when the class
distribution is imbalanced. For example, imagine a scenario where
90% of the samples are from the negative class and only 10% are
from the positive class. In this case, we can easily construct a well-
performing classifier (accuracy of 90%) by assigning all samples to
the negative class. This showcases why it is useful to consider perfor-
mance measures that are appropriate when the class distribution is
imbalanced.
Sensitivity and Specificity Sensitivity and specificity are well-suited
when the distribution of class labels is imbalanced because sensitivity
represents the performance on the samples from the positive class,
while specificity represents the performance on the samples from the
negative class. These two quantities are defined in the following way:
sensitivity = TPR =
TP
TP + FN
= 1− FNR = 1− FN
FN + TP
specificity = TNR =
TN
TN + FP
= 1− FPR = 1− FP
FP + TN
Note that true positive rate (TPR) and true negative rate (TNR) are
synonyms for sensitivity and specificity, respectively. Moreover,
sensitivity and specificity correspond to one minus false negative rate
(FNR) and one minus false positive rate (FPR), respectively.
There are several ways in which sensitivity and specificity can
be summarized as a single quantity. One way is presented by the
balanced accuracy, which is the arithmetic mean of sensitivity and
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specificity. Another way of summarizing sensitivity and specificity is
Youden’s index, which is defined as Y = sensitivity + specificity− 1.
Additional Quantities Using the confusion matrix, we can define
additional useful quantities. Precision gives the fraction of positively
predicted samples that were correctly predicted. The false discovery
rate (FDR) indicates the fraction of positively labeled samples that
were falsely predicted. The negative predictive value (NPV) gives the
fraction of negatively predicted samples that were correctly predicted.
These quantities are formally defined as follows:









Note that precision and positive predictive value (PPV) are synony-
mous. When precision is used as a performance measure, sensitivity
is typically referred to as recall.
3.3.3 Performance Measures for Scoring Classifiers
A scoring classifier outputs numeric values (scores) that are asso-
ciated with the labels via ŷ ∈ R. To obtain estimates of the class
labels from a scoring classifier, it is necessary to define a cutoff that
separates the estimates for observations from the two classes. For
example, in support vector classifications (SVCs) No Rain would be
encoded as −1 and Rain as 1. If the classifier performs well, it will
predict negative values when it will not rain but positive values when
it will rain. However, the question is where the decision boundary
(cutoff) should lie. For example, is it better to classify observations
with scores ŷ > 0 as Rain or would the predictive performance be
higher if ŷ > 0.5 were required? To determine the quality of a scor-
ing classifier, it is useful to consider its performance across multiple
cutoffs.
To evaluate the predictive performance of a classifier across all
relevant cutoffs, the area under the receiver operating characteristic
curve (AUC) is frequently used13. The receiver operating character-
istic (ROC) curve plots sensitivity as a function of the FPR; the AUC
is simply the area under this curve. The AUC is in the range [0, 1].
Since a random classifier has an AUC of 0.5, the AUC is typically
greater than 0.5. A classifier that allows for the perfect separation
of the estimates for observations from two classes has an AUC of 1.
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AUCs below 0.5 typically do not occur as they only arise when the
class labels have been switched.
Figure 3.5: Example for the
AUC. Scores for the positive
class (70 samples) were drawn
from N (−1, 1), while those
from the negative class (30
samples) were drawn from
N (1, 1.25).
Figure 3.5 exemplifies the AUC. The left-hand side of the plot
shows the distribution of the classifier estimates. Evidently, the scores
allow for separating the samples from the two classes well. However,
since the separation is not perfect, the AUC, which is shown on the
right-hand side of the figure, is slightly below 1.
3.4 Models for Supervised Learning
A multitude of machine learning models for supervised learning is
available. In this work, two supervised models were used: logistic
regression and support vector machines (SVMs). Logistic regression
(Section 3.4.1) is a simple and interpretable approach for classifica-
tion. SVMs (Section 3.4.2) allow for models with varying levels of
complexity through the use of kernel functions and can be used for
both, classification and regression.
3.4.1 Logistic Regression
Logistic regression models the posterior probabilities of K classes via




Pr(Y = 1|X = x)




Pr(Y = 2|X = x)





Pr(Y = K− 1|X = x)
Pr(Y = K|X = x) = β(K−1)0 + β
T
K−1x
The probabilities of the individual classes can be obtained via
Pr(Y = k|X = x) =
exp(βk0 + βTk x)
1 + ∑K−1l=1 exp(βl0 + β
T
l x)
, ∀k ∈ {1 . . . , K− 1}
Pr(Y = K|X = x) = 1
1 + ∑K−1l=1 exp(βl0 + β
T
l x)
Logistic regression models are fit by maximizing the conditional like-






log pgi (xi; θ) ,
where pk(xi; θ) = Pr(Y = k|xi; θ). Assume that there are two classes
that are encoded by yi ∈ {0, 1}. Further, let p1(x; θ) = p(x; θ) and










yiβT − log(1 + eβ
T xi ) .
The parameters of the two-class logistic regression model, β, are
defined by β = {β10, β1}. The feature vector xi is assumed to contain
the constant term 1 for the intercept. The log-likelihood can be







xi(yi − p(xi; β)) = 0 .
The model coefficients can be determined by solving these score
equations using the Newton-Raphson algorithm.
3.4.2 Support Vector Machines
SVMs were introduced by Cortes and Vapnik (1995). They minimize
a vector of coefficients β to find a hyperplane that maximizes the
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Figure reproduced with permission from Springer Series in
Statistics (Hastie et al., 2009).
Figure 3.6: Hyperplanes of
SVMs. The left panel shows the
separable case. The right panel
shows the inseparable case
where the hyperplane was con-
structed using slack variables
ξ∗.
margin between observations from two classes whose observations












yi(xTi β + β0) ≥ (1− ξi)
ξi ≥ 0, ∀i .
Here, ||β|| indicates the L2-norm of the vector of coefficients, which




i . The outputs of the SVM decision
function are called decision values. A suitable function for the classifi-
cation of a new measurement x ∈ Rp based on the decision function
f̂ (x) = xT β̂ + β̂0
is given by
ĝ(x) =
1 if xT β̂ + β̂0 > 0−1 else .
In order to select a separating hyperplane for scenarios in which
observations are inseparable, the SVM relies on slack variables ξi ≥ 0
that indicate the extent to which the i-th observation lies within
the margin or on the wrong side of the margin (Figure 3.6). The
constraints guarantee that the estimate for xi agrees with the outcome
yi up to a slack of ξi. The user-defined regularization parameter C ≥
0 regulates the extent to which misclassifications are allowed. For
large C, the model is barely regularized as the hyperplane is adjusted
with the goal of preventing any form of misclassification (little slack).
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necessarily a support vector, that is, has
αi > 0.
16 Chen et al. 2005
17 Grid search determines a suitable
combination of model parameters
by empirically evaluating predictive
performance using a discrete set of
parameter combinations.
For low C, on the other hand, the model is more regularized because
misclassifications are rather tolerated (much slack).
By solving the dual optimization problem using Lagrange mul-







SVM models can be specified based solely on their eponymous
support vectors. If the observations from two classes are perfectly
separable, the support vectors are those feature vectors xi that lie
inside the margin of the optimal hyperplane. More generally, the
support vectors have αi > 0 and are sufficient for defining the
optimal decision hyperplane. Let S be the set containing the indices
of the support vectors. Then, the SVM decision function can be
formulated solely based on the support vectors via
f̂ (x) = xT β̂ + β̂0 = ∑
i∈S
α̂iyixTxi + β̂0 .
The ν-SVM formulation, which was introduced by Schölkopf et al.
(2000), uses ν ∈ [0, 1] rather than the regularization parameter C. The











subject to yi(xTi β + β0) ≥ ρ− ξi, ∀i = 1, . . . , N
with ξi ≥ 0, ρ ≥ 0
The parameter ν is an upper bound on the samples with ξi > 0 and
a lower bound on the fraction of support vectors.15 For example for
ν = 0.3, at most 30% of the training samples are either inside the
margin or on the wrong side of the hyperplane, while at least 30%
of samples are support vectors. Asymptotically, under certain condi-
tions16, ν equals both the fraction of support vectors and the fraction
of samples with ξi > 0. In practice, it is often more convenient to use
the ν-formulation of SVMs because it is easier to tune ν than C via
grid search17.
Support Vector Regression
The approach of SVMs can be applied to regression tasks through the
use of support vector regression (SVR). Similarly to SVMs, SVR also
uses the concept of a margin. Here, the margin is a consequence of
Vapnik’s ε-insensitive loss (Figure 3.7), which is defined by







Figure 3.7: The epsilon-
insensitive tube in support
vector regression. Slack vari-
ables ξ are associated with
observations that lie outside of
the ε-tube. Observations that
are located inside the ε-region
do not appear in the target
function.
The ε-insensitive loss curbs overfitting as it ensures that small ab-
solute prediction errors are permissible. The decision function of
linear SVR is f̂ (x) = xT β̂ + β̂0 where β̂ ∈ Rp is the vector of esti-
mated feature coefficients and β̂0 indicates the intercept. To estimate







|yi − f̂ (xi)|ε .
Here, C is a tuning parameter that determines the extent to which
prediction errors are penalized and β is L2-regularized.
To ensure that predictions are sufficiently close to the observed
outcomes a slack variable is introduced for each side of the ε-
insensitive region: ξ for cases with f (xi)− yi > ε and ξ∗ for those
observations with yi − f (xi) > ε. The collection of all slack variables
is referred to as ξ(∗). The introduction of slack variables leads to the











subject to f (xi)− yi ≤ ε + ξi
yi − f (xi) ≤ ε + ξ∗i
ξi, ξ∗i ≥ 0, ∀i = 1, . . . , N
Only observations i with ξi + ξ∗i > 0, that is, those observations lying
outside or on the border of the ε-region are relevant for the objective
function. The subset of these observations that is characterized by
nonvanishing coefficients gives rise to the support vectors of SVR.
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The SVR optimization problem is solved by introducing Lagrange

















(α∗i − αi)(α∗j − αj)xTi xj





(αi − α∗i ) = 0.
The regression estimate takes the form
f̂ (x) = ∑
i∈S
(α̂∗i − α̂i)xTi x + β̂0.
This formulation of SVR is called ε-SVR because the model is speci-
fied in terms of the hyperparameter ε. In ν-SVR, the following primal









|yi − f (xi)|ε
)
.
Here, ε ≥ 0 is considered as a parameter over which one minimizes
and its value is implicitly determined by the choice of ν. The in-
terpretation of the hyperparameter ν is the same as for SVMs for
classification: ν is an upper bound on the fraction of points allowed
outside the ε-tube and a lower bound on the fraction of support vec-
tors18. For example, with ν = 0.3, at least 30% of the training samples
are support vectors and at most 30% of samples lie outside the ε
region.
Until now, we have only dealt with SVMs that model linear rela-
tionships via dot products. In the following, I will introduce kernel
functions, one of the main assets of SVMs.
Kernel Functions
In many prediction scenarios, there exist higher-order interactions be-
tween features, which cannot be captured by linear models. To deal
with such prediction settings, feature vectors xi, xj can be implicitly
mapped into another space through kernel functions K(xi, xj). Kernel
functions represent the inner product of two observations xi and xj
that are mapped to reproducing kernel Hilbert space via a mapping
function, Φ:
K(xi, xj) = Φ(xi)TΦ(xj).
92
Kernel functions must be continuous, symmetric, and must result in
a positive-semidefinite matrix19 K with entries Kij = K(xi, xj). The
requirement that kernel functions are positive-semidefinite ensures
that the SVM optimization problem is convex.
The technique of replacing the dot product in the SVM formula-
tion with a kernel function is called the kernel trick. Applying the
kernel trick to the SVM estimates yields
f̂ (x) = ∑
i∈S
α̂iyiK(x, xi) + β̂0 .
Applying the kernel trick to the SVR estimate results in
f̂ (x) = ∑
i∈S
(α̂∗i − α̂i)K(x, xi) + β̂0.
Note that linear SVMs, which are based on dot products, have to fit
merely p + 1 parameters. The use of kernel functions that act on pairs
of observations means that nonlinear SVMs have inputs on the scale
of N. Therefore, linear SVMs are considered as a parametric method,
while nonlinear SVMs are considered as a nonparametric method.
The SVM decision function can still be computed quickly because it
only involves the evaluation of |S| kernel functions.
In the following, I present several relevant kernel functions.
Linear Kernel The linear (vanilla) kernel,
K(x, x′) = xTx′ ,
is defined by a conventional dot product. The linear kernel is suitable
for data that has a linear relationship with the outcome.
Polynomial Kernel The polynomial kernel,
K(x, x′) = (sxTx′ + o)d ,
takes the d-th power of the dot product. In this way, interactions
between up to d features can be modeled. Further adjustment of the
kernel is possible by tuning the offset o and the scalar s.
Gaussian Radial Basis Function Kernel The Gaussian radial basis
function (RBF) is defined by
K(x, x′) = exp(−σ||x− x′||2) .
It is dependent on a parameter σ that determines the width of the
Gaussian. For small values of σ, the RBF kernel has a narrow but












































































Figure 3.8: K-means clustering
of artificial data with K = 3.
The three clusters are indicated
by distinct colors.
Edit Kernel Edit kernels provide a means for determining the simi-
larity between observations representing nucleotide sequences20. The
edit kernel function is defined as
K(x, x′) = exp(−γ× edit(x, x′))
where edit(x, x′) indicates the edit distance between x and x′. The
positive parameter γ ∈ R scales the kernel value and ensures nu-
merical stability. The edit function represents the genetic distance
between two sequences. It can be defined by considering Pr(x′i |xi),
the probability of observing mutation x′i given xi:
edit(x, x′) = −∑
i
log Pr(x′i |xi) .
For modeling Pr(x′i |xi), matrices indicating the rate of amino-acid
substitutions such as the PAM matrix21 can be used.
3.5 Clustering
Clustering is a form of unsupervised learning that is concerned with
the assignment of unlabeled data points into groups. In the following
sections, I introduce two clustering methods that were employed
in this work: K-means (Section 3.5.1) and hierarchical clustering
(Section 3.5.2).
3.5.1 K-Means Clustering
K-means clustering groups observations into K clusters (Figure 3.8)
by iteratively adjusting the K cluster centers with the goal of mini-
mizing the total within-cluster variance. After fixing an initial set of
clustering centers randomly, K-means alternates the following two
steps:
1. For each cluster center, determine which observations belong to
the cluster. For this purpose, all points that are closer to this center
than to any other center are selected.
2. For every cluster, determine a new clustering center by computing
the mean of each feature from the observations belonging to the
cluster.
These two steps are iterated until the procedure converges, that is,
when the assignment of observations to clusters does not change
anymore. The formal motivation for this procedure is provided in the
following paragraphs.
The quality of a K-means cluster assignment, C, is described by the





























Figure 3.9: The elbow test for
finding an appropriate number
of clusters. Using the artificial
data shown in Figure 3.8, the
elbow test has identified the
highlighted point at K = 3 as a
suitable number of clusters.
to which observations assigned to the same cluster tend to be close to









||xi − xk||2 .
The mean vector associated with the observations of the k-th cluster
is indicated by xk = (x1k, . . . , xpk) and Nk = ∑Ni=1 I(C(i) = k) denotes
the number of observations in cluster k.
In order to find a cluster assignment, C∗, minimizing the scatter,
W(C), it is useful to note that the mean of any set of observations S
fulfills
xS = arg minm ∑
i∈S
||xi −m||2 .










Using this formulation, it is possible to solve the problem using the
previously described algorithm, which iteratively sets the current
clustering means to mk.
There are several drawbacks to K-means clustering. One draw-
back is the definition of cluster scatter according to variance, which
enforces the assumption that clusters consist of observations that
spherically scatter around a mean. Thus, K-means is unsuited for
non-spherical clusters. Another problem is that the optimization pro-
cedure of K-means may become stuck in a local optimum, which can
lead to misleading cluster assignments. The final shortcoming of K-
means is that K has to be specified a priori. Quantitative methods for
selecting K are based on analyzing the within-cluster dissimilarity Wk
for several number of clusters k = {1, . . . , Kmax}. Since Wk decreases
with increasing k, it is not feasible to simply select the value of k
minimizing Wk. Instead, the change of Wk for consecutive values of k
needs to be considered. The intuition behind this approach becomes
clear if we assume that the data is actually grouped into K∗ clusters.
Then, as long as k < K∗, we have Wk+1  Wk because an increased
number of observations will be assigned to their natural clusters. But
when k ≥ K∗, additional, artificial clusters are generated such that
Wk+1 will only be marginally smaller than Wk. A reasonable value for
k can be obtained by plotting Wk against k and applying the elbow
test, which selects the value of k above which Wk is merely being
reduced marginally (Figure 3.9).
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Figure reproduced with permission from Springer Series in
Statistics (Hastie et al., 2009).
Figure 3.10: Hierarchical clus-
tering. Comparison of dendro-
grams resulting from perform-
ing hierarchical clustering on




Hierarchical clustering does not require the prior definition of the
number of clusters but requires a definition for the dissimilarity
between observations in different groups instead. Hierarchical clus-
tering provides a ranked representation of the data as clusters at one
level of the hierarchy are constructed by merging clusters from the
next lower level. At the lowest level, clusters are singletons consist-
ing of individual observations. At the highest level, there is a single
cluster comprising all data. Since hierarchical clustering enforces a
hierarchical structure even if none is present in the data, it should be
applied only if such a structure can be presumed.
There are two strategies for hierarchical clustering: agglomerative
(bottom-up) and divisive (top-down) clustering. In the following, I
describe the agglomerative strategy in more detail. Agglomerative
strategies start with singletons and, at every level, merge the two clus-
ters with the smallest intergroup dissimilarity into a single cluster.
The resulting grouping at the next higher level of the hierarchy thus
consists of one cluster less than before.
The popularity of hierarchical clustering is due to the fact that
recursive binary agglomeration can be represented by a rooted binary
tree. Since the dissimilarity between merged clusters is monotone
increasing when an agglomerative approach is used, the binary tree
can be visualized by setting the height of nodes according to the
intergroup dissimilarity between its children. The leaves of the tree
are plotted at height zero. This method of plotting a hierarchical
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clustering is called a dendrogram.
There are several variants of agglomerative clustering, which are
characterized by their definition of dissimilarity between groups of
observations. Given two groups of observations G and H, the dis-
similarity d(G, H) is determined from all pairwise dissimilarities dii′
where i ∈ G and i′ ∈ H. In contrast to K-means, hierarchical clus-
tering also allows the use of dissimilarity metrics dii′ other than the
Euclidean distance. There are three main approaches for determining
intergroup dissimilarities, which are presented in the following.
Single linkage (SL) agglomerative clustering merely considers the
dissimilarity of the least dissimilar pair via




The complete linkage (CL) approach is the opposite as it defines the
intergroup dissimilarity according to the most dissimilar pair, by
setting




Another agglomerative clustering method is group average (GA)
clustering, which defines the intergroup dissimilarity by taking the









Exemplary results for the three agglomerative clustering strategies
are shown in Figure 3.10. The figure demonstrates that SL clustering
can lead to series of clusters in which a cluster is expanded by similar
individual observations. This effect is called chaining. CL clustering
does not suffer from this phenomenon as it ensures that the maximal
dissimilarity between points in a cluster is small. At the same time,
however, members assigned to a cluster may be closer to members
of another cluster than to some members of their own cluster. GA
clustering is a compromise between SL and CL clustering. Its dis-
advantage is that it is not invariant to monotone strictly increasing
transformations on the dissimilarities.
3.6 Statistical Significance Tests
Significance tests are used to identify whether an observed effect was
due to chance or whether the effect truly exists. Significance tests are
crucial for the analysis of data because these tests take the sample
size into account. Assume two classifiers are evaluated on a data set
consisting of ten samples. One classifier obtains an accuracy of 70%,
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while the other classifier obtains an accuracy of 80%. Although the
performance difference of 10% may suggest that the second classifier
performs considerably better than the first, it actually classifies only
a single additional sample correctly. Therefore, the performance
difference is probably not significant.
In Section 3.6.1, I introduce the fundamentals of hypothesis testing.
Since different tests are appropriate for different tasks, I discuss three
statistical tests : McNemar’s test (Section 3.6.2), Fisher’s exact test
(Section 3.6.3), and Wilcoxon rank-sum test (Section 3.6.4). Finally,
I offer two techniques that correct for multiple hypothesis testing
(Section 3.6.5).
3.6.1 Introduction to Hypothesis Testing
Statistical significance tests aim at quantifying the likelihood that a
certain effect was merely observed by chance. This quantity, called
the p-value, answers the following question: What is the probability,
under the null hypothesis, that an observation at least as extreme
as the current observation is made? The result of a hypothesis test
is considered significant when the p-value is below a prespecified
significance threshold α. Commonly, a significance threshold at
α = 5%, is used.22
Each significance test considers two hypotheses. Typically, the null
hypothesis, H0, represents the absence of an effect (e.g. no difference
in group means), while the alternative hypothesis, Ha, represents the
presence of an effect (e.g. a difference in group means). A statistical
hypothesis test identifies which of the two alternatives is more likely
by calculating a decision value, x, on which basis the p-value is com-
puted. For a one-tailed test, the p-value represents the probability of
observing a decision value that is either larger or smaller than x. Let
X indicate the random variable associated with the decision value x.
Then, a right-tailed test computes the p-value as Pr(X ≥ x|H0), while
a left-tailed test uses Pr(X ≤ x|H0). For a two-tailed test, both tails of
the decision value distribution are considered. The p-value is there-
fore two times larger than the p-value of a single-tailed test, namely
2 min (Pr(X ≤ x|H0), Pr(X ≥ x|H)). When the p-value is smaller than
the significance level, the result is significant and the null hypothesis
can be rejected. This suggests that the alternative hypothesis is a
more suitable hypothesis given the data at hand. If, however, the
p-value is greater or equal to the significance level, the result is not
significant and one has failed to reject the null hypothesis.
Different types of statistical tests are characterized by the use of
distinct techniques for the calculation of decision values. There are
two classes of significance tests: parametric and non-parametric tests.
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Classifier 2 Correct Classifier 2 Incorrect Row total
Classifier 1 Correct a b a + b
Classifier 1 Incorrect c d c + d
Column total a + c b + d n
Table 3.2: Structure of a contin-
gency table. The row totals as
well as the column totals are
also called the margin totals.
23 The statistical power of a significance
test denotes its sensitivity, that is,
whether the test will reject the null
hypothesis if the alternative hypothesis
is true. A study is said to be well
powered if statistical testing will most




26 The test statistic of McNemar’s test
is denoted by χ2 because it follows a
chi-squared distribution.
27 The test is exact because its false
rejection rate exactly matches the
specified significance level.
Parametric tests assume that the data follow a specific distribution
(mostly the Gaussian distribution), while non-parametric tests do
not make such assumptions. Although parametric tests allow for
greater statistical power23 when their assumptions are met, they can
be rendered invalid if the test assumptions are not fulfilled24. In the
following, I describe three non-parametric tests: McNemar’s test,
Fisher’s exact test, and Wilcoxon rank-sum test.
3.6.2 McNemar’s Test
McNemar’s test25 is a non-parametric method for testing the symme-
try (marginal homogeneity) of entries in a 2 × 2 contingency table
that was constructed from pairwise measurements pertaining to two
groups. The test relies on identifying whether there exists a differ-
ence in the distribution of the marginal frequencies associated with
the measurements from the two groups. In this work, I used McNe-
mar’s test to compare the predictive performance of two classifiers.
Therefore, I will use the classification terminology in the following.
To construct a 2× 2 contingency table for two classifiers (Table 3.2),
we simply calculate a, the number of cases in which both classifiers
were correct; d, the number of cases in which both classifiers were
incorrect; b, the number of cases where the first classifier was correct
and the second classifier was incorrect; and c, the number of cases
in which the first classifier was incorrect and the second classifier
was correct. Let pa, pb, pc, and pd indicate the probabilities of the
outcomes shown in Table 3.2. The test’s null hypothesis assumes
that both classifiers have the same ratios of correct and incorrect
predictions, in which case we have pa + pb = pa + pc and pc +
pd = pb + pd. Hence, the null hypothesis of the test is defined as
H0 : pb = pc, while the alternative hypothesis is Ha : pb 6= pc. The
test statistic26, χ2 = (b−c)
2
b+c , can be rejected when the test statistic is
significantly extreme, which would suggest that the tested classifiers
exhibit substantially different predictive performances.
3.6.3 Fisher’s Exact Test
Fisher’s exact test27 is a non-parametric method for testing whether
the frequencies of measurements from two groups are independent
of each other. The test is typically applied on 2 × 2 contingency
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as extreme if its probability is less or
equal to the observed probability of the
table.
29 The rank of an observation is the
one-based index of that observation in a
list of increasing order.
30 The formulas are based on the
famous rule by Gauss according to
which ∑ni=1 i =
n(n+1)
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matrices. Given a contingency table with the structure indicated in







the probability of observing a certain contingency table. The p-
value is determined as the sum of probabilities from all contingency
tables with the same margin totals that are at least as extreme as the
observed table.28 Since the factorials can become very large when
computing the p-value, Fisher’s exact test may not be applicable for
large sample sizes. The effect size associated with Fisher’s exact test








Fisher’s exact test is usually performed to identify whether the odds
ratio differs from 1.
3.6.4 Wilcoxon Rank-Sum Test
Wilcoxon rank-sum test is a non-parametric method that evaluates
whether the measurements from two groups have distinct orderings.
The test can be performed in the following, procedural manner.
After pooling the measurements from both groups, we determine
the rank of each observation29. For identical values, the arithmetic
means of the unadjusted ranks are used. Next, we sum the ranks of
observations from the first and the second group, obtaining R1 and
R2, respectively. In the final step, the ordering of values from the first
group is evaluated using




while the ordering of values from the second group is determined as




The variables n1 and n2 in these formulas correspond to the number
of samples from the first and the second group, respectively.30 Then,
the test statistic is calculated as U = min(U1, U2).
3.6.5 Multiple Hypothesis Testing
The multiple hypothesis testing problem is concerned with the
increased number of false positives that ensues when several hy-
potheses are tested on a single data set. To ensure that the number
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31 A family of hypothesis tests arises
when several tests are performed on
different subsets of the same data set.
For example, to determine whether HIV
viral loads are different for patients
that are infected with different HIV
subtypes, one might first compare
patients infected with subtype A to
those infected with subtype B and then
compare patients infected with subtype
C to those infected with subtype B. In
this case, two hypothesis tests were
performed.
32 Nakagawa 2004
of false positive test results is controlled, approaches that correct for
multiple comparisons are used. Two frequently used methods for this
task are Bonferroni correction and the Benjamini-Hochberg method.
For discussing these methods, let us assume that we have performed
m hypothesis tests. Then, we need to consider a family of hypothesis
tests31, H1, . . . , Hm, with p-values p1, . . . , pm. Further, let m0 indicate
the number of null hypotheses that are correct (i.e. the number of
null hypotheses that should not be rejected).
Bonferroni Correction Bonferroni correction adjusts the significance
level, α, according to the number of tests, m > 1, that are performed.
The adjusted significance level is defined as αadj = αm . The null
hypothesis of the i-th test is rejected if its p-value fulfills pi ≤ αadj.
By setting αadj in the specified manner, Bonferroni correction









and indicates the probability that at least one null hypothesis is
falsely rejected. Bonferroni correction can be derived from Boole’s
inequality. The inequality states that, given a countable set of events
E1, E2, . . ., the probability that at least one event happens is less or









By applying Boole’s inequality to the definition of the FWER, we can






















Bonferroni correction is a conservative method to correct for multiple
testing because it controls the FWER. On the one hand, this is an
advantage, because it reduces the number of false alarms. On the
other hand, this is a disadvantage because Bonferroni correction may
also considerably reduce the statistical power of the tests that are
performed32.
The Benjamini-Hochberg Procedure The approach from Benjamini-
Hochberg is a method for controlling the FDR at a significance level
α. The approach can be implemented in two steps. First, we order
all p-values in ascending fashion and denote them by p(1), . . . , p(m).
Second, we determine k = arg maxi p(i) : p(i) ≤ im α and define
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Figure 3.11: Representation
of a linear program with two
variables and six inequalities.
The 2-dimensional polytope
indicates the set of feasible
solutions. The cost function
is shown by the red line and
the direction of optimization is
shown by the black arrow.
Retrieved from Wikipedia, licensed
under CC0 1.0 Universal Public Domain
Dedication.
the adjusted p-value as αadj = p(k). The i-th null hypothesis is then
rejected if pi ≤ αadj. The Benjamini-Hochberg procedure is valid
when the m tests are independent. For a proof why the Benjamini-
Hochberg procedure controls the FDR, I refer to Benjamini and
Hochberg (1995).
Compared to Bonferroni correction, the use of the Benjamini-
Hochberg procedure allows for greater statistical power at the price
of a larger number of false discoveries. This is because the FDR
denotes the fraction of false positive tests among all positive tests,
while the FWER is the probability that any of the m tests yields
a false positive result. To illustrate the two concepts, consider a
situation where both the FWER and the FDR are at 5%. An FWER
at 5% merely states that the probability of at least one false positive
result is at 5%. On the other hand, when the FDR is at 5%, this
means that 5% of all positive tests are expected to be false positives.
When 100 statistical tests are performed, we would expect five false
positives at an FDR of 5%. However, with an FWER at 5%, it is
unlikely that any of the tests are false positives.
3.7 Optimization with Linear Programs
Mathematical optimization is concerned with the determination of
solutions to maximization or minimization problems. Optimization is
pervasive in machine learning. For example, quadratic programming
is used to solve the SVM optimization problem that I introduced
in Section 3.4.2, while logistic regression models (Section 3.4.1) are
fitted using gradient descent. In this dissertation, I used integer
linear programs (ILPs) to solve an instance of the set cover problem
(SCP) for multiplex primer design. After an introduction to linear
and integer linear programming (Section 3.7.1), I present the branch-
and-bound algorithm to solving ILPs in Section 3.7.2. The set cover
problem is introduced in Section 3.7.3.
3.7.1 Linear and Integer Linear Programming
Linear programming involves the optimization of a linear objective
function subject to linear constraints. The feasible region of a linear
program is a convex polytope, which is determined by the intersec-
tion of finitely many half spaces that are each defined by a linear
inequality. Linear programming algorithms find points within the
polytope where the objective function assumes an extreme (minimum
or maximum) value (Figure 3.11). Note that, in the context of this the-
sis, the terms maximum and minimum refer to the global maximum
and minimum, respectively, while the terms maximal and minimal
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refer to local maximum and minimum, respectively.
In their canonical form, linear programs are defined as
minimize cTx
subject to Ax ≤ b
with x ≥ 0
where x is the vector of variables that is to be determined. The vector
c provides the coefficients of the variables. The vector b determines
the inequalities associated with the constraint matrix A. The inequal-
ities Ax ≤ b and x ≥ 0 are the constraints that define the set of
feasible solutions.
Linear programs are often solved using the Simplex algorithm.
The idea of the algorithm is to generate a feasible solution at a vertex
of the polytope and to move along the edges to vertices with non-
decreasing objective functions until the optimum is found. The
Simplex algorithm does not guarantee an optimal solution for ILPs,
in which all variables are required to be integer.33
3.7.2 Branch and Bound
Branch and bound is an algorithmic approach for solving combinato-
rial optimization problems. Branch-and-bound algorithms enumerate
candidate solutions using a state space search. The set of candidate
solutions forms a rooted tree where the root represents the full set of
solutions, while branches represent solution subsets. Before entering
a branch, estimates for the lower and upper bounds of the optimal
solution are determined. Branches that cannot improve the currently
best solution according to the estimates are discarded. The main
challenge of implementing a branch and bound algorithm is the re-
quirement of heuristics for computing lower and upper bounds. The
worst-case runtime of branch-and-bound algorithms is exponential.
3.7.3 The Set Cover Problem
The SCP is an NP-complete combinatorial optimization problem that
can be used for formulating the primer design problem that is solved
in this work. Given a universe U and a family S of subsets of U , the
SCP is concerned with finding a minimal subfamily C ⊆ S whose
union is U . The problem can be formulated as an ILP by defining
decision variables xS ∈ {0, 1} ∀S ∈ S , which indicate whether the
set S is selected (xS = 1) or not (xS = 0). The optimal assignment of









xS ≥ 1 ∀e ∈ U
Minimizing the target function ensures that we find the smallest
combination of sets among all combinations whose union equals the
universe.
The SCP can also be approximated in polynomial time using a
greedy algorithm that selects the set cover with the largest number of
uncovered elements at every step. Given a set with n elements that
are to be covered, this algorithm achieves an approximation ratio that








This means that the set cover obtained from a greedy algorithm is at




The following chapters describe the original scientific contributions of
this dissertation. geno2pheno[ngs-freq] performs drug resistance
testing using next-generation sequencing data (Chapter 4), while
geno2pheno[coreceptor-hiv] determines HIV-2 coreceptor usage
(Chapter 5). Both systems support the personalization of antiviral
treatments. The approach of openPrimeR, which is presented in
Chapter 6, enables the design of primers for multiplex polymerase
chain reaction. Using the approach, the isolation of broadly
neutralizing antibodies against HIV-1 can be supported. The
statistical model presented in Chapter 7 can assist primer design
through the identification of polymerse chain reaction amplification
events.

We need to proactively
address the rising levels of
resistance to HIV drugs if we
are to achieve the global target
of ending AIDS by 2030.
WHO director general Tedros
Ghebreyesus, 2017
4
Interpreting Drug Resistance from
Next-Generation Sequencing Data
In this chapter, I introduce geno2pheno[ngs-freq], a web server for iden-
tifying drug resistance from HIV-1 or HCV samples that were processed
using next-generation sequencing. I have conceptualized, prototyped, and
implemented the web server. Alejandro Pironti and Achim Büch have
developed the framework on whose basis geno2pheno[ngs-freq] was devel-
oped. Additionally, Achim Büch provided technical assistance during the
development. Georg Friedrich implemented the core components of the
web frontend of geno2pheno[ngs-freq], which were further refined by me.
Prabhav Kalaghatgi provided an initial, stand-alone implementation of the
geno2pheno[hcv] interpretation system, which I integrated into the web
service. Martin Däumer and Alexander Thielen developed the frequency file
format that is used by the server and provided their technical expertise on
next-generation sequencing of viral populations. Elena Knops, Eva Heger,
Martin Obermeier, and Rolf Kaiser supported the development process with
their expertise in viral diagnostics and performed extensive validations. The
project was initiated and supervised by Thomas Lengauer and Nico Pfeifer.
The content of this chapter expands upon the publication by Döring et al.
(2018) in two regards. First, an overview of genotypic resistance testing
is provided. Second, the description of the methodology was updated and
extended.
Drug resistance mutations can emerge rapidly in individuals
infected with pathogens such as HIV-1 or HCV. In order to select
effective combinations of antiviral drugs against HIV-1 (Section 2.3.6)
and HCV (Section 2.4.5), genotypic resistance tests can be used.
These tests consist of two steps: sequencing the relevant segments of
the viral genome followed by the interpretation of drug resistance
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based on the amino-acid sequence of the viral proteins that are drug
targets1. Sanger sequencing (Section 2.5.3) is unable to detect minor-
ity variants because it can only detect viral variants that comprise
at least 10%–20% of the total viral RNA in the sample2. The more
recently developed NGS, on the other hand, can detect treatment-
relevant variants that are present at low abundances3. Thus, NGS has
recently become more commonly used for drug resistance testing.
To date, few web services for the interpretation of NGS data with
respect to drug resistance are available4. These services typically rely
on the raw sequencing data resulting from subjecting a viral sample
to NGS, for example, in terms of a FASTQ file. After a sample has
been uploaded, the processing pipelines of these services perform
the following tasks: (1.) Reads are trimmed in order to remove low-
quality positions; (2.) reads are mapped5 to a reference sequence;
(3.) the abundance of mutations is quantified independently for each
aligned position; and (4.) resistance is inferred. While web services
that interpret Sanger sequences provide near-instant responses to a
query, web services relying on NGS data such as HyDRa or PASeq
perform more time-intensive computations and notify users via
email when the results are available. These services also support only
rules-based interpretations.
The goal of the work presented in this chapter was the develop-
ment of a web server for determining HIV-1 and HCV resistance
based on NGS data. Initially, the server was intended to offer a
new prediction model for HIV-1 on the basis of NGS reads. Due to
a lack of clinical data this intention became infeasible. Therefore,
the decision was made to rely on the well-established methods of
geno2pheno[resistance]6 and geno2pheno[hcv]7. Since these ap-
proaches are based on Sanger sequences, it was no longer necessary
to require the raw NGS data. Thus, we chose to develop a web ser-
vice that predicts drug resistance on the basis of already processed
NGS data, which are converted to an appropriate representation for
the use of established approaches for Sanger sequences.
The structure of this chapter is as follows. Section 4.1 introduces
the genotypic methods that are used by geno2pheno[ngs-freq] and
summarizes available interpretation systems based on NGS. In
Section 4.2, the approach of geno2pheno[ngs-freq] is delineated.
Section 4.3 exemplifies the usefulness of the web service in two
case studies. The chapter concludes with Section 4.4, in which the
approach of geno2pheno[ngs-freq] is critically discussed.
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4.1 Genotypic Resistance Testing
Genotypic resistance tests analyze viral genomic sequences with
respect to drug resistance mutations. These approaches are cheap,
can be performed quickly, and correlate well with results from phe-
notypic drug resistance tests. After introducing genotypic resistance
tests in Section 4.1.1, I describe geno2pheno[resistance] (Section 4.1.2)
and geno2pheno[hcv] (Section 4.1.3). This section concludes with an
overview of the processing steps required for performing resistance
tests based on NGS data (Section 4.1.4).
4.1.1 Overview
Genotypic resistance testing is based on sequencing the viral genomic
regions of interest and subsequently analyzing their translated amino-
acid sequences8. The critical advantage of genotypic approaches over
phenotypic methods (Section 2.5.2) is that genotypic approaches do
not require any wet lab work except for sequencing, which is fast
and cheap. Once the sequencing results are available, the remainder
of the work is done in silico. Since genotypic approaches are not
only less intensive with regard to cost and time than phenotypic
approaches but also offer advantages in clinical applications9, they
have become the standard of care for determining drug resistance for
viruses such as HIV10.
Clinical testing of HIV drug resistance is based on viral RNA
extracted from patient plasma. Only if resistance tests based on
plasma RNA cannot be performed due to low VLs (e.g. < 400 copies
per mL), is proviral DNA used as a substitute. Results from tests
based on proviral DNA may not agree with those from plasma RNA
for three reasons: (1.) proviral DNA may reflect non-replicating
proviruses; (2). the negative predictive value of proviral DNA is low
because PBMCs do not reflect the entirety of immune cells infected
by HIV11; (3). proviral DNA may be mutated by APOBEC12.
Genotypic tests overcome two shortcomings of phenotypic tests
in clinical applications. First, phenotypic tests are not capable of
detecting emerging resistance. This means that phenotypic tests
may classify an isolate as susceptible although it contains mutations
that lead to the emergence of resistance in the near future13. These
associations can be taken into account by genotypic tests. Second,
phenotypic tests lack sensitivity when they are applied to clinical
samples representing heterogenous viral populations14. For exam-
ple, consider a viral population in which 80% of the population are
susceptible to a drug and 20% of the population carries resistance
mutations. Then, the experimentally determined IC50 may only be
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marginally higher than the wild-type IC50, although this viral popu-
lation carries resistant strains. Due to the low RF, a phenotypic test
may fail to detect resistance in such a sample. Genotypic methods, on
the other hand, can consider the impact of variants at any abundance.
Several studies have shown that genotypic methods and pheno-
typic methods exhibit high concordances15. A perfect correlation
between genotypic and phenotypic methods, however, should not
be expected for the following reasons16. First, phenotypic tests are
subject to a certain degree of technical variation17. Second, most
genotypic tests do not model phenotypic resistance (in vitro resis-
tance) but rather the impact of amino-acid mutations on treatment
outcomes (in vivo resistance). Since in vivo resistance implicitly con-
siders the influence of viral fitness18, drug metabolism19, and likely
evolutionary trajectories20, apparent differences between genotypic
and phenotypic tests may simply reflect the diverging orientations of
the tests.
The main challenge of genotypic resistance testing lies in interpret-
ing the viral sequence with respect to drug resistance. Rules-based
interpretation systems rely on the identification of individual muta-
tions in order to estimate the clinical impact of resistance mutations.
Rules-based systems are easy to interpret and are nevertheless ca-
pable of modeling relationships with varying degrees of complexity.
For example, a simple rule is given by If M184V is present in RT of an
HIV-1 strain, then it exhibits intermediate resistance to FTC, while the
following rule is more intricate: If M46I, I54V, and V82A are present in
PR of an HIV-1 strain, then it is resistant to IDV21.
The sets of rules that are applied by rules-based system are cu-
rated by panels of experts that scrutinize available clinical and
phenotypic data. The spectrum of expert opinions has given rise
to several sets of rules for interpreting HIV-1 drug resistance, for
example, the rule sets from ANRS, HIVdb22, HIV-GRADE, and the
Rega institute.23 Rules-based systems typically provide only categor-
ical estimates of resistance according to the SIR scheme24. Among
rules-based engines, HIVdb is the only system that also provides
a quantitative output, which is determined by assigning resistance
scores to individual mutations and summing them up25.
Statistical interpretation engines are principally based on the same
data that is available to the expert panels. They, however, interpret re-
sistance using statistical models that are generated via machine learn-
ing algorithms. While human experts structure information on drug
resistance in terms of rules, statistical models afforded by machine
learning algorithms enable more intricate forms of knowledge repre-
sentation. Statistical approaches differ among each other with respect
to the applied machine learning algorithms and the data sets that are
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used for training the models. For example, geno2pheno[resistance]26
uses support vector regression and classification, while the more
recent SHIVA software27 employs random forests. An advantage of
statistical interpretation systems is that they are not influenced by
human biases. For example, expert panels could put greater weight
on studies that were published in journals that are considered more
influential while disregarding articles published in less respectable
journals. Although machine learning models are limited by the as-
sumptions of the model and influenced by the possible biases in the
composition of the training data, these problems can be avoided by
judiciously selecting the model and the training data. Beyond this,
there are even problem-specific methods for debiasing the learning
process28 and techniques for analyzing fitted models with respect
to their biases29. Human biases, on the other hand, can neither be
corrected for nor identified so easily. Thus, statistical methods afford
rationally determined, quantitative estimates of resistance levels.
Albeit methodologically distinct, rules-based and statistical meth-
ods are not completely independent from one another. Statistical
engines have generated novel insights that were later incorporated
into rules-based systems. For example, the HIV-GRADE engine was
not only informed by expert knowledge but also by information en-
coded in the model of geno2pheno[resistance]30, which is described
in the next section.
4.1.2 geno2pheno[resistance]: A Statistical Resistance Interpretation
System
geno2pheno[resistance] is a statistical genotypic resistance testing
system for Sanger sequences from HIV-1. At the heart of the tool
are two types of predictive models. While the original model of
geno2pheno[resistance] estimates phenotypic RFs31, the recently
developed drug-exposure model uses clinical data to estimate a quan-
tity that is correlated with the exposure to a drug32. Both models
output estimates in terms of z-scores, which indicate the number of
standard deviations that an estimate is above or below the mean of
estimates for treatment-naive patients. In the following, I describe the
two models in more detail and compare them with each other. The
approach that is used for turning the quantitative predictions of these
models to the discretized SIR representation concludes this section.
Prediction of Phenotypic Drug Resistance
The original approach of geno2pheno[resistance] relies on drug-
specific support vector regression models using linear kernel func-
tions. These models were trained on genotype-phenotype pairs
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consisting of Sanger sequences of HIV-1 PR and RT as well as cor-
responding measurements of phenotypically determined RFs33.
Phenotypic resistance testing was performed for at least 300 samples
for drugs from the three classes of NRTIs, NNRTI, and PIs34.35
For the development of these models, amino-acid sequences were
represented using a binary encoding where 1 indicates the presence
of an amino acid and 0 its absence. For each drug, a SVR model
(Section 3.4.2) based on an epsilon-insensitive loss function with
ε = 0.1 was fitted. The regularization parameter C was optimized via
grid searching and CV. The models were validated using 10-fold CV.
The mean squared correlation with phenotypically determined RFs
was 0.6± 0.14.
Prediction of Drug Exposure from Clinical Data
The drug-exposure approach of geno2pheno[resistance] is based
on drug-specific SVC models using linear kernel functions. These
models were trained on clinical data consisting of Sanger sequences
and corresponding binary labels indicating whether a sequence
originates from a patient that was treated with a drug or not36. The
decision value resulting from application of an SVM (Section 3.4.2) is
interpreted in terms of the drug-exposure score (DES) whose value
indicates the degree of drug exposure.
The approach was validated in the following way. SVC models
with linear kernel functions were trained for predicting exposure
to individual drugs of the three classes PIs, NRTIs, and NNRTIs.
The training sets for most drugs consisted of thousands of obser-
vations. Viral sequences were represented using a binary encod-
ing. Performance was evaluated on independent test sets where
the performance of DESs was analyzed in three prediction scenar-
ios: (1.) prediction of drug exposure; (2.) prediction of phenotypic
drug resistance, and (3.) prediction of treatment success. The drug-
exposure model outperformed the original, phenotypic model of
geno2pheno[resistance] in two of three scenarios: prediction of drug
exposure (AUC 0.78 vs AUC 0.71) and prediction of treatment out-
comes (AUC 0.73 vs AUC 0.68). With a mean correlation of 0.51 to
the results from the PhenoSense assay, the drug-exposure model
exhibited poorer performance than geno2pheno[resistance] when
estimating phenotypic resistance.
Comparison of the Phenotypic and Clinical Model
Since the original model of geno2pheno[resistance] estimates RFs re-
sulting from phenotypic resistance tests, this model is best suited for
the determination of in vitro drug resistance. As the drug-exposure
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model is based on clinical data, it is better suited for in vivo ap-
plications, for example taking treatment decisions. This is clearly
demonstrated by the results from the validation of the drug-exposure
model. Investigating the M184V mutation, can make this difference
more tangible.
M184 is known for its association with FTC resistance in vitro37
but not in vivo38. When the two geno2pheno[resistance] models
are presented with the same viral sequence carrying M184V, the
phenotypic model classifies the sequence as resistant to FTC, while
the clinical model classifies the sequence as intermediate. Obviously,
the prediction that is obtained with the phenotypic model agrees well
with the in vitro evidence, while the prediction of the clinical model
agrees well with the in vivo evidence. In this case, the prediction
from the drug-exposure model can be directly integrated into clinical
decision making, while the prediction from the phenotypic model
requires expert interpretation.
The drug-exposure model has a critical advantage over the phe-
notypic model. In contrast to phenotypic data whose generation is
costly and time-consuming, clinical data is generated as a by-product
of clinical routine and more widely available. Although models
based on clinical data cannot immediately take novel drugs into
account39, these models may still include novel drugs sooner than
phenotypic models because they do not require experts that deter-
mine drug resistance experimentally. This can be exemplified by the
geno2pheno[integrase] server that provides predictions of phenotypic
resistance for INSTIs. Although DTG was FDA-approved already
in 2013, geno2pheno[integrase] still (as of January 2019) provides
merely rules-based predictions for DTG due to a lack of phenotypic
data. Clinical data on DTG, on the other hand, are already numerous.
Besides the point that models based on clinical data may be updated
faster, there is another benefit of these models: Clinical databases are
large. This means that, for many drugs, the natural variation of drug
resistance mutations is represented well.40.
Phenotypic methods, on the other hand, have two disadvantages.
First, phenotypic methods that rely on measurements from multiple
assays may suffer from batch effects. Even commercially available
assays exhibit different RF distributions as evidenced by the re-
quirement for different cutoffs when transforming RFs to levels of
resistance41. Without correction, this problem can be circumvented
by ensuring that the measurements for individual drugs were all per-
formed with the same assay, under the same experimental conditions.
Second, phenotypic models may also be limited by the diversity of vi-
ral sequences that can be observed in vitro. Since training data reflect
the adaption of viruses subject to the selection pressure from a single
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antiretroviral drug, not all patterns of mutations that are observed in
vivo may be represented.
A limitation of the drug-exposure model is that it derives DESs
for individual drugs based on the properties of sequences that were
exposed to combinations of drugs. If treatment selection were a
random process, this would not be a problem. However, ART is
strongly influenced by recommended first-line treatments, which
consist of a handful of combinations42. Thus, it may not be possible
to discriminate between features that are predictive of exposure to
coprescribed drugs if the activity of these drugs is modulated by
the same viral protein. As a result, the DESs for such drugs may be
misleading because they may reflect the mutational profiles from
multiple drugs rather than individual drugs. For example, this could
be the case for the NRTIs TDF and FTC, which are often combined
in the first-line regimen TDF + FTC + DRV. To alleviate this problem,
two approaches could be considered. The first approach relies on
changing the feature encoding for drug-specific models using prior
knowledge. For example, when training and applying the TDF
model, the features that are known to be associated with FTC drug
resistance but not with TDF resistance could be encoded by zeros
to limit their influence. The second approach is based on multi-task
learning. By learning from data for all antiviral drugs, the resulting
model may be able to discern between mutations that only arise for
a specific drug and those mutations that arise due to coprescribed
agents. geno2pheno[resistance] corrects for the coprescription of
drugs only after DESs have been computed, namely at the time when
DESs are discretized to resistance levels. This approach is described
in the following section.
Discretization of Quantitative Estimates
The estimates of geno2pheno[resistance] (RFs or DESs) are trans-
formed to three interpretable, clinically-motivated levels of resistance:
susceptible, intermediate, or resistant. In the following, I outline how
geno2pheno[resistance] determines cutoffs based on the approach by
Pironti et al. (2017b), which relies on estimated RFs.43
In order to determine the natural variation of resistance among
therapy-naive patients, RFs are determined by applying geno2pheno[resistance]
to viral sequences from this population. To exclude RFs from sam-
ples that are subject to transmitted drug resistance (TDR), all strains
exhibiting any major drug resistance mutation (DRM) are excluded.
In the next step, the probability of susceptibility (POS) is computed
for each clinical isolate in the EuResist database by fitting a two-
component Gaussian mixture model to the RF distribution of every
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In the following step, treatment episodes (TEs) are collected. In
short, TEs encompass the following measurements: the genomic
regions of interest at baseline, the treatment regimen, a follow-up VL,
and, optionally, a baseline VL. Each TE is labeled either as a success
or a failure depending on the follow-up VL. All TEs with a VL below
400 HIV-1 RNA copies per mL or with a VL reduction of at least 100-
fold with respect to the baseline are considered successful treatments
and all others as failed. Treatments for which resistance testing was
performed during treatment or close to treatment interruption are
also considered as failed treatments.
Finally, cutoffs are determined in the following way. For each TE,
RFs are predicted from baseline genotypes using geno2pheno[resistance].
Using weighted-kernel density estimation45, RF-dependent densities
are estimated for treatment failure and success, respectively. Sus-
ceptibility to the other drugs in the treatment regimen is taken into
account by considering the POS of each backbone compound. Since
combination treatments are considered, it is necessary to correct RFs
estimated for individual drugs based on the potency of the other
drugs in the regimen.
In order to correct the density representing successful treatments,
the RF of a drug is weighted based on the estimated susceptibility
to the other drugs in the regimen. For example, if a viral strain is
susceptible to the considered drug but resistant to the other drugs in
the combination, then the impact of the considered drug is increased
because the success of the treatment seems to hinge on the suscepti-
bility to the considered drug. However, if a viral strain is susceptible
to all drugs in the regimen, then the impact of the considered drug is
reduced since the success of the treatment cannot be attributed to the
considered drug alone. The density associated with failed treatments
also needs to be corrected because not all failures are due to drug
resistance; other factors such patient non-compliance also play a role.
Therefore, the impact of failed treatments for which no resistance was
detected, is reduced.
For the analytic determination of suitable cutoffs, the following
sigmoidal is fit to the probabilities of success for the i-th drug:
P̂i(x) =
a− d
1 + exp (−b(x− c)) + d
where a, b, c, d ∈ R0 and non-negative. A lower and an upper cutoff
can be found from P̂i by determining the inflection points, which
represent the points at which the probability of success changes
considerably or is marginal. In case that the determined lower cutoff
is below the 95th percentile of RFs from treatment-naive persons,
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the lower cutoff is set to this value in order to curb overcalling of
intermediate resistance.
The method from Pironti et al. (2017b) was compared to the ap-
proach from Stanford’s HIVdb by computing genotypic susceptibility
scores (GSSs). For this purpose, each drug was scored according to
its resistance level (1 for susceptible, 0.5 for intermediate, 0 for resistant).
Next, the GSS of a treatment was determined by summing up the
scores from all constituent drugs. The GSSs resulting from the two
methods achieved similar levels of performance when predicting
treatment success on a test data set (AUC of 0.63 for the presented
approach vs 0.65 for HIVdb). This result indicates that the presented
approach affords a suitable discretization to resistance levels.
4.1.3 geno2pheno[hcv]: A Rules-Based Resistance Interpretation Sys-
tem
geno2pheno[hcv] relies on a set of rules that was chosen by an ex-
pert panel through extensive reviewing and weighting of litera-
ture related to HCV drug resistance46. These rules are drug- and
genotype/subtype-specific. For example, given a virus with sub-
type 1b, the mutation 41R would not affect susceptibility to the NS3
inhibitor asunaprevir but susceptibility would be considered to be
reduced if both 41R and 80R were present. To determine the level of
drug resistance associated with associated with an input sequence,
geno2pheno[hcv] scans the amino-acid mutations of NS3, NS5A, and
NS5B for matches to any of the rules. When a rule matches an ob-
served mutation, the resistance level is updated if the resistance level
has increased compared to the prior resistance level. In this way, the
highest level of resistance from all matched rules is reported for every
drug. For example, when a sequence carries 41R and 80R (reduced
susceptibility) but also 168A (resistant), then the resistance level for
asunaprevir is resistant.
Since geno2pheno[hcv] performs geno- and subtype-specific pre-
dictions, it is necessary to obtain alignments to a large set of HCV
reference sequences representing several geno- and subtypes. For
every genomic region of HCV, just under 200 reference sequences
are considered.47 Computing alignments for such a large number of
sequences would be infeasible, which is why geno2pheno[hcv] aligns
input sequences only with respect to the HCV reference sequence
H7748, which has subtype 1a. The tool then relies on stored align-
ments of the subtype-specific reference sequences with respect to the
H77 sequence. In this way, the similarity between query and refer-
ence can be determined by iterating along the aligned sequences and
increasing the match score by 1 when the amino acids at a position
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in the alignment agree. The inferred subtype is that of the reference
sequence maximizing the similarity to the aligned query sequence.
For the determination of drug resistance, a subtype-specific reference
that exhibits a minimum number of polymorphisms associated with
resistance is selected.
4.1.4 Resistance Testing Based on Next-Generation Sequencing
While the result of Sanger sequencing is a nucleotide sequence, in
which ambiguous bases indicate the presence of multiple peaks at
the same position in the chromatogram, NGS (Section 2.5.3) produces
millions of ultra-short reads that require further processing. The
basic processing of NGS reads begins with quality control procedures.
These procedures ensure that only high-quality positions (i.e. those
that likely reflect the true nucleotide) are considered. After cleaning
the reads, the fragmented data needs to be structured. For this
purpose, one can either perform de novo read assembly or read
mapping49. Assembly tries to determine scaffolds by finding sets
of contiguous segments. Mapping, on the other hand, reconstructs
the original, unsegmented sequence by aligning reads to a reference
genome. De novo assembly is particularly useful when a reference
sequence is not available (e.g. for less studied species) or when reads
originate from mixtures of species (e.g. in metagenomics). In other
cases, mapping is typically used because it is less time-intensive
and provides a frame of reference, which is useful for downstream
analyses. Since samples for genotypic resistance testing only contain
genomic material from a single viral species and since a frame of
reference is expedient, the data are processed with read mapping.
Once the reads have been mapped, variant calling is performed.
Variant calling is particularly important for samples representing
heterogenous populations. Here, the question is, whether a variant
that was detected at a low frequency (e.g. at 1%) is actually present
in the sample or whether it is the result of sequencing errors. This
question can be answered using statistical tests that consider the
technology-dependent error distributions in unison with the evidence
for the variants.
Due to the time intensity of processing NGS data, there are many
stand-alone tools for the interpretation of drug resistance from
NGS data. Examples include the freely available tools ShoRah50,
V-Phaser51, VirVarSeq52, and MinVar53 as well as the commercial
DeepCheck software54. To my best knowledge, the only two freely
available web services for interpreting HIV-1 drug resistance are
HyDRa and PASeq55. In the following, I provide more details on the
steps that are typically performed when processing NGS data.56
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Quality Control
The most important quantity for quality control are Phred scores57,
Q, which measure the quality of each position according to
Q = −10 log10 P .
Here, P is the probability of a base calling error. High values of Q
indicate low error rates. For example, Phred scores of 10, 20, and
30 correspond to base calling accuracies of 90%, 99%, and 99.9%,
respectively. Phred qualities are determined during the sequencing
procedure and are encoded together with the sequence using the
FASTQ format. Since sequencing is subject to inherent, technology-
dependent biases, quality scores should be recalibrated before
they are interpreted58. Thereafter, complete reads or individual
nucleotides can be excluded based on Phred quality scores. A simple
strategy for improving the quality of NGS data is the exclusion of
reads with median qualities below a cutoff (e.g. 20). Additionally, for
data generated by the Illumina/Solexa approach, the ends of reads
should be truncated when a drop in Phred quality scores is detected.
Once the reads have been mapped to a reference sequence, it
is crucial to consider the depth of coverage, which describes the
number of nucleotides that are observed at a genomic position.
While human genome sequencing is typically performed with low
coverages (often less than 30-fold)59, sequencing of viral genomic
regions can be performed with 10 000-fold coverages due to the
smaller size of viral genes.60 By considering the depth of coverage,
it is possible to estimate the population prevalence of variants in the
viral sequence.
Since HIV-1 plasma samples may be contaminated with proviral
DNA, it is important to investigate the presence of APOBEC mu-
tations.61 A mutation is called an APOBEC mutation if it matches
the mutational pattern of the APOBEC protein. APOBEC3G, the
cytidine deaminase that targets the HIV provirus, causes G→ A
substitutions in the GG and GA dinucleotide context. If the activ-
ity of APOBEC3G is not inhibited by vif, the provirus is rendered
replication-incompetent. Since APOBEC mutations can occur at
resistance-associated positions, the presence of APOBEC mutations
can distort the results of resistance analysis. Due to the action of
APOBEC3G, the RT resistance mutations E138K (GAG→ AAG)
and M184I (ATGG→ ATAA) can emerge even without prior drug
exposure62. Since APOBEC activity typically results in extensive
hypermutation63, reads exhibiting extensive patterns of APOBEC
activity can be excluded64. Note that there is evidence indicating
that APOBEC may also induce sparse, non-lethal mutations whose
detection may be difficult65.
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Read Mapping
There is a large number of methods for aligning reads to a refer-
ence genome. Algorithmically, this is either achieved by the use of
Burrows-Wheeler transform, suffix trees, or hashing of the template
sequence66. In practice, the selection of a suitable mapping algorithm
depends on the application and the constraints on available time and
memory space. Comparing the performance of different mappers is
hindered by the unavailability of suitable reference data sets. Popular
mappers for short reads from DNA include MOSAIK67, Bowtie68,
and BWA69.
Variant Calling
Calling variants at low population frequencies (e.g. at a prevalence
small than 1%) can be difficult due to the presence of sequencing
errors, particularly at low coverage positions. Thus, variant calling
should consider sequencing-run specific error rates in order to im-
prove the specificity of variant detection. Available variant calling
approaches provide different sensitivity/specificity trade-offs. Sim-
ilarly to read mapping, however, benchmarking of variant callers is
difficult due to limited availability of benchmarking data sets70. Thus,
available benchmarking studies have provided only inconclusive re-
sults71. Well-established variant callers include LoFreq72, FreeBayes73,
and, more recently, DeepVariant74.
Resistance Interpretation
Available tools interpret drug resistance from NGS samples by deter-
mining consensus sequences for individual prevalence cutoffs and
applying established rules-based systems for Sanger sequences such
as the approach from Stanford’s HIVdb75.
4.2 Approach of geno2pheno[ngs-freq]
In the following sections, I detail how geno2pheno[ngs-freq] predicts
resistance for NGS samples from HIV-1 and HCV. For this purpose,
I introduce the frequency file format in Section 4.2.1. The prevalence
cutoffs that are used by geno2pheno[coreceptor] are discussed in
Section 4.2.2. Section 4.2.3 describes how input samples are processed
by geno2pheno[ngs-freq]. Thereafter, I outline the considered quality
control measures (Section 4.2.4). A novel method for visualizing viral
resistance is introduced in Section 4.2.5. The manner in which the
web service was validated is presented in Section 4.2.6. This section
concludes with the technical details about the implementation of the
120
web service (Section 4.2.7).
Figure 1 from Döring et al. (2018) is licensed under CC-BY 4.0
Figure 4.1: Transformation of
a single-nucleotide frequency
file to a consensus sequence at a
prevalence cutoff of 10%. (a) Ex-
ample of a nucleotide frequency
file providing the nucleotide
counts for the first three po-
sitions in a viral genome. (b)
Table of prevalence ratios in
which observations with ratios
of at least 10% are shown in
red. The corresponding motif
logo in which the height of
individual nucleotides reflects
their prevalence is shown be-
low. (c) Consensus sequence
constructed for a prevalence
cutoff of 10%. Ambiguous posi-
tions are encoded according to
International Union of Pure and
Applied Chemistry (IUPAC)
nomenclature.
4.2.1 Format of Input Files
Frequency files (Figure 4.1) are comma-separated values (CSV) files
containing either the counts of observed codons or nucleotides along
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a viral genome. These files can be generated as a result of applying
NGS processing pipelines to raw NGS data (Section 4.1.4). In the
following, I consider a frequency file as a matrix F ∈ Nm×n0 whose
number of rows, m ∈ N, is determined by the number of genomic
positions and whose number of columns, n ∈ N, is defined either
by the number of nucleotides or triplets. Let A = {−, A, C, T, G, N}
be the nucleotide alphabet and let A3 = (A \ {−, N})3 ∪ {−}3 be
the triplet alphabet. Nucleotide frequency files contain entries fi,j,
which denote the number of reads supporting the nucleotide j ∈ A
at position i, while codon frequency files are defined by entries fi,j
where j ∈ A3 relates to triplets instead.76
Note that single-nucleotide frequency files should not be used to
indicate the presence of insertions as these could shift the transla-
tional frame.77 Codon frequency files, on the other hand, respect the
frame of translation and thus allow for the meaningful representation
of insertions.
4.2.2 Prevalence Cutoffs
geno2pheno[ngs-freq] enables comparing the impact of mutations
at low abundances with those at greater abundances through the
selection of two prevalence cutoffs, the personal cutoff and the refer-
ence cutoff. By default, the personal cutoff is set to 2%. This cutoff
serves two purposes. First, the cutoff is high enough to ensure tol-
erance with regard to sequencing errors78. Second, the cutoff is low
enough to allow for the consideration of clinically relevant minority
variants79. The default setting for the reference cutoff was chosen in
order to obtain drug resistance interpretations that are comparable
to the results that would be obtained with Sanger sequencing. The
detection limit of Sanger sequencing80 provides a reasonable frame
of reference for choosing a default reference cutoff. The default ref-
erence cutoff for samples from HCV was set to 15% as this is the
established cutoff for interpreting NGS data with respect to HCV
drug resistance81. Data for HIV-1 suggest that Sanger sequencing is
highly sensitive to NRTI mutations such that a lower NGS prevalence
cutoff at 10% is necessary in order to recover all relevant NRTIs muta-
tions with NGS82. Thus, the default reference cutoff for samples from
HIV-1 was set to 10%.
4.2.3 Workflow
Once a user has supplied a set of prevalence cutoffs, a frequency file,
and an optional sample identifier, geno2pheno[ngs-freq] performs the
steps indicated in Figure 4.2: (1.) Generation of a consensus sequence
for every prevalence cutoff; (2.) inference of the viral species; and
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/ NRTI at 10%/2%
/ NNRTI at 10%/2%
/ PI at 10%/2%
Graphical abstract from Döring et al. (2018) is licensed under CC-BY
4.0.
Figure 4.2: Workflow of
geno2pheno[ngs-freq].
(3.) identification of viral resistance for every consensus sequence.
The following sections provide the computational details for the
individual processing steps.
Generation of Consensus Sequences
For each prevalence cutoff cF ∈ [0, 1] that is provided for a frequency
file F ∈ Nm×n0 , the web service generates a consensus sequence in
the following manner. Let di = ∑j fi,j indicate the depth of coverage
at position i ∈ {1, 2, . . . , m} in the frequency file. If F is a codon
frequency file, the ratio at which the codon z ∈ A3 occurs at position




If F is a single-nucleotide file, the computations are slightly more
involved because we need to determine the prevalence of codons in
order to compute the prevalence of individual amino acids. Starting
with the first nucleotide of the protein sequence of interest, we only
consider positions i that form the first position of a coding triplet
consisting of positions i, i + 1, and i + 2. Without loss of generality,
assume that nucleotides j ∈ A, k ∈ A, and l ∈ A are observed at
the three respective positions. Under the assumption of positional
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are computed to determine the codon prevalence ratio xi,z = xi,j ×
xi+1,k × xi+2,l at which z = (j, k, l) is expected to be observed. Given
that
Di = min {dw|w ∈ {i, i + 1, i + 2}}
indicates the maximal possible codon coverage, the expected number
of reads supporting codon z is Dixi,z. Thus, the prevalence of codon z





Having determined the codon frequencies, the consensus sequence
is constructed in the following way. For the i-th position, only the set
of observations (i.e. nucleotides or triplets) Ai,cF = {j|xi,j ≥ cF} ⊆ A,
whose prevalence is at least cF is considered. Then, position i of the
consensus sequence is set to si,cF = φ(Ai,cF ). The function φ converts
nucleotides or codons into their corresponding IUPAC representa-
tion83 (Table A.1). In case that Ai,cF is empty (i.e. no observations
were selected because all frequencies were less than the cutoff), the
greedy criterion Ai,c f = arg maxj xi,j is used instead. The use of this
criterion ensures that no artificial deletions are introduced into the
consensus sequence. As an example, let us consider the first position
shown in Figure 4.1. Given a prevalence cutoff of cF = 10% and the
observed prevalence ratios xiA = 10%, xiC = 1%, xiG = 9%, and
xiT = 80%, we would set si,10% = φ(Ai,10%) = φ(A, T) = W because
only the frequencies of A and T exceed the cutoff.
Due to the redundancy of the genetic code, there are amino acids
that are encoded by multiple nucleotide triplets (Figure 4.3).84 To
compute the frequency of an amino acid at a certain position, it
is therefore necessary to sum over the frequencies of all codons
encoding that amino acid. Let Φ indicate a function that translates
from codons to amino acids and let
B = {A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y}
indicate the alphabet for the twenty amino acids. The prevalence of
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coverage.
amino acid a ∈ B at position i is determined as
Pi,a = ∑
codon z with Φ(z)=a
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Figure 4.3: Translation of
codons to amino acids. To
obtain the translation of a nu-
cleotide triplet, one needs to
move from the innermost to
the outermost circle. Note that
uracil (U), which occurs in
RNA, corresponds to thymine
(T) in DNA.
In order to prevent the consideration of positions with insufficient
coverage, a coverage cutoff, which is set to dcut = 20, was defined.
Positions with di < dcut are assigned the ambiguity code N that
represents any possible base. The benefit of this approach over the
previously used, more stringent truncation strategy85,86 is that it
allows for the simultaneous interpretation of resistance for multiple
genomic regions even if their amplicons are separated by stretches of
low coverage (e.g. NS3, NS5A, and NS5B).
In the following, I use the term default consensus sequence to denote
the consensus sequence of a sample that was constructed at the
default reference cutoff for the corresponding virus. Let scF indicate
a consensus sequence at a specific cutoff cF ∈ [0, 1]. Then, the default
consensus sequences for HIV-1 and HCV are denoted by s10% and
s15%, respectively.
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Inference of the Viral Species
The viral species from which an input sample originates is inferred
by aligning the sample’s default consensus sequence to the genomic
regions of the reference sequences for HIV-1 and HCV, HXB287 and
H7788, respectively. To ensure that resistance is interpreted only for
supported viral species, the existence of at least one high-quality
alignment is required. An alignment is considered a high-quality
alignment if it induces a high degree of similarity between query
and reference sequence. More formally, a high-quality alignment
must satisfy two similarity criteria, which are defined by dividing
the number of matching amino acids in the alignment either by the
length of the alignment (alignment similarity) or by the length of the
reference sequence (reference similarity).
For sequences from HIV-1, a minimal alignment similarity of 60%
and a minimal reference similarity of 50% are used for all regions,
except for RT. Since all major drug resistance mutations are located
within the first half of the gene89, RT is frequently merely partially
amplified. Thus, a reference similarity of only 20% is required for the
RT. Due to the greater phylogenetic divergence of HCV, an alignment
similarity of 40% and a reference similarity of 20% are required for
all HCV regions. If no high-quality alignments are available, it is
assumed that the sample derives from a species that is not supported
and no further computations are performed. In all other cases, the
viral species of the reference sequence with the greatest alignment
score is used.
Identification of Viral Resistance
Viral resistance of HIV-1 and HCV samples is interpreted using
the approach of geno2pheno[resistance]90 and a reimplemented
version of geno2pheno[hcv]91, respectively. HIV-1 drug resistance is
classified using the SIR scheme (Section 2.5.2).
For geno2pheno[ngs-freq], geno2pheno[hcv] was reimplemented
in C++, with the following two changes. First, when the similarity
to the reference sequence is calculated, ambiguous nucleotides are
taken into account in the following way. Let n indicate the number
of nucleotides that are represented by an (ambiguous) nucleotide
in the reference sequence (e.g. n = 1 for T but n = 2 for W) and
let m be the number of disambiguated nucleotides at the current
position in the query that match the disambiguated nucleotides in
the reference sequence. Then, the match score is mn . Thus, when the
query nucleotide is W and the reference nucleotide is T, then W is
disambiguated to A and T. Since T is observed in both query and
reference, we have m = n = 1 and the match score is 1 rather than
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0 as before (W does not match T). Second, the original approach of
geno2pheno[hcv] may ignore resistance-relevant positions because it
considers only mutated positions. However, since some of the HCV
reference sequences carry resistance-associated positions, this leads
to an underestimation of resistance for sequences exhibiting these
wild-type amino acids. Therefore, when evaluating the rule set, the
reimplementation does not only scan mutated amino acids but all
amino acids. The following resistance levels are used for samples
from HCV: susceptible, substitution on scored position (rule matches
the position but not the amino acid), resistance-associated mutation in
closest subtype (for rare subtypes only92: matched a rule for the closest
non-rare subtype), reduced susceptibility, resistant, and unlicensed (drug
is not approved for the identified subtype).
The presence of ambiguities at more than a single codon posi-
tion can lead to the inclusion of spurious codons into consensus
sequences. Imagine, for example, that the codons ATA (Ile) and
TTT (Phe) are observed at the same genomic position. In this case,
the triplets ATT (Ile) and TTA (Leu) would be considered in ad-
dition to the observed codons when constructing the consensus
sequence. Then, the resistance interpretation algorithm would incor-
rectly consider three (Ile, Phe, and Leu) rather than two (Ile and Phe)
amino acids at this position. To prevent this, geno2pheno[ngs-freq]
considers the prevalence of codons when translating consensus se-
quences in order to ignore codons that were not actually observed.
Assume that the codons {z1, z2, . . . , zn} were observed at the i-th po-
sition. Then, only codons z′ ∈ {z1, z2, . . . , zn} with Pi,z′ ≥ cF, where
cF ∈ [0, 1] is the selected prevalence cutoff, are translated.
4.2.4 Quality Control Mechanisms
Besides the requirement of high-quality alignments, geno2pheno[ngs-
freq] uses several additional measures for evaluating the quality
of a sample. With regard to coverage, the tool outputs the extent
to which individual genomic regions were covered as well as the
depth of coverage. Moreover, individual positions are annotated
with their depth of coverage and warnings are issued if positions
associated with resistance exhibit a coverage less than 100.93 The
quality of consensus sequences constructed at different cutoffs can
be analyzed with respect to the presence of stop codons, frame shifts,
and ambiguous positions. For HIV-1, potential APOBEC mutations
are annotated using the approach from Rhee et al. (2016). Here,
APOBEC signature mutations are defined as G to A mutations at GG
or GA dinucleotides that are conserved across 98% of Los Alamos
National Laboratory (LANL) HIV sequences.94 If more than one
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4.2.5 Visualization of Drug Resistance
Figure 4.4: Resistance ta-
ble for a sample sequence,
as determined by the
geno2pheno[resistance] web
service.
A new approach for the visualization of quantitative predictions of
drug resistance was developed in order to improve the interpretation
of resistance estimates. geno2pheno[resistance] provides a table
of drug resistance such as the one shown in Figure 4.4. Here, the
level of resistance is provided in terms of the SIR system such that
susceptibility is shown in green, intermediate resistance in yellow,
and, resistance in red. Interpreting whether the z-score for a drug is
relatively high or low given its SIR class requires knowledge of the
lower and upper z-score cutoffs that were used for the classification,
which are not publicly available.
Therefore, the following approach was used to arrive at a visual-
ization for the relative level of resistance. Z-scores were estimated
for all sequences contained in the geno2pheno[resistance] training
data set. The minimum and maximum z-score, denoted by zmin and
zmax, respectively, were determined for each drug. Let zlow and zhigh
denote the corresponding lower and upper cutoffs of the SIR clas-
sification as determined by the approach presented in Section 4.1.2.
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Based on these values, z-score vectors zl ∈ R2 representing each level
of resistance l ∈ {S, I, R} were constructed:
zS = (zmin, zlow)
zI = (zlow, zhigh)
zR = (zhigh, zmax)
Given a prediction consisting of a z-score, z ∈ R, and a resistance
level, l, the relative level of resistance, zl ∈ [0, 1], is computed as
zl =

0 if z < zl1





Thus, zl of 1 indicates the highest possible level of resistance for
a resistance class and 0 the lowest. In order to obtain an overall












3 zl if l = R
.
The values plotted in the radar visualization of drug resistance for
HIV-1 (Figure 4.6) and the gauges shown in Figure 4.7 are based on
the mapping provided by φ. Besides improving the interpretabil-
ity of z-scores, the transformation has the benefit of enabling the
comparison of z-scores resulting from different prediction mod-
els. This is important since the default HIV-1 prediction model of
geno2pheno[ngs-freq] relies on a combination of prediction models:
The phenotypic model of geno2pheno[resistance] is applied for all
drugs except for ETR and RPV, for which the drug-exposure model is
used.95
4.2.6 Validation
geno2pheno[ngs-freq] was validated by analyzing a total of 3 844
frequency files of which 926 files represented samples from HIV-1
(24.1%) and 2 918 files represented samples from HCV (75.9%). Re-
sistance interpretations were obtained for 922 of 926 HIV-1 samples
(99.6%) and 2 898 of 2 918 HCV samples (99.3%). For the remaining
samples, geno2pheno[ngs-freq] did not provide a result due to low
depth of coverage.
To validate the reimplemented version of geno2pheno[hcv], I inves-
tigated the concordance between the predictions of geno2pheno[ngs-
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freq] and the geno2pheno[hcv] web service using the default con-
sensus sequences constructed from the 2 866 successfully analyzed
HCV frequency files. The concordance between geno2pheno[ngs-
freq] and geno2pheno[hcv] was 99.7%. The differences are a result of
two modifications of the original approach from geno2pheno[hcv],
which are described in Section 4.1.3. Since the reimplementation
takes ambiguous nucleotides into account when computing sequence
similarities, there are instances in which different reference sequences
(i.e. different genotypes) were selected such that different resistance
levels ensued. Moreover, the reimplementation scans all of the rules
rather than evaluating merely those rules matching the mutations
in the sequence. Therefore, the resistance levels of sequences whose
wild-type amino acids are associated with resistance were different in
the reimplementation.
An analogous validation was not performed for the HIV-1 samples
because predictions for HIV-1 samples are based on the established
version of geno2pheno[resistance], which has already been exten-
sively validated96. The median runtimes required for analyzing
HIV-1 and HCV samples were 6 seconds and 4 seconds, respectively.
4.2.7 Technical Details
Figure 4.5: Computational archi-
tecture of the geno2pheno[ngs-
freq] web service.
130
Figure 4.5 depicts the computational architecture of the geno2pheno[ngs-
freq] web service. The frontend has been implemented in Type-
script and relies on the React library. Once a user has requested the
geno2pheno[ngs-freq] website, the JavaScript application that pro-
vides the user interface is retrieved from the backend server. The
subsequent communication between client and server is facilitated
through a representational state transfer (REST) service. When a user
performs an action in the web interface, a javasript object notation
(JSON) query is created. This query is passed from the frontend web
server (Apache) to the backend server, which runs an instance of the
Play framework (Java). The backend server queries the application
programming interface (API) that is defined by the geno2pheno[ngs-
freq] C++ library, which interprets the request and computes the
result of the query. The library uses an Oracle database for data re-
trieval. Once the result has been determined, it is returned to the
client via JSON and the results are displayed by the client’s web
browser. The web interface affords the analysis of batches containing
at most 20 files.
4.3 Case Studies
In the following, I provide two case studies that illustrate how
geno2pheno[ngs-freq] can offer insights that may impact clinical
decision making. The case studies can be replicated by accessing
the geno2pheno[ngs-freq] web service, ensuring that the default
prevalence cutoffs (2%, 10%, and 15%) are selected, and loading the
exemplary frequency files. The HIV-1 case study (Section 4.3.1) was
performed on the basis of the phenotypic geno2pheno[resistance]
model, while the HCV case study (Section 4.3.2) was performed
using the approach of geno2pheno[hcv].
4.3.1 HIV-1 Resistance Interpretation
This case study is based on a plasma isolate from an HIV-1 infected
patient with a VL of 102,000 copies per mL. The plot of viral drug
resistance (Figure 4.6) reveals that the major viral populations, at
the reference cutoff of 10%, seem to be susceptible to nearly all
drugs. When minor viral populations are included in the analysis
by considering the consensus sequence at the personal cutoff of
2%, considerably increased levels of resistance against the NRTIs
ABC, ddI, and 3TC are found. Using the resistance table shown in
Figure 4.7, it is possible to see that the increased levels of resistance
are caused by the well-studied resistance mutation M184V, which was
not considered in the prediction for the reference cutoff because the
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Figure 4.6: Radar plot of pre-
dicted drug resistance for the
sample from the HIV-1 case
study. Each spoke in the plot
relates to an antiretroviral
drug. The points defining
the surfaces are determined
through the standardized
RF that are predicted by
geno2pheno[resistance]. The
three colored circle sectors in-
dicate the estimated levels of
drug resistance. The inner sur-
face shows the estimated level
of resistance for the consensus
sequence based on the reference
prevalence cutoff at 10%, while
the outer surface indicates the
level of resistance for the con-
sensus sequence based on the
personal cutoff at 2%.
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Figure 4.7: Resistance table for
the sample from the HIV-1 case
study. The color of the gauges
indicates the predicted level of
resistance; their fill level reflects
the extent of resistance. The
ten features with the highest
impact on the prediction are
shown, ordered by decreas-
ing weight. The features are
shown using color (green/red
indicates decreased/increased
resistance), underlining (mu-
tations), and bold font (only
reported at the personal cutoff).
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mutation occurs at a population prevalence of 2.36%. M184V is not
only known for enhancing the susceptibility to the NRTIs ZDV, d4T,
and TDF, but also for delaying the emergence of resistance to these
drugs.97 Therefore, a combination therapy consisting of two such
NRTIs and one PI such as TDF + ZDV + DRV would be a reasonable
choice.
An alternative treatment with fewer side effects could consist
of TDF + FTC + DRV. The idea behind this treatment is that FTC
could stabilize M184V such that susceptibility to TDF is ensured98.
Moreover, although M184V is associated with a more than 100-fold
reduction in susceptibility to FTC in vitro99, FTC exhibits residual
activity in the presence of M184V in vivo100. Therefore, even if the
minority population characterized by M184V were to become more
prevalent over time, FTC would still be residually active.
4.3.2 HCV Resistance Interpretation
In this HCV case study, resistance to NS5A inhibitors is investigated.
The visualization of resistance for the considered sample (Figure 4.8)
shows that the viral population at the 15% cutoff seems to be sus-
ceptible to all DAAs targeting NS5A, while the population at the 2%
cutoff seems to be resistant to most NS5A inhibitors due to the pres-
ence of the resistance mutation 30R (Figure 4.9), which was found at
a prevalence of 6.1%. Using this information, the treating clinician
may decide to avoid the use of the NS5A inhibitors DCV, EBR, LDV,
and OBV to which the minor viral population seems to be resistant
and instead use VEL, for which no resistance was reported.
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4.4 Discussion
This chapter presented a new approach for genotypic resistance test-
ing based on NGS data. The result of this work is geno2pheno[ngs-
freq], a web server for the genotypic interpretation of drug resistance
for HIV-1 or HCV samples, which is freely available via the internet.
geno2pheno[ngs-freq] facilitates the analysis of viral drug resistance
in minority populations. While other web services offering NGS resis-
tance interpretation for HIV-1 are based on rules-based approaches,
geno2pheno[ngs-freq] enables the use of the statistical models from
geno2pheno[resistance] in the NGS setting. Moreover, to the best of
my knowledge, the server provides the first freely available interpre-
tation engine for NGS samples from HCV.
In contrast to other web services for interpreting viral resistance
for NGS samples, geno2pheno[ngs-freq] uses frequency files instead
of raw NGS data. The use of frequency files over raw sequencing
data offers three benefits. First, due to their small size (kilobytes vs
megabytes), frequency files can be uploaded quickly even in settings
with limited bandwidth. Second, skipping the time-intensive step
of processing the raw NGS data allows for rapid analyses (a few
seconds vs several minutes or hours). Third, the use of frequency
files decouples the step of NGS data processing from drug resistance
analysis. Services requiring the input of raw sequencing data are
limited by the application of largely pre-determined processing
pipelines. geno2pheno[ngs-freq], on the other hand, does not impose
limitations on the manner in which NGS samples are processed.
This enables the use of customized NGS processing pipelines. The
fact that geno2pheno[ngs-freq] requires local data preprocessing is
not a barrier to its application because I have developed a reference
implementation for transforming binary alignment map (BAM) files
to frequency files, which is publicly available via bamToFreq.
The use of frequency files naturally also entails a loss of infor-
mation. For nucleotide frequency files, amino-acid frequencies
need to be estimated and spurious amino acids may be generated.
These problems can be avoided by using codon rather than single-
nucleotide frequency files because this file format accurately models
amino-acid frequencies and allows for the correct translation of
codons containing multiple ambiguous positions. This is also an ad-
vantage of geno2pheno[ngs-freq] over the direct input of consensus
sequences to geno2pheno[resistance] or geno2pheno[hcv]: since these
services do not have prevalence information available, they cannot
correct for spurious observations. The frequency file format does
not allow for the consideration of co-occurrence patterns beyond the
codon level. However, this is not a practical disadvantage, because
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such patterns are not yet taken into account by any genotypic drug
resistance test. Frequency files also do not allow for quasispecies
reconstruction, which is possible with raw sequencing data. How-
ever, the low precision/recall trade-off of methods for quasispecies
reconstruction poses the question whether these methods are mature
enough for routine use101, although the improved performance of
more recent approaches inspires hope102.
Recently, the Winnipeg consortium has proposed the amino-acid
variant format (AAVF) as a means of representing the NGS results
for viral samples.103 This format is similar to the variant call format
(VCF)104, which is a general format for denoting variants detected
by NGS. However, the AAVF is tailored towards viral sequencing be-
cause it provides the prevalence of observed amino-acid variants. In
contrast to the frequency file format, which considers all possible nu-
cleotides or codons for every position, the AAVF is more succinct as
it considers only the observed amino acids. Time will tell whether the
AAVF will establish itself as the standard for summarizing the results
of viral sequencing and whether it will form a basis for interpreting
viral drug resistance.
An important contribution of geno2pheno[ngs-freq] is that the
service eases the interpretation of viral drug resistance compared
to previous approaches. The visualization of viral drug resistance
as a radar plot has several advantages over other representations
(compare Figure 4.6 with Figure 4.4). First, drug resistance for all
antiviral drugs is intuitively represented in a single diagram. Sec-
ond, drug resistance for minor and major viral populations can be
contrasted. Third, for predictions of HIV-1 drug resistance, relative
differences in resistance become evident. To illustrate the third point,
consider the predictions for APV shown in Figure 4.6. Although
the discretized level of resistance is identical for the populations
at the 2% and the 10% prevalence cutoff, it becomes apparent that
resistance is markedly increased in the minor population.
A general limitation of genotypic resistance testing based on NGS
data is that the clinical impact of minor populations carrying resis-
tance mutations is still largely unclear. While NNRTI resistance mu-
tations at low abundances are associated with virological failure105,
the general impact of minority resistant variants on the treatment
outcomes of HIV-1 infected patients is still unclear106. The impact of
HCV minority resistant variants is less studied than for HIV-1 but the
presence of minority resistant variants has recently been shown to de-
teriorate the outcomes in subtype-1 patients being treated with NS5A
inhibitors107. Treatment choices that are informed by minority vari-
ants should be taken with care108 for two reasons. First, the presence
of minority resistance mutations seem to have different ramifications
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on treatment success for different drugs. Second, the detected level
of resistance for a minor viral population may be inaccurate due to
biological and technical factors. On the one hand, minority resistance
mutations are not always biologically meaningful because they may
be found on reads that belong to viral variants with low replicative
capacity (due to low fitness) or without any replicative capacity (due
to the action of APOBEC). On the other hand, applying prediction
models that were developed for Sanger sequences to NGS data may
incur inaccuracies. This is because currently available approaches
consider only the amino acid with the greatest impact on drug resis-
tance when multiple amino acids are observed at a single position.
Selecting only the amino acids most strongly associated with drug
resistance is particularly problematic for consensus sequences at
low abundances (e.g. at 1%) as it is likely that constructed sequences
contain resistance-associated mutations that do not occur on the
same viral strand in vivo. This can lead to overestimated levels of
drug resistance because all of these mutations are taken into account
in unison. Models that do not rely on consensus generation would
allow for more accurate estimates of biological reality.
The following work could be done in the future. For HIV, predic-
tion models for other genomic regions could be added to geno2pheno[ngs-
freq]. Most importantly, the server should be able to identify viral
susceptibility towards INSTIs, which have become the pillars of an-
tiretroviral therapy. Although coreceptor prediction109 could also
be integrated into geno2pheno[ngs-freq], this would not be a pri-
ority because the geno2pheno[454] web server110 already predicts
HIV-1 coreceptor usage under consideration of co-occurring muta-
tions on individual reads, which is not possible using the frequency
file format. At a later point in time, support for samples from other
viral species such as hepatitis B virus (HBV), for which the emer-
gence of resistance is relevant111, could be added. The usefulness of
geno2pheno[ngs-freq] could be enhanced through a publicly avail-
able API with which the service could be queried programmatically.
Moreover, the prediction models underlying geno2pheno[ngs-freq]
could be further improved. For example, clinical models that deter-
mine drug exposure112 could benefit from learning from the combi-
nations in which drugs are prescribed through the use of multi-task
learning113.
In the future, a greater amount of NGS data with correspond-
ing clinical outcomes should allow for the development of novel
models trained on NGS data. By directly encoding either the fre-
quencies of amino-acids (e.g. using frequency files) or incorporating
information on the level of individual reads (e.g. using the FASTQ
format), these models could learn the specific circumstances under
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which minority variants influence therapeutic outcomes. For exam-
ple, read-based models could learn the co-occurrence patterns of
mutations in individual reads. These models could be formulated
in terms of multiple-instance learning problems, for example, using
set kernels114. An alternative would be to form prediction models
based on reconstructed quasispecies115, under consideration of their
prevalence and fitness116. These new models could simplify the in-
terpretation of drug resistance from NGS data because they would
provide a single prediction for every drug instead of multiple predic-
tions for populations at different abundances, which is currently the
case due to consensus generation. By learning from the frequencies at
which mutations are observed, these models would also have an edge
over currently used rules-based approaches, which do not consider
the abundance of mutations yet.
In summary, geno2pheno[ngs-freq] is a web service that allows
for the detection of minor viral populations carrying drug resistance
mutations, which is important for two reasons. First, although the
impact of minority variants is still unclear, it is never detrimental to
exclude drugs from consideration when their effectiveness could be
impaired by resistant minorities, as long as suitable alternative treat-
ment options are available. Second, by improving the surveillance of
drug-resistant minorities, it should be possible to further elucidate
the impact of resistant minor variants. geno2pheno[ngs-freq] is freely
available via ngs.geno2pheno.org.
Having shown how genotypic drug resistance testing based on
NGS data can improve the selection of antiviral therapies, it is im-
portant to note that drug resistance testing by itself cannot guide
the selection of all ARVs. Let me provide two examples. First, the
antiretroviral drug ABC should be prescribed only to persons that
do not carry the HLA variant HLA-B*5701 as this variant is linked to
hypersensitivity to the drug, which can be life-threatening117. Second,
the coreceptor antagonist maraviroc is an HIV entry inhibitor that
blocks one of the human coreceptors that is required for HIV cell en-
try. The next chapter (Chapter 5) presents a method for the genotypic
testing of HIV-2 coreceptor usage, which can guide the prescription
of maraviroc.
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Figure 4.8: Radar plot of pre-
dicted viral drug resistance
for the HCV sample from the
case study. Each spoke of the
plot relates to a DAA and the
colored circle sectors indicate
different levels of drug resis-
tance. Predicted drug resistance
is indicated by two surfaces:
one surface showing the drug
resistance estimate for the con-
sensus sequence based on a
prevalence cutoff at 2% and the
other for a prevalence cutoff at
15%.
Figure 4.9: Table of resistance
mutations for the sample from
the HCV case study.

For all these infectious
diseases, the goal is to
eventually get rid of them.
And to do that we need to
invent new tools, but nobody
was doing that because there
was no money to buy on
behalf of the poorest, even the
existing tools.
Bill Gates, 2016
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Predicting HIV-2 Coreceptor Usage
In this chapter, I introduce geno2pheno[coreceptor-hiv2], a freely available
web server for identifying the human coreceptor that is used by HIV-2
during cell entry. I developed, validated, and interpreted the model that is
used for coreceptor identification. The web server was implemented with
support from Achim Büch and Georg Friedrich. Pedro Borrego, Andreia
Martins, and Nuno Taveira made experimental measurements that were
used for training and validating the model. Ricardo Camacho, Josef Eberle,
and Rolf Kaiser provided expert insights. Nico Pfeifer and Thomas Lengauer
supervised the project. This chapter augments the publication by Döring
et al. (2016) with an overview of established genotypic approaches for
coreceptor identification.
Studying HIV coreceptor usage provides insights into disease
progression and allows for improved clinical decision making. Core-
ceptor usage (Section 2.3.4) determines viral tropism, which de-
scribes the types of immune cells that can be infected by HIV (e.g.
macrophages and T cells). Upon initial infection with HIV, the virus
typically binds to the CCR5 coreceptor to infect macrophages. In
the course of infection, HIV can evolve the ability to use the CXCR4
coreceptor1, an event referred to as a coreceptor switch. Viruses using
the CXCR4 coreceptor can infect naive T cells2 and are associated
with increased severity of immunosuppression3. Thus, coreceptor
testing can be used for monitoring HIV disease progression.
Coreceptor usage influences available treatment options. Core-
ceptor antagonists such as maraviroc, a drug that blocks the CCR5
coreceptor, prevent viral cell entry by inhibiting the interaction of
HIV with its coreceptors4. Since maraviroc is only effective against
viruses using CCR5, coreceptor usage should be determined before
the start of treatment. Besides modulating the effectiveness of core-
ceptor antagonists, coreceptor usage also modulates the effectiveness
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of bNAbs. For example, the bNAbs PG9 and PG 16 bind mostly
within V2 and V35. Considering that these regions are important
determinants of HIV coreceptor usage, it could be shown that both
antibodies neutralize R5 variants more effectively6.
HIV-1 coreceptor usage has been intensively studied7 and many
methods for identifying its coreceptor usage are available8. In con-
trast, much less is known about HIV-2 coreceptor usage9; only a
single rules-based method for identifying HIV-2 coreceptor usage
has been developed10. However, this rules-based approach is not
available as an online tool. Thus, prescription of maraviroc to HIV-
2-infected patients was based on phenotypic coreceptor testing
(Section 2.5.1) for a long time. Phenotypic testing is generally more
cost- and time-consuming than genotypic testing. This is particularly
true for HIV-2 for which no standardized phenotypic assay11 exists.
Therefore, it is desirable to have a web service that accurately deter-
mines HIV-2 coreceptor usage based on the composition of the viral
sequence.
The goal of this study was to develop a genotypic tool for pre-
dicting whether a population of HIV-2 viruses uses only the CCR5
coreceptor or whether the population can use the CXCR4 corecep-
tor. Since the interaction with cellular coreceptors is facilitated by
viral surface glycoproteins, only genomic sequences from Env were
considered. Because nucleotide sequences of full-length Env and
corresponding phenotypic coreceptor usage are uncommon, I focused
on the more prevalent V312. The use of coreceptors other than CCR5
and CXCR4 was not considered because the use of other coreceptors
is correlated with CXCR4 usage13 and cell entry independent of
CCR5 and CXCR4 is rarely observed14.
The significance of this work lies in the contribution of a publicly
available tool for identifying HIV-2 coreceptor usage based on the
V3 amino-acid sequence alone. Such a tool is useful for three groups
of users. Clinicians can use such a tool in order to take informed
treatment decisions. Epidemiologists can use the tool to perform
large-scale studies that investigate the association between tropism
and clinical markers of infection. Last, virologists can use the tool
to study the influence of individual V3 amino acids on coreceptor
usage.
An overview of established methods for genotypic coreceptor
determination is provided in Section 5.1. Section 5.2 explains the
steps that are required for the implementation of a statistical model
for the prediction of HIV-2 coreceptor usage. The resulting prediction
model is validated and interpreted in Section 5.3, in which I also
introduce the geno2pheno[coreceptor-hiv2] web server. I conclude
this chapter with a discussion of the results in Section 5.4.
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5.1 Genotypic Methods for Coreceptor Identification
While phenotypic assays can accurately detect a broad range of
coreceptor usage patterns, using such assays is expensive and time-
consuming. Genotypic testing of coreceptor usage, on the other hand,
requires only the genomic sequence of the virus. The advantage of
these approaches is that they are fast, inexpensive, and at the same
time agree well with the results from phenotypic tests15. Similarly
to HIV resistance testing, genotypic approaches for determining
coreceptor usage can be differentiated into rules-based and statistical
methods. In the following, I first give an overview of the genotypic
approaches that are used for identifying HIV-1 coreceptor usage
(Section 5.1.1) and then come to HIV-2 coreceptor identification
(Section 5.1.2).
When reporting the performances of genotypic approaches for
coreceptor prediction, it is important to differentiate whether these
approaches were evaluated on clonal or bulk data (population-based
data). While clonal data reflect the genetic makeup of individual
viruses, bulk data result from applying Sanger sequencing to viral
populations, which is typically done in clinical applications. There-
fore, population-based sequences contain ambiguities at genomic
positions for which different variants exist in the viral population.
Determining coreceptor usage on population-based Sanger se-
quencing data is more challenging than on clonal sequences16 for two
reasons. First, Sanger sequencing does not allow for the detection
of minority variants (e.g. variants with an abundance smaller than
10%). This means that approaches based on Sanger sequences cannot
consider the coreceptors that are used by minor variants although
they may be relevant. Second, genotypic methods need to devise
suitable ways for modeling the presence of ambiguities. For example,
if multiple amino acids are observed at a single position, worst-case
encodings17 consider only those amino acids that are most associated
with X4-capability. While such an encoding improves sensitivity,
it also potentially increases the rate at which false positives are re-
ported. Thus, in the following, I will refrain from comparing the
predictive performance of methods that were evaluated on data of
disparate origin (i.e. clonal vs bulk).
5.1.1 Identification of HIV-1 Coreceptor Usage
The first available genotypic approach for the identification of HIV-1
coreceptor usage was established by the 11/25 rule18. Under this
rule, an HIV-1 strain is considered to be X4-capable if it exhibits a
positively charged amino acid at the 11th or 25th position in the V3.
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Otherwise, the sequence is considered to be from an R5-tropic virus.
Although evaluations on clinical isolates have shown that the 11/25
rule is highly specific (93%), it severely lacks sensitivity (30%)19.
Therefore, several new approaches for determining coreceptor usage
were developed in the 2000s, with one branch of research investigat-
ing extended sets of rules and the other studying quantitative models
brought forth by statistical learning.
Rules-based Approaches The predictive performance of rules-based
approaches was improved considerably by extensions of the 11/25
rule. Examples for such extensions are the 11/24/25 rule and Gar-
rido’s rule. The 11/24/25 rule classifies a sequence as X4-capable if
a positively charged amino acid is found at the 11th, 24th, or 25th
V3 position (sensitivity of 89% at a specificity of 96% on a small data
set of mostly clonal sequences)20. Garrido’s rule classifies a sequence
as X4-capable if it fulfills the 11/25 rule or if it exhibits a net charge
≥ +5 (sensitivity of 80% at a specificity of 79% for population-based
sequences)21.
Statistical Approaches The most frequently used bioinformatic ap-
proaches for the identification of HIV-1 coreceptor usage are Wet-
Cat22, WebPSSM23, and geno2pheno[coreceptor]24, all of which are
available as web servers processing the V3 amino-acid sequence. Wet-
Cat offers a SVM and two types of decision trees that were trained
on 292 V3 amino-acid sequences. WebPSSM, on the other hand, uses
position-specific scoring matrices, which are defined according to the
observed frequencies of amino acids in the V3 for X4-capable and R5
variants. Based on the scoring matrices, the odds of a position being
rather associated with X4-capable or R5-using variants are computed
and integrated into a final score.
geno2pheno[coreceptor] relies on a linear support vector ma-
chine whose decision values are transformed to FPRs, which provide
a measure of confidence for the predictions. Due to its high pre-
dictive accuracy and interpretability, geno2pheno[coreceptor] has
achieved considerable popularity in the field25. The initial version
of geno2pheno[coreceptor], which was released in 2004, has been
further developed throughout the years. The geno2pheno[454] ser-
vice, which relies on geno2pheno[coreceptor] and was released
in 2010, provides an interface for identifying HIV-1 coreceptor us-
age based on data from 454 next-generation sequencing26. In 2012,
geno2pheno[coreceptor] was extended by a model trained on next-
generation sequencing data that is also applicable to Sanger sequenc-
ing data27.
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Performance Comparison Both SVMs and position-specific scoring ma-
trices were shown to constitute a considerable improvement over the
established 11/25 rule (sensitivity 59.5%, specificity 92.5%), achieving
a sensitivity of 71.9% and 76.4% at a specificity of 92.5%, respec-
tively28. Despite their different methodological approaches, current
rules-based and statistical approaches for the genotypic identification
of HIV-1 coreceptor usage seem to be similarly accurate29.
5.1.2 Identification of HIV-2 Coreceptor Usage
The first genotypic approach for predicting the coreceptor usage
of HIV-2 was developed by Visseaux et al. (2011). In their work,
they studied the amino-acid sequence of the HIV-2 V3 in order to
find associations between coreceptor usage and specific features
in the V3 region. They generated a new data set of V3 amino-acid
sequences from 53 HIV-2 infected persons. Using these data, they
identified nine markers in V3 exhibiting significant associations
with coreceptor usage according to Fisher’s exact test or the χ2 test.
The four markers that performed best at identifying X4-capable
variants (sensitivities greater than 70% and specificities of 100%)
were classified as the major determinants of X4-capable HIV-2: any
substitution at position 18, V19K/R30, any insertion after position
24, and a V3 net charge exceeding 6. The remaining five markers of
X4-capability were considered to be minor markers of X4-capability:
S22A/F/Y, Q23R, I25L/Y, R28K, and R30K.
Using the four major determinants of X4-capable variants, they
defined the following rules-based approach. If an HIV-2 V3 exhibits
any of the four major markers, it is identified as X4-capable and,
otherwise, as R5. Applying this approach on an independent data set
consisting of 51 V3 sequences from the literature and the LANL HIV
database yielded a sensitivity of 65% at a specificity of 100% for the
detection of X4-capable variants.
5.2 Model Development
In this section, I describe the data and methods that were used for
formulating a new model for HIV-2 coreceptor usage prediction.
In Section 5.2.1, I describe the phenotypic measurements that were
performed in order to generate an independent validation set. The
steps that were necessary for obtaining the learning data set are
described in Section 5.2.2. The characteristics of the data set are
presented in Section 5.2.3. Section 5.2.4 describes the framework for
model selection and validation. Finally, Section 5.2.5 summarizes the
work that was done for implementing the geno2pheno[coreceptor-
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hiv2] web server.
5.2.1 Phenotypic Measurements
The phenotypic measurements that are described in the following
paragraphs were carried out by Pedro Borrego, Andreia Martins, and
Nuno Taveira.
Reagents HEK293T cells were purchased from American Type
Culture Collection (Rockville, MD). The following reagents were
provided by the AIDS Research and Reference Reagent Program,
National Institutes of Health: TZM-bl cells31, TAK-77932, and bicy-
clam JM-2987, a hydrobromide salt of AMD-310033. The wild-type
pROD10 plasmid was a gift from Keith Peden34. HEK293T and TZM-
bl cells were cultured in complete growth medium consisting of
Dulbecco’s modified eagle medium (DMEM) supplemented with
10% of fetal bovine serum, 100 U/ml of penicillin-streptomycin, 2
mM of L-glutamine, 1 mM sodium pyruvate, and 1× of MEM non-
essential amino acids (Gibco/Invitrogen, USA). All cell cultures were
maintained at 37 ◦C in 5% of CO2.
Viral Isolates Two new primary isolates, 15PTHSJIG and 15PTHCEC,
were obtained from HIV-2-infected Portuguese patients by cocultiva-
tion with peripheral blood mononuclear cells from seronegative sub-
jects, as described previously35. In addition, six new HIV-2 ROD10
mutants were analyzed that contained the following mutations in the
V3: H18L, H23∆ + Y24∆, K29T, H18L + H23∆ + Y24∆, H18L + K29T,
and H18L + H23∆ + Y24∆ + K29T36. HIV-2 ROD10 mutants were
obtained by transient transfection of HEK293T cells. Transfections
were performed with 10 µg of DNA in a 100 mm tissue culture dish,
using the jetPrime transfection reagent (Polyplus) according to the
instructions of the manufacturer. Cell culture supernatants were
collected 48 h post-transfection, filtered, and stored at −80 ◦C.
The half maximum tissue culture infectious dose (TCID50) of
each isolate was determined in a single-round viral infectivity as-
say using a luciferase reporter assay with TZM-bl cells. First, 10 000
TZM-bl reporter cells were seeded in 96-well tissue culture plates
and incubated overnight. On the next day, the growth medium was
removed and replaced by 200 µL of fresh growth medium supple-
mented with 19.7 µg/ml of DEAE-dextran. A total of 100 µL of virus
supernatant was added to the first well, from which serial threefold
dilutions were prepared in the next wells. The assay was performed
in quadruplets. After 48 h, luciferase expression was quantified by
measuring luminescence with the Pierce Firefly Luciferase Glow
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Assay Kit (Thermo Fisher, USA) and the Infinite M200 luminometer
(TECAN), according to manufacturer’s instructions. Control wells
containing only target cells and growth medium were used to mea-
sure background luminescence. The TCID50 was calculated using the
statistical method of Reed and Muench37.
Phenotypic Determination of Coreceptor Usage CCR5 and CXCR4 core-
ceptor usage was determined in a single-round viral infectivity assay
with TZM-bl cells38. First, 10 000 TZM-bl reporter cells were seeded
in 96-well tissue culture plates and incubated overnight. On the next
day, the growth medium was removed and the cells were incubated
for 1 h (at 37 ◦C in 5% CO2) with growth medium either in the pres-
ence or in the absence of excessive amounts of the CCR5 antagonist
TAK-779 (10 µM) and/or of the CXCR4 antagonist AMD3100 (1.2
µM). A fixed amount of virus supernatant, corresponding to 200
TCID50 was added to each well and cells were cultured with a total
volume of up to 200 µL of growth medium in the presence of 19.7
µg/mL of DEAE-dextran. After 48 h, luciferase expression was quan-
tified by measuring luminescence with the Pierce Firefly Luciferase
Glow Assay Kit (Thermo Fisher, USA) and the Infinite M200 lumi-
nometer (TECAN), according to manufacturer’s instructions. Control
wells containing only target cells and medium were used to measure
background luminescence.
A viral population was classified as R5-tropic when viral infec-
tivity was inhibited in the presence of TAK-779 but unaltered in the
presence of AMD3100, and, as X4-tropic when infectivity was inhib-
ited in the presence of AMD3100 but unaltered in the presence of
TAK-779. When infectivity was completely inhibited only by the si-
multaneous presence of TAK-779 and AMD3100, the virus population
was classified as dual/mixed (D/M) for viral isolates or as R5/X4
tropic for ROD10 mutants.
5.2.2 Data Collection and Processing
Due to the established association between V3 and HIV-2 coreceptor
usage39, I aimed at gathering all available amino-acid sequences
of V3 with corresponding measurements of phenotypic coreceptor
usage. The majority of samples40 were retrieved from the LANL HIV
database. Further observations were acquired from the literature41
and my collaborators as described earlier. In total, 314 genotype-
phenotype pairs were included in the training data set. Since a
fraction of the samples represented full-length Env, a small number
of V1 and V2, which have also been reported to influence coreceptor
usage42, were obtained additionally.
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Identifier #R5 #X4 V3 Decision
DQ870430 21 1 CKRPGNKTVVPITLMSGLVFHSQPINKRPRQAWC R5
NARI-12 5 1 CKRPGNKTVLPITLMSGLVFHSQPINTRPRQAWC R5
GU204945 3 1 CKRPGNKTVRPITLLSGRRFHSQVYTVNPKQAWC Exclude
310248 1 1 CRRPGNKTVVPITLMSGLVFHSQPINKRPRQAWC X4-capable
Table 5.1: Overview of ob-
servations with identical V3
amino-acid sequence but discor-
dant annotation of phenotypic
coreceptor usage. #R5 and #X4
indicate the number of obser-
vations that were annotated as
R5 and X4-capable, respectively.
The identifier and V3 sequence
of the X4-capable isolate is
shown.
43 Blaak et al. 2005; van Der Ende et al.
2000; Owen et al. 1998
44 Visseaux et al. 2011; Kulkarni et al.
2005; Skar et al. 2010; Jadhav et al. 2009;
Borrego et al. 2008; de Silva et al. 2012
45 Visseaux et al. 2011; Kulkarni et al.
2005; Owen et al. 1998; Jadhav et al.
2009
46 Skar et al. 2010
47 Visseaux et al. 2011
Data Processing Each observation in the data set was labeled either
as R5 or X4-capable. Isolates for which CXCR4 usage was reported
(X4, R5X4, or dual/mixed) were annotated as X4-capable and isolates
for which only usage of the CCR5 coreceptor was reported were
annotated as R5. All of the samples using additional coreceptors
(e.g. GPR15 or CXCR6) were capable of using the CXCR4 coreceptor,
which is in line with the literature43. Observations representing
clonal genotype-phenotype pairs from the same patient were merged
by forming consensus sequences if their phenotypes agreed.
Duplicate Removal With the intent of constructing a representative
training data set, I removed duplicated observations from the V3
data set (i.e. observations sharing the same V3 amino-acid sequence).
One of two operations was performed for every set of duplicate ob-
servations with discordant phenotypes: either one of the discordant
observations was included in the data set or all of the sequences were
excluded. The decisions were made by first considering the frequency
at which a duplicate observation was phenotyped in a certain way
and then, if necessary, considering further evidence from the litera-
ture. In the following, I discuss the decisions taken for the four sets
of discordant observations that are summarized in Table 5.1.
Each of the samples sharing the same V3 amino-acid sequence
as DQ87043044 and NARI-1245 was phenotyped as an X4-capable
variant only once, while a decidedly larger number of samples
was phenotyped as R5 (21 and 5 sequences, respectively). Hence, I
regarded the X4-capable measurements as outliers and the respective
sequences were included with the R5 label. The V3 sequence with
the accession GU20494546 was identified as X4-capable once and as
R5 thrice. Due to lacking evidence of actual coreceptor usage, this
sequence was removed from the data set.
For the V3 sequence with the identifier 310248, one study reported
the use of CCR5 and another the use of CXCR4. The sequence had
been identified in an X4-capable isolate by Owen et al. (1998), but
also in an R5 isolate with the same V3 sequence except for an R/K
ambiguity at position 2747. Interestingly, the R5 isolate showed a
marginal signal for the CXCR4 coreceptor, which was discarded
because the signal was smaller than 5% of the signal for CCR5 us-
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age. Further evidence pointing towards the usage of CXCR4 was
presented by Owen et al. (1998) who reported a minor induction of
syncytia for their isolate. Additionally, applying a CXCR4 antagonist
to cells lacking the CCR5 coreceptor revealed a reduction in infectiv-
ity between 40% and 90% for this strain, which was enough evidence
to include this sequence in the data set with the X4-capable label.
Profile Alignments To allow for the alignment of a single V3 amino-
acid sequence with respect to the composition of the overall HIV-2
V3, I used profile alignments. While standard pairwise alignment
algorithms48 are based on a single reference sequence, profile align-
ments are better suited for divergent sequences such as the V3 from
HIV-2. Here, alignment scores were computed under consideration
of both, the frequency of amino-acid substitutions given by the align-
ment profile and the value from an amino-acid substitution matrix49.
In order to construct an amino-acid profile for the HIV-2 V3, I
retrieved all available amino-acid sequences of the HIV-2 envelope
region from the LANL HIV database and selected the V3 region
through pattern matching in the following manner. If a sequence
exhibited the highly conserved V3 start motif (CKRP or CRRP) as well
as the end motif (QAWC), the corresponding subsequence was selected.
In cases where either only the start or end motif could be found, a
search for a substring of the missing motif was conducted and the
corresponding subsequence was selected if a substring of the missing
motif could be found. The 1 979 retrieved V3 amino-acid sequences
were aligned using the well-established tool ClustalW (version 2.1
with the accurate switch and otherwise default parameters)50. The V3
profile was then constructed by determining the frequency of each
amino acid for every alignment position.
Feature Encoding Let B indicate the set of 20 amino acids augmented
with the gap character, –. The feature vector xi ∈ Rp of observation
i ∈N is determined from the amino-acid sequences of the considered
HIV-2 regions in the following way. Let si indicate the i-th position
of an aligned sequence and let sij indicate the set of disambiguated
amino acids (Table A.1) occurring at position j in the i-th input
sequence. We use xij[c] to denote whether the character c ∈ B
appears at position j in the sequence of the i-th observation. For each





, for c ∈ sij
0, for c /∈ sij
.
Data set labels were encoded by setting yi = −1 for observations
labeled as X4-capable and yi = 1 for samples labeled as R5.51
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Phenotype Phylogenetic Group Frequency
R5 A 61 (48.4%)
X4-capable A 46 (36.5%)
R5 B 12 (9.5%)
X4-capable B 5 (3.9%)
X4-capable D 1 (0.08%)
R5 Unknown 1 (0.08%)
Table 5.2: Distribution of pheno-
typically determined coreceptor
usage and phylogenetic groups
of HIV-2 in the V3 data set.
52 Groups A and B are most prevalent
phylogenetic groups. Group A strains
cause the majority of infections (Chen
et al., 1997; Gao et al., 1994; Marlink,
1996).
53 Li and Jiang 2005
5.2.3 Characteristics of the V3 Data Set
The distribution of phenotypic coreceptor annotations and HIV-2
phylogenetic groups for the V3 data set are shown in Table 5.2. After
filtering the V3 data set, 126 genotype-phenotype pairs remained of
which 74 (58.7%) were labeled as R5 and 52 (41.3%) as X4-capable.
The samples in the data set originate from diverse geographic regions.
In total, 87 (69%) samples were collected in Europe, of which 42
(48.3%) come from France, 33 (37.9%) from Portugal, and 12 (13.8%)
from Sweden. All of the 10 (10.3%) Asian samples originate from
India. Of the 24 (19%) West African samples, 15 (60%) were collected
in Guinea-Bissau, 5 (20.8%) in Ivory Coast, 2 (8.3%) in Gambia, and 2
(8.3%) in Senegal.
Most isolates in the data set (84.9%) had been genotyped as HIV-2
group A. Only a minority of samples (13.5%) had been identified as
group B. The remaining samples (1.6%) either had been identified
as group D or had not been genotyped. The group distribution of
the samples in the data set reflects the global distribution of HIV-2
groups52.
5.2.4 Model Selection and Validation
Since SVMs (Section 3.4.2) that use the amino-acid sequence of the V3
region as an input have already been successfully applied for identi-
fying the coreceptor usage of HIV-1 (Section 5.1), I also considered
the use of SVMs in the HIV-2 setting. For the coreceptor prediction
problem, SVMs find a vector of coefficients and an intercept that
define a hyperplane maximizing the margin between observations
from the two classes X4-capable and R5.
As kernel functions, I considered linear, RBF, polynomial, and edit
kernels53 (Section 3.4.2). To simplify model selection via grid search,
I opted for the ν-SVM formulation. This formulation has the benefit
that its regularization parameter ν is bounded by the interval [0, 1],
while the original formulation uses the soft-margin parameter C ∈ R.
The grid search was conducted with ν between 0.1 and 0.4. Higher
values were not considered as these led to infeasible optimization
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problems. Additionally, the following hyperparameters were consid-
ered for the individual kernels: σ ∈ {1× 10−3, 1× 10−2, 1× 10−1} for
the RBF kernel, d ∈ {2, 3, 4} for the polynomial kernel, and
γ ∈ {1× 10−3, 2.5× 10−3, 5× 10−3, 7.5× 10−3, 1× 10−2, 5× 10−2}
as well as PAM ∈ {30, 70, 250} for the edit kernel.
The model parameters were tuned by maximizing the AUC (Sec-
tion 3.3.3) in ten runs of tenfold CV (Section 3.2.5). To determine the
expected performance of the models taking into account the model
selection procedure, I performed tenfold NCV. To compare the per-
formance of the rules-based approach by Visseaux et al. (2011) with
the statistical models, it was necessary to define a data set contain-
ing only those observations that had not been used for identifying
discriminatory features by Visseaux et al. in order to prevent over-
estimating the performance of their approach. Thus, I selected an
appropriate subset of the available data (N = 84), which is referred to
as the comparison data set in the following.
To evaluate whether there exists a significant difference between
the rules-based approach and SVMs, I applied McNemar’s test
(Section 3.6.2). The result of the test indicates whether the predictions
from the two approaches have differential rates of agreement with
phenotypically determined coreceptor usage.
5.2.5 Development of geno2pheno[coreceptor-hiv2]
The following paragraphs describe how the geno2pheno[coreceptor-
hiv2] web server was developed. I first explain how the interpretabil-
ity of the SVM can be improved by transforming decision values to
FPRs and visualizing the SVM model weights. Thereafter, I describe
the feature encoding that is used by the web service, which allows for
increased sensitivities for low-quality sequences and clinical isolates.
Transforming Decision Values
SVM decision values were transformed to probabilities (Wu et al.,
2004) indicating the likelihood that a V3 amino-acid sequence orig-
inates from an X4-capable virus. These probabilities are called X4-
probabilities in the following. Since these probabilities do not offer
insights into the specificity of coreceptor prediction, X4-probabilities
were transformed to FPRs, which have already been established
for the quantification of HIV-1 coreceptor usage54. Here, the FPR
indicates the estimated rate at which R5 samples would be falsely
predicted as X4-capable if the SVM estimate were used as a cutoff for
classifying observations into the two classes.
To transform X4-probabilities to FPRs, I constructed a mapping
from predicted X4-probabilities to FPRs during the training stage.
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Each predicted X4-probability was used as a cutoff for classifying
the samples once: All samples with X4-probabilities below the cutoff
were assigned the label R5 and all samples with X4-probabilities
greater or equal to the cutoff were assigned the label X4-capable.
This cutoff-dependent class assignment in combination with the
phenotypic labels for each observation yielded a 2 × 2 contingency
table indicating FPs and TNs, from which I could compute the FPR
as FPR = FPFP+TN . Low FPRs indicate confident predictions of X4-
capable variants, while high FPRs designate R5-tropic viruses.
Choice of Reference Sequence
To display alignments of query sequences in the user interface of
the web service, the well-described HIV-2 reference strain M33262
(Mac239)55 is used.
Visualizing the Impact of Individual Amino Acids
Although SVMs are often considered as black boxes, their inter-
pretability depends on the used kernel functions. Linear SVMs are
particularly easy to interpret because a fitted linear SVM can be com-
pactly described by the vector α∗ ∈ R|S| whose length, |S|, is defined
by the number of support vectors. The vector’s entries, α∗i = α̂iyi,
are defined as the product of the weight, α̂i, and the corresponding
outcome yi. Let X∗ ∈ R|S|×p be the feature matrix containing only
the support vectors x∗. Then the impact of individual amino acids
according to the model can be determined via β = (α∗TX∗)T ∈ Rp.
Given a new input sequence with the feature vector x ∈ Rp, the
contribution of feature j ∈ {1, . . . , p} is given by b(j) = xj × β j ∈ R.
This quantity can be used for visualizing how individual amino acids
in a query sequence impact coreceptor usage.
Modified Feature Encoding
When applying the SVM model to input sequences, the query se-
quence is modified in two ways in order to improve predictive per-
formance. The first modification concerns gaps in the sequence and
the second relates to ambiguous positions. Note that since the la-
bels for training the SVM were encoded by −1 for X4-capable and
1 for R5, positive coefficients designate features associated with R5
variants and negative coefficients designate features associated with
X4-capable variants.
Gap Replacement Errors during sequencing or problems with the
alignment can lead to the introduction of gaps in the V3 sequence
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that have no functional meaning. Although functionally irrelevant,
gaps with absolute weights close to 0 can still influence the outcome
because their absence reduces the decision value, thereby pulling
the prediction towards X4-capable. Therefore, the following approach
is used to deal with this problem. Let β j(c) be the coefficient that
corresponds to the character c at sequence position j and let ε = 0.01.
For every position j where c represents a gap, the model weight
associated with the gap, β j(c), is considered. If |β j(c)| < ε, then
the gap is replaced with the encoded consensus amino acid c′ from
position i of the V3 alignment profile by setting xj[c] = c′ before
predicting coreceptor usage. Otherwise, if |β j(c)| ≥ ε, the gap is
deemed to be functionally relevant and is retained.
Worst-Case Encoding Ambiguous positions typically indicate the
presence of multiple viral variants within the same host. These
variants may use different coreceptors for cell entry. Therefore am-
biguous positions can encompass amino acids representative of both,
R5 and X4-capable viruses. To be more sensitive towards X4-capable
variants, the encoding is changed in the following way. For every
ambiguous sequence position j with observed amino acids sj, the
position is adjusted to sj = arg minc∈sj β j(c).
The fact that this worst-case encoding may give rise to sequences
that might not exist in vivo is only a minor concern due to the follow-
ing reasoning. Assume that a viral population consists of an R5- and
an X4-capable quasispecies, which means that the prediction should
be X4-capable. In this case, every ambiguous position should contain
an amino acid representing the X4-capable variant such that for every
ambiguous position j, there exists β j(c) ≤ 0. Selecting the observed
amino acid whose weight contributes most to X4-capability means
choosing the character c obtaining the most negative weight, β j(c).
Consequently, the decreased decision value enhances the prediction
of X4-capable variants. The same logic can be applied to two distinct
X4-capable quasispecies.
Assume now that there exist two quasispecies that use only the
CCR5-coreceptor. In this case, the prediction should be R5 and the
weights of ambiguous positions should be positive, because no
amino acids associated with X4-capability should be observable.
Hence, the worst-case choice would result in min β j(c) ≥ 0 for all
characters c at every ambiguous position j. This, however, does not
enhance the prediction of X4-capable variants and thus does not
degrade the prediction of R5 when the decision boundary is set to
0. Even for decision boundaries at values above zero, the prediction
would not be influenced much because it is likely that there is a
sufficient number of non-ambiguous positions with positive weights
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for sequences from R5 viruses.
5.3 Results
To generate statistical models capable of predicting HIV-2 coreceptor
usage, a data set of 126 pairs of HIV-2 genomic amino-acid sequences
and phenotypic coreceptor usage annotations (either R5 or X4-capable)
was gathered. Based on this data set, SVMs with various kernel
functions were trained and validated using the amino-acid sequences
of either the V1, V2, V3, or all three regions.
Section 5.3.1 describes the selection of the linear SVM trained on
V3 amino-acid sequences that was used for all subsequent analyses.
Section 5.3.2 analyzes the predictive performance of the approach
from Visseaux et al. (2011) and Section 5.3.3 compares the rules-based
approach with the linear SVM. The features in the V3 imparting
the X4-capable phenotype are investigated in Section 5.3.4. A cutoff
for separating R5 and X4-capable observations is presented in Sec-
tion 5.3.5. Finally, the geno2pheno[coreceptor-hiv2] web service and
its validation are presented in Sections 5.3.6 and 5.3.7, respectively.
5.3.1 Model Selection and Performance
Model Selection In the following, I report the best performing models
as determined by 10-fold CV for every considered genomic region of
HIV-2. Linear SVMs based on V1 and V2 (N = 62) achieved AUCs of
0.84 and 0.65, respectively. For the V3 region (N = 126), an SVM with
a linear kernel performed best (AUC of 0.95). SVMs based on other
kernel functions achieved similarly high performances except for the
SVMs based on the edit kernel, which had distinctly smaller AUCs
(Table 5.3).
The performance of SVMs trained on a concatenation of the amino-
acid sequences of all three variable regions V1/V2/V3 (N = 62 sam-
ples) was also investigated. The best model resulting from the use
of all three regions performed worse (AUC of 0.89) than the best
model based on the V3 alone (AUC of 0.95). Models based on V1/V2
were not further investigated for the following reasons. First, models
incorporating information from the V1/V2 region performed worse
than models based on V3 alone. Second, V1/V2 are more variable
than V3, which may cause problems with the alignment. Third, data
for V1/V2 is limited, while genomic data from the V3 is more com-
monly available. Thus, the linear ν-SVM (ν = 0.3) trained on 126 V3
amino-acid sequences was selected for all further applications. In the
following, this SVM is referred to as the linear SVM.
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CV Run RBF Linear Polynomial Edit Kernel
1 0.9475 0.9459 0.941 0.8629
2 0.9509 0.9506 0.9452 0.851
3 0.9504 0.9579 0.9444 0.8655
4 0.9449 0.947 0.9379 0.8634
5 0.9472 0.9467 0.9413 0.8744
6 0.9467 0.9467 0.9457 0.8689
7 0.9532 0.9535 0.9475 0.8377
8 0.9522 0.9532 0.9306 0.8623
9 0.9524 0.9524 0.9478 0.9012
10 0.9441 0.9431 0.9384 0.8672
µ 0.949 0.9497 0.942 0.8654
σ 0.0033 0.0045 0.0053 0.0162
Table 5.3: AUCs per run of
tenfold cross validation for
SVMs trained on V3 amino-acid
sequences. For every kernel
function, only the best perform-
ing parameter combination
is shown. All classifiers per-
formed best with the SVM
parameter ν = 0.3. The hy-
perparameters for the kernel
functions resulting in the best
performance were σ = 1× 10−3
for the RBF kernel, a degree
of 2 for the polynomial kernel,
and γ = 5× 10−3 with a PAM
70 matrix for the edit kernel.
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Model Performance The AUCs reported in Table 5.3 are optimistic
because the best performing models were chosen a posteriori. In order
to obtain a more accurate estimate of the prediction error, NCV was
used. In the 10 inner runs of NCV, SVMs using a linear kernel were
chosen seven times and SVMs using an RBF kernel were chosen three
times according to their AUCs. The AUC of tenfold NCV was 0.88
(sensitivity of 76.9% and specificity of 97.3%).
5.3.2 Validation of the Rules-Based Approach
In order to validate the major markers of HIV-2 coreceptor usage that
were established by Visseaux et al. (2011), profile alignments were
computed for all V3 amino-acid sequences in the comparison data
set. The alignment positions were enumerated according to the HIV-2
reference M33262. Of the 34 X4-capable sequences in the comparison
data set, only 5 (14.7%) samples did not have any major marker, 2
(5.9%) had a single marker, 2 (5.9%) had two markers, 4 (11.8%) had
three markers, and 21 (61.8%) had four markers. Interestingly, the
five X4-capable sequences without any markers for CXCR4 usage
(accession numbers/isolate identifiers: DQ21303556, GU20494457,
consensus V3 from clones JX219591-JX219598, GB8758, and 31024859)
could be identified as X4-capable neither by the rules-based method
nor by the linear SVM.
The performance of the rules-based approach from Visseaux et al.
(2011) was evaluated on the comparison set by requiring different
numbers of major markers of X4-capability (either 1, 2, 3, or 4). The
balanced accuracy decreased when the required number of major
markers was increased (balanced accuracies 0.89, 0.88, 0.85, and 0.81,
respectively). This confirms that requiring one major marker for
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Number of Rules Sensitivity Specificity Balanced Accuracy
1 0.85 0.94 0.89
2 0.79 0.96 0.88
3 0.74 0.96 0.85
4 0.62 1 0.81
Table 5.4: Performance of the
approach from Visseaux et al.
on the comparison data set.
The column Number of Rules
indicates the number of re-
quired major rules for calling
X4-capability.
Rule Sensitivity Specificity Accuracy P-value
L18X 0.79 0.96 0.88 2.3× 10−13 (∗)
Insertion after position 24 0.74 1 0.87 3.4× 10−14 (∗)
Net charge > +6 0.77 0.96 0.86 6.8× 10−11 (∗)
V19K/R 0.74 0.96 0.85 8.7× 10−11 (∗)
R28K 0.5 0.96 0.73 8.9× 10−7 (∗)
Q23R 0.29 1 0.65 4.7× 10−5 (∗)
R30K 0.47 0.7 0.57 1.7× 10−1
S22A/F/Y 0.15 1 0.59 9× 10−3 (∗)
I25L/Y 0.08 0.97 0.53 4.7× 10−1
Table 5.5: Performance of indi-
vidual rules from Visseaux et
al. on the comparison data set.
The column Accuracy provides
the balanced accuracy. The
major discriminatory features
are highlighted in bold. Signif-
icant p-values as identified by
Fisher’s exact test are shown by
asterisks.
X4-capability provides the best trade-off between sensitivity and
specificity. Note, however, that the presence of additional markers
could be used to corroborate predictions since the requirement of a
larger number of major markers increases specificity (Table 5.4). For
example, requiring four major markers results in a specificity of 100%
at a sensitivity of 62%.
To determine the predictive performance of individual markers
of X4-capability, I applied a two-sided Fisher’s exact test on the con-
fusion matrices resulting from the application of individual rules.
P-values were corrected for multiple testing using the Benjamini-
Hochberg procedure (Section 3.6.5), for which the FDR was set to
5%. All established discriminatory features except for R30K and
I25L/Y were significant predictors of X4-capability on the compar-
ison data set (Table 5.5). The four major discriminatory markers of
X4-capability (accuracies of 85%–88%) outperformed the other mark-
ers considerably with respect to predictive performance (accuracies
53%–73%).
5.3.3 Comparison of Predictions from SVMs and Rules
For comparing the predictive performances of SVMs and the rules-
based method, both approaches were evaluated on the comparison
data set. The rules-based method from Visseaux et al. (2011), which
requires just a single major determinant to predict X4-capability,
achieved a sensitivity of 85.3% at a specificity of 94% (balanced
accuracy 89.6%). Tenfold NCV of SVMs resulted in a sensitivity of
73.5% at a specificity of 96% (balanced accuracy 84.7%). Despite the
slightly higher performance of the rules-based method on this data
predicting hiv-2 coreceptor usage 155
set, the predictive performances were not found to be significantly
different according to McNemar’s test (p-value 0.37).






















































































































































































































































Figure 1 from Döring et al. (2016) is licensed under CC-BY 4.0
Figure 5.1: X4-probabilities
predicted by the linear SVM
for V3 amino-acid sequences
exhibiting the established
discriminatory features in-
dicative of X4-capability listed
on the x-axis. The left-hand
panel shows the predicted
X4-probabilities for sequences
labeled as R5, while the right-
hand panel shows the predicted
X4-probabilities for sequences
labeled as X4-capable. The bot-
tom line of a box indicates the
1st quartile (Q1) of predicted
X4-probabilities, the bar inside
the box indicates the median,
and the top line indicates the
3rd quartile (Q3). The whiskers
extending from a box indi-
cate predicted X4-probabilities
that lie within 1.5 × IQR (in-
terquartile range, IQR = Q3 -
Q1). Outlier values that are not
within the whisker region are
shown as dots. Segments on the
x-axis without a box reflect the
absence of the corresponding
feature and phenotype.
I investigated how well the linear SVM reproduces the established
markers for X4-capability by analyzing the SVM estimates for se-
quences exhibiting specific markers of X4-capability. Figure 5.1 shows
that the SVM assigns high X4-probabilities to sequences from X4-
capable viruses exhibiting the established X4-markers. However,
the SVM also assigns high X4-probabilities to the rare R5 samples
carrying markers of X4-capability.
Table 5.6 shows the SVM features with the greatest impact on the
prediction. All major markers of X4-capability are among the features
contributing 75% of the total absolute model weight. The model also
considers additional features that have not been described previously.
To determine whether these features are significant, I applied Fisher’s
exact test on the 2 × 2 matrix resulting from using these features
as rules for predicting X4-capability. The multiple-testing corrected
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V3 Position R5 feature X4 feature R5 weights X4 weights
18 L H, Q, F, M 0.69 -0.23, -0.15, -0.12, -0.1
Ins 24 - I, V 0.45 -0.22, -0.21
19 I R, K, V 0.19 -0.25, -0.23, -0.19
Ins 22 - H, Y 0.36 -0.18, -0.18
24 P NA 0.17 NA
23 Q R 0.14 -0.14
27 Q K 0.09 -0.12
13 T R 0.11 -0.07
26 NA N NA -0.09
10 A K 0.09 -0.07
14 I L 0.08 -0.08
22 S NA 0.08 NA
15 A G 0.08 -0.07
8 K S 0.07 -0.07
Table 5.6: Features of the linear
SVM contributing 75% of the
total absolute model weight.
Positions of discriminatory
features that were not described
previously are shown in bold.
Entries prefixed with Ins in-
dicate the presence of any
insertion after a certain V3 posi-
tion. Entries annotated with NA
indicate that the corresponding
feature did not contribute to
75% of the model weight.
p-values (as above, FDR 5%) indicate that the previously undescribed
substitutions 8S, 15G, and 27K are indeed predictive of X4-capability.













Figure 5.2: Distribution of X4-
probabilities estimated by the
linear SVM. Blue bars indicate
sequences labeled as R5, while
red bars indicate sequences
labeled as X4-capable.
The distribution of predicted X4-probabilities was determined by
applying the linear SVM on the V3 data set using ten runs of tenfold
CV. Figure 5.2 shows that X4-probabilities separate the V3 amino-
acid sequences from R5 and X4-capable viruses well. Note that the
region of low X4-probabilities is interspersed with a greater number
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of observations labeled as X4-capable than there are observations
labeled R5 in the high X4-probability region. This indicates that the
SVM more easily obtains a high specificity than a high sensitivity.
In order to dichotomize the SVM estimates for classifying samples
into one of the two classes R5 and X4-capable, I performed K-means
clustering (Section 3.5.1) on the X4-probabilities. A suitable number
of clusters was selected using the elbow test on the within sum of
squares60 and X4-probabilities were subsequently clustered using
the K-means algorithm. From the cluster representing X4-capable
viruses, the minimal X4-probability (53.4%) was selected and the
corresponding FPR was determined (3.4%). The recommended cutoff
for HIV-2 coreceptor prediction was set to an FPR of 5% for two
reasons. First, in case that the model’s TPR (as determined from the
population sample) overestimates the TPR that would be observed
for the population, it would be worthwhile to increase the TPR at the
cost of an increased FPR. This is because incorrectly classifying an
R5 sample as X4-Capable has little consequences (e.g. maraviroc will
not be prescribed), while incorrectly classifying an X4-Capable sample
as R5 may have severe consequences (e.g. treatment failure because
maraviroc is not effective). Second, a value of 5% is more memorable
than a value of 3.4%.
5.3.6 The geno2pheno[coreceptor-hiv2] Web Server
Figure 2 from Döring et al. (2016) is licensed under CC-BY 4.0
Figure 5.3: Visualization of the
model coefficients for the V3
amino-acid sequence of the
mutant ROD10 isolate (H18L
+ K29T). Amino acids with
positive coefficients are asso-
ciated with R5-tropic viruses,
while negative coefficients are
associated with X4-capable vari-
ants. The legend on the right
indicates the color-coded amino
acids and gives the FPR of the
prediction. Because the pre-
dicted FPR is below the selected
cutoff at 5%, the sequence is
predicted to be X4-capable,
which is indicated by the dark
color of the X4-capable label
in the bottom left corner. The
labels of the x-axis refer to
the positions and amino acids
of the HIV-2 reference strain
M33262.
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Implementation The linear SVM for the prediction of HIV-2 core-
ceptor usage is available via the geno2pheno[coreceptor-hiv2] web
service . The backend of the service was implemented in C++ with
LibSVM61 and the frontend was developed in PHP. Based on the
approach presented in Section 5.2.5, a visualization for the feature
weights associated with a query sequence was implemented with
gnuplot.
Usage The geno2pheno[coreceptor-hiv2] web service requires the
selection of a cutoff on the FPR. The selected cutoff specifies the
trade-off between sensitivity and specificity. The user can either
simply use the recommended cutoff at 5%, which maximizes the
overall predictive performance, or customize the cutoff depending on
the application scenario. Finally, one or multiple nucleotide/amino-
acid sequences in FASTA format (at most 500) containing the V3 of
an HIV-2 sample can be uploaded. Once the input data have been
provided, each input sequence is aligned to a profile of HIV-2 V3
amino-acid sequences (Section 5.2.2) and the FPR is estimated using
the linear SVM (Section 5.3.1). Once the predictions are available, the
user can obtain an alignment of the input V3 sequence relative to the
reference M33262 in order to investigate relevant mutations.
To facilitate the interpretation of the results, the web service does
not only provide the classification (either X4-capable or R5) accord-
ing to the selected FPR cutoff, but also the FPR itself. Additionally,
the web service generates a visualization of the weights assigned
to individual amino acids in the input sequences for a more intu-
itive way of interpreting the results (Figure 5.3). For the application
of geno2pheno[coreceptor-hiv2] in clinical settings, a PDF report
summarizing the results of an analysis is available. To facilitate the
application of geno2pheno[coreceptor-hiv2] in research settings, the
results of batch computations can be retrieved in CSV format.
5.3.7 Validation of the Web Service
The implementation of the geno2pheno[coreceptor-hiv2] web
service was validated using an independent test set containing
eight additional V3 samples (Section 5.2.1). These samples had
not been used for training the predictive model. Predictions from
geno2pheno[coreceptor-hiv2] were compared to the phenotypically
measured coreceptor usages for these samples. Using the recom-
mended FPR cutoff at 5%, all samples were classified correctly by
geno2pheno[coreceptor-hiv2], while the approach from Visseaux
et al. (2011) misclassified two of the samples (Table 5.7). The R5-
isolate ROD10 (H18L + H23∆ + Y24∆) was incorrectly classified as
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0.01 L18X, V3 net
charge > 6
X4 X4 X4
ROD10 (K29T) 0.01 L18X X4 X4 X4





0.01 L18X X4 X4 X4
ROD10 (H18L +
K29T)
0.03 NA R5 X4 X4
ROD10 (H18L +
H23∆ + Y24∆)




H23∆ + Y24∆ +
K29T)
0.15 NA R5 R5 R5
15PTHSJIG 0.36 NA R5 R5 R5
15PTHCEC 0.01 L18X,
V19K/R,
Ins 24, V3 net
charge > 6
X4 X4 X4
Table 5.7: Results from validat-
ing geno2pheno[coreceptor-
hiv2] using additional V3 se-
quences. The FPR column indi-
cates the FPR that is estimated
by geno2pheno[coreceptor-
hiv2] and the SVM column
indicates the corresponding
prediction according to the 5%
FPR cutoff. The Major mark-
ers column shows the major
markers of X4-capability that
were detected according to the
approach from Visseaux et al.
and the Rules column shows
the corresponding prediction.
The Phenotype column provides
the gold standard according
to phenotypic measurements
of coreceptor usage. Note that
table entries annotated as X4
indicate X4-capable variants.
Correct classifications are
indicated by blue font, while in-
correct classifications are shown
in red font. ROD10 refers to
the HIV-2 group A reference
strain, which uses both CCR5
and CXCR4. Mutations from
the ROD10 wild-type sequence
are indicated in brackets, where
∆ indicates deletions.
X4-capable due to its net charge of +7 and the X4-capable sequence
ROD10 (H18L + K29T) was misclassified as R5 because it did not
exhibit any of the four major markers for X4-capability.
5.4 Discussion
This chapter investigated the prediction of HIV-2 coreceptor usage
from amino-acid segments of the viral surface glycoprotein and
corresponding phenotypic measurements. The results suggest that
specific V3 amino acids are the key markers of HIV-2 coreceptor us-
age. In fact, three novel markers that are significantly associated with
X4-capability, namely 8S, 15G, and 27K were identified (Table 5.6).
It could also be shown that geno2pheno[coreceptor-hiv2], which
uses a linear SVM to predict coreceptor usage from V3 amino-acid
sequences, is interpretable and accurate.
Analyzing the predictive performance of SVMs based on vari-
ous kernel functions revealed that linear kernel functions are well
suited for the prediction of HIV-2 coreceptor usage. Kernel functions
capturing higher-order interactions do not seem to offer additional
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benefits in this prediction scenario. This finding confirms that HIV-2
coreceptor is largely based on individual amino-acid mutations in
V3 rather than on interdependent substitutions of amino acids as in
HIV-162. The hypothesized open structure of the HIV-2 V3, which
might reduce the role of interactions among the amino acids in the
V363, would support this result. However, determining and analyzing
the structure of gp125 with intact and ordered V3 would be crucial
for confirming the independence of positions by elucidating the
accessibility of the V364.
Since geno2pheno[coreceptor-hiv2] is based on an SVM, it con-
siders all V3 positions when predicting coreceptor usage. Rules-
based systems, on the other hand, use only a pre-selected set of
discriminatory features from the V3 to identify coreceptor usage.
Investigating the model coefficients of the X4-isolate ROD10 (H18L
+ K29T), which are shown in Figure 5.3, highlights the advantage of
statistical over rules-based methods. In this case, the combination of
multiple negative weights associated with the features R2K, P11K,
V12K, T13M, I14L, insertions after position 22, and N26N resulted
in the prediction of X4-capability rather than fulfilling any of the
established rules. The superior performance of the approach from
geno2pheno[coreceptor-hiv2] over the rules-based approach from Vis-
seaux et al. (2011) was shown on a small test set (Table 5.7). Recently,
further phenotypic measurements by Cerejo et al. (2018) showed
that the identification of HIV-2 coreceptor usage based on a limited
number of positions can be problematic. The predictive performance
of geno2pheno[coreceptor-hiv2] is at least as high as the predictive
performance of geno2pheno[coreceptor] for HIV-165.
This study confirmed that the V3 is the major determinant for the
usage of the CCR5 and the CXCR4 coreceptors by HIV-2. However,
there is also further evidence66 indicating that other envelope regions
besides V3 seem to contribute to HIV-2 coreceptor usage. First, SVMs
based on the V1 and V2 regions achieved substantial predictive
accuracies. Second, the V3 sequences of some X4-capable viruses did
not exhibit any known features indicative of CXCR4 usage and some
V3 sequences of R5-tropic isolates exhibited markers of X4-capability
(Figure 5.1). Third, several samples sharing the same V3 amino-acid
sequence but exhibiting discordant measurements of phenotypic
coreceptor usage were observed (Table 5.1).67
R5-tropic HIV-2 exhibiting X4-markers could also be explained
by a switch from CXCR4 to CCR5 usage (X4-R5 reversion). X4-R5
reversions have already been reported in HIV-1-infected patients
after immune reconstitution68. Because recent findings indicate that
X4-capable HIV-1 viruses are less susceptible to neutralization by
autologous antibodies than R5 viruses from the same host69, X4-
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R5 reversions could result from the normalization of naive T-cell
turnover following immunological recovery70, after which the infec-
tion of naive T-cells by X4-capable variants may not be productive
enough71. Since X4-capable HIV-2 also seem to be less susceptible to
neutralization than CCR5-using strains72, X4-R5 reversions in HIV-2
could be explained by the same mechanism.
Besides these interpretations, discrepancies between the measured
phenotypic coreceptor usage and features in the V3 amino-acid se-
quence could also be a by-product of the qualitative interpretation
of phenotypic assays. In vivo, coreceptor usage is on a continuous
scale and several, consecutive structural changes within the surface
glycoprotein occurring along the viral evolutionary trajectory enable
an increasingly effective coreceptor usage. However, this fact is ne-
glected when the results of phenotypic assays are reported. Although
the assays produce quantitative measurements (e.g. fluorescence,
luminescence, or antigen levels), these measurements are typically
converted to a qualitative scale for the sake of convenience regarding
further analyses73. For the sake of accuracy, however, it would be
paramount to work on the raw data (e.g. fluorescence, luminescence,
or antigen levels). Using these quantitative measurements, it would
be possible to develop models capable of placing a virus onto the
evolutionary continuum stretching from viruses using only CCR5 to
dual-tropic viruses, and finally viruses using only CXCR4. Moreover,
working on raw data from phenotypic assays would facilitate the ap-
plication of established statistical techniques for the normalization of
data subject to batch effects (e.g. due to different types of phenotypic
assays), which could improve the accuracy of large-scale studies on
coreceptor usage considerably. In the meantime, the FPRs provided
by geno2pheno[coreceptor-hiv2] could serve as a useful quantity for
placing a virus on the coreceptor continuum.
To shed more light on why identical V3 amino-acid sequences
with discordant phenotypic measurements of coreceptor usage exist,
three aspects should be investigated. First, the agreement between
different phenotypic assays should be validated or, even better, a
standardized phenotypic assay for identifying HIV-2 coreceptor
usage should be developed. Second, further research investigating
the intra-host evolution of HIV-2 with respect to coreceptor usage
and its impact on viral fitness seems necessary to determine whether
X4-R5 reversions do occur. Third and most importantly, it should be
investigated whether amino acid substitutions in the V1/V2 region
can impart the X4-phenotype independently of substitutions in the
V3, a question for whose resolution more data is required74.
Based on the conducted analyses, it was possible to identify four
characteristics that differentiate the V3 of HIV-2 and HIV-1 with
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respect to coreceptor usage. While individual mutations in the V3
of HIV-2 are highly predictive of coreceptor usage (e.g. 18X has a
sensitivity of 79% and a specificity of 96%), there is no discriminatory
signal in the HIV-1 V3 that allows for the accurate identification of
coreceptor usage by itself. For example, the 11/25 rule, which classi-
fies HIV-1 as X4-capable if its V3 contains a positively charged amino
acid at the 11th or 25th position only obtains a sensitivity of 30%
albeit at a specificity of 93%75. Second, while the major discrimina-
tory markers for CXCR4 usage of HIV-2 (18X, 19K/R, insertions after
position 24) appear at the V3 C-terminus, discriminatory features of
HIV-1 coreceptor usage occur along the full extent of the V3 region.
Third, while a V3 net charge exceeding six is significantly associated
with the usage of CXCR4 by HIV-2, there is no significant association
between the overall charge of the HIV-1 V3 and coreceptor usage76,
although CCR5 and CXCR4 exhibit contrasting electrostatic potential
surfaces77. Fourth, a comparison of the predictions for X4-capable
variants from HIV-1 (Figure A.1) and HIV-2 (Figure 5.2) suggests that
the V3s of X4-capable HIV are genetically more distant to R5 variants
in HIV-2 than in HIV-1.
In the future, geno2pheno[coreceptor-hiv2] could be improved by
ensuring that input sequences originate from HIV-2, for example, by
implementing a cutoff on the alignment score. In this way, misuse of
the service could be prevented, for example, when a V3 of HIV-1 is
unintentionally provided.
To conclude, geno2pheno[coreceptor-hiv2] is the first web service
for the prediction of HIV-2 coreceptor usage. By using geno2pheno[coreceptor-
hiv2], clinicians can decide whether they can prescribe the CCR5 core-
ceptor antagonist maraviroc, while epidemiologists can use the tool
to investigate the association between HIV-2 coreceptor usage and
disease progression. geno2pheno[coreceptor-hiv2] is freely available
via coreceptor-hiv2.geno2pheno.org.
This chapter and the previous chapter (Chapter 4) described geno-
typic methods that enable the personalization of antiviral therapies.
Persons that are under antiviral therapy often have to ingest mul-
tiple drugs daily, which can result in side effects including fatigue,
lipodystrophy, nausea, or diarrhea78. This is one of the reasons why
it is not only necessary to support therapy selection but also to sup-
port the development of novel antiviral agents. The following chapter
(Chapter 6) is concerned with an approach that can advance the
development of antibody-based antiretroviral treatments.
Few scientists acquainted with
the chemistry of biological
systems at the molecular level





complicated and delicate of
tasks.
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Designing Multiplex PCR Primers
for Human Immunoglobulins
In this chapter, I present a new primer design approach that improves the
amplification of cDNA from highly mutated antibodies via PCR. I devised
and implemented the approach that resulted in the primer design tool
openPrimeR. The primer design approach was developed in collaboration
with Christoph Kreer, Nico Pfeifer, and Florian Klein. In close collaboration
with Christoph Kreer, I used openPrimeR to design and computationally
validate primer sets for IGHV, IGKV, and IGLV. The designed primer sets
were experimentally validated by Nathalie Lehnen, Philipp Schommers,
Meryem Seda Ercanoglu, and Christoph Kreer. The project was initialized
by Florian Klein. The work was supervised by him and Nico Pfeifer, who
contributed to the development of openPrimeR. This chapter expands upon
a manuscript entitled "openPrimeR for Multiplex Amplification of Highly
Diverse Templates", which has been submitted to Nature Biotechnology.
Elite neutralizers, which make up a small fraction of HIV-1 in-
fected persons (≈ 1%), develop potent bNAbs against HIV-1 that are
capable of neutralizing HIV-1 virions from several clades even at low
concentrations1. Therefore, bNAbs are currently being investigated as
a novel strategy for treating and preventing HIV-1 infection2.
The in vitro investigation of human antibodies requires the extrac-
tion of single B-cell transcripts from immunoglobulin heavy chain
genes (IGHs) and corresponding immunoglobulin lambda genes
(IGLs) or immunoglobulin kappa genes (IGKs), which encode the im-
munoglobulin light chains3. After amplification of these transcripts
via multiplex RT-PCR4, the antibody cDNA is cloned into eukaryotic
expression vectors that are inserted into cells for antibody secretion5.
Designing primers for mPCR is challenging because the smallest
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possible combination of primers covering (amplifying) all templates
has to be found. bNAbs introduce an additional burden because they
are highly mutated6 and may prevent the annealing of primers that
have been optimized for germline immunoglobulins.
Permission for reproduction was kindly granted by John Wiley and
Sons (Rada et al., 1994).
Figure 6.1: Variability in dif-
ferent antibody regions. The
leader region at the 5’ end con-
sists of two parts (shown as
rectangles) that are separated
by an intron.
While conventional immunoglobulin G (IgG) antibodies (Sec-
tion 2.2.4) carry 18.0± 8.17 somatic mutations in their heavy chain vari-
able (VH) genes8, HIV-1-specific IgG antibodies exhibit roughly twice
as many VH mutations9.10 Second-generation bNAbs (Section 2.3.7)
even frequently carry in excess of 60 VH mutations11,12. However,
immunoglobulin heavy chain variable region genes (IGHVs) show
a decrease in mutation frequencies towards the leader region13 (Fig-
ure 6.1). The leader is a short 5’ untranslated region of immunoglob-
ulin mRNA upstream of the translation start site. Designing primers
in the conserved immunoglobulin leader region has the potential
for improving the amplification of IGHVs from bNAbs14. Therefore,
the goal of this work was to develop a rational approach for design-
ing primers targeting the leaders of IGHV, immunoglobulin kappa
variable region gene (IGKV), and immunoglobulin lambda variable
region gene (IGLV) in order to improve the amplification of highly
mutated human immunoglobulin sequences.
This chapter is structured as follows. Section 6.1 provides an
overview of the considerations for mPCR primer design and intro-
duces related work. The approach of openPrimeR is delineated in
two sections. In the first methodological section (Section 6.2), I intro-
duce the notation that is used in this chapter and describe techniques
for the evaluation of primers and primer sets. The second method-
ological section (Section 6.3) presents algorithms for the design and
selection of mPCR primer sets. Section 6.4 presents the primer sets
that were designed for IGHV, IGKV, and IGLV. This chapter con-
cludes with Section 6.5 in which I discuss the results of this work.
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6.1 Multiplex Primer Design
The design of primers for mPCR requires a deep understanding
of the mechanism by which mPCR allows for the successful am-
plification of nucleic acids (Section 6.1.1). Approaches for mPCR
primer design have to consider the physicochemical properties of
the primers in order to find suitable primer sets (Section 6.1.2). Due
to the unavailability of a suitable primer design tool for human im-
munoglobulin sequences, openPrimeR was developed (Section 6.1.3).
6.1.1 Biophysical Characteristics of PCR
For the design of mPCR (Section 2.5.4) primers, the following aspects
should be taken into account. A template can only be amplified if
both primer annealing and elongation by polymerase are successful15.
Efficient primer annealing is determined by the overall comple-
mentarity of primer and template. Elongation, on the other hand,
critically depends on the structure of the primer 3’ hexamer, which
forms the binding region of the polymerase16.17
Primers should fulfill a multitude of physicochemical properties
that are relevant for the success of mPCR, which are discussed in the
following.
Melting Temperature The melting temperature, Tm, of an oligonu-
cleotide is defined as the temperature at which half of the DNA
strands are denatured, while the other half is still double-stranded.
The melting temperature provides insights into the stability of the
primer-template duplex: primers with high melting temperatures
bind tightly to complementary templates, while primers with low
melting temperatures bind more loosely.
The PCR annealing temperature depends on the melting tem-
peratures of the primers. A simple rule of thumb is to choose the
annealing temperature to be about 5◦C lower than the smallest Tm.
While low annealing temperatures may lead to unspecific annealing,
high annealing temperatures may prevent annealing.
The two factors that influence melting temperature the most
are primer length and GC content. This is because longer primers
exhibit a larger number of nucleotide interactions and high GC
contents facilitate a greater number of stable G-C pairings. Hence, a
simple formula based on the nucleotide distribution was developed
for calculating the melting temperature for sequences of length n
exceeding 13 nucleotides18:
Tm = 64.9 + 41
|G|+ |C| − 16.4
n
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Here, |G| and |C| indicate the number of guanines and cytosines in
the sequence. A typical primer has a length of 18 nucleotides and a
typical GC ratio is 50%. If we assume that |G| = 4 and |C| = 5, we
would have
Tm = 64.9 + 41
4 + 5− 16.4
18




according to the formula.
Current approaches for determining the melting temperature
correct for the PCR ion concentrations19 and rely on nearest-neighbor
thermodynamics, which considers the thermodynamic contributions
of neighboring base pairs20.
GC Clamp Primers are often designed to exhibit a so-called GC
clamp21, which typically consists of one to three Gs or Cs at the 3’
end. Having one or multiple GCs at the 3’ end of primers is desirable
because GC pairs, which are sustained by three hydrogen bonds, are
more stable than AT pairs, which are stabilized by two hydrogen
bonds. Since the 3’ region is crucial for polymerase binding, high
affinity in this region ensures stable binding of polymerase. A large
number of GCs (e.g. more than 3) among the last 3’ bases should be
avoided, as this could facilitate primer dimer formation and lead to
mispriming.
GC Content The GC content of a primer is defined by the ratio of
Gs or Cs among its constituent nucleotides. Primers should have
balanced GC contents (e.g. ranging from 40%–60%) because high GC
contents are associated with secondary structure formation, while
primers exhibiting low GC contents may not stably hybridize to
templates.
Primer Length The length of primers should be chosen under con-
sideration of priming specificity, efficiency of hybridization, and
experimental costs. While short primers may save costs, they also
lack specificity as their use may result in off-target amplifications.
Longer primers ensure higher specificities due to their increased
sequence complexity. The higher specificity of longer primers can be
detrimental to multiplex PCR where higher specificity also implies
lower coverage. The length of typical primers ranges from 18 to 22
nucleotides22. Since longer primers have higher melting temperatures
than shorter primers, primer sets typically consist of primers with
similar lengths.
Nucleotide Runs and Repeats A run refers to the consecutive repeti-
tion of a single nucleotide in a primer. Large number of repetitions
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(e.g. more than 4) should be avoided because they can lead to mis-
priming. The same holds for repeats, that is, consecutive repetitions
of the same dinucleotide.
Secondary Structures Primers can form secondary structures due to
interactions between complementary nucleotides within the primer
that lead to spatial orientations other than simple coils. Primers
exhibiting secondary structures should be avoided because secondary
structures can prevent annealing to the template. Experimentally,
secondary structures can be avoided by using dimethyl sulfoxide
(DMSO).
Primer Dimerization Primer dimerization refers to the hybridization
of primers to other primers rather than hybridization to the template
sequence. Preventing the formation of primer dimers is one of the
main concerns when designing primers because primer dimers
reduce product yields and can lead to unintended amplicons when
dimers are formed at the 3’ ends. A primer that binds to a copy
of itself is called a self-dimer, while a primer that binds to another
oligomer is called a cross-dimer.
6.1.2 Related Work
In the following, established approaches are evaluated with respect
to the following demands on a suitable tool for the design of im-
munoglobulin primers:
• The tool should estimate the coverage of the primers. This is a
necessary requirement in order to find a minimum set of primers
maximizing the coverage by solving the SCP.
• Designed primers should fulfill stringent quality criteria regarding
their physicochemical properties. Low-quality primers may fail to
amplify their target templates.
• The tool should be easily usable and provide a graphical user
interface (GUI). The end users of primer design tools typically
have life science backgrounds. Thus, they may shy away from
unintuitive software, for example software that is only usable
through a command line interface.
• The tool should be able to design degenerate primers. A degener-
ate primer is an oligonucleotide sequence that is not only made
up of the four standard nucleobases but also contains IUPAC
ambiguity codes, which indicate the presence of multiple bases.
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24 Jabado et al. 2006
25 Srivastava and Xu 2007
26 Rychlik 2007
27 Kalendar et al. 2014
28 Pearson et al. 1996
29 Gardner et al. 2014
30 Jabado et al. 2006; Gardner et al. 2009
31 Hsieh et al. 2003; Bashir et al. 2007
32 Huang et al. 2005
33 Linhart and Shamir 2002
34 Souvenir et al. 2003
35 Jabado et al. 2006
Degenerate primers are economically desirable because the corre-
sponding mixtures of primers can be ordered at the same cost as
individual primers.
• The tool should facilitate the comparison of primer sets. By com-
paring primer sets in silico, it is possible to identify which set
performs favorably without any experimental expenses.
These requirements for multiplex primer design give rise to the no-
tion of rational primer design. In rational primer design, the minimum
number of high-quality primers maximizing the coverage is selected.
To find high-quality primers, the properties of the primers should be
comprehensively analyzed. Since rational primer design is computa-
tionally intensive, such approaches are only feasible using specialized
software and cannot be performed by hand.
Table 6.1 provides an overview of published primer design ap-
proaches. Unfortunately, for the majority of published primer design
approaches, no corresponding tool is available. Nearly all avail-
able tools provide GUIs, which affords a high usability. However,
the GUIs of most tools such as GeneFisher23, PrimerStation24, or
PRIMEGENS25 are rather rudimentary in that they do not allow for
the interactive investigation of the results. In this regard, the com-
mercial softwares OLIGO26 and FastPCR27 are considerably more
advanced. Still, their GUIs neither allow for investigating primer sets
with regard to coverage nor for comparing the properties of sets.
The main challenge of primer design for multiplex PCR lies in
finding the smallest possible set of primers that ensures the ampli-
fication of all template sequences28. This optimization problem can
be formulated in terms of the NP-complete SCP (Section 3.7.3). How-
ever, only few approaches actually solve the SCP. This is because
one branch of primer design methods solves the degenerate primer
design problem, which is discussed in the next paragraph, and an-
other branch aims at high throughput (HT) applications such as tiling
whole genomes29. Most approaches that solve the SCP either do so
approximately using a greedy algorithm30 or exactly using an ILP
formulation31. Genetic algorithms32, which can find approximate
solutions, are less frequently used. Approaches that do not solve
the SCP such as PRIMEGENS typically output a list with suggested
primers for each template. This, however, leaves the user with the
burden of finding an optimal combination of primers — a task that
typically cannot be completed by hand.
Relatively few approaches are able to find degenerate primers.
Degenerate primers are typically constructed via hashing33, beam
search34, or alignment35. There are two groups of methods for com-
puting degenerate primers. The first group consists of approaches
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Year Reference Tool Availability GUI SCP HT Degeneracy
1989 (Rychlik, 2007) OLIGO 3 3 7 7 7
1996 (Giegerich et al., 1996) GeneFisher 3 3 7 7 3
1998 (Pesole et al., 1998) GeneUp 7 7 3 7 7
2003 (Rose et al., 1998, 2003) j-CODEHOP 3 3 7 3 3
2001 (Kämpke et al., 2001) DoPrimer 7 7 7 3 7
2002 (Linhart and Shamir, 2002) HYDEN 3 7 7 7 3
2003 (Emrich et al., 2003) PROBEMER 7 3 7 7 7
2003 (Souvenir et al., 2003) MIPS 7 7 7 7 3
2004 (Jarman, 2004) Amplicon 3 3 7 7 3
2004 (Wang et al., 2004a) G-PRIMER 7 3 3 7 7
2005 (Huang et al., 2005) PDA-MS/UniQ 7 7 3 7 3
2005 (Rachlin et al., 2005) MuPlex 7 3 7 3 7
2006 (Jabado et al., 2006) Greene SCPrimer 7 3 3 7 7
2006 (Yamada et al., 2006) PrimerStation 3 3 7 3 7
2006 (Lee et al., 2006) MultiPrimer 7 7 7 7 7
2007 (Srivastava and Xu, 2007) PRIMEGENS 3 3 7 3 7
2007 (Bashir et al., 2007) NA 7 7 3 3 7
2009 (Gardner et al., 2009) MPP 7 7 3 7 7
2009 (Kalendar et al., 2009, 2014) FastPCR 3 3 7 3 3
2010 (Shen et al., 2010) MPPrimer 3 3 7 7 7
2012 (Chuang et al., 2012) URPD 7 3 7 7 7
2012 (Hysom et al., 2012; Gardner et al., 2014) PriMux 3 7 3 3 3
2016 (O’Halloran, 2016) PrimerMapper 3 3 7 3 7
Table 6.1: Overview of mul-
tiplex primer design tools.
SCP indicates that a set cover
problem is solved in order to
minimize the primer set. Avail-
ability indicates whether an
implementation of the tool is
publicly available (as of June
2018). HT indicates whether
the tool is high-throughput,
that is, whether it is suitable for
large-scale applications. Degen-
eracy indicates whether primers
containing degeneracies can be
designed.
36 The degeneracy of a primer is the
number of non-degenerate sequences
it represents. For example, the oligonu-
cleotide acrgacgtgacr has degeneracy
2× 2 = 4 since r occurs two times and
represents A or G.
37 Linhart and Shamir 2002
38 Souvenir et al. 2003
39 Jabado et al. 2006
40 Rose et al. 2003
41 The set from Tiller et al. (2008) has 4
(5) primers, while the set from Lim et al.
(2010) has 8 (23) primers. The number
of disambiguated primers are shown in
parentheses.
that solve the degenerate primer design problem in which a single
primer with minimum degeneracy36 and maximum coverage is
sought. Tools solving the degenerate primer design problem such
as HYDEN37 and MIPS38 can provide elegant solutions since they
output only a single primer. However, these tools are also subject
to severe limitations. For example, it may not be possible to obtain
a single degenerate, high-quality primer that covers all of the tem-
plates. In this case, the degenerate primer design problem needs to
be iteratively solved for several positions in the templates (similar to
a greedy algorithm), which may lead to suboptimal solutions.
The second group consists of approaches that determine several
degenerate primer candidates and then solve the SCP. An example
for such an approach is the primer design tool GreeneSCPrimer39.
Since the approach of openPrimeR also implements this strategy, I
refer the reader to Section 6.3, in which I provide more details.
To my best knowledge, the only published primer set for im-
munoglobulin sequences that was designed using a computational
tool was described by Sun et al. (2012) who designed primer sets
for individual IGHV gene groups using CODEHOP40 and manually
combined them. However, the designed forward primers did not find
acceptance in the immunological community, presumably due to two
reasons. First, the designed primer set was quite large because the
seven primers were heavily degenerate, representing a total of 112
individual oligomers. Second, the combination of primers was not
selected with stringent quality criteria in mind.
Popular primer sets such as the one from Tiller et al. (2008) or the
one from Lim et al. (2010) consist of fewer primers41 that were man-
ually chosen by studying multiple sequence alignments. In another
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42 If software dependencies are not
fulfilled, the corresponding features
are not available. For example, if
ViennaRNA is not installed, constraints
on the secondary structure cannot be
considered. Similarly, if MAFFT is not
installed, it is not possible to design
degenerate primers.
43 Dumousseau et al. 2012
44 Tafer et al. 2011
45 Markham and Zuker 2008
46 Kuraku et al. 2013
study, Scheid et al. (2011) pioneered a new primer design strategy
in which primers were designed for the leader region of IGHV.
However, these primers were not rationally designed. Therefore,
the resulting primer set is quite large (21 primers) and evaluations
with openPrimeR have shown that the set seems to suffer from cross
dimerization (22 pairs with ∆G < −6 kcal/mol) and high melting
temperature differences (melting temperature differences are between
10
◦C and 20◦C).
6.1.3 Technical Details of openPrimeR
The approaches and data presented in the following sections have
been made available through openPrimeR, an open-source tool for de-
signing, evaluating, and comparing primer sets for mPCR. To design
primers, the tool solves a SCP using either a greedy algorithm or an
ILP. openPrimeR was implemented in R. The graphical user interface
was developed using the Shiny framework. The tool is available in
the form of two Bioconductor packages. While openPrimeR provides
a programmatic interface, openPrimeRui provides a GUI in terms of a
Shiny application.
To use all functionalities of openPrimeR, the following programs
should be installed42:
MELTING Melting temperature calculations43
ViennaRNA Secondary structure detection44
OligoArrayAux Thermodynamic evaluation of primer binding
events45
MAFFT Determination of multiple sequence alignments46 for initial-
izing degenerate primers
Pandoc Generation of PDF reports
A Docker container satisfying all dependencies of openPrimeR is
available at Docker Hub.
6.2 Evaluation of Primers
This section introduces the methods for the evaluation of mPCR
primer sets that are used by openPrimeR. Section 6.2.1 defines the
notation that is used for the remainder of this chapter. Section 6.2.2
introduces an approach for the estimation of primer coverage. The
physicochemical properties and quality metrics that are considered
by openPrimeR are presented in Section 6.2.3. These metrics are
important for the primer design algorithms that are presented in
Section 6.3.
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6.2.1 Preliminaries
Templates t ∈ T = {t1, . . . , t|T|} and primers p ∈ P = {p1, . . . , p|P|}
are sequences of length n, m ∈ N such that t ∈ An and p ∈ Am. The
alphabet, A = A1 ∪A2, consists of conventional nucleotides,
A1 = {A, C, G, T} ,
and ambiguous IUPAC nucleotides (Table A.1),
A2 = {M, R, W, S, Y, K, V, H, D, B, X, N} .
When primer p ∈ P is expected to cover template t ∈ T, we write
p . t. Equivalently, we can write t / p to express that t is expected to
be covered by p. Note that p . t does not necessarily guarantee that t
is actually amplified by p during PCR. This is because the theoretical
coverage may deviate from the actual coverage; the accuracy with
which the coverage can be approximated depends on which notion
of coverage is employed (Section 6.2.2). The set of expected amplifica-
tion events (EAEs) of primer p with respect to the set of templates T
is denoted by
p.T = {ti ∈ T|p . ti} .
The number of templates in T that are covered by p are determined
via |p.T |, which is also referred to as primer coverage. The set of
primers that cover a template t ∈ T is given by
t/P = {pi ∈ P|t / pi} .
A template t ∈ T is considered to be covered if and only if |t/P| ≥ 1,
that is, if there is at least one primer covering the template.








In the following, the coverage of P with respect to T, which is given
by |P.T |, is called the (overall) coverage.
Primers with Multiple Orientations Since PCR requires the amplifica-
tion of sense- and anti-sense strands of DNA, every template should
be covered by a forward primer, p→, which allows for synthesizing
the sense strand, and a reverse primer, p←, which allows for syn-
thesizing the anti-sense strand. In case that only primers of a single
orientation, that is, either only forward or only reverse primers are
present, coverage is defined as above. Otherwise, if primers of both
orientations are present, the set of primers covering a template t ∈ T
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47 The term coverage refers to the
constrained coverage if not stated
otherwise.
is defined by considering primers of both orientations via
t/P =
∅ if 6 ∃p→, p← : p→ . t, p← . t{p→ ∈ P|t / p→} ∪ {p← ∈ P|t / p←} else .
This means that the number of primers that cover a template is zero
if there is no pair of forward and reverse primer that covers the
template. Otherwise, the number of primers that cover the template
is defined by the union of forward and reverse primers covering the
template. The coverage of a primer pair (p→, p←) is defined as the
intersection of EAEs from its constituent primers:
(p→, p←).T = p→.T ∩ p
←
.T .
Note that when primers of multiple orientations are considered, they
are not represented as pairs before the optimization has completed
since it would be unclear how pairing should be performed. This
is because the primers constituting a pair should have overlapping
EAEs and similar physicochemical properties (Section 6.3.3).
6.2.2 Detection of Amplification Events
openPrimeR supports several notions of coverage because different
coverage conditions are suitable in dependence on the intended use
of the primers. For example, primers for qPCR should be designed
using a more conservative coverage definition than those for conven-
tional PCR. Since complementarity between primer and template is
a fundamental requirement for the amplification of a template, it is
necessary to determine the most likely binding region of the primer
in the template. Since primers may also bind with mismatches, I
introduce the parameter nmm, which defines the maximally allowed
number of mismatches between a primer and a template. For every
primer, the most likely binding region in every template is deter-
mined by scanning the template for matches between the primer and
template sequence with at most nmm mismatches and returning the
match with the smallest number of mismatches, if available.
Determining primer coverage events in this way gives rise to the
notion of basic coverage according to which a primer covers a template
if a match with at most nmm mismatches is found. Including further
requirements (Table 6.2) leads to the notion of constrained coverage.47
In the following, I discuss the parameters that influence the notion of
primer coverage.
Allowed Mismatches The choice of a suitable value for nmm depends
on two factors. The first factor is the fidelity of amplification. Since
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Property Enabled Setting
Mismatches 3 ≤ 7
Prevention 3’ terminal mismatches 7 ≤ 0
Prevention of stop codons 7 NA
Prevention of amino-acid substitutions 7 NA
Free energy of annealing 7 ≤ −5 kcal/mol
Amplification efficiency 7 ≥ 0.1%
TMM model 3 FPR ≤ 6%
Table 6.2: Default settings for
the evaluation of primer cover-
age. If the prevention of stop
codons or substitutions is active,
then the EAEs of primers that
would induce stop codons or
amino-acid substitutions into
the amplicons are discarded.
48 Wright et al. 2014
mismatch binding events induce changes in the nucleotide sequence
of amplicons, large values of nmm should be avoided in order to
preserve the original template sequences. The second factor is the
sensitivity and specificity at which amplification events should be
called. While high values of nmm (e.g. nmm = 5) allow for increased
sensitivities, they also reduce the specificity of calling amplification
events. Low values of nmm (e.g. nmm = 1), on the other hand, ensure
higher specificities at reduced sensitivity.
For primer design, it is crucial to achieve high specificities in order
to ensure that all templates can be covered. By selecting a small
value for nmm, it is possible to reduce false positive coverage calls.
This ensures that designed primers actually allow for amplifying
all of the templates. However, a conservative (i.e. small) choice of
nmm may also lead to prohibitively large primer sets since mismatch
amplification events are discarded. In these scenarios, a larger value
for nmm may be chosen. Then, however, a model that estimates
whether EAEs correspond to actual amplification events, should be
employed. Such models are introduced in the next paragraph.
Additional Criteria There are further criteria besides the maximal
number of allowed mismatches according to which proposed amplifi-
cation events can be limited. These approaches are particularly useful
when nmm is large because they can increase the specificity of the
proposed amplification events. For example, a simple criterion may
involve setting a minimal value for the free energy of annealing, ∆G.
However, there are also more intricate models for the determination
of amplification events. Chapter 7 provides a comprehensive discus-
sion of models for this task and introduces the logistic regression
model TMM that is available via openPrimeR.
openPrimeR provides the following approaches for detecting
amplification events:
• The thermodynamic model from DECIPHER48 that estimates
amplification efficiency.
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Constraint Denomination Target range Limit range
Length |p| , ∀p ∈ P [18, 22] [18, 22]
Specificity spec [1, 1] [0.8, 1]
GC clamp |GC| [1, 3] [0, 4]
GC ratio GC% [40%, 60%] [30%, 70%]
Runs Runs [0, 4] [0, 6]
Repeats Reps [0, 4] [0, 6]
Self dimers ∆Gsd [kcal/mol] [-5, ∞] [-7, ∞]
Melting temperature Tm [◦C] [50, 70] [50, 70]
Folding ∆G f [kcal/mol] [-1, ∞] [-2, ∞]
Tm deviation∗ ∆Tm [◦C] [0, 5] [0, 7.5]
Cross dimers∗ ∆Gcd [kcal/mol] [-5, ∞] [-7, ∞]
Table 6.3: Permissible proper-
ties of PCR primers as defined
in the default settings of open-
PrimeR. The column Target
range indicates the permissi-
ble values for each constraint,
which are used for filtering
primers. The column Limit
range indicates the value range
that is used when constraints
are relaxed during the selec-
tion procedure. Constraints
annotated with asterisks are
not included in the set of fil-
tering constraints and instead
considered only during the
optimization phase.
• The logistic regression model TMM for estimating the likelihood
of amplification.
• The free energy of annealing.
• The positions in the 3’ hexamer in which mismatches are forbid-
den.
There are also other criteria for ensuring the fidelity of amplifica-
tion for designed primers. These criteria influence the selection of
EAEs. Using openPrimeR, it is possible to disregard EAEs that are
associated with stop codons or amino-acid substitutions.
6.2.3 Physicochemical Constraints
In order to evaluate the quality of a primer, it is useful to define
constraints on its physicochemical properties (Section 6.1.1). The
constraint on the i-th physicochemical property is defined as the pair
fi = ( f mini , f
max




i indicate the minimum and
maximum desired value, respectively. Constraints define desirable
ranges on the physicochemical properties of primers. For example,
the GC ratio of primers should be within the interval [40%, 60%].
Thus, if the i-th constraint relates to the GC ratio, we would include
the constraint f=(0.4, 0.6). Based on the set of active constraints
F = { f1, . . . , f|F |}, the quality of a primer can be evaluated. An
overview of the default constraint settings is shown in Table 6.3.
Table 6.4 shows the PCR parameters that are applied when these
properties are computed. In the following, I provide details on the
computation of the constraints for melting temperatures, primer
dimerization, and secondary structures.
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if combining them in a multiplex
reaction does not negatively affect their
amplification efficiency.
50 Dumousseau et al. 2012
Melting Temperature The melting temperature can be constrained
in two ways. First, a desired range of primer melting temperatures
[T1, T2] can be specified. Let Tm(p) indicate the melting temperature
of primer p. The constraint [T1, T2] ensures that only primers p ∈ P
with T1 ≤ Tm(p) ≤ T2 are retained. Second, the maximum allowed
difference between the melting temperatures of selected primers
can be constrained via ∆Tmaxm . This constraint contributes to the
compatibility of primers49 by requiring that primers in the same set
exhibit similar melting temperatures via
max
pi ,pj∈P
|Tm(pi)− Tm(pj)| ≤ ∆Tmaxm .
Since the maximum melting temperature difference depends on
the set of selected primers, the constraint on ∆Tm is applied when
primers are optimized, while the allowed melting temperature range
is used when primers are filtered.
openPrimeR computes melting temperatures via the MELTING
software50. The program uses a nearest-neighbor approach based
on the parameters from SantaLucia (1998) and corrects for the salt
concentration.
Dimerization There are two types of dimerization that are consid-
ered: self dimerization and cross dimerization. Self-dimerization
refers to the tendency of a primer to bind to a copy of itself. Since
self dimerization does not depend on the set of selected primers, self-
dimerizing primers can be excluded during the filtering procedure.
Cross-dimerization, on the other hand, describes the association of
a primer with another primer. Since cross dimerization requires the
consideration of the selected set of primers, this constraint is only
considered by the primer design optimization procedure.
The selection of cross dimers is prevented through symmetric
dimerization matrix D ∈ {0, 1}m×n, which is defined by its entries
dpi ,pj =
1 if ∆G(pi, pj) < ∆Gmincd0 else .
Parameter Value Affected quantities
[Na+] Concentration Tm, ∆Gcd, ∆Gsd
[Mg2+] Concentration Tm, ∆Gcd, ∆Gsd
[K+] Concentration Tm, ∆Gcd, ∆Gsd
[Tris] Concentration Tm, ∆Gcd, ∆Gsd
Polymerase type Taq/Non-Taq p.T , ∀p ∈ P
Annealing temperature Manual/Automatic ∆G f , ∆Gcd, ∆Gsd
Table 6.4: PCR settings that
enter the computation of
constraints. Tm refers to the
melting temperature. ∆Gcd
and ∆Gsd refer to free energy
of cross dimerization and self




51 Markham and Zuker 2008
52 Tafer et al. 2011
The entry Dpi ,pj indicates whether primers pi and pj dimerize based
on ∆Gmincd , a threshold on the smallest allowed free energy of cross
dimerization. Therefore, entries dpi ,pj with pi = pj indicate the
presence of self dimers, while entries dpi ,pj with pi 6= pj indicate the
existence of cross dimers. To exemplify the use of D, let us consider
three primers p1, p2, and p3 with the following dimerization matrix:
D =
0 1 11 0 0
1 0 0
 .
In this case, p1 forms cross dimers with primers p2 and p3. Thus, p1
can be combined with neither p2 nor p3. Since p2 and p3 do not hy-
bridize, they can be included in the same primer set. More formally,
this means that a combination of primers that is compatible with
regard to cross dimerization induce a submatrix whose entries are
zero.
Dimerizing primers are detected by computing the free energy
using OligoArrayAux51 and applying the user-definable cutoffs ∆Gsd
(for self dimers) and ∆Gcd (for cross dimers).
Secondary Structure Secondary structure refers to the folding of a
primer onto itself. In order to identify possible primer secondary
structures, openPrimeR employs ViennaRNA52 to compute ∆G f
based on the thermodynamic parameters from Turner and Mathews
(2010). Since secondary structures should be prevented during the
primer annealing phase, the temperature for computing ∆G f is set to
the annealing temperature.
6.2.4 Metrics for Physicochemical Constraints
To determine the properties of a primer p, I define the evaluation
vector eval(p,F , T) ∈ R|F | with respect to the template set T and
the constraint set F . Its i-th entry, eval(p,F , T)i, contains the i-th
property of primer p ∈ P.
In the following paragraphs, I introduce several useful measures
for evaluating the quality of primers. For this purpose, I first de-
fine the conditions under which a constraint is fulfilled and then
introduce a way to test whether a set of primers exhibits significant
constraint fulfillment. Next, I define the rate of constraint fulfillment
and introduce the deviation from the target constraints.
Constraint Fulfillment A primer p is said to fulfill the i-th constraint,
fi ∈ F , that is, p |= fi if and only if
f maxi ≥ eval(p,F , T)i ≥ f mini .
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Number |p| |GC| GC% Runs Reps ∆Gsd [Tm] ∆G f ∆Tm ∆Gcd
Fulfilled 212 285 245 407 427 232 235 301 88 351
Failed 215 142 182 20 0 195 192 126 339 76
Table 6.5: Reference distri-
bution of fulfilled and failed
constraints.
Data Set Satisfied Constraints Failed Constraints
Current Set nCS nCF
Reference nRS nRF
Table 6.6: Structure of the con-
straint fulfillment matrix for
testing whether the fulfillment
of constraints is significant. The
second and third column show
the total number of fulfilled
and failed constraints, respec-
tively. The first row contains
the values for the primer set
whose significance is to be
tested, while the second column
contains the tallies from the
reference distribution.
In case that, p 6|= fi, we say that p does not fulfill (violates) fi.
Testing the Significance of Primer Set Quality The theoretical signifi-
cance of the quality of a primer set can be computed by determining
the number of primers that either fulfill or violate individual con-
straints. Then, these counts are compared with the reference distri-
bution shown in Table 6.5. This reference distribution was obtained
from tabulating the constraint fulfillment of the established primer
sets listed in Tables A.3, A.4, and A.5, which were evaluated using
the default constraint settings shown in Table 6.3.
The total number of fulfilled and failed constraints for the input
and the reference primer sets, respectively, gives rise to a two by two
constraint fulfillment matrix whose structure is shown in Table 6.6.
Using a one-tailed Fisher’s exact test (Section 3.6.3), it is possible




greater than 1. If this is the case, the tested primer set fulfills a signifi-
cantly greater number of constraints than the sets from the reference
distribution. Thus, primer sets with significant p-values exhibit
favorable properties in comparison to the reference primer sets.
Rate of Constraint Fulfillment The constraint fulfillment vector
Ful(P,F , T) ∈ R|F | indicates the fraction of primers that fulfill
individual constraints. The rate of constraint fulfillment is formulated
using an indicator function,
1 fi (p) =
1 if p |= fi0 else ,
which determines whether the constraint fi ∈ F is fulfilled by
primer p. Given j ∈ {1, 2, . . . , |F |}, the j-th entry of the constraint
fulfillment vector is defined by the fraction of primers fulfilling
constraint f j ∈ F :
Ful(P,F , T)j =
∑pi∈P 1 f j(pi)
|P| .
The rate of constraint fulfillment is a useful quantity for evaluating
the quality of a primer set. A disadvantage of this measure is that
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it does not consider the extent to which a constraint is broken. For
example, consider a primer that fulfills 9 of 10 constraints. Based on
the high fulfillment rate, one might conclude that this primer is of
high-quality even though the primer may substantially deviate from
one of the constraints. For example, with ∆Gmincd = −15 kcal/mol,
the primer would excessively deviate from the default minimum free
energy of cross dimerization of ∆Gmincd = −5 kcal/mol, which may
jeopardize the success of PCR. Thus, primer sets exhibiting high rates
of constraint fulfillment should still be investigated with respect to
their deviation from the individual constraints.
Constraint Deviation The extent to which the physicochemical
properties of a primer, p, deviate from the constraints is repre-
sented by the constraint deviation vector, Dev(p,F , T) ∈ R|F |. For
i ∈ {1, 2, . . . , |F |}, its entries are defined by












In the deviation vector, positive values indicate that a property ex-
ceeded the maximal allowed value, negative values indicate that a
property was below the minimal required value, and a value of zero
indicates constraint fulfillment.
Quality Penalty Based on the total absolute and maximum deviation
of a primer from the constraints, the quality penalty associated with
selecting the primer p can be defined using a tuning parameter
0 ≤ α ≤ 1:
Pen(p,F , T, α) = α||Dev(p,F , T)||∞ + (1− α)||Dev(p,F , T)||1 .
Here, ||x||∞ = maxi={1,...,n} |xi| is the maximum norm and ||x||1 =
∑ni=1 |xi| is the L1-norm. The maximum norm ensures that extreme
deviations from individual constraints are penalized, while the
L1-norm ensures that overall deviations across all constraints are
considered. The parameter α defines the trade-off between the max-
imum norm and the L1-norm. For α → 1, the maximum deviation
dominates giving rise to a local penalty reflecting the largest absolute
deviation for a single constraint. For α→ 0, the total deviation domi-
nates giving rise to a global penalty reflecting the sum of all absolute
constraint deviations. By default α is set to 0.5. This setting ensures
that among two primers with the same total constraint deviation, the
primer with the smaller maximum deviation is less penalized. The
quality penalty that is associated with the selection of a primer is a
useful quantity for performing global primer design (Section 6.3.5).
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depend on the quality of the alignment.
6.3 Primer Design and Selection Algorithms
This section introduces algorithms for designing and selecting mPCR
primer sets. The local primer design procedure (Section 6.3.4) is
based on the subsequent steps of initialization (Section 6.3.1), filtering
(Section 6.3.2), and optimization of primers (Section 6.3.3). The global
primer design algorithm (Section 6.3.5) goes through the same steps
but replaces the filtering procedure with a scoring procedure. An
approach for checking the feasibility of a primer design problem
is discussed in Section 6.3.6. An algorithm for subsetting already
optimized primer sets is provided in Section 6.3.7.
6.3.1 Primer Initialization
The goal of primer initialization is the allocation of a candidate set of
primers that fulfills the following three properties. First, the primers
should be sufficiently complementary to the target binding region in
the templates. Second, the primers should have appropriate lengths.
Third, the primers should carry ambiguous nucleotides at positions
that allow for increasing the number of EAEs of the primer.
Since initialization procedures for degenerate primers have dif-
ferent requirements, I implemented two strategies for primer initial-
ization: nondegenerate and degenerate primer initialization. While
the first strategy is simple and fast, the second strategy is more in-
tricate and time-consuming. Both procedures require the input of
a set of templates T with annotated binding regions as well as the
permissible lengths (lmin, lmax) of the primers.
Nondegenerate Primer Initialization The initialization of nondegen-
erate candidate primers is achieved by enumerating all possible
substrings with length l ∈ [lmin, lmax] for each template binding
region as illustrated in Algorithm 1.
Degenerate Primer Initialization The initialization of degenerate
primers is afforded by a clustering-based strategy that consists of
the five steps that are performed by the initPrimersDegenerate
procedure, which is described in Algorithm 2. In the first step, the
template binding regions are aligned using MAFFT53 (line 2), which
is a fast and accurate tool for the determination of multiple sequence
alignments54,55. Next, for each subalignment of a given primer
length l, the following steps are performed. The dissimilarities of all
sequences in a subalignment are computed based on their Hamming
distance (line 12). Given two strings x = (x1, . . . , xn) ∈ Σn and
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Algorithm 1: Nondegenerate primer initialization.
Input:
Set of templates T, range of allowed primer lengths (lmin, lmax)
Output:
An initial set of primer strings P
1: procedure initPrimersNaive(T, (lmin, lmax))
2: P← ∅
3: for t in T do
4: t← getBindingRegion(t)
5: for s ∈ {1, 2, . . . , |t| − lmax + 1} do . Start position
6: for l ∈ {lmin, lmin + 1, . . . , lmax} do . Primer length
7: e← s + l − 1 . End position
8: if e > |t| then
9: break
10: else
11: p← t.substring(s, e)
12: P← P ∪ p
13: return P
y = (y1, . . . , yn) ∈ Σn, their Hamming distance is defined as
∆(x, y) = |{i ∈ {1, . . . , n}|xi 6= yi}|
and the corresponding dissimilarity is d(x, y) = ∆(x,y)n . Based on the
dissimilarities, complete-linkage hierarchical clustering (Section 3.5.2)
is performed in order to construct a dendrogram representing the
relationship of the subsequences (line 13). Then, the generateDegen-
eratePrimers procedure is called, which processes the leaves of the
dendrogram (line 21).
Starting from the leaves l, the procedure iterates towards the root
of the tree in the following way. Line 22 determines the degeneracy
of the consensus sequences of the ungapped sequences associated






where disambig(si) disambiguates the IUPAC nucleotide si to a set of
conventional nucleotides. Only consensus sequences with degen(s)
below a cutoff, ndegen (default: 16), are considered as primer candi-
dates in order to exclude highly degenerate primers (e.g. primers
with many amibiguous positions). The iteration for a single leaf
terminates either when the degeneracy of the consensus sequence
resulting from the current node, l, exceeds ndegen (line 22) or when
the root of the dendrogram is reached (line 26).
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56 The constraints that can be considered
in the filtering procedure via the set of
filtering constraints F are those entries
in Table 6.3 without an asterisk.
Since ungapped sequences of length smaller than lmin have to be
discarded, it is possible that the generated primers do not cover all
target regions. To ensure that the alignment-based initialization strat-
egy can obtain the same coverage as the nondegenerate initialization
approach, line 16 augments the set of degenerate primers by the set
of nondegenerate primers.
6.3.2 Primer Filtering
In order to select only primers with favorable physicochemical prop-
erties, a filtering procedure is applied to the initial set of primer
candidates. The filtering procedure iterates over each filtering con-
straint56 and eliminates a primer from the set as soon as a constraint
is broken. The selection of high-quality primers is not the only pur-
pose of the filtering procedure. Since the filtering procedure removes
a large number of candidate primers, it is critical for rendering the
optimization procedure, which is performed subsequently, computa-
tionally feasible.
If the target coverage (typically 100%) cannot be reached because
too many primer candidates were excluded during the filtering
phase, the constraints are relaxed in order to retain primers that cover
missing templates. For this purpose, Algorithm 3 couples filtering
of primers with a procedure that relaxes the constraints until the
target coverage can be reached. The filterPrimers procedure
executes a while loop that performs the following steps. First, the
primers are filtered according the current constraints by calling
the filterPrimersNaive procedure (line 5). Note that line 16
of this procedure implicitly evaluates the property of the primer
associated with a given constraint if it has not been determined yet
and otherwise retrieves the previously computed value. Second, the
constraints are relaxed using the relaxConstraints procedure
(line 23), which relaxes a constraint only if there exists a primer that
provides additional coverage and violates the current constraint.
The extent to which a constraint is relaxed in the relaxCon-
straints procedure is determined by the target constraints and the
constraint limits, which are included in the set of filtering constraints,
F. While target constraints indicate the desired properties of primers,
constraint limits indicate properties that would not be ideal but still
acceptable. The relaxation is performed by the relax procedure
(line 28) in which the current constraint is adjusted according to the
difference between the initially defined constraint limit and the target
value. To showcase a relaxation, consider the entry for GC ratio in Ta-
ble 6.3, which defines a target range of 40%–60% and a limit range of
30%–70%. Thus, if required for reaching the target coverage, the GC
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Algorithm 2: Degenerate primer initialization.
Input:
Set of templates T, range of allowed primer lengths (lmin, lmax),
maximum degeneracy per primer ndegen
Output:
An initial set of primers P
1: procedure initPrimersDegenerate(T, (lmin, lmax), ndegen)
2: A← alignBindingRegions(T)
3: |A| ← lengthOfAlignment(A)
4: P← ∅
5: for s ∈ {1, 2, . . . , |A| − lmax + 1} do . Start of subalignment
6: for l ∈ {lmin, lmin + 1, . . . , lmax} do . Length
7: e← s + l − 1 . End of subalignment
8: if e > |A| then
9: break
10: else
11: A[s,e] ← A.getSubAlignment(s, e)
12: d← computeHammingDissimilarities(A[s,e])
13: H ← computeHierarchicalClustering(d)
14: p← generateDegeneratePrimers(H, ndegen)
15: P← P ∪ p
16: P← P ∪ initPrimersNaive(T, (lmin, lmax))
17: return P
18:
19: procedure generateDegeneratePrimers(H, ndegen)
20: P← ∅
21: for each l ∈ leaves(H) do
22: while degen(computeConsensus(l)) ≤ ndegen do
23: p← computeConsensus(l)
24: P← P ∪ p
25: l ← getAncestor(l)
26: if l is none then
27: break
28: return P
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ratio constraint would be relaxed from 40%–60% to 30%–70% in the
first relaxation, from 30%–70% to 20%–80% in the second relaxation,
and so on. Since reaching the target coverage has a higher priority
than primer quality, breaches of the constraint limits are allowed by
default.
6.3.3 Primer Set Optimization
This figure is based on an example provided by Pearson et al. (1996).
Figure 6.2: The set cover prob-
lem. Circles represent templates
and primers are indicated by
rectangles. Templates that
are enclosed by a primer are
considered to be covered by
that primer. The minimum
primer set covering all tem-
plates, which can be deter-
mined by an integer linear
program, is {I1, I2}. An approx-
imate solution consisting of
{G1, G2, G3, G4} is obtainable
with a greedy algorithm.
openPrimeR provides a greedy algorithm and an ILP formulation
for solving the SCP. The practical difference between these two
approaches is that an ILP can find the optimal solution, while a
greedy algorithm may only find an approximate solution. Figure 6.2
illustrates the set cover problem for mPCR primer design using a toy
example with 16 templates, that is, T = {t1, t2, . . . , t16} and 6 primers,
that is, P = {G1, G2, G3, G4, I1, I2}. Assume the primers have the
following amplification events:
G1.T = {t1, t2, t3, t4, t5, t6, t7, t8}
G2.T = {t9, t10, t11, t12}
G3.T = {t13, t14}
G4.T = {t15, t16}
I1.T = {t1, t2, t3, t4, t9, t10, t13, t15}
I2.T = {t5, t6, t7, t8, t11, t12, t14, t16}
An ILP would find the optimal solution consisting of the two primers
I1 ∪ I2, while a greedy algorithm would only find the approximate
solution consisting of the four primers, G1 ∪ G2 ∪ G3 ∪ G4. This is
because the greedy approach, at every iteration, selects the primer
providing the maximal gain in coverage. Hence, the algorithm can
get stuck in a local minimum. To illustrate this, consider the follow-
ing iterations of a greedy algorithm:
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Algorithm 3: Filtering of primers.
Input:
Set of templates T, set of primers P, filtering constraints F, target
coverage c ≥ 0
Output:
Reduced set of primers fulfilling the (relaxed) filtering constraints
F
1: procedure filterPrimers(T, P, F, c)
2: c← min(c, |P.T |) . Number of templates to cover
3: PF ← ∅
4: while |PF.T | < c do
5: PF ← filterPrimersNaive(T, P, F)
6: PE ← P \ PF . Excluded primers
7: TM ← P.T \ PF.T . Missing templates
8: PC ← TM/PE . Excluded primers with additional coverage
9: F ← relaxConstraints(F, PC)
10: return PF
11:
12: procedure filterPrimersNaive(T, P, F)
13: PF ← P
14: for f in F do
15: for p in PF do
16: if p 6|= f then
17: PF ← PF \ p
18: return PF
19:
20: procedure relaxConstraints(F, P)
21: for f in F do
22: if ∃p ∈ P 6|= f then
23: f ← relax( f )
24: return F
25:
26: procedure relax( f )
27: (∆min, ∆max)← initialLimit( f )− initialSetting( f ) . Step size
28: f ← f + (∆min, ∆max)
29: return f
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G1.T = {t1, t2, t3, t4, t5, t6, t7, t8}
G2.T = {t9, t10, t11, t12}
G3.T = {t13, t14}
G4.T = {t15, t16}
I1.T = {t1, t2, t3, t4, t9, t10, t13, t15}
I2.T = {t5, t6, t7, t8, t11, t12, t14, t16}
Figure 6.3: Greedy state 0.
G1.T = {}
G2.T = {t9, t10, t11, t12}
G3.T = {t13, t14}
G4.T = {t15, t16}
I1.T = {t9, t10, t13, t15}
I2.T = {t11, t12, t14, t16}
Figure 6.4: Greedy state 1.
G1.T = {}
G2.T = {}
G3.T = {t13, t14}
G4.T = {t15, t16}
I1.T = {t13, t15}
I2.T = {t14, t16}




G4.T = {t15, t16}
I1.T = {t15}
I2.T = {t16}







Figure 6.7: Greedy state 4.
1. Initially (Figure 6.3), the selection of either G1, I1, or I2 would
lead to the maximal coverage gain of 8. Thus, the algorithm may
arbitrarily select G1, which has G1.T = {t1, t2, t3, t4, t5, t6, t7, t8}.
Due to the selection of G1, it is no longer necessary to consider
coverage events relating to the templates t1, t2, t3, t4, t5, t6, t7, or t8.
2. Based on the updated coverage (Figure 6.4), the selection of either
G2, I1, or I3 would lead to the maximal coverage gain of 4. Thus,
the algorithm may select primer G2. Since G2 provides coverage of
t9, t10, t11, t12, these templates do no longer have to be considered.
3. Based on the updated coverage (Figure 6.5), the selection of either
G3, I1, or I2 would lead to the maximal coverage gain of 2. Hence,
the algorithm may select primer G3. As G3 covers t13 and t14,
these templates no longer need to be considered.
4. Based on the updated coverage (Figure 6.6), G4 has the maximal
coverage gain of 2 and is therefore selected. As G2 covers t15 and
t16, these templates no longer have to be considered (Figure 6.7).
The greedy procedure terminates after this step since no additional
coverage could be gained by considering additional primers.
Note that, primer optimization necessitates that two additional
constraints are included in the SCP: the maximum allowed melting
temperature difference, ∆Tmaxm ≥ 0, and the minimum allowed free
energy of cross dimerization, ∆Gmincd ≤ 0. In the following, the greedy
and the ILP-based optimization strategies are presented.
Formulation as a Greedy Algorithm Algorithm 4 illustrates the greedy
procedure, optimizeGreedy, for the design of multiplex PCR primers.
The algorithm constructs a small set of primers according to the
following criterion: In every iteration, select a compatible primer that
provides the greatest gain in coverage until the maximal possible coverage
has been reached. A primer is considered compatible if it fulfills the
constraints on the permissible melting temperature difference and
on the free energy of cross dimerization. These constraints ensure
that only non-dimerizing primers with suitable melting temperatures
are combined into the same set. To ensure that primer combinations
exhibit similar melting temperatures, primer subsets within a melting
temperature range [ti, tj], that is, P(ti ,tj) with tj − ti ≤ ∆Tm, are
constructed by the createTemperatureRanges procedure (line 2).
Cross-dimerizing primers are prevented by the greedyChoice
procedure, which selects only non-dimerizing primers (line 55).
The createTemperatureRanges procedure selects suitable
melting temperatures using the following approach. First, the cre-
ateTemperatureRangesNaive procedure determines evenly-
186
spaced temperatures whose subsequent differences are below ∆Tm
(line 35). Second, the isCoverageSufficient procedure deter-
mines whether any of the primer sets that are induced by the selected
melting temperatures reach the target coverage. While this is not the
case (line 16), the maximal allowed melting temperature difference,
∆Tm, is relaxed (line 17) and a new array of melting temperatures is
constructed via createTemperatureRangesNaive (line 18). Finally,
the constructed array of melting temperatures is returned.
The optimizeGreedy procedure performs the following com-
putations until at least one primer set whose coverage exceeds the
target coverage has been found (line 4). First, the cross-dimerization
matrix, D, is computed (line 5). Second (line 6), for each melting
temperature, ti, greedy primer selection is performed via greedySet.
If a primer set with sufficient coverage is found, it is stored in the list
of primer sets, R (line 9). Third, once all melting temperatures have
been considered, the cross-dimerization constraint is relaxed (line 10).
Since the optimizeGreedy procedure generates small primer
sets for several melting temperature ranges, line 11 determines the
smallest set with the greatest coverage among all constructed primer
sets. To exemplify this point, assume that the procedure constructs
three primer sets with optimal annealing temperatures at 50◦ C, 55◦







assume |T| = 150 and let the sets have coverages of |P50◦.T | = 120,
|P55◦.T | = 148, and |P60
◦
.T | = 130. Then, primer set P55
◦
is selected
because it has the largest coverage (148 of 150 templates) among all
constructed sets.
The greedySet procedure works as follows. Only primers whose
melting temperature is in the current melting temperature range,
[t1, t2], are considered (line 41). Then, primers are selected accord-
ing to the greedy criterion until the maximal possible coverage is
obtained (line 42). When the greedyChoice procedure has selected
a primer according the greedy criterion, the primer is removed from
the candidate set of primers, added to the selected set of primers, and
the coverage of the remaining primers is updated using the update-
Coverage procedure (line 48), which discounts the templates that
are covered by the selected primer. If no primer could be selected
(i.e. no compatible primer could be found), the procedure terminates
(line 44).
The greedyChoice procedure, which selects a primer according
to the greedy criterion, is implemented as follows. After sorting
the primers according to decreasing coverage (line 52), the non-
dimerizing primer providing the greatest gain in coverage is selected
by considering the entries of the dimerization matrix D (line 55). If
no primer fulfilling the dimerization constraint could be found, the
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procedure returns none.
Theoretically, the size of a greedy set cover is at most approxi-
mately ln(|T|) times larger than the size of the minimum cover57.
This upper bound also holds for the presented greedy primer de-
sign strategy. However, in this case, the size of the minimum cover
relates to the minimum primer set that fulfills the (relaxed) filtering
constraints as well as the (relaxed) optimization constraints.
Formulation as an Integer Linear Program Multiplex PCR primer
design can be formulated as an ILP in the following manner. First,
we define the indicator vector x ∈ {0, 1}|P| according to its entries
xi =
1 if primer pi ∈ P is selected0 if primer pi ∈ P is not selected
such that entry xi indicates whether the candidate primer pi is part of
the optimal primer set. Further, the coverage information is summa-
rized in the coverage matrix C ∈ {0, 1}|T|×|P|, which is defined by its
entries
cij =
1 if pj . ti0 else .





xi Minimize number of primers (6.1)
subject to (6.2)
Cx ≥ 1 Cover each template (6.3)
(xi + xj)Dpi ,pj ≤ 1 ∀pi, pj ∈ P Prevent dimers (6.4)
In this formulation, dimers are prevented using side constraint 6.4,
which ensures that never both of two dimerizing primers are se-
lected58. In order to keep the number of side constraints manageable,
the melting temperature constraint is not explicitly modeled. Instead,
similarly to the greedy approach, the ILP is solved for primer subsets
at various melting temperature ranges, as depicted in Algorithm 5.
To select an optimal set of primers through an ILP, the optimizeILP
procedure is used. Similarly to the greedy approach, the ILP proce-
dure uses createTemperatureRanges to select appropriate melting
temperatures (line 2). The procedure then performs the following
steps until an optimal primer set has been found.
After the dimerization matrix, D, has been calculated (line 5),
for each selected melting temperature (line 6), a solution to the
primer design ILP is determined by calling the solveILP function
(line 7), which uses the exact branch-and-bound implementation of
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Algorithm 4: Greedy primer optimization.
Input:
Set of templates T, set of primers P, melting temperature con-
straint ∆Tm, dimerization constraint ∆Gcd, target coverage c ≥ 0
Output:
Approximation of a minimum primer set P̂∗ with maximum pos-
sible coverage of template sequences T subject to the temperature
constraint ∆Tm and the dimerization constraint ∆Gcd
1: procedure optimizeGreedy(T, P, ∆Tm, ∆Gcd, c)
2: [t1, . . . , tN ]← createTemperatureRanges(P, T, ∆Tm, c)
3: R← ∅ . Optimal primer sets for temperature ranges
4: while R = ∅ do
5: D← (dpi ,pj) =
1 if ∆G(pi, pj) < ∆Gmincd0 else
6: for i ∈ [1, . . . , N − 1] do
7: P̂∗ ← greedySet(T, P, [ti, ti+1], D) . Best set for [ti,
ti+1]
8: if |P̂∗.T | ≥ c then
9: R← R ∪ {P̂∗}
10: ∆Gcd ← relax(∆Gcd)
11: P̂∗ ← selectBestSet(R, T) . Best set across all temperatures
12: return P̂∗
13:
14: procedure createTemperatureRanges(P, T, ∆Tm, c)
15: [t1, . . . , tN ]← createTemperatureRangesNaive(P, ∆Tm)
16: while ¬isCoverageSufficient(P, T, [t1, . . . , tN ], c) do
17: ∆Tm ← relax(∆Tm)
18: [t1, . . . , tN ]← createTemperatureRangesNaive(P, ∆Tm)
19: return [t1, . . . , tN ]
20:
21: procedure isCoverageSufficient(P, T, [t1, . . . , tN ], c)
22: cOK ← false
23: for i ∈ [1, . . . , N − 1] do
24: P(ti ,ti+1) ← {p|p ∈ P, ti ≤ Tm(p) ≤ ti+1}
25: if |P(ti ,ti+1).T | ≥ c then . Set with sufficient coverage found
26: cOK ← true
27: break
28: return cOK
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Algorithm 4: Greedy primer optimization (continued).
29: procedure createTemperatureRangesNaive(P, ∆Tm)
30: T = [ ] . Array with temperatures
31: (tmin, tmax)← (minpi∈P Tm(pi), maxpi∈P Tm(pi))
32: ti ← tmin
33: while ti < tmax do
34: T.append(ti)




39: procedure greedySet(T, P, (t1, t2), D)
40: P̂∗ ← ∅ . Selected primer set
41: P(t1,t2) ← {p ∈ P|t2 ≥ Tm(p) ≥ t1}
42: while |P̂∗.T | 6= |P.T | do
43: p← greedyChoice(T, P(t1,t2), D, P̂
∗)
44: if p = none then
45: return P̂∗
46: P(t1,t2) ← P(t1,t2) \ {p}
47: P̂∗ ← P̂∗ ∪ {p}
48: P(t1,t2) ← updateCoverage(P(t1,t2), T, p)
49: return P̂∗
50:
51: procedure greedyChoice(T, P, D, P̂∗)
52: P← sortByDecreasingCoverage(P)
53: p← none . Selected primer
54: for each pi ∈ P do
55: ndimers ← ∑
|P̂∗ |
j=1 Dpi ,pj






Algorithm 4: Greedy primer optimization (continued).
61: procedure selectBestSet(R, T)
62: P̂∗ ← none . The best primer set
63: Cmax = 0 . The highest coverage
64: for each Ri ∈ R do
65: Ci ← Ri.T
66: if (Ci > Cmax) or (Ci = Cmax and |Ri| < |P̂∗|) then
67: P̂∗ ← Ri
68: Cmax ← Ci
69: return P̂∗
70:
71: procedure updateCoverage(P, T, p)
72: for each pi ∈ P do
73: pi.T ← pi.T \ p.T
74: return P
60 Caprara et al. 1999
lpsolve59. If the constructed set reaches the target coverage (line 8), it
is included in the set of optimal primer sets, R. Once all melting tem-
peratures have been considered, the cross-dimerization constraint is
relaxed (line 10). Finally, in line 11, the best set across all temperature
ranges is returned, in the same way as described for the greedy algo-
rithm. Note that Lagrangian-based heuristics for solving the set cover
problem60, which could considerably improve the runtime, are not
applicable to the formulated ILP due to the dimerization constraint.
Reporting Results for Forward and Reverse Primers When both for-
ward and reverse primers are designed, pairs of forward and reverse
primers are formed for clarifying the results. Pairing primers is possi-
ble only after the optimization procedure because designed primers
have passed stringent quality control criteria and should therefore be
compatible with each other. To pair primers of contrary orientation,
the following procedure is used. First, all combinations of forward
and reverse primers are generated. Second, the EAEs of primers
constituting a pair are intersected. Pairs whose EAE intersection is
empty are removed. Third, since the remaining pairs may exhibit
redundancies (i.e. they may cover only templates that are already
covered by the other primer pairs), a set cover ILP (Problem 6.1
without the dimerization constraint) is solved to find the minimum
combination of primer pairs that retains the overall coverage.
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Algorithm 5: ILP primer optimization.
Input:
Set of templates T, set of primers P, melting temperature con-
straint ∆Tm, dimerization constraint ∆Gcd, target coverage c ≥ 0
Output:
A minimal primer set P̂∗ fulfilling the filtering constraints F with
maximal possible coverage of template sequences T subject to the
temperature constraint ∆Tm and the dimerization constraint ∆Gcd
1: procedure optimizeILP(T, P, ∆Tm, ∆Gcd, c)
2: [t1, . . . , tN ]← createTemperatureRanges(P, T, ∆Tm, c)
3: R← ∅ . Optimized primer sets for temperature ranges
4: while R = ∅ do
5: D← (dpi ,pj) =
1 if ∆G(pi, pj) < ∆Gmincd0 else
6: for i ∈ [1, . . . , N − 1] do
7: P̂∗ ← solveILP(T, P[ti ,ti+1], D) . Best set for [ti, ti+1]
8: if |P̂∗.T | ≥ c then
9: R← R ∪ {P̂∗}
10: ∆Gcd ← relax(∆Gcd)
11: P̂∗ ← selectBestSet(R, T) . Best set across all temperatures
12: return P̂∗
6.3.4 Local Primer Design
Based on the algorithms for initializing (Algorithms 1 and 2), filtering
(Algorithm 3), and optimizing (Algorithm 4 and 5) primers, the local
primer design procedure (Algorithm 6) determines an optimum set
of primers for a single DNA strand via designPrimersSingle. This
procedure first initializes a set of primers using initPrimers, filters
the primers using filterPrimers, and then optimizes the primers
using optimizePrimers. The initPrimers procedure provides an
option for initializing either nondegenerate primers via initPrimer-
sNaive (line 12) or degenerate primers via initPrimersDegenerate
(line 10). The procedure optimizePrimers solves the optimization
problem either using the greedy formulation provided by the opti-
mizeGreedy procedure (line 20) or the ILP formulation provided by
the optimizeILP procedure (line 18).
The local primer design strategy for a single DNA strand is suf-
ficient for designing primers targeting immunoglobulin variable
regions because this task requires only the design of forward primers
for the variable region; reverse primers for the constant region do not
need to be optimized due to the high conservation of this region. In
general, primer design is concerned with determining both forward
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61 This approach is called global because
the primer search space is not limited
by the filtering procedure.
and reverse primers. Algorithm 7, which presents the designPrimers
procedure, is concerned with this problem. The procedure requires
an argument d that specifies whether only forward primers, only re-
verse primers, or primers of both orientations should be designed. If
primers of a single orientation are designed, the designPrimersSin-
gle procedure is called by providing the templates in the appropriate
orientation according to d (line 4). Otherwise, an optimal set of for-
ward primers is constructed first (line 7) and then an optimal set of
reverse primers is determined (line 9). Finally, the sets of forward
and reverse primers are combined (line 10).
6.3.5 Global Primer Design
For small instances of the primer design problem (e.g. for few tem-
plates and short binding regions), it is not necessary to filter the
primers before the optimization procedure commences. Algorithm 8
demonstrates such a global primer design strategy via the design-
PrimersGlobalSingle procedure.61
The global primer design approach replaces the filtering proce-
dure of the local primer design approach with scorePrimers, a
procedure that determines the quality penalty associated with ev-
ery primer (line 4, as described in Section 6.2.4). Primer sets with
varying deviations from the constraints are generated by adjusting
the maximum allowed quality penalty ξ (line 6). For each ξ, a subset
of primers whose penalties do not exceed ξ is constructed and opti-
mized (line 8). Finally, the procedure returns a list containing small
primer sets fulfilling the constraints to varying degrees. The choice
of a suitable primer set can be facilitated by considering the primer
quality penalty with respect to coverage and set size. Because the
global primer design approach can be adapted to multiple strands
in the same way as the local strategy (Algorithm 7), the analogous
implementation for the global strategy is not described in this disser-
tation.
The benefit of the global primer design approach is that it does
not merely return a single primer set fulfilling the constraints but
allows for designing primer sets fulfilling the constraints to differing
degrees. Based on the results, it is possible to find a suitable trade-
off between relatively large primer sets with small deviations from
the target constraints and relatively small primer sets with large
deviations from the target constraints.
6.3.6 Feasibility of Primer Design
Since computational primer design is time-consuming, it is useful to
have an approach for estimating whether it is possible to design a set
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Algorithm 6: Primer design for a single strand.
Input:
Set of templates T, filtering constraints F, melting temper-
ature constraint ∆Tm, dimerization constraint ∆Gcd, oO ∈
{Greedy, ILP}, oI ∈ {Naive, Degenerate}, desired primer
lengths (lmin, lmax), target coverage c ≥ 0, maximal primer
degeneracy ndegen
Output:
A minimum primer set P̂∗ fulfilling the (relaxed) filtering con-
straints F with maximum possible coverage of template se-
quences T subject to the temperature constraint ∆Tm and the
dimerization constraint ∆Gcd
1: procedure designPrimersSingle(T, F, ∆Tm, ∆Gcd, oO, oI ,
(lmin, lmax), c, ndegen)
2: P← initPrimers(T, oI , (lmin, lmax), ndegen)
3: PF ← filterPrimers(T, P, F, c)
4: P̂∗ ← optimizePrimers(T, PF, ∆Tm, ∆Gcd, oO, c)
5: return P̂∗
6:
7: procedure initPrimers(T, oI , (lmin, lmax), ndegen)
8: Tb ← getBindingRegions(T)
9: if oI = Degenerate then
10: P← initPrimersDegenerate(T, (lmin, lmax), ndegen)
11: else
12: P← initPrimersNaive(T, (lmin, lmax))
13:
14: procedure optimizePrimers(T, P, ∆Tm, ∆Gcd, oO, c)
15: c← min(c, |P.T |) . Number of templates to cover
16: P̂∗ ← none
17: if oO = ILP then
18: P̂∗ ← optimizeILP(T, P, ∆Tm, ∆Gcd, c)
19: else
20: P̂∗ ← optimizeGreedy(T, P, ∆Tm, ∆Gcd, c)
21: return P̂∗
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Algorithm 7: Generalized primer design procedure.
Input:
Set of templates T with forward (Tfw) and reverse binding re-
gions (Trev), filtering constraints F, melting temperature con-
straint ∆Tm, dimerization constraint ∆Gcd, oO ∈ {Greedy, ILP},
oI ∈ {Naive, Degenerate}, desired primer lengths (lmin, lmax),
target coverage ratio c ∈ [0, 1], maximal primer degeneracy ndegen,
orientation of primers d = {fw, rev, both}
Output:
A minimal primer set P̂∗ with primers of orientation d fulfilling
the filtering constraints F with maximal possible coverage of
template sequences T subject to the temperature constraint ∆Tm
and the dimerization constraint ∆Gcd
1: procedure designPrimers(T, F, ∆Tm, ∆Gcd, oO, oI , (lmin, lmax), c,
ndegen, d)
2: c← c|T| . Number of templates to cover
3: if d ∈ {fw, rev} then
4: P̂∗ ← designPrimersSingle(Td, F, ∆Tm, ∆Gcd, oO, oI , (lmin, lmax), c, ndegen)
5: return P̂∗
6: else
7: P̂∗fw ← designPrimersSingle(Tfw, F, ∆Tm, ∆Gcd, oO, oI , (lmin, lmax), c, ndegen)
8: T ← ˆP∗fw.T . Cover the appropriate templates of the other
strand
9: P̂∗rev ← designPrimersSingle(Trev, F, ∆Tm, ∆Gcd, oO, oI , (lmin, lmax), c, ndegen)
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Algorithm 8: Global primer design.
Input:
Set of templates T, filtering constraints F, melting temper-
ature constraint ∆Tm, dimerization constraint ∆Gcd, oO ∈
{Greedy, ILP}, oI ∈ {Naive, Degenerate}, desired primer
lengths (lmin, lmax), primer penalty parameter α ∈ [0, 1], max-
imum allowed primer penalty ξmax ≥ 0, step size for primer
penalties ξε > 0
Output:
A collection P̂∗ξ of optimal primer sets whose members exhibit
differing deviations from the constraints F as defined by ξmax and
ξε
1: procedure designPrimersGlobalSingle(T, F, ∆Tm, ∆Gcd, oO,
oI , (lmin, lmax), α = 0.5, ξmax, ξε)
2: P̂∗ξ ← ∅
3: P← initPrimers(T, oI , (lmin, lmax))
4: PE ← scorePrimers(T, P, F, α)
5: ξ ← 0 . Current maximal allowed penalty
6: while ξ ≤ ξmax do
7: Pξ ← {p ∈ PE|Pen(p, F, T, α) ≤ ξ}
8: P̂∗ξ ← optimizePrimers(T, Pξ , ∆Tm, ∆Gcd, oO)
9: P̂∗ξ ← P̂∗ξ ∪ P̂∗ξ
10: ξ ← ξ + ξε
11: return P̂∗ξ
12:
13: procedure scorePrimers(T, P, F, α)
14: PE ← P
15: for p in PE do




of primers of appropriate size before beginning with the design. The
key idea for developing such an approach is that the time-intensive
steps of evaluating and optimizing the primers should be avoided.
In fact, it is possible to estimate the feasibility of a primer design
problem solely based on the distribution of the EAEs because there
is a relationship between the coverage distribution and the size
of the optimized primer set. Templates that are well-conserved
are associated with sets of primers containing multiple primers
exhibiting high coverages, which lead to small optimized primer sets.
Less conserved templates, on the other hand, are associated with
low-coverage primers and, correspondingly, large primer sets. Based
on this observation, the feasibility of a primer design problem can
be evaluated by comparing the primer coverage distribution with
reference distributions.
Each reference distribution represents a distinct amplification sce-
nario exhibiting a certain level of feasibility with respect to designing
primers. For feasible primer design problems, primer candidates
comprise a considerable number of high-coverage primers (e.g. cover-
ing 10%–20% of templates), while infeasible primer design problems
exhibit few such primers. To illustrate this, imagine a set of 100
templates. If there were 10 primers, each covering a distinct set con-
taining 10% of the templates, it would be possible to obtain a primer
set of size 10. However, if there were 10 complementary primers,
each with a coverage of only 1%, the size of the primer set would be
100, which is too large.
By empirically investigating the coverage distribution for sev-
eral sets of templates, I found that the coverage distribution can be
modeled well using a beta distribution. The beta distribution is a
continuous probability distribution that is controlled by two posi-
tive shape parameters α and β. Its probability density function for





The beta function B(α, β) = Γ(α)Γ(β)Γ(α)+Γ(β) serves as a normalization
constant, which ensures that the probability integrates to 1. For
positive integers, the gamma function Γ(n) = (n− 1)! is simply an
extension of the factorial function.
Algorithm 9 gives the classifyDesignProblem procedure,
which classifies the difficulty of a primer design problem. Using
the defineReferenceDistributions function (line 2), it defines reference
distributions representing primer design instances with distinct
levels of feasibility (Figure 6.8): Easily Feasible with β(1, 10), Feasible
with β(0.8, 20), Hardly Feasible with β(0.6, 40), and Unfeasible with
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62 The parameters of the beta distribu-
tions were selected by hand so as to
obtain distributions that are represen-
tative of the corresponding levels of
primer design feasibility.
63 By using the fractional coverage
rather than the coverage, the approach
is independent of the number of
templates.
64 Delignette-Muller and Dutang 2015
β(0.3, 200).62 Since the computation of the coverage distribution
would be too time-consuming, a lower bound on the coverage of each
primer is computed through the estimateCoverageDistribution function
(line 3) in the following way.
For a specific primer length k, all template k-mers are generated.
Next, the fractional coverage is determined by counting the occur-
rences of each k-mer and dividing by the number of templates.63
Based on the coverage distribution of the primers, the parameters
of a beta distribution are determined using a maximum likelihood
approach64 via the function fitBetaDistribution (line 4). The fitted beta
distribution is then compared to each of the reference distributions
based on the total variation distance (line 8), which is introduced in
the following.
Beta distributions representing coverage ratios induce an infinite
probability space with Ω = [0, 1]. Given two probability distributions
P and Q on a sigma-algebra C of subsets of the sample space Ω, the
total variation distance is defined as
δ(P, Q) = supC∈C |P(C)−Q(C)| .
The total variation distance δ(P, Q) can be interpreted as the largest
difference in probabilities that P and Q assign to the same event.
By determining δ(P, Q) for the fitted beta distribution, P, and all
reference distributions, Q, the feasibility of the primer design task is
obtained according to the reference distribution minimizing δ(P, Q)
(line 9). In the openPrimeR frontend, the difficulty of a primer design
task is represented by a traffic light where Easily Feasible and Feasible
problems are indicated by a green light, Hardly Feasible problems by
an orange light, and Unfeasible problems by a red light (Figure 6.9).
Although the classifyDesignProblem procedure makes several
assumptions, its inaccuracies may theoretically balance out. First,
since a lower bound on primer coverage the determined feasibility
is rather pessimistic with respect to coverage. Second, since primers
are not filtered and optimized, a set of primers exhibiting redundant
coverage or low-quality primers would require a larger number of
primers. Thus, regarding quality and redundancy of coverage, the
estimated feasibility may be too optimistic.
6.3.7 Optimal Subset Selection
Determining subsets of an optimized primer set can be desirable
in two scenarios: when a primer set is too large or when specific
primers amplifying a subset of templates should be selected. In
the following, I provide examples for both scenarios. For the first
scenario, consider a set of 20 primers of which 5 primers provide
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Algorithm 9: Classifying the feasibility of a primer design task.
Input:
Set of templates T, primer length k
Output:
Primer design problem difficulty class
1: procedure classifyDesignProblem(T, k)
2: β← defineReferenceDistributions()
3: x ← estimateCoverageDistribution(T, k)
4: βx ← fitBetaDistribution(x)
5: class← none
6: dmin ← none
7: for each βi ∈ β do
8: d← totalVariationDistance(βx, βi)
9: if d < dmin then
10: dmin ← d
11: class← classOf(βi)
12: return class
Hardly Feasible :  β(0.6, 40) Unfeasible :  β(0.3, 200)
Easily Feasible :  β(1, 10) Feasible :  β(0.8, 20)





















Figure 6.8: Reference beta dis-
tributions for estimating the
feasibility of primer design
tasks. The plots show the cov-
erage distributions that were
obtained by drawing 100 000
samples from the indicated beta
distributions.
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Figure 6.9: Traffic light repre-
sentation for primer design
difficulty. In this case, the light
is green, so it should be possi-
ble to design a suitably small
set of primers for the given
templates.90% coverage. If coverage of all templates is not required, it may
be beneficial to remove the 15 primers that provide little additional
coverage and work with the subset of 5 primers that already achieves
90% coverage. For the second scenario, imagine that there is a set of
primers suitable for all subtypes of HIV-1 group M but one would
like to isolate only sequences from subtype B. Then, one would
need to determine the subset of primers maximizing the coverage of
subtype B sequences.
Since best subset selection targets well-designed primer sets,
the physicochemical properties of the primers do not have to be
considered. The problem can be formulated in terms of the NP-
hard maximum coverage problem. Since optimized primer sets are
small, the problem can be solved exactly using the following ILP.
As previously, let xi ∈ {0, 1} refer to the decision variables and
let C ∈ {0, 1}|T|×|P| indicate the coverage matrix. Let Px denote
the primer set that is induced by x, that is, Px = {pi ∈ P|xi = 1}.
Additionally, let yj ∈ {0, 1} refer to decision variables indicating
whether template tj is covered by any member of Px, that is,
yj =
1 if |tj/Px | ≥ 10 else .
Further, let k ∈ N indicate the size of the primer subset. Then, the










xi = k Select a subset of size k (6.7)
Cx ≥ y Definition of y (6.8)
In this ILP, the critical part is the last constraint, Cx ≥ y, which
ensures that yj is only set to 1 if template tj is covered by at least one
selected primer. The trade-off between the size of a primer set P and
its coverage can be analyzed by solving the ILP for k ∈ {1, . . . , |P|}
(Figure A.2).
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65 For an overview of the in silico
results for IGKV and IGLV, I refer the
interested reader to the Figures A.4, A.5,
A.6, and A.7 in the appendix.
66 Ruiz et al. 2000; Lefranc 2004; Giudi-
celli et al. 2004; Lefranc et al. 2015
67 A sequence is classified as functional
by IMGT if it has coding regions with
open reading frames without stop
codons and there are no defects in
splicing sites, recombination signals
and/or regulatory elements.
6.4 Primer Design for Human Immunoglobulin Sequences
In this section, I present the application of openPrimeR on primers
targeting human immunoglobulin variable sequences from IGH,
IGK, and IGL (Section 6.4.1). Primers targeting the leaders of IGH
(Table 6.7), IGK (Table 6.8), and IGL (Table 6.9) were designed accord-
ing to the settings shown in Table A.2. These settings were obtained
by iteratively adjusting the constraints according to experimentally
obtained PCR yields. Since the number of overall mismatches was
limited to either zero (for IGHV) or three (for IGKV and IGLV) and
3’ mismatches were not allowed at all, it was not necessary to apply
a model for filtering the EAEs. The three designed primer sets were
determined through the local primer design procedure; the SCP was
solved using the ILP formulation.
The designed primer sets for IGH, IGK, and IGL were validated
both in silico and in vitro. For the sake of brevity, the following sec-
tions provide only the validation results for IGHV.65 The designed
IGHV primers (openPrimeR, 15 primers) were compared to the well-
established primer sets from Tiller et al. (2008) (Tiller, 4 primers) and
Ippolito et al. (2012) (Ippolito, 8 primers) both in silico (Section 6.4.2)
and in vitro (Section 6.4.3).
6.4.1 Data for Immunoglobulin Primer Design
For the purpose of designing primers for human immunoglobulin
sequences, germline sequences for IGH, IGK, and IGL were retrieved
from the international immunogenetics information system (IMGT)
database66. Only those sequences that were classified as functional
according to IMGT67 were selected in order to limit primer design to
sequences from expressed genes. Additionally, template sequences
with partial leader sequences were either removed (for IGK and IGL)
or augmented by our own NGS measurements (for IGH). Based
on this procedure, 152 IGH, 62 IGK, and 35 IGL templates were
selected (Table 6.10). For the purpose of comparing the properties of
designed primer sets with existing sets, established primer sets for
IGH (Table A.3), IGK (Table A.4), and IGL (Table A.5) were collected
from IMGT and the literature.
6.4.2 In Silico Validation
Figure 6.10 shows that all of the openPrimeR primers are expected to
exclusively bind in the conserved leader region, which is neither the
case for the primers from Tiller nor those from Ippolito. Panel A of
Figure 6.11 demonstrates that the designed primers fulfill most of the
required physicochemical constraints and have a higher constraint
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Primer Sequence Main target Coverage Tm [◦C]
1-IGHV atggactggacctggagcatcc IGHV1 8.6% 60.68
2-IGHV atggactggacctggaggatcctc IGHV1 11.2% 61.59
3-IGHV atggactggacctggagggtcttc IGHV1 2% 61.95
4-IGHV atggactggatttggagggtcctcttc IGHV1 1.3% 61.30
5-IGHV atggacacactttgctacacactcctgc IGHV2 0.7% 61.99
6-IGHV actttgctccacgctcctgc IGHV2 13.2% 60.07
7-IGHV ggctgagctgggttttccttgttg IGHV3 27% 60.33
8-IGHV ggctccgctgggttttccttgttg IGHV3 1.3% 62.80
9-IGHV cacctgtggttcttcctcctgctg IGHV4 28.3% 61.51
10-IGHV atgaaacacctgtggttcttcctcctcc IGHV4 27.6% 61.43
11-IGHV acatctgtggttcttccttctcctggtg IGHV4 1.3% 61.19
12-IGHV gcctctccacttaaacccaggctc IGHV5 0.7% 61.41
13-IGHV atgtctgtctccttcctcatcttcctgc IGHV6 1.3% 60.88
14-IGHV atggagttggggctgagctgg IGHV3 26.3% 61.74
15-IGHV atggggtcaaccgccatcctc IGHV5 2.6% 61.74
Table 6.7: Overview of designed
IGHV primers. Sequence pro-
vides the oligomer sequence for
the forward primer. Main target
indicates the IGHV gene group
that is predominantly targeted
by the primer. Coverage refers
to the overall coverage of the
template sequences.
Primer Sequence Main target Coverage Tm [◦C]
1-IGKV atgaggctccttgctcagcttctgg IGKV2 1.6% 62.59
2-IGKV atggaagccccagctcagcttc IGKV3D 14.5% 61.59
3-IGKV cccagctcagcttctcttcctcctg IGKV3D 16.1% 62.88
4-IGKV tggtgttgcagacccaggtcttcatttc IGKV4 1.6% 62.09
5-IGKV gtcccaggttcacctcctcagcttc IGKV5 1.6% 63.05
6-IGKV gccatcacaactcattgggtttctgctg IGKV6 6.5% 61.54
7-IGKV tccctgctcagctcctggg IGKV1 64.5% 61.68
8-IGKV cctgggactcctgctgctctg IGKV1 38.7% 62.22
Table 6.8: Overview of designed
IGKV primers. Sequence pro-
vides the oligomer sequence for
the forward primer. Main target
indicates the IGKV gene group
that is predominantly targeted
by the primer. Coverage refers
to the overall coverage of the
template sequences.
Primer Sequence Main target Coverage Tm [◦C]
1-IGLV ccctgggtcatgctcctcctgaaatc IGLV10 2.1% 62.91
2-IGLV ctctgctgctcctcactctcctcac IGLV2 10.6% 62.51
3-IGLV atggcatggatccctctcttcctcg IGLV3 2.1% 61.89
4-IGLV cctctctggctcactctcctcactc IGLV3 2.1% 61.94
5-IGLV acactcctgctcccactcctcaac IGLV3 4.3% 62.40
6-IGLV atggcctggatccctctacttctcc IGLV3 4.3% 61.34
7-IGLV atggcctgggtctccttctacc IGLV4 2.1% 60.21
8-IGLV atggcctggactcctctctttctgttc IGLV7 6.4% 61.34
9-IGLV atggcctggatgatgcttctcctc IGLV8 2.1% 60.39
10-IGLV gtcccctctcttcctcaccctcatc IGLV1 2.1% 62.15
11-IGLV ctcctcgctcactgcacagg IGLV3 21.3% 60.21
12-IGLV cctctcctcctcaccctcctc IGLV1 19.1% 60.56
13-IGLV ctcctcctcaccctcctcactc IGLV2 19.1% 60.41
14-IGLV atggcctggacccctctcc IGLV3 21.3% 61.59
15-IGLV atggcctggaccccactcc IGLV3 8.5% 62.12
Table 6.9: Overview of designed
IGLV primers. Sequence pro-
vides the oligomer sequence for
the forward primer. Main target
indicates the IGLV gene group
that is predominantly targeted
by the primer. Coverage refers
to the overall coverage of the
template sequences.
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Locus Total Functional Functional with leader
IGH 243 156 152
IGK 132 64 62
IGL 61 36 35









































Figure 6.10: IGHV primer bind-
ing regions. The leader region
is indicated by the horizontal
blue bar, while the horizontal
red bar indicates the variable
region. The region for which
the new primers were designed
is indicated by vertical red lines.
The vertical bars indicate the
number of expected amplifi-
cation events for individual
primers.
fulfillment rate than the primers from Tiller and Ippolito. The only
constraint that is minimally broken by two primers from openPrimeR
(absolute deviation slightly above 3%) relates to the GC ratio (Fig-
ure A.3). In fact, the constraint fulfillment rate of the newly designed
primers is significant at the 5% significance level according to Fisher’s
exact test (p-value of 1.6e-36). Panel B of Figure 6.11 shows that the
newly designed primers are estimated to cover 100% of germline
IGHVs. The coverage of the new IGHV primers seems to be particu-
larly superior to the coverage of the primers from Tiller.
6.4.3 In Vitro Validation

















































































Figure 6.11: Properties of IGHV
primer sets as determined
by openPrimeR. (A) Rate of
constraint fulfillment for each
constraint as determined by
Ful(P,F , T). A value of 100%
for a given constraint indicates
that all primers in the set fulfill
the constraint. Thus, the greater
the surface area in the radar
chart, the greater the quality of
the primer set. (B) Percentage
of covered templates per IGHV
gene group. A cumulative value
of 100% indicates that a set of


































































































































































































































































IGHV1 IGHV2 IGHV3 IGHV4 IGHV5 IGHV6 IGHV7
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Schematic representation of Immunglobulin heavy chain
Multiplex PCR with computed or published primer sets that bind to different regions
Subcloned IGHV germline sequences
Figure courtesy of Christoph Kreer.
Figure 6.12: Validation of
primer sets on germline IGHVs.
(A) Experimental procedure. 47
functional IGHV genes were
cloned into expression vectors
in order to obtain correspond-
ing antibody transcripts. These
transcripts were amplified with
three different primer sets and
the differential amplification of
individual IGHV genes was an-
alyzed using gel electrophoresis.
(B) Amplified IGHV genes for
five PCRs per primer set. The
bar plot summarizes the per-
centage of amplified templates.
The diagram below shows a
digitized version of the five
observed gel electrophoresis
results. Here, black squares
indicate failed amplifications,
white squares indicate negative
controls, and the remaining
squares indicate successful
amplifications.
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For the in vitro validation of the IGHV primers, three wet lab ex-
periments were performed by Nathalie Lehnen, Philipp Schommers,
Meryem Seda Ercanoglu, and Christoph Kreer. The first experiment
was done in order to determine whether the estimated coverage
agreed with the experimentally observed coverage. In this exper-
iment, a set of 47 functional IGHV genes representing all of the 7
heavy chain gene groups was selected. These sequences were cloned
into eukaryotic expression vectors and subsequently expressed in
order to amplify them via RT-PCR using the openPrimeR, Tiller, and
Ippolito primer sets (Panel A of Figure 6.12). PCRs were performed
in five replicates each and results were visualized using gel elec-
trophoresis. The evaluation of the coverage revealed that all primer
sets achieved close to 100% coverage (Panel B of Figure 6.12), al-
though the coverage of Tiller was slightly lower than that of the
other sets. The further investigation of the PCR results revealed that
the lack of coverage of Tiller was attributable to the fact that not all
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Figure courtesy of Christoph Kreer.
Figure 6.13: Validation of
primer sets on IGHVs from
single B cells. (A) Experi-
mental procedure. Naive or
antigen-experienced B-cells
were sorted and the cDNA
of their transcripts was deter-
mined. The cDNA was then
amplified through triplicate
PCRs using three different
primer sets whose performance
was evaluated using gel elec-
trophoresis. (B) Amplified
IGHV genes. The left-hand
panel shows the coverage of
IGHVs from naive B cells, while
the right-hand panel shows
the coverage of IGHVs from
antigen-experienced B cells.
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68 Ye et al. 2013b
The goal of the second experiment was to investigate whether
the results from the first experiment could be reproduced for im-
munoglobulin sequences obtained from single B cells. In order to
differentiate how the presence of mutations influences the amplifica-
tion rate, naive (unmutated) and antigen-experienced single B cells
(mutated) were separated via cell sorting (Panel A of Figure 6.13).
After transforming B-cell receptor transcripts to cDNA, PCRs were
performed in triplicates for each of the three primer sets. The gel
electrophoresis results for naive B cells closely mirrored the results
that were obtained for germline sequences in the first experiment.
All primer sets achieved close to 100% coverage but Tiller obtained
a slightly smaller coverage (Panel B of Figure 6.13) . On antigen-
experienced B cells, this effect was enhanced as the coverages for
Ippolito and openPrimeR remained high but the coverage of Tiller
dropped to slightly above 90%.
The final experiment was conducted in order to evaluate the per-
formance of the primer sets on highly mutated antibody cDNA.
For this purpose, HIV-1 reactive B cells were retrieved from an elite
neutralizer and corresponding cDNA was amplified. Panel A of Fig-
ure 6.14 demonstrates that, on these sequences, openPrimeR achieved
the highest coverage (> 90% coverage), followed by Tiller and Ippolito
(both with approximately 80% coverage). Note that Tiller slightly
outperformed Ippolito with respect to both, coverage (Panel A of Fig-
ure 6.14) and amplification of heavily mutated sequences (Panel B of
Figure 6.14).
The amplicons generated by openPrimeR were sequenced and
mapped to their germline correspondents using IgBLAST68. This
revealed that openPrimeR particularly improved the amplification
of heavy chains with reference similarities less than 70% (Panel B
of Figure 6.14). In fact, openPrimeR amplified roughly three times
as many highly mutated sequences as each of the other primer sets.
Most importantly, further experimental work demonstrated that these
















































































































< 70% V gene identityB
Figure courtesy of Christoph Kreer.
Figure 6.14: Validation on
IGHVs from a HIV-1-infected
person. (A) Amplification of
IGHV transcripts from B cells
of an HIV-1 positive person for
three primer sets, each of which
was measured in triplicates. (B)
Amplification of IGHVs as a
function of sequence similarity
to corresponding germline se-
quences. Blue samples indicate
sequences that were amplified
by the primers designed by
openPrimeR or at most one
other primer set. The bar chart
on the right shows the number
of IGHVs with a germline sim-
ilarity less than 70% that were
amplified by each of the primer
sets.
6.5 Discussion
This chapter introduced openPrimeR, a computational tool for the
evaluation and design of primer sets for mPCR. Based on the hy-
pothesis that primers binding to the immunoglobulin leader region
should allow for the improved amplification of highly mutated
antibody sequences, primer sets targeting the leaders of IGHV,
IGKV, and IGLV were developed. The reliability of openPrimeR
and the high performance of the newly designed primers targeting
immunoglobulin heavy chain sequences was shown in three exper-
iments. The first experiment revealed that the designed primers
achieve coverage of all germline immunoglobulin variants (Fig-
ure 6.12). The second experimented showed that the primers also
perform well on cDNA from single B cells (Figure 6.13), which sug-
gests their suitability for repertoire analyses.
The third experiment revealed that Tiller slightly outperformed
Ippolito on highly mutated sequences (Figure 6.14), which was inter-
esting because this was the case neither on germline nor on naive
nor on antigen-experienced sequences. An explanation for this is
presented by the binding regions of Tiller and Ippolito. While Tiller
overlaps with both leader and variable region, Ippolito solely binds
in the variable region (Figure 6.10). Consequentially, the high muta-
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tional load of the variable region69 may prevent the annealing of a
larger number of primers from Ippolito than from Tiller. The superior
performance of the primers designed by openPrimeR suggest that
primers binding to the early leader region are more suitable for the
amplification of highly mutated sequences than primers that bind
to the late leader region (Tiller) or the variable region (Ippolito). This
finding suggests that the first positions in the immunoglobulin leader
are the most conserved stretch of the 5’ end.
Most importantly, it was possible to show that the newly designed
primers facilitate the amplification of cDNA sequences from bNAbs.
In the future, the newly designed primer sets could allow for the
isolation of previously unknown bNAbs, which might be used in
novel antibody-mediated treatment and prevention strategies against
HIV-1 infection. To determine whether this is the case, previously
collected samples from elite neutralizers such as the data from (Simek
et al., 2009) could be re-analyzed using the novel primer sets.
openPrimeR fulfills all of the requirements for designing suitable
primers for human immunoglobulins. Most importantly, the tool can
be used to estimate the template amplification status with sufficient
specificity for finding the smallest set of primers covering all tem-
plates. This is possible by enforcing a stringent notion of coverage
and requiring tight constraints on the physicochemical properties of
primers. The high coverage obtained in the experimental validation
of openPrimeR suggests that the tool can identify coverage events
with sufficient accuracy. Note that the experimental coverage was
generally higher than the estimated coverage. This is attributable
to the conservative definition of coverage that was used for the in
silico evaluations, for which only a single mismatch was allowed.
Since the tool allows for specifying allowed binding ranges in the
templates, it is possible to design primers for specific regions such
as the leader. Through its GUI, openPrimeR is intuitively usable.
Additionally, openPrimeR contains a programmatic interface that
provides access to a rich set of functions that can be used for various
tasks such as performing batch runs or implementing custom primer
design approaches. Although openPrimeR was developed with im-
munological applications in mind, the tool is versatile and could be a
useful resource for other primer design tasks.
There are several ways in which openPrimeR could be improved
in the future. One aspect for improvement regards the programming
language. Currently, openPrimeR is implemented solely in R. Re-
placing some aspects with function calls to a C++ library would be
beneficial. First, the runtime of the code could be improved. Second,
the robustness of the tool could be improved because in contrast to
C++, which is strictly typed, R is typed dynamically. Using a strictly
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infeasible for large sets of templates.
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typed language for critical functions could improve maintainability
by reducing the potential for runtime errors.
The following paragraphs deal with algorithmic aspects. The
procedure for the determination of primer coverage is a bottleneck
when designing primers because all templates have to be scanned for
thousands of primer candidates. It would be possible to considerably
improve the runtime of the algorithm using hashing70, for example,
by hashing all hexamers in the template binding regions, matching
all primer 3’ hexamers to the hash map, and then extending the
hits. A limitation of this approach, however, is that it would not
allow for the generation of primers exhibiting mismatches in the 3’
hexamers. Another possible improvement pertains to the selection
of the expected region in the template to which a primer binds.
This approach may be refined by not only searching for the primer-
template conformation with the smallest number of mismatches but
by considering several conformations and selecting the most likely
one by using models that estimate the likelihood of amplification.
openPrimeR could also be further automated. For example, the
approach for classifying the difficulty of a primer design task (Sec-
tion 6.3.6) could be used to construct multi-tube solutions. Given
an infeasible primer design task, the software could automatically
iteratively split the set of templates into smaller subsets (e.g. using
clustering) until each subset yields a feasible primer design problem
and then design an individual set of primers for each subset. Further
potential for optimization lies in the automatic selection of the param-
eters for primer design. For example, the tightness of the constraints
could be based on the observed coverage distribution and the selec-
tion of the optimization algorithm could be based on the number of
candidate primers.71
With regard to the optimization problem, the primer design prob-
lem was formulated in terms of a SCP. In the local primer design pro-
cedure, I introduced a relaxation procedure to ensure that a primer
set obtaining full coverage can be found. In the global version, sev-
eral solutions are computed in order to explore the trade-off between
the three objectives of primer design (from highest to lowest): cover-
age, set size, and primer quality. An alternative way of formulating
the global variant would have been via lexicographic goal program-
ming72 in which the priority of competing objectives is preemptively
determined. Using goal programming, several linear programs are
solved iteratively such that each one fulfills the constraints of the pre-
vious programs. In this case, the first solution would just satisfy the
coverage criterion, the second would minimize the set size (subject
to maximum coverage), and the third would maximize the quality
(subject to maximum coverage and minimum set size). Although goal
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programming represents a rational way of selecting a single, optimal
set, it is also more of a black box than when users are provided with
an overview of several possible results.
Another limitation concerns the computation of primer melting
temperatures. Currently, only the melting temperature of complemen-
tary primer-template pairs are considered. The melting temperatures
of primers binding with mismatches, however, are actually lower
than those of complementary primers. Thus, primer sets that are
designed with many allowed mismatches may not perform well be-
cause the primers likely do not amplify the templates at the same
annealing temperature. A solution to this problem could be obtained
by considering the mismatch melting temperatures for individual
EAEs. This would, however, incur increased runtime.
In summary, openPrimeR uses techniques from mathematical
optimization for the design of mPCR primer sets. In this work, the
approach was used to improve the isolation of bNAbs targeting HIV-
1. In the future, openPrimeR could be applied to improve the amplifi-
cation of other variable sequences, for example, those of viral origin
(e.g. HIV-1). openPrimeR is freely available via openprimer.mpi-
inf.mpg.de.
This chapter has shown that methods for the estimation of ampli-
fication events are key for the design of mPCR primers. The subse-
quent chapter (Chapter 7) investigates the molecular characteristics
of successful amplification events and presents TMM, a logistic
regression model that estimates the likelihood of amplification.

I was working for Cetus,
making oligonucleotides. They
were heady times.
Biotechnology was in flower
and one spring night while the
California buckeyes were also
in flower I came across the
polymerase chain reaction.
. . . It was the first day of the
rest of my life.
Kary B. Mullis on the
discovery of polymerase chain
reaction, 1994
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Predicting PCR Amplification Events
This chapter deals with approaches for the identification of PCR amplifica-
tion events. I developed a new statistical model and statistically analyzed
the PCR data set. Christoph Kreer planned the IGHV template generation
and the PCR experiments. Nathalie Lehnen performed the PCR reactions.
Florian Klein initiated the project and guided the work. Nico Pfeifer super-
vised the analysis. This chapter largely corresponds to a manuscript entitled
"Modeling the Amplification of Immunoglobulins through Machine Learn-
ing on Sequence-Specific Features", which has been submitted to Nature
Scientific Reports.
PCR (Section 2.5.4) forms the foundation for a multitude of molec-
ular methods. Typical applications in virological research involve
the determination of viral drug resistance1 and viral loads2. Primers
— short nucleotide oligomers complementary to template DNA —
are critical for the success of PCR because primer binding proper-
ties determine whether amplification is successful or not. Therefore,
successful primer design hinges on the ability to model whether a
primer allows for template amplification. Predictive models can be
categorized into two groups. Models that estimate PCR efficiencies
can guide primer design for qPCR3 (Section 2.5.4), while models es-
timating the likelihood of amplification are suitable for conventional
PCR4. These models need to consider the two consecutive molecular
interactions that determine whether a primer allows for the ampli-
fication of a PCR template. In the first reaction, the primer anneals
to the template, which leads to the formation of the primer-template
heteroduplex. In the second reaction, polymerase attaches to the
duplex region and extends the primer to a full-length sequence5.
Efficient primer annealing is largely determined by the comple-
mentarity of primer and template6. More specifically, mismatches
between the nucleotide sequences of primers and templates should
214
7 Klein et al. 2001; Whiley and Sloots
2005; Stadhouders et al. 2010; Kwok
et al. 1990; Bru et al. 2008; Ghedira et al.
2009
8 Kwok et al. 1990; Ghedira et al. 2009
9 Stadhouders et al. 2010; Kwok et al.
1990; Ayyadevara et al. 2000; Day et al.
1999; Huang et al. 1992; Li et al. 2004;
Wu et al. 2009
10 No et al. 2014; Lorenz 2012; Thornton
and Basu 2011
11 Wright et al. 2014
12 We used immunoglobulin sequences
as templates because we were research-
ing the amplification of antibody
sequences, as described in Chapter 6.
13 Döring and Pfeifer 2017
14 Tiller et al. 2008
be avoided as mismatches increase the free energy of annealing. Mis-
matches within the 3’ hexamer of the primer-template duplex (i.e.
within the terminal six nucleotides) are especially detrimental as
they can disrupt polymerase binding7. Since the disruptive effect of
3’ mismatches increases with growing proximity to the 3’ terminus,
a mismatch at the 3’ terminus is more severe than a mismatch at
the penultimate position8. The extent to which mismatches at the 3’
terminus reduce the efficiency of PCR depends on the type of mis-
match.9 For example, a terminal A/G misatch is more detrimental
than a terminal A/C mismatch. To stabilize the 3’ region, primers
are often designed to exhibit a so-called GC clamp10, which typically
consists of one to three Gs or Cs at the 3’ end.
Until March 2018, the thermodynamic model from DECIPHER11
was the only publicly available model for identifying whether a
primer allows for amplification. The model of DECIPHER incorpo-
rates empiric evidence about the impact of position- and nucleotide-
specific mismatches within the last seven positions of the 3’ region.
These data were gathered by measuring the elongation efficiency
of Taq polymerase in PCRs performed with 171 primers exhibiting
different binding properties. The model considers three reactions:
the interaction between primer and template, unimolecular folding
of the primer, and unimolecular folding of the template. Based on
the underlying kinetic differential equations for these reactions, the
concentrations of the considered molecular states are mechanistically
computed so as to estimate the efficiency of PCR.
The work presented in this chapter investigates the molecular
determinants of PCR amplification status. For this task, a novel Taq
PCR data set providing the amplification status for 47 IGHV genes
was generated.12 Triplicate measurements were performed with
primers from two sets. Set1 consists of 16 forward primers that have
been recently designed using openPrimeR13, while Set2 is a well-
established set of four forward primer14. PCR was performed for
each combination of the 20 primers and 47 templates giving rise to
a total of 940 triplicate measurements. In contrast to other studies
investigating PCR amplification, which are largely based on qPCR,
the data that was generated in our work provides the amplification
status according to gel electrophoresis.
The structure of this chapter is as follows. Section 7.1 describes
the collected IGHV data and introduces the feature encodings and
statistical methods that were used for analyzing the data. The identi-
fied associations between the molecular properties of primer-template
pairs and their amplification status are investigated in Section 7.2. In
the same section, a new model for estimating the likelihood of am-
plification events is presented and compared with other approaches.
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Primer ID Sequence GC Ratio ∆Gsd ∆Gf
Set1.1 cacctgtggttcttcctcctcc 59.1% -0.8 0
Set1.2 cacctgtggttcttcctcctgc 59.1% -0.8 0
Set1.3 atggagtttgggctgagctgg 57.1% -2.3 0
Set1.4 atggagttggggctgagctg 60% -2.3 0
Set1.5 tggagttttggctgagctggg 57.1% -2.3 -0.1
Set1.6 actttgctccacgctcctgc 60% -0.3 0
Set1.7 atggactggacctggagcatc 57.1% -1.9 0
Set1.8 atggactggacctggaggttcc 59.1% -2.1 -1.9
Set1.9 atggactgcacctggaggatc 57.1% -1.9 0
Set1.10 atggactggacctggagggtcttc 58.3% -1.9 -3.6
Set1.11 tctgtctccttcctcatcttcctgc 52% 0.4 0
Set1.12 ggactggatttggagggtcctcttc 56% -2.2 -3.2
Set1.13 gctccgctgggttttccttg 60% 0.4 0
Set1.14 tggggtcaaccgccatcc 66.7% -0.7 -1.6
Set1.15 ggcctctccacttaaacccagg 59.1% -1.9 0
Set1.16 tggacacactttgctacacactcc 50% 0 0
Set2.1 acaggtgcccactcccaggtgcag 66.7% -0.8 -1.2
Set2.2 aaggtgtccagtgtgargtgcag 54.3% -1.2 0
Set2.3 cccagatgggtcctgtcccaggtgcag 66.7% -1.3 -2.6
Set2.4 caaggagtctgttccgaggtgcag 58.3% -0.8 -0.3
Table 7.1: Primers that were
used in IGHV PCRs. The extent
of the primer 3’ GC clamp is
indicated in bold. Primers pre-
fixed with Set1 indicate primers
from Set1, while those prefixed
with Set2 refer to primers from
Set2. The free energies of self-
dimerization and folding are
indicated by ∆Gsd and ∆Gf,
respectively.
Finally, Section 7.3 discusses the results and puts them into context
with available knowledge.
7.1 PCR Data, Features, and Statistical Models
This section deals with the generation of IGHV PCR data and the
manner in which these data were analyzed. Section 7.1.1 describes
how IGHV data were generated and Section 7.1.2 describes how
these data were transformed to a structured data set. The employed
feature encodings are provided in Section 7.1.3. The use of logistic
regression for estimating the likelihood of amplification is described
in Section 7.1.4. Thereafter, additional approaches that can be used
for identifying amplification events are introduced (Section 7.1.5).
7.1.1 Template Design and PCR Measurements
The experimental work described in the following paragraphs was
carried out by Nathalie Lehnen and Christoph Kreer.
47 heavy chain fragments from naive B cells were cloned into
pCR4-TOPO-vector backbones. Each fragment comprised a different
functional IGHV gene and contained the complete leader region,
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Figure courtesy of Christoph Kreer.
Figure 7.1: Construction of
PCR data set. The right panel
illustrates the classification
of triplicates by a single inde-
pendent evaluator (light blue
colors). The overall classifica-
tion is defined as the majority
label (dark blue) from the
triplicate labels.
15 Ye et al. 2013a
the complete variable region, and a short part of the constant region.
The individual variable genes served as representative templates for
two different IGHV-specific primer sets. Set1 is a set of 16 forward
primers that was recently designed using openPrimeR, while Set2
consists of four forward primers that were designed by Tiller et al.
(2008). We performed three independent PCR reactions for each of
the 20 primers on all 47 templates with the same IgM constant region-
specific reverse primer from Ippolito et al. (2012) (GGTTGGGGCG-
GATGCACTCC). All primers used in the experiments are listed in
Table 7.1.
PCRs were performed in 25 µL reactions with 2U/rxn Platinum
Taq (Thermofisher), 0.2 µM forward and reverse primer, 0.2 mM
dNTPs, 1.5 mM MgCl2, and 6% kb extender under the following
cycling conditions: 2 min initial denaturation at 94 ◦C followed by
25 cycles of 30 s at 94 ◦C, 30 s at 57 ◦C (Set2) or 55 ◦C (Set1), and 55
s at 72 ◦C. The expected 600–700 bp fragments were visualized on a
2% agarose gel supplemented with SYBR Safe (Thermofisher) and
documented with the BioRAD Gel DocTM XR+ Imaging system.
7.1.2 Data Set Construction
The 47 IGHV fragments, which were described in the previous sec-
tion, were sequenced using the approach from Sanger and annotated
with IgBLAST15. Every experimentally evaluated primer-template
pair (PTP) was assigned a label, yi ∈ {Amplified, Unamplified}, based
on the results of gel electrophoresis. If a band was visible in the gel,
the corresponding PTP was labeled as Amplified and otherwise as
Unamplified (Figure 7.1). The data set was independently labeled by
five experts. The labels provided by each expert were integrated by
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Data set N N(yi = Amplified) N(yi = Unamplified)
Full 908 (100%) 382 (42.1%) 526 (57.9%)
Validation 227 (25%) 96 (42.3%) 131 (57.7%)
Training 454 (50%) 197 (43.4%) 256 (56.6%)
Testing 227 (25%) 92 (40.5%) 135 (59.5%)
Table 7.2: Distribution of data
set labels. The number of obser-
vations are shown for the full
data set and the constructed
subsets for validation, training,
and testing.
16 Markham and Zuker 2008
merging triplicate PCR measurements in the following way. If at least
two of three measurements were labeled as Amplified, the correspond-
ing PTP was included with the label Amplified and otherwise with the
label Unamplified. Finally, for every PTP, the label that was provided
by the majority of experts was selected.
I used openPrimeR to enrich the PCR data with several physico-
chemical properties relating to primers and PTPs. Using openPrimeR,
the most likely binding mode for every PTP was identified by se-
lecting the local alignment of primer and template subsequence
minimizing the number of mismatches, as described in Chapter 6.
Such a pairing is called aligned PTP in the following. In order to limit
the analysis to PTPs that can be detected with a certain level of confi-
dence, aligned PTPs with more than 12 mismatches were discarded.
This reduced the size of the data set from 940 to 908 observations.
Based on the aligned PTPs, further properties such as the positions
of primer-template mismatches were derived. The free energy of
annealing, ∆G, was computed with OligoArrayAux16, a software
for thermodynamic calculations on oligonucleotides. The calcula-
tions were performed using the optimal annealing temperatures for
aligned PTPs from Set1 and Set2, 55 ◦C and 57 ◦C, respectively. Addi-
tionally, the following primer-specific properties were computed via
openPrimeR (see Chapter 6): primer length, extent of GC clamp, GC
ratio, melting temperature, number of repeats/runs, free energy of
folding ∆Gf, and free energy of self-dimerization ∆Gsd.
For model development purposes, I split the full data set into three
distinct parts: validation set, training set, and test set (Table 7.2). For
selecting classifier cutoffs, 25% of the observations were randomly
sampled for inclusion in the validation set. Of the remaining observa-
tions, 50% were randomly sampled for inclusion in the training set,
which was used for fitting a logistic regression model. The remain-
der of observations was included in the test set, which was used for
evaluating model performance.
7.1.3 Feature Encoding
In order to investigate the impact of 3’ terminal mismatches, I im-
plemented several encodings for 3’ mismatches (Figure 7.2). The
mismatch feature vector z ∈ {0, 1}6 relies on a binary encoding to
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Figure 7.2: Encodings for
primer-template 3’ mismatches.
Primers are indicated by arrows
and templates by rectangles.
Black bars indicate comple-
mentary bases, while red bars
indicate mismatches. (a) A
primer annealing without any
3’ mismatches. (b) A primer
annealing with two 3’ mis-
matches.
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indicate whether a mismatch was identified at the j-th position in the
3’ hexamer via
zj =
1 if there was a mismatch at position j in the 3’ hexamer0 otherwise .
Here, j ∈ {1, . . . , 6} identifies the 3’ hexamer position such that zj = 1
indicates the first position in the 3’ hexamer and zj = 6 indicates
the 3’ terminal position. To explicitly model the augmenting effect of
co-occurring mismatches in the 3’ hexamer17, the total number of 3’
hexamer mismatches was encoded as XN = ∑6j=1 zj.
Due to the small number of PTPs, it should be challenging to
learn the association of zj, ∀j ∈ {1, . . . , 6}, with the outcome. Since
positions closer to the 3’ terminus deteriorate PCR efficiency to a
greater degree18, a reasonable alternative strategy is to concentrate all
the information on 3’ mismatches into a single quantity,
iX =
maxj∈{1,...,6}{j|zj = 1} if XN 6= 00 else ,
the 3’ hexamer mismatch closest to the 3’ terminus.
For an example of the 3’ hexamer feature encodings consider
Figure 7.2. A primer without 3’ mismatches has z = (0, 0, 0, 0, 0, 0)T ,
XN = 0, and iX = 0 (Panel a), while a primer exhibiting mismatches
at positions 4 and 6 in the 3’ hexamer has z = (0, 0, 0, 1, 0, 1)T , XN =
2, and iX = 6 (Panel b).
7.1.4 Logistic Regression Models
I used multivariate logistic regression models (Section 3.4.1) in order
to investigate the influence of individual features on the template am-
plification status. Logistic regression is a commonly used approach
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for problems with categorical outcomes. In this case, we would like
to estimate the amplification status yi ∈ {Amplified, Unamplified}.
Let Pr(yi = Amplified) denote the probability that the i-th PTP is
successfully amplified and let p̂ indicate the corresponding estimated
likelihood. Further, let β0 indicate the model intercept and let βi with
i ∈ {1, . . . , p} indicate the weight associated with the i-th feature.




1− p̂ = β0 + β1x1 + . . . + βpxp .
For the definition of a logistic regression model for PCR amplifica-
tion, only features relating to PTPs were considered as terms of the
logistic regression models19. This choice was motivated by the char-
acteristics of the primers (Table 7.1). Since all of the selected primers
were designed for the effective amplification of templates, they have
similar physicochemical properties. Therefore, features based on the
physicochemical properties of the primers would not be helpful for
differentiating the amplification status.
Two logistic regression models relying on different sets of features
were constructed for studying feature importance. The logistic re-
gression model LR1 was defined using the mismatch feature vector,
z ∈ {0, 1}6, the number of mismatches in the 3’ hexamer, XN , and
the free energy of primer-template annealing, ∆G. In order to study
whether 3’ terminal mismatches can be summarized by a single
feature, LR2 was defined. This model additionally includes a term
for the 3’ hexamer mismatch closest to the 3’ terminus, iX, and the
cross-term ∆GiX, which corrects for the association between ∆G and
iX .
For the definition of a logistic regression model estimating the
probability of amplification, I performed feature selection using
the best subset selection approach from Morgan-Tatar20 using the
features from LR2. By minimizing the AIC (Section 3.2.5), a model
with a reduced number of features, the thermodynamic mismatch
model (TMM), was identified.
7.1.5 Validation of Models and Classifiers
In addition to TMM, I considered two other approaches for pre-
dicting template amplification status: a model based solely on the
free energy of annealing (FE) and the thermodynamic model from
DECIPHER21 (DE), which considers the impact of mismatches on
the efficiency of polymerase elongation. All of these models pro-
vide quantitative outputs. In order to evaluate their corresponding
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classifiers, cutoffs were used. For FE, I used the classification rule
f (x)∆G =
Amplified if ∆G(x) < ∆GcUnamplified else
where ∆G(x) is the free energy of annealing of PTP x and ∆Gc is a
cutoff on the free energy of annealing. For DE, I performed classi-
fication by applying a cutoff, ηc, on the PCR efficiency, η(x), that is
computed by DECIPHER:
f (x)η =
Amplified if η(x) > ηcUnamplified else
For TMM, I applied a cutoff, p̂c, on the estimated likelihood of ampli-
fication, p̂:
f (x) p̂ =
Amplified if p̂(x) > p̂cUnamplified else
To exemplify these classifiers, let us assume the following cutoffs:
∆Gc = −5, ηc = 0.01, and p̂c = 0.75. Further, let us consider the
PTP, x, with the following associated quantities: ∆G(x) = −10
kcal/mol, η(x) = 0.2, p̂(x) = 0.6. Then, f (x)∆G = Amplified because
−10 kcal/mol < −5 kcal/mol, f (x)η = Amplified because 0.2 > 0.01,
and f (x) p̂ = Unamplified because 0.6 ≤ 0.75.
Two cutoffs were selected for each of the three approaches: one
cutoff ensuring an empiric specificity of at least 99% (denoted by
s) and another cutoff maximizing Youden’s index. For FE and DE,
which did not require model training, I selected optimal cutoffs by
maximizing the two criteria on a data set containing training and
validation observations. For TMM, on the other hand, cutoffs were
chosen by performing ten runs of fivefold CV on the validation
data set, again maximizing either specificity or Youden’s index.
Finally, all model and classifier performances were determined on the
independent test set.
In the following, classifiers optimized for overall performance
and classifiers optimized for high specificity are denoted by sub-
scription of Y and s, respectively. For example, TMMs denotes the
high-specificity TMM classifier and TMMY denotes the TMM classi-
fier that was optimized for overall performance.
7.2 Results
This section presents the results from analyzing the IGHV data set.
First, the results from the descriptive analysis of the IGHV data set
are provided (Section 7.2.1). Next, the properties of the fitted logistic
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regression models, LR1, LR2, and TMM are presented (Section 7.2.2).
Section 7.2.3 compares the predictive performance of TMM, DE, and
FE. The properties of TMM are presented in Section 7.2.4.
7.2.1 Properties of the Data Set
Figure 7.3: Impact of 3’ mis-
matches and free energy of
annealing on amplification
status. Every point represents
a primer-template pair. Pairs
that are labeled as Amplified
are shown in blue, while those
that are labeled as Unamplified
are shown in red. Observations
from Set1 are indicated by cir-
cles and those from Set2 by
triangles. The vertical dashed
line indicates the end of the 3’
hexamer, while the horizontal
dashed line indicates a free
energy of -5 kcal/mol.
Table 7.3 shows the distribution of the physicochemical properties
of the aligned PTPs in the data set. The primers from Set2 and Set1
are characterized by contrasting rates of amplification. While 165
of 188 PTPs (87.8%) in Set2 were labeled as Amplified, only 217 of
720 (30.1%) observations in Set1 had a positive amplification status.
Accordingly, observations from Set1 exhibited a greater number
of mismatches and higher free energies. The aligned PTPs from
Set1 had an average of 2.3 mismatches in the 3’ hexamer, while the
primers from Set2 had an average of 0.5 mismatches in this region.
Moreover, while samples from Set2 had a ∆G inter-quartile range
(IQR) of [-8.6 kcal/mol, -5.2 kcal/mol], the primers from Set1 set
were associated with a higher range of [-4.9 kcal/mol, -2.0 kcal/mol].




∆G [kcal/mol] [-4.9, -2.0] [-8.6, -5.2]
iX [2,6] [0, 1]
XN [1, 3] [0, 1]
|GC| [1,2] [1,1]
∆G f [kcal/mol] [-1.53, -0.24] [-1.24, -0.76]
∆Gsd [kcal/mol] [-2.1, -0.7] [-1.2, -0.8]
|{yi|yi = Amplified}| 217 of 720 (30.1%) 165 of 188 (87.8%)
∑Ni=1 zi,1 271 25
∑Ni=1 zi,2 226 4
∑Ni=1 zi,3 272 31
∑Ni=1 zi,4 246 11
∑Ni=1 zi,5 308 12
∑Ni=1 zi,6 308 12
Table 7.3: Primer set properties.
Values shown in brackets in-
dicate inter-quartile ranges of
observed values. N indicates
the number of PTPs from each
primer set. zi,j indicates the
value of zj for the i-th observa-
tion.
Number of mismatches ∆G [kcal/mol] iX Amplification rate
0 [-16.616, -15.696] [0, 0] 100%
1 [-14.353, -12.1] [0, 3] 100%
2 [-12.0455, -9.656] [0, 3] 100%
3 [-11.607, -7.9185] [0, 4] 100%
4 [-10.796, -7.409] [2, 6] 92.31%
5 [-7.047, -6.047] [0, 3] 88.89%
6 [-8.603, -5.11325] [0, 0] 83.33%
7 [-5.39, -4.212] [0, 3] 67.19%
8 [-5.56075, -2.539] [3, 6] 34.04%
9 [-3.5335, -2.1325] [4, 6] 23.08%
10 [-4.09, -1.724] [4, 6] 18.02%
11 [-3.74, -1.695] [4, 6] 10.53%
12 [-2.624, -1.413] [6, 6] 3.75%
Table 7.4: Impact of primer
binding properties on the rate
of amplification.
and the rate of amplification was identified (Table 7.4). In this IGHV
data set, all primers binding with at most three mismatches suc-
cessfully amplified their templates. Even primers binding with six
mismatches successfully amplified their templates in 83.3% of cases.
Comparing amplified and unamplified PTPs (Figure 7.3) revealed
that the ∆G IQR of unamplified observations was higher and more
concentrated ([-2.17 kcal/mol, -1.69 kcal/mol]) than for amplified
observations ([-12.70 kcal/mol, -5.21 kcal/mol]). Amplified samples
generally exhibited fewer mismatches in the 3’ hexamer (XN IQR of
[0,1] vs [2,4]) and mismatches occurred further from the 3’ terminus
(iX IQR of [0,3] vs [5,6]) than for unamplified samples. Applying
two-sided Wilcoxon rank-sum tests (Section 3.6.4) revealed that the
distributions of ∆G (p-value 1.68e-107) and iX (p-value 1.51e-91)
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were significantly different when comparing Amplified (N = 382) and
Unamplified (N = 526) observations.
7.2.2 Logistic Regression Models
Figure 7.4: Relationship be-
tween variables in LR2. Arrows
indicate causal relationships.
Based on the properties of aligned PTPs in the IGHV data set,
three logistic regression models for estimating the likelihood of
template amplification were developed: LR1, LR2, and TMM. TMM
was constructed by best subset selection on the features from LR2.
This procedure reduced the AIC of the initial model from 112.34 to
98.41 by eliminating all features except for the intercept, ∆G, and the
interaction term ∆GiX .
An overview of all generated models is shown in Table 7.5. The
significance of features was evaluated based on an initial signifi-
cance threshold of 0.05, which was adjusted to 0.05/9 = 0.0056 (LR1),
0.05/11 = 0.0045 (LR2), and 0.05/4 = 0.0125 (TMM) via Bonferroni
correction (Section 3.6.5). According to LR1, the features ∆G, z3, z4,
and z6 were significantly predictive of the amplification status. When
correcting for the association between ∆G and iX by including the
∆GiX cross-term in LR2 (Figure 7.4), only ∆G and ∆GiX were found
to be significantly predictive of the amplification status (Table 7.5).
7.2.3 Comparison of Model and Classifier Performance
The predictive performance of TMM was compared with the model
DE from DECIPHER22 and FE, a baseline model that relies only on
∆G. Quantitative model responses were compared with categorical
amplification statuses from gel electrophoresis according to the area
under the AUC (Section 3.3.3). TMM achieved the highest AUC
(0.953) but was closely followed by FE (0.941) and DE (0.896). Testing
the statistical significance of the AUCs from TMM and DE using
the approach from DeLong et al. (1988) led to the rejection of the
null hypothesis that there is no difference between the AUCs at a
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Figure 7.5: Performance of mod-
els identifying amplification
events. TMM indicates our
newly developed logistic regres-
sion model, DE refers to the
approach from DECIPHER, and
FE is solely based on the free
energy of annealing. Models
subscripted with s use cutoffs
optimized for high specificity,
while models subscripted with
Y use cutoffs optimized for
overall performance.
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LR1 LR2 TMM
Feature Estimate p-value Estimate p-value Estimate p-value
Intercept -2.86 1.56e-12 * -5.76 6.16e-08 * -3.99 <2e-16 *
z1 -0.50 0.058 -0.187 0.4929 – –
z2 -0.00 0.977 -0.144 0.6164 – –
z3 -0.92 0.0005 * -0.424 0.1359 – –
z4 -0.97 0.001 * -0.46 0.1340 – –
z5 0.04 0.894 0.574 0.1085 – –
z6 -1.57 8.25e-08 * -0.659 0.1069 – –
XN NA NA NA NA – –
∆G -0.83 < 2e− 16 * -1.576 1.78e-11 * -1.19 <2e-16 *
iX – – 0.400 0.0829 – –
∆GiX – – 0.180 5.12e-05 * 0.11 <2e-16 *
Table 7.5: Comparison of the
logistic regression models LR1,
LR2, and TMM. NAs indicates
features that could not be esti-
mated due to singular matrices.
Dashes indicate features that
were not considered by a model.
Asterisks indicate significant
features.
Model Outcome High-specificity cutoff s High-performance cutoff Y
TMM Pr(yi =Amplified) 83.9% 46.1%
DE Efficiency of PCR η 9.71e-05 1.88e-05
FE ∆G [kcal/mol] -6.05 -4.83
Table 7.6: Optimized cutoffs
for the considered models for
predicting PCR amplification.
The column Outcome indicates
the values on which cutoffs
were applied.
To compare classifier performances, two types of cutoffs were de-
termined for each model (Table 7.6). Figure 7.5 shows the predictive
performance of high-performance and high-specificity classifiers.
Among models using cutoffs optimized for overall performance,
TMMY (balanced accuracy of 90.1%) slightly outperformed DEY
(89%) and FEY (89.9%). Among high-specificity classifiers, TMMs and
DEs outperformed FEs with respect to sensitivity (77% and 78% vs
64%).
7.2.4 Interpretation of TMM
For interpreting TMM, a final model was trained on the full data set.
Given ∆G and iX, the model estimates p̂ = P̂r(yi = Amplified) using
the coefficients β0 = −3.99, β1 = −1.19, and β2 = 0.11. The model
can be formulated in the following way:
ln
p̂
1− p̂ = β0 + β1∆G + β2∆GiX
= β0 + (β1 + β2iX)∆G
= −3.99 + (−1.19 + 0.11iX)∆G
Since the intercept of the model is β0 = −3.99, the odds of template
amplification are low if the other terms in the model are negligible
(i.e. for ∆G → 0 and iX → 0). The second term, (−1.19 + 0.11iX)∆G,
is dominated by the free energy of annealing. For typical (negative)
values of ∆G, the odds of amplification increase with decreasing ∆G
because −1.19 + 0.11iX is always negative since 0 ≤ iX ≤ 6. However,
if 3’ terminal mismatches are present (i.e. iX 6= 0), the extent to which
the odds of amplification increase is attenuated.
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Figure 7.6: Visualization of
TMM. Small dots indicate
samples from the prediction
function of the model. Red
dots indicate low probabilities
of amplification while blue
dots indicate high probabilities.
Large squares show the model
estimates for the observations
contained in the IGHV data
set. Here, red squares indicate
primer-template pairs that are
labeled as Unamplified, while
blue squares indicate observa-
tions labeled as Amplified.
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Figure 7.6 shows the decision surface of TMM. The illustration
demonstrates that for high and low values of ∆G (e.g. at -20 and -3
kcal/mol), p̂ is hardly influenced by iX. At intermediate values of
∆G (e.g. between -5 and -10 kcal/mol), however, high values of iX
considerably reduce p̂.
7.3 Discussion
In this chapter, I analyzed the molecular conditions under which
primers allow for the amplification of templates using a novel data
set indicating the amplification status for all combinations of 47 im-
munoglobulin sequences and 20 primers. The following findings
were made. First, statistical analyses revealed that the amplification
status of primer-template pairs is governed by the interplay of the
free energy of annealing and the presence of 3’ terminal mismatches.
Second, TMM, a new logistic regression model for estimating the
likelihood of amplification was developed. The predictive perfor-
mance of TMM was found to be favorable when compared with
the thermodynamic model DE from DECIPHER23 as well as FE, a
simple approach based only on the free energy of annealing. In the
following paragraphs, these findings are discussed in more detail.
With regard to the factors influencing the amplification of primer-
template pairs, the analysis of the IGHV data at hand largely con-
firmed the established factors. The data revealed that primer-
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template pairs whose amplification could not be detected via gel
electrophoresis exhibit high free energies of annealing, an increase in
the number of mismatches within the 3’ hexamer, and a tendency for
displaying mismatches close to the 3’ terminus. Logistic regression
modeling, however, revealed that terminal mismatches by themselves
are not significantly predictive of the amplification status but only
when considered in concert with the free energy of annealing. Thus,
it is possible that previously reported effect sizes relating to 3’ ter-
minal mismatches may not be solely attributable to the inhibition of
polymerase attachment but also to the inhibition of primer annealing.
This suggests that future studies investigating the impact of 3’ mis-
matches on polymerase elongation could benefit from considering
how 3’ mismatches influence the free energy of annealing.
Several approaches for predicting the likelihood of PCR amplifica-
tion achieved comparably high predictive performances on the IGHV
data set. Still, TMM achieved the largest AUC and its AUC was
found to be significantly different from the AUC of DE. Although the
predictive performance of FEY was surprisingly high, the consider-
ably lower performance of FEs indicates that the free energy of an-
nealing by itself lacks robustness. In contrast to DE, which estimates
the efficiency of polymerase elongation according to the impact of
position- and base-specific effects in the 3’ region, TMM considers
only the position of 3’ mismatches. The following three observations
could explain why the consideration of base-specific effects by DE
did not provide an advantage over TMM. First, none of the primers
contained in the IGHV data set displayed terminal nucleotides other
than G or C (Table 3). Second, since base-specific differences in ampli-
fication efficiencies were reported only for RT-PCR24, these difference
may simply not be observable in the present data set due to the high
sensitivity of gel electrophoresis. Third, terminal mismatches seem
to have the greatest influence on the amplification status indicated
by gel electrophoresis at low to intermediate free energies of an-
nealing (∆G ∈ [−10,−5}). Since these values of ∆G are associated
with multiple mismatches, the computational placement of primers
relative to templates is subject to a certain level of uncertainty. In-
correctly aligned primer-template pairs may exhibit 3’ mismatches
that are not actually observed. In this case, it would be challenging to
find an association between specific types of 3’ mismatches and the
amplification status.
The newly developed TMM model for predicting amplification
events has several advantages over DE. First, since the model is based
only on ∆G and iX, it is easily interpretable and it is unlikely that
the model suffers from overfitting. Second, the model computes an
intuitive measure, the probability of amplification. Third, the model
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performs at least as well as DE on the IGHV data set. A limitation
of TMM is that it does not consider as many predictors as a previous
model25, which is not publicly available. Since TMM was developed
using primers exhibiting favorable properties such as the absence of
self-dimers and the presence of a GC clamp (Table 7.3), it is likely to
overestimate the amplification status for primers exhibiting less fa-
vorable properties or when templates exhibit secondary structures26.
Therefore, the model should not be applied on primers that exhibit
unfavorable physicochemical properties that may preclude their
amplification.
Finally, I would like to discuss the choice of models for multiplex
primer design. In multiplex primer design, false positive predictions
should be avoided at all costs as they may preclude the amplifica-
tion of templates that are not redundantly covered. False negative
predictions, on the other hand, are much more tolerable because
they merely result in larger primer sets in which primers exhibit
redundant coverage. Therefore, amplification events should be de-
tected with high specificities. The present data suggest that even
simple approaches can be used for this purpose. For example, a speci-
ficity of 100% can be obtained by designing primers with at most
3 mismatches (Table 7.4). Models such as TMMs and DEs have the
advantage that they provide higher sensitivities at similar specificities.
Therefore, these models could assist in designing primer sets for
template libraries for which no set of appropriate size has been found
yet27.
To conclude, this chapter demonstrated that the interplay of the
free energy of annealing and the presence of 3’ terminal mismatches
are the main factors influencing the success of PCR amplification.
Based on this insight, TMM, a simple logistic regression model for
predicting amplification events was developed. On the present data,
TMM performs at least as well as other models for predicting PCR
amplification and is freely available through openPrimeR, which can
be found at openprimer.mpi-inf.mpg.de.
Part III:
Synthesis
This part connects the contributions that were presented in Part II.
Chapter 8 summarizes and critically discusses the developed
methods. Chapter 9 reflects on the use of intelligent systems in
medicine and comments on the fight against viral infections.

Everything should be made as





In this dissertation, I developed computational methods with the
aim of improving treatment and prevention of viral infections. In the
following paragraphs, I draw conclusions for the individual scientific
contributions that were presented in Chapters 4, 5, 6, and 7. There-
after, I reflect on the impact and implications of my contributions.
Chapter 4 introduced the geno2pheno[ngs-freq] web service,
which allows for the detection of drug resistance from NGS samples
of HIV-1 or HCV. In this way, the tool supports the selection of antivi-
ral treatment regiments. The main contributions of geno2pheno[ngs-
freq] are threefold. First, the tool allows for the detection of drug
resistance in minority populations, which is not possible with ap-
proaches that accept only Sanger sequences as an input. Second, in
contrast to other web services, the approach decouples NGS data
processing and drug resistance interpretation through the use of
frequency files. Third, geno2pheno[ngs-freq] eases the interpretation
of drug resistance through novel visualizations. geno2pheno[ngs-
freq] could be expanded to support additional viral regions (e.g.
HIV-1 integrase) or other viral species. Currently, drug resistance
predictions for minor viral populations should be considered with
particular care due to biological and technical reasons. In the future,
novel prediction models based on NGS data could improve the inter-
pretation of drug resistance in the following way. Multi-task learning,
with which multiple drugs can be considered simultaneously, could
improve the performance of predictive models based on clinical data.
Cutoff-based consensus generation could be eliminated via encoding
amino acids by their frequencies (e.g. as provided by frequency files)
or through multi-instance learning, in which sets of individual NGS
reads are considered. Finally, quasispecies reconstruction may allow
for the consideration of resistance mutations that occur on the same
strand while taking viral replicative competence into account.
In Chapter 5, I investigated HIV-2 coreceptor usage and trained an
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SVM model that has advantages over the only available rules-based
approach for HIV-2 coreceptor identification1. The model was inte-
grated into geno2pheno[coreceptor-hiv2], the first web server for the
identification of HIV-2 coreceptor usage. The service can support
the management of HIV-2 infection by assisting clinicians consid-
ering the prescription of coreceptor antagonists and enables the
realization of large-scale epidemiological studies on HIV-2 coreceptor
usage. The work confirmed that the V3 is the major determinant of
HIV-2 coreceptor usage, for which novel molecular markers were
revealed. Moreover, geno2pheno[coreceptor-hiv2] improves upon
the interpretability of previous work through a new visualization
for coreceptor predictions based on V3 amino-acid sequences. A
limitation of the approach is that it considers only amino acids in the
V3 and not those in other regions of the viral surface glycoprotein.
The analyzed data suggest that it would be important to develop a
standardized assay for the phenotypic determination of HIV-2 core-
ceptor usage, to shed more light on HIV-2 intra-host evolution, and to
investigate the V1 and V2 regions in more detail.
Chapter 6 introduced openPrimeR, a reliable, open-source soft-
ware that provides a novel approach for designing, evaluating, and
comparing primer sets for mPCR. The application of openPrimeR
on human immunoglobulin sequences led to novel primer sets for
IGHV, IGKV, and IGLV. The analysis of the IGHV primers revealed
that primers, which bind to the early leader region, allow for the
enhanced amplification of highly mutated antibody sequences. Most
importantly, it could be shown that the newly designed primer sets
enable the isolation of bNAbs against HIV-1 that are especially heav-
ily mutated. In the future, samples from elite neutralizers should be
re-analyzed using the newly designed primer sets in order to inves-
tigate whether novel bNAbs can be discovered. openPrimeR could
be further enhanced by providing an efficient, stand-alone library for
multiplex primer design (e.g. in C++) and improving the algorithmics
of the primer design procedures.
Chapter 7 investigated the features that are predictive of successful
PCR amplification events and introduced TMM, a new model for
the prediction of amplification events, which performs similarly to
the thermodynamic model from DECIPHER2. The free energy of
annealing and the simultaneous presence of 3’ mismatches were
identified as the key drivers of amplification success. Since the free
energy of annealing seems to be the main factor controlling whether
amplification takes place, simple strategies such as calling amplifi-
cation events with at most three mismatches or with less than -10
kcal/mol can already reach sufficient specificities for primer design.
More intricate methods such as TMM, however, allow for greater
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sensitivities. TMM should be useful to all practitioners of PCR be-
cause the model enables improved primer design. Due to the high
quality of the primers in the training data, TMM should not be ap-
plied to estimate the amplification of primers with less favorable
physicochemical properties. The findings of this work are limited by
the scarcity of PCR data. To obtain a more generalizable model for
the prediction of PCR amplification events, it would be necessary to
perform a dauntingly large number of PCR measurements because
two criteria need to be considered simultaneously. First, the impact of
all types of 3’ mismatches would need to be systematically analyzed
across all possible values of the free energy of annealing. Second,
to consider the physicochemical properties of primers, it would be
necessary to experimentally measure the amplification of primers
with varying physicochemical properties.
The work presented in this dissertation constitutes advances for
treatment and prevention of viral infections. Only a few months
after its inception, geno2pheno[ngs-freq] has already entered clin-
ical routine and is in constant use by the virologists from the Uni-
versity of Cologne. Since the tool provides a more detailed ac-
count of drug resistance than previously used approaches such as
geno2pheno[resistance] and geno2pheno[hcv], geno2pheno[ngs-freq]
allows for the further personalization of treatments against HIV-1
and HCV infection. The unique feature of geno2pheno[coreceptor-
hiv2] is that it represents the only web service for the identification
of HIV-2 coreceptor usage. Thus, geno2pheno[coreceptor-hiv2] is
the first place for clinicians to go to when they consider prescribing
coreceptor antagonists to HIV-2-infected patients. The primer sets
that were designed by openPrimeR enhance the isolation of bNAbs
to HIV-1. The use of these primer sets may enable the discovery of
novel antibodies that could be used for treating and preventing HIV-1
infection in the future.
To conclude, I would like to highlight the significance of geno2pheno[ngs-
freq] and openPrimeR. The availability of antiviral drugs with in-
creased potency has reduced the rate of treatment failure due to
drug resistance. Nevertheless, drug resistance is a major concern of
antiviral treatment because drug resistant strains are still frequently
transmitted and resistant variants emerge especially commonly in
countries of the global South, which lack well-developed clinical
infrastructures and access to potent drugs. The existence of freely
available resistance interpretation engines is particularly important
for guiding the treatment of infected persons from these countries. It
is important that available interpretation engines are not only main-
tained but also further developed. geno2pheno[ngs-freq] constitutes
such an advancement. The treatment of HIV infection could undergo
234
substantial changes in the coming years due to the implementation
of antibody-based therapies. Antibodies are especially promising
treatment options for patients that are infected with highly resistant
viral strains, patients with organ damage, or patients that struggle
with daily medication. Due to their long half life, antibodies are also
promising agents for PrEP. The primer sets that were designed by
openPrimeR could aid the discovery of antibodies that may, at one
point, enter clinical routine.
Having recapitulated the significance of my scientific contributions,
I would like to use the outlook (Chapter 9) to comment on the re-
quirements for the further digitalization of medicine and to reflect on
our progress towards the elimination of viral infectious disease.
I will follow that system of
regimen which, according to
my ability and judgment, I
consider for the benefit of my
patients, and abstain from
whatever is deleterious and
mischievous.




In this final chapter of the main matter, I would like to comment
on two aspects that are relevant for my work on computational
approaches for improving treatment and prevention of viral infec-
tions. The first aspect concerns how intelligent systems can support
medical decision making and the roadblocks that may prevent their
widespread use. The second aspect deals with the progress that
has been made in the fight against viral infectious disease and the
challenges that still need to be overcome.
On the Use of Intelligent Systems in the Biomedical Sector The ever-
increasing amount of medical data is accompanied by rising techno-
logical requirements for their storage, processing, and interpretation.
There is no sign that this trend is going to decline, which is why it
is crucial that the necessary infrastructures for smart information
management are established as soon as possible. Only then can data
from several sources be effectively connected, investigated, and used
for deploying machine learning models. Naturally, to obtain such
models, we need machine learning experts. However, the success of
these models does not only hinge on the technical expertise of the
developers but also on their domain knowledge and understanding
of the user requirements. On the one hand, domain knowledge is
important in order to prevent fallacies during predictive modeling.
For example, if a machine learning expert would create a model that
predicts HCV drug resistance without accounting for distinct HCV
geno- and subtypes, the model would perform poorly. On the other
hand, a deep understanding of the user requirements is necessary to
ensure that the resulting system will be accepted by the medical com-
munity. Clinicians in particular favor interpretability over predictive
performance. To ensure that both conditions (i.e. domain knowledge
and understanding of the user requirements) are met, it is necessary
to include medical experts in the development of predictive engines,
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in order to allow for an exchange of information. Additionally, by
including clinicians during the development process, they will have
a better grasp of how predictive engines function, which should im-
prove their acceptance in the community. For this, clinicians need to
be open to learning new concepts. A successful example for a fruitful
exchange between developers and users is geno2pheno[coreceptor]1.
Because clinicians were involved in the development process, it was
possible to produce an interpretable tool that introduced the statisti-
cal concept of false positive rates into the virological community.
A roadblock that may prevent the establishment of intelligent sys-
tems in the biomedical field is constituted by prediction engines that
supplant human decision making rather than supporting it. Since
personal decision making informs individualism, a fundamental
constituent of Western culture, it is unlikely that automated decision
making will replace human decision making without a profound
cultural shift. Maintaining the paradigm of expert decision making
is also in the self-interest of physicians. If expert decision making is
deemed to be the ne plus ultra by society, automated computational
systems do not pose a threat to the medical profession and it is ac-
ceptable to disregard them. This could be the reason why treatment
recommendation systems such as THEO2 or the EuResist engine3
have not been adopted by the medical community even though they
have been shown to be more capable at selecting effective antiviral
treatments than a selection of physicians4. It seems plausible that
intelligent systems that do not compete with humans but rather facil-
itate human decision making, will find a greater level of acceptance.
For example, genotypic resistance testing systems, which assist the
drug selection procedure and increase the agency of physicians, are
widely used.
Another factor is the complexity of the problem and that of the
predictive model. When a statistical model solves a complex problem,
users may be skeptical of the model, wondering whether all factors
were correctly taken into account. For example, resistance interpre-
tation systems deal with a manageable problem whose solution can
be found based on the amino-acids of the viral sequence alone. Treat-
ment optimization, on the other hand, is a more complex problem,
as it should take characteristics relating to the patient (e.g. ethnicity
or lifestyle)5, treatment information (e.g. previous and current treat-
ments or polypharmacy6), and data from clinical monitoring (e.g.
VLs or CD4 counts)7 into account. Even state-of-the-art treatment rec-
ommendation systems such as geno2pheno[integrated] do not take
all of the aforementioned, potentially relevant features into account
but are solely based on viral amino-acid sequences. It is natural that
physicians are skeptical when an intelligent system outputs treatment
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recommendations based on a subset of the relevant predictors that
are available to physicians.
However, such skepticism should not be a general skepticism but
skepticism that is based on the properties of the predictive engine.
Let us consider the commercial treatment recommendation system
Watson Oncology as an example. Watson’s training data solely orig-
inates from Memorial Sloan Kettering Cancer Center in New York.
Therefore, the system is not only biased towards the characteristics
of American patients but also to the treatment strategies that are
employed by the physicians from a single institution8. Accordingly,
it could be shown that the system exhibits a low concordance with
treatment decisions that are taken in hospitals located outside the
USA9. As a consequence, it would be reasonable to avoid the use of
Watson in countries other than the USA. However, whether Watson
is used should be decided based on the facts (e.g. the properties of
the training data) rather than general skepticism about intelligent
systems.
In the following two paragraphs, I will sketch two scenarios for
the future of clinical decision making, one where automated decision
making permeates medicine and one where it is rejected. In the first
scenario, clinicians have all necessary information at their fingertips
due to advances in clinical information-technology infrastructures.
However, rather than spending their valuable time pondering treat-
ment decisions, they mostly use automated systems for this purpose.
The time that is freed up in this way, is used for interacting with pa-
tients and dealing with challenging cases, which still require human
intervention. Since open data is the norm, all clinical centers feed
their anonymized data into a central, publicly available repository
that is hosted by the World Health Organization. Prediction models
for the most common diseases are provided without charge, in terms
of cloud services hosted by the World Health Organization. Since
these models have been developed with the utmost care in collabora-
tions with clinicians, they are trustworthy, interpretable, and highly
accurate as they incorporate all global health data. Commercial
providers fill the gaps by providing models with additional features
or models that target rare diseases.
In the second scenario, clinics still produce a large amount of data
but sharing of data has come to a stop because clinics are concerned
about lawsuits, which are becoming more and more common due to
tight data protection laws. Since few data are publicly available, there
exist only commercial prediction engines, which rely on privately
generated data. Because every clinic only purchases the predictive
system that performs best, companies are either pushed out of the
business or are bought up, resulting in a monopoly on intelligent
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medical systems. Because these commercial systems are intranspar-
ent, outsiders cannot gauge whether they are biased or not. Moreover,
the existence of a monopoly allows for arbitrarily high licensing fees
for prediction systems such that only affluent individuals can afford
to be treated at institutions that have access to the best-performing
engines.
The future of clinical decision making probably lies somewhere
between these two scenarios. To set the course towards the first sce-
nario, the following steps should be undertaken. First, infrastructures
have to be improved such that every clinic systematically collects
and shares treatment-relevant data. This requires that funding for
the digitalization of hospitals is increased. Second, clinicians need
to become acquainted with modern, open approaches for dealing
with data10. It should be the norm that data that have been gener-
ated using public funds, are made available to the public. Of course,
to protect the privacy of the patient, these data should be stored in
an anonymized fashion11. Third, when models are made publicly
available, their properties should be clearly communicated. For ex-
ample, stored models should provide summary statistics about the
training data, performance on test sets, as well as meta information.
Currently, there is already an active online exchange of data sets as
well as (deep learning) models using online platforms such as Kaggle.
However, statistical models and data for medical purposes are still
not widely available. Fourth, clinicians and model developers need
to learn from each other. In order to make intelligent systems more
accessible to clinicians, clinicians should receive more training in
statistics and computer science. On the other hand, model developers
need to learn from clinicians in order to avoid fundamental modeling
fallacies and to ensure that models are interpretable. Fifth, model
developers should stringently validate models to ensure high gener-
alizability. Finally, to make sure that patients are compliant, patient
data need to be handled with care and the conditions under which
data are stored need to be clearly communicated. Most importantly,
patients should be informed about how their data could improve the
treatment of future patients.
Recent advances in the fields of machine learning combined with
the increasing digitalization have the potential to revolutionize
biomedical research and medicine.12 However, while everyone is
talking about industry 4.0 (i.e. the 4th industrial revolution)13, a
state in which industry is more digitalized and automated, the
equivalent term for medicine, medicine 4.0, is rarely used14. One
potential reason why medical digitalization seems to progress more
slowly is that there are strict laws specifying the requirements for
medical devices. For example, decision support software qualifies
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15 European Commission 2016
16 Sheth et al. 2016
17 Puoti et al. 2018
18 WHO 2017
19 Gisslén et al. 2017
20 ECDC 2017
21 Pokrovskaya et al. 2014
22 PEPFAR 2017
23 Data on the global progress towards
the 90-90-90 goals can be visualized on
the 90-90-90 Watch website.
as a medical device according to the guidelines of the European
Commission15. Making the vision of medicine 4.0 a reality requires
that we close the gap between biomedical researchers, physicians,
and experts from quantitative disciplines such as bioinformatics,
statistics, and computer science.
On The Fight Against Viral Infections The last years have brought
tremendous changes to the treatment of HIV and HCV infection. Re-
search into antiretrovirals has led to novel medications with greater
potency at reduced side effects. The improved durability of antiretro-
viral regimens is showcased by US patients enrolled in the HOPS
study. Within roughly ten years, the median duration of first-line
treatments increased from one year (1996–1999 period) to four and a
half years (2008–2011 period)16. The increased potency of antiretrovi-
ral agents has led to increased rates of viral suppression. Treatment
data from eight American hospitals show that viral suppression
(defined as less or equal to 400 HIV RNA copies per mL) increased
from 32% in 1997 to 86% in 2015. Similarly, the introduction of new
compounds has revolutionized the treatment of HCV. Recently in-
troduced pangenotypic DAAs targeting HCV allow for SVR rates
of up to 99% within twelve weeks of treatment17. Although drug
resistance is an issue that needs to be considered when treating pa-
tients infected with either of the two viruses, these challenges can be
overcome using a wide range of computational tools.
The advancement of antiviral treatment and the availability of
tools for handling drug resistance suggest that the main challenges
for containing and eradicating HIV and HCV lie elsewhere. Let us
first deal with HIV. The WHO has postulated the 90-90-90 goals in
2017
18. According to these goals, by 2020, 90% of HIV-infected per-
sons should be diagnosed, 90% of diagnosed persons should be on
treatment, and 90% of those on treatment should have suppressed
viral loads. For well-developed countries such as Sweden, Germany,
or France, it is easily possible to achieve these values. For example,
Sweden was the first country to meet the 90-90-90 targets, currently
achieving 90-95-9219, while Germany is close to reaching the tar-
gets, with 85-84-9320. This is because the aforementioned countries
have strong healthcare systems, well-developed clinical infrastruc-
tures, a sufficient number of well-trained medical personnel, and the
necessary resources for accessing the most potent drugs. However,
countries that are struggling economically (e.g. Russia or the major-
ity of African as well as South American nations), will have a hard
time reaching these targets. For example, Russia is at 94-23-8121 and
Nigeria is at 53-48-8122,23. With regard to the total number of HIV-
infected persons in Russia and Nigeria, these numbers correspond to
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24 WHO 2016
25 The combined diagnosis and treat-
ment rates of HBV and HCV are only at
5% and 1%, respectively, which is much
lower than for HIV.
suppression rates of merely 17.5% and 20.6%, respectively.
Evidently, the rate of suppression relative to the treated population
is similar for all countries, with a rate of 92% in Sweden, 93% in
Germany, and 81% in both Russia and Nigeria. These data suggest
that, if treatment is performed, viral suppression can be reached for
most patients, independent of the country where they are treated.
Thus, it seems that the main difference between high-income and
low-income countries is that high-income countries have much
higher rates of diagnosis (e.g. 90% in Sweden vs 53% in Nigeria) and
treatment (e.g. 95% in Sweden vs 23% in Russia).
For HCV, similar conclusions can be drawn. Since anti-HCV
treatments are highly effective, HCV can typically be eliminated
as long as the infection is diagnosed and appropriate drugs are
available. The 2030 WHO action plan for HBV and HCV treatment24
suggests that the low rate at which HCV is diagnosed and treated is
the main challenge25.
All in all, the data suggest that it is necessary to invest more re-
sources into aid programs that are active in low-income countries
in order to educate persons at risk of infection, support the develop-
ment of clinical infrastructures, and provide medical training. Only
by assisting the countries that are hotspots of HIV and HCV infection
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M A or C
R A or G
W A or T
S C or G
Y C or T
K G or T
V A or C or G
H A or C or T
D A or G or T
B C or G or T
N G or A or T or C
Table A.1: IUPAC nucleotide
ambiguity codes.
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Retrieved from the help page of the geno2pheno[coreceptor] website
on December 19th, 2018.
Figure A.1: Decision values
from geno2pheno[coreceptor]
for HIV-1 V3 sequences. The
positive class corresponds to
X4-capable variants, while the
negative class corresponds to
viruses using CCR5.
IGHV IGKV IGLV
Property Setting Limit Setting Limit Setting Limit
Binding region [-60,-20] NA [-60,-20] NA [-60,-10] NA
Primer length [18,28] NA [18,28] NA [18,30] NA
Max mismatches 1 NA 3 NA 3 NA
Max 3’ mismatches 0 NA 0 NA 0 NA
Prevent stop codons 3 NA 3 NA 3 NA
Prevent substitutions 7 NA 7 NA 7 NA
Free energy of annealing 7 NA 7 NA 7 NA
Amplification efficiency 7 NA 7 NA 7 NA
TMM model 7 NA 7 NA 7 NA
Specificity [1, 1] [1, 1] [1, 1] [1, 1] [1, 1] [1, 1]
|GC| [1, 3] [1, 3] [1, 3] [1, 3] [1, 3] [1, 3]
GC% [0.4, 0.6] [0.3, 0.7] [0.4, 0.6] [0.3, 0.7] [0.4, 0.6] [0.3, 0.7]
Runs [0, 4] [0, 6] [0, 4] [0, 6] [0, 4] [0, 6]
Repeats [0, 4] [0, 6] [0, 4] [0, 6] [0, 4] [0, 6]
∆Gsd [kcal/mol] [-5, ∞] [-5, ∞] [-5, ∞] [-5, ∞] [-5, ∞] [-5, ∞]
Tm [◦C] [60, 75] [57, 78] [60, 75] [57, 78] [60, 75] [57, 78]
∆Tm [◦C] [0, 3] [0, 3] [0, 3] [0, 3] [0, 3] [0, 3]
∆Gcd [kcal/mol] [-5, ∞] [-5, ∞] [-5, ∞] [-5, ∞] [-5, ∞] [-5, ∞]
Table A.2: Primer design set-
tings for IGH, IGK, and IGL.
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Identifier Reference Year Size
Brezinschek1995_1st (Brezinschek et al., 1995) 1995 6 (6)
Brezinschek1995_2nd (Brezinschek et al., 1995) 1995 6 (14)
Ippolito2012 (Ippolito et al., 2012) 2012 8 (23)
Marks1991 (Marks et al., 1991) 1991 6 (6)
Glas1999 (Glas et al., 1999) 1999 43 (43)
Persson1991 (Persson et al., 1991) 1991 4 (4)
Cardona1995 (Cardona et al., 1995) 1995 6 (6)
vanEs1991 (van Es et al., 1991) 1991 5 (5)
Rubinstein1998 (Rubinstein et al., 1998) 1998 7 (7)
vanEs1991 (van Es et al., 1991) 1991 5 (5)
Chong2002 (Chong et al., 2002) 2002 6 (6)
Weng1992 (Weng et al., 1992) 1992 1 (1)
Glamann1998 (Glamann et al., 1998) 1998 9 (9)
Manheimer1991 (Manheimer-Lory et al., 1991) 1991 4 (4)
Verhagen2000 (Verhagen et al., 2000) 2000 7 (7)
Szczepa2001 (Szczepański et al., 2001) 2001 6 (6)
vanDongen2003_A (Van Dongen et al., 2003) 2003 6 (6)
vanDongen2003_B (Van Dongen et al., 2003) 2003 7 (7)
vanDongen2003_C (Van Dongen et al., 2003) 2003 7 (7)
vanDongen2003_single (Van Dongen et al., 2003) 2003 1 (1)
Kueppers1993_1st (Küppers et al., 1993) 1993 6 (10)
Lim2010 (Lim et al., 2010) 2010 8 (23)
Murugan2015_1st (Murugan et al., 2015) 2015 9 (11)
Murugan2015_2nd (Murugan et al., 2015) 2015 1 (2)
Sblattero1998 (Sblattero and Bradbury, 1998) 1998 7 (22)
Scheid2011_1st (Scheid et al., 2011) 2011 21 (21)
Tiller2008_1st (Tiller et al., 2008) 2008 4 (5)
Tiller2008_2nd (Tiller et al., 2008) 2008 6 (6)
Wardemann2003_1st (Wardemann et al., 2003) 2003 4 (5)
Wu2010 (Wu et al., 2010b) 2010 6 (6)
Table A.3: Overview of IGHV
primer sets provided by open-
PrimeR. Size indicates the
number of primers where the
number of disambiguated
primers is shown in brackets.
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Identifier Reference Year Size
Atkinson1996 (Atkinson et al., 1996) 1996 3 (3)
Beishuizen1997 (Beishuizen et al., 1997) 1997 3 (3)
Cardona1995 (Cardona et al., 1995) 1995 4 (4)
Chen1986 (Chen et al., 1986) 1986 1 (1)
Chen1987 (Chen et al., 1987) 1987 1 (1)
Cox1994 (Cox et al., 1994) 1994 6 (19)
Giachino1995 (Giachino, 1995) 1995 2 (2)
Glamann1998 (Glamann et al., 1998) 1998 5 (5)
Huber1993 (Huber et al., 1993) 1993 4 (4)
Ippolito2012 (Ippolito et al., 2012) 2014 4 (27)
Juul1997 (Juul et al., 1997) 1997 1 (1)
Kueppers1993_1st (Küppers et al., 1993) 1993 6 (26)
Lim2010 (Lim et al., 2010) 2010 6 (30)
Manheimer1991 (Manheimer-Lory et al., 1991) 1991 4 (4)
Marks1991 (Marks et al., 1991) 1991 6 (6)
Murugan2015_1st (Murugan et al., 2015) 2015 3 (6)
Murugan2015_2nd (Murugan et al., 2015) 2015 1 (24)
Padyukov2001 (Padyukov et al., 2001) 2001 2 (2)
Persson1991 (Persson et al., 1991) 1991 2 (2)
Pongers1999 (Pongers-Willemse et al., 1999) 1999 8 (8)
Rubinstein1998 (Rubinstein et al., 1998) 1998 4 (4)
Sblattero1998 (Sblattero and Bradbury, 1998) 1998 4 (27)
Tiller2008 (Tiller et al., 2008) 2008 3 (6)
Timmers1993 (Timmers et al., 1993) 1993 5 (5)
vanBurg2001 (van der Burg et al., 2001) 2001 9 (9)
vanDongen2003 (Van Dongen et al., 2003) 2003 6 (6)
vanEs1991 (van Es et al., 1991) 1991 4 (4)
Wardemann2003_1st (Wardemann et al., 2003) 2003 3 (6)
Table A.4: Overview of IGKV
primer sets provided by open-
PrimeR. Size indicates the
number of primers where the
number of disambiguated
primers is shown in brackets.
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Identifier Reference Year Size
Cardona1995 (Cardona et al., 1995) 1995 1 (1)
Farner1999_1st (Farner et al., 1999) 1999 8 (27)
Farner1999_2nd (Farner et al., 1999) 1999 9 (20)
Ippolito2014 (Ippolito et al., 2012) 2014 9 (49)
Lim2010 (Lim et al., 2010) 2010 10 (51)
Marks1991 (Marks et al., 1991) 1991 7 (7)
Moraes2003 (Junta and Passos, 2003) 2003 3 (3)
Murugan2015_1st (Murugan et al., 2015) 2015 7 (11)
Murugan2015_2nd (Murugan et al., 2015) 2015 2 (10)
Rubinstein1998 (Rubinstein et al., 1998) 1998 1 (1)
Sblattero1998 (Sblattero and Bradbury, 1998) 1998 9 (49)
Stiernholm1994 (Stiernholm et al., 1994) 1994 4 (4)
Tiller2008 (Tiller et al., 2008) 2008 7 (11)
vanBurg2001 (van der Burg et al., 2001) 2001 7 (7)
vanDongen2003 (Van Dongen et al., 2003) 2003 2 (2)
Wardemann2003 (Wardemann et al., 2003) 2003 7 (11)
Table A.5: Overview of IGLV
primer sets provided by open-
PrimeR. Size indicates the
number of primers where the
number of disambiguated





































Figure A.2: Subset coverage
of IGHV primers. Bars indi-
cate the coverage of individual
primers. The line indicates the
overall coverage of optimal









































































Figure A.3: Constraint devia-
tion of IGHV primers. Each dot
indicates the absolute deviation




















































































Figure A.4: IGKV primer set
constraint fulfillment and cov-
erage. (A) Rate of constraint






































Figure A.5: IGKV primer bind-
ing regions. The leader region
is indicated by the horizontal
blue bar, while the horizontal
red bar indicates the variable
region. The region for which
the new primers were designed
is indicated by vertical red lines.
The vertical bars indicate the





















































































Figure A.6: IGLV primer set
constraint fulfillment and cov-
erage. (A) Rate of constraint












































Figure A.7: IGLV primer bind-
ing regions. The leader region
is indicated by the horizontal
blue bar, while the horizontal
red bar indicates the variable
region. The region for which
the new primers were designed
is indicated by vertical red lines.
The vertical bars indicate the
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Plagiarism Prevention
The contents of this dissertation were evaluated using the plagiarism
prevention software iThenticate on December 19th, 2018. The analysis
was performed using two corpora. To determine overall similarity, I
used the full text corpus of iThenticate. To determine the similarity
to text that was not written by myself, I excluded the publications on
which Chapters 4 and 5 are based1, giving rise to the adjusted corpus.
For evaluating the similarity index for the whole dissertation, the
bibliography section was excluded from the analysis. The evaluations
were performed using the default settings of iThenticate; the results
of running iThenticate on individual chapters as well as the whole
dissertation are shown in Table C.1.
For the unadjusted corpus, there are high similarity indices for
Chapter 4 (24%), Chapter 5 (41%), and the discussion in Chapter 8
(18%) because these chapters are based on work that I have published
previously. Note that the similarity indices for these chapters drop
considerably when my own published work is excluded from the
corpus: For the adjusted corpus, the similarity indices are merely 2%,
6%, and 3%, for Chapter 4, Chapter 5, and Chapter 8, respectively.
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Chapter Similarity Index Similarity Index (Adjusted Corpus)
Chapter 1 5% 5%
Chapter 2 8% 8%
Chapter 3 18% 17%
Chapter 4 24% 2%
Chapter 5 41% 6%
Chapter 6 4% 4%
Chapter 7 2% 2%
Chapter 8 16% 3%
Chapter 9 2% 2%
Overall 17% 9%
Table C.1: Results from run-
ning the plagiarism detection
software iThenticate on this
dissertation.
General Terms
gag denotes the HIV group-specific antigen, which encodes the
structural proteins of the virus. 39, 40, 63
A refers to the purine nucleobase adenine. 67
C refers to the pyrimidine nucleobase cytosine. 67
env denotes the HIV envelope gene that encodes the transmembral
gp41 protein and the gp120 protein, which are exposed on the
cellular suface. 39, 40, 63
FASTA is the standard, text-based format that is used for storing the
results from first-generation sequencing approaches (e.g. from
Sanger sequencing). 158
FASTQ is the standard, text-based format that is used for storing
the results from second-generation sequencing approaches. In
contrast to FASTA, FASTQ stores not only sequences but also
their corresponding nucleotide qualities in terms of Phred quality
scores. 108, 118, 135
G refers to the purine nucleobase guanine. 67
IN denotes the HIV integrase, which allows for the integration of
reverse-transcribed viral DNA into host DNA. 38, 40, 63
NS3 refers to non-structural protein 3, the HCV protease. 55, 58, 59,
116, 124
NS5A refers to non-structural protein 5 A, which is an important
factor for HCV replication. 55, 58, 59, 116, 124, 132, 134
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NS5B refers to non-structural protein 5 B, the HCV polymerase. 55,
58, 116, 124
pol is the HIV gene that encodes the structural proteins (PR, RT, and
IN) of the virus. 39, 63
PR denotes the HIV protease, which is required to produce mature
virions from an infected cell. 38, 40, 48, 63, 110, 112
RT denotes the HIV reverse transcriptase, which transcribes viral
RNA to DNA. 38, 40, 48, 62, 63, 110, 112, 118, 125
SIR refers to a scheme of drug resistance classification that relies
on three levels of drug resistance: susceptible, intermediate, and
resistant. 65, 110, 111, 125, 127
T refers to the pyrimidine nucleobase thymine. 67
Drugs against HIV
3TC is the antiretroviral drug lamivudine. It belongs to the class of
nucleoside-reverse transcriptase inhibitors. Since 3TC and FTC
are associated with the same resistance mutations, these drugs are
typically not differentiated when interpreting resistance. 112, 130
ABC is the antiretroviral drug abacavir. It belongs to the class of
nucleoside-reverse transcriptase inhibitors. 112, 130, 136
APV is the antiretroviral drug amprenavir. It belongs to the class of
protease inhibitors. 112, 134
ATV is the antiretroviral drug atazanavir. It belongs to the class of
protease inhibitors. 112
d4T is the antiretroviral drug stavudine. It belongs to the class of
nucleoside-reverse transcriptase inhibitors. Use of d4T can lead to
thymidine-analog mutations. 112, 132
ddI is the antiretroviral drug didanosine. It belongs to the class of
nucleoside-reverse transcriptase inhibitors. 112, 130
DRV is the antiretroviral drug darunavir. It belongs to the class of
protease inhibitors. 50, 112, 114, 132
DTG refers to dolutegravir, an integrase strand-transfer inhibitor. 113
EFV is the antiretroviral drug efavirenz. It belongs to the class of
non nucleoside-reverse transcriptase inhibitors. 112
ETR is the antiretroviral drug etravirine. It belongs to the class of
non nucleoside-reverse transcriptase inhibitors. 112, 128
FTC is the antiretroviral drug emtricitabine. It belongs to the class
of nucleoside-reverse transcriptase inhibitors. Since 3TC and FTC
are associated with the same resistance mutations, these drugs are
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typically not differentiated when interpreting resistance. 110, 113,
114, 132
IDV is the antiretroviral drug indinavir. It belongs to the class of
protease inhibitors. 110, 112
LPV is the antiretroviral drug lopinavir. It belongs to the class of
protease inhibitors. 50, 112
NFV is the antiretroviral drug nelfinavir. It belongs to the class of
protease inhibitors. 112
NVP is the antiretroviral drug nevirapine. It belongs to the class of
non nucleoside-reverse transcriptase inhibitors. 112
RPV is the antiretroviral drug rilpivirine. It belongs to the class of
non nucleoside-reverse transcriptase inhibitors. 112, 128
RTV refers to ritonavir, a booster for protease inhibitors. Protease
inhibitors that are boosted through ritonavir are identified by
appending /r. For example, darunavir boosted with ritonavir is
denoted by DRV/r. 48, 52
SQV is the antiretroviral drug saqinavir. It belongs to the class of
protease inhibitors. 50, 112
T-20 is the antiretroviral drug enfuvirtide. It is an entry inhibitor that
prevents HIV cell fusion. 53
TDF is the antiretroviral drug tenofovir. It belongs to the class of
nucleoside-reverse transcriptase inhibitors. 52, 65, 112, 114, 132
TPV is the antiretroviral drug tipranavir. It belongs to the class of
protease inhibitors. 112
ZDV is the antiretroviral drug zidovudine (3’-azidothymidine, AZT).
It belongs to the class of nucleoside-reverse transcriptase inhibitors.
Use of ZDV can lead to thymidine-analog mutations. 65, 112, 132
Drugs against HCV
ASV refers to asunaprevir, an NS3 inhibitor. 59
BOC refers to bocprevir, an NS3 inhibitor. 59
DCV refers to daclatasvir, an NS5A inhibitor. 59, 132
DSV refers to dasabuvir, an NS5B inhibitor. 59
EBR refers to elbasvir, an NS5A inhibitor. 59, 132
GLE refers to glecaprevir, an NS3 inhibitor. 59
GZR refers to grazoprevir, an NS3 inhibitor. 59
LDV refers to ledipasvir, an NS5A inhibitor. 59, 132
OBV refers to ombitasvir, an NS5A inhibitor. 59, 132
PIB refers to pibrentasvir, an NS5A inhibitor. 59
PTV refers to paritaprevir, an NS3 inhibitor. 59
SMV refers to simeprevir, an NS3 inhibitor. 59
SOF refers to sofosbovir, an NS5B inhibitor. 59
TVR refers to telaprevir, an NS3 inhibitor. 59
VEL refers to velpatasvir, an NS5A inhibitor. 59, 132
VOX refers to voxilaprevir, an NS3 inhibitor. 59

Acronyms
AAVF amino-acid variant format. 134
ADCC antibody-dependent cell-mediated cytotoxicity. 37
AIC Akaike information criterion. 78, 79, 82, 219, 223
AIDS acquired immunodeficiency syndrome. 21, 29, 37, 38, 46, 51
APC antigen-presenting cell. 33, 34
API application programming interface. 130, 135
APOBEC apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like. 47, 109, 118, 126, 127
ART antiretroviral therapy. 42, 47–49, 53, 114
ARV antiretroviral. 46, 52, 53, 63, 65, 136
AUC area under the receiver operating characteristic curve. 85, 86,
112, 116, 149, 152, 153, 223, 227
BAM binary alignment map. 133
bNAb broadly neutralizing antibody. 51–54, 140, 163, 164, 207, 209,
211, 232, 233
bp base pairs. 44, 68
CCR5 C-C chemokine receptor type 5. 42–44, 61, 139, 140, 145–147,
151, 159–162
CD cluster of differentiation. 34
CD4 cluster of differentiation antigen 4. 36, 40, 42, 43, 46, 50, 62, 236
CD4bs CD4 binding site. 51–53
CDC complement-dependent cytotoxicity. 37
264
cDNA complementary deoxyribonucleic acid. 40, 48, 163, 207–209
CDR complementarity-determining region. 34, 36
CL complete linkage. 96
CSV comma-separated values. 120, 158
CTL cytotoxic T lymphocyte. 34, 35
CV cross validation. 80, 81, 112, 149, 152, 156, 220
CXCR4 C-X-C chemokine receptor type 4. 42–44, 61, 139, 140, 145–
147, 153, 159–162
DAA direct-acting antiviral. 55, 58, 59, 132, 137, 239
ddNTP didexobyribose nucleoside triphosphate. 67
DES drug-exposure score. 112, 114
DMEM Dulbecco’s modified eagle medium. 144
DNA deoxyribonucleic acid. 30, 31, 40, 48, 67–69, 71, 109, 118, 119,
165, 171, 191
dNTP deoxyribose nucleoside triphosphate. 67, 69
DRM drug resistance mutation. 114
EACS European AIDS Clinical Society. 50
EAE expected amplification event. 171–174, 179, 190, 196, 200, 211
EI entry inhibitor. 48
Env envelope glycoprotein. 51, 140, 145
ER endoplasmatic reticulum. 40, 55, 57
ESTA enhanced-sensitivity Trofile assay. 61
Fab fragment antigen-binding. 36
Fc fragment crystallizable. 36, 37
FDA federal drug administration. 44, 53, 58
FDR false discovery rate. 85, 97, 100, 101, 154, 156
FN false negative. 83
FNR false negative rate. 84
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FP false positive. 83, 150
FPR false positive rate. 84, 85, 142, 149, 150, 157–159
FWER familywise error rate. 100, 101
GA group average. 96
GALT gut-associated lymphoid tissue. 45
gp120 glycoprotein 120. 36, 40, 52
gp41 glycoprotein 41. 40, 48, 52
GSS genotypic susceptibility score. 116
GUI graphical user interface. 167, 168, 170, 209
HAART highly active antiretroviral therapy. 49
HBV hepatitis B virus. 135, 240
HCC hepatocellular carcinoma. 54, 58
HCV hepatitis C virus. 21–23, 29, 30, 53–55, 57–60, 107, 108, 116, 119,
121, 124–126, 128–130, 132–134, 231, 233, 235, 239, 240
HIV human immunodeficiency virus. 21–23, 29, 30, 36–40, 42, 44–48,
50–52, 54, 58, 60, 61, 63, 66, 109, 126, 135, 136, 139–141, 145, 147,
162, 233, 239, 240
HIV-1 human immunodeficiency virus type 1. 21–24, 37–40, 43, 44,
46, 50, 51, 53, 54, 57, 107, 108, 110–112, 115, 117–119, 121, 124–126,
128–130, 133–135, 140–143, 148, 149, 160–164, 199, 209, 211, 231–233
HIV-2 human immunodeficiency virus type 2. 22, 24, 37–40, 43,
44, 46, 50, 136, 140, 141, 143–145, 147, 148, 150, 152, 153, 157–162,
231–233
HLA human leukocyte antigen. 33, 136
HT high throughput. 168
IC50 half maximal inhibitory concentration. 51, 63–66, 109, 110
IgG immunoglobulin G. 164
IGH immunoglobulin heavy chain gene. 163, 200
IGHV immunoglobulin heavy chain variable region gene. 164, 169,
170, 202, 205, 207, 208, 214–216, 220, 223, 232
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IGK immunoglobulin kappa gene. 163, 200
IGKV immunoglobulin kappa variable region gene. 164, 200, 208, 232
IGL immunoglobulin lambda gene. 163, 200
IGLV immunoglobulin lambda variable region gene. 164, 200, 208,
232
ILP integer linear program. 101, 102, 168, 170, 183, 185, 187, 190, 199,
200
IMGT international immunogenetics information system. 200
INSTI integrase strand-transfer inhibitor. 48, 49, 113, 135
IQR inter-quartile range. 221, 222
IRES internal ribosome entry site. 55
IRIS immune reconstitution inflammatory syndrome. 53
IU international units. 57
IUPAC International Union of Pure and Applied Chemistry. 120, 123,
167, 171, 180
IVDU intravenous drug use. 45, 57
JSON javasript object notation. 130
LANL Los Alamos National Laboratory. 126, 143, 145, 147
MAC membrane attack complex. 37
MHC major histocompatibility complex. 33, 34
MHC I major histocompatibility complex class I. 33–35
MHC II major histocompatibility complex class II. 33, 34
mPCR multiplex polymerase chain reaction. 23, 24, 60, 70, 163–165,
170, 179, 183, 208, 211, 232
MPER membrane proximal external region. 52
mRNA messenger RNA. 40, 164
MSE mean squared error. 76
MSM men who have sex with men. 45, 57
acronyms 267
NAb neutralizing antibody. 51, 52
NCV nested cross validation. 81, 149, 153, 154
NGS next-generation sequencing. 22–24, 66, 68, 69, 108, 109, 117–119,
121, 133–136, 200, 231
NK natural killer. 32, 37
NNRTI non-nucleoside reverse transcriptase inhibitor. 48, 50, 112,
134
NPV negative predictive value. 85
NRTI nucleoside reverse transcriptase inhibitor. 48, 112, 114, 121, 130,
132
PBMC primary blood mononuclear cell. 43, 61, 62, 109, 160
PCR polymerase chain reaction. 30, 63, 68–71, 165, 166, 168, 171, 172,
178, 200, 205, 207, 213–215, 219, 228, 232, 233
PI protease inhibitor. 48, 50, 66, 112, 132
POS probability of susceptibility. 114, 115
PPV positive predictive value. 85
PrEP pre-exposure prophylaxis. 50, 54, 234
PTP primer-template pair. 216–223
qPCR quantitative polymerase chain reaction. 70, 71, 172, 213
RAS resistance-associated substitution. 59
RAV resistance-associated variant. 59
RBF radial basis function. 92, 148, 149, 153
REST representational state transfer. 130
RF resistance factor. 64–66, 110–115, 131
RNA ribonucleic acid. 30, 31, 38, 40, 47, 48, 55, 63, 109, 115
ROC receiver operating characteristic. 85
RT-PCR reverse transcription polymerase chain reaction. 63, 163, 205,
227
SCP set cover problem. 101–103, 167–170, 183, 185, 200, 210
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SEVI semen-derived enhancer of viral infection. 45
SHM somatic hypermutation. 34
SL single linkage. 96
ss single-stranded. 38, 55
SVC support vector classification. 85, 112
SVM support vector machine. 86–89, 91, 92, 101, 112, 142, 143, 148–
150, 152–160, 232
SVR sustained virologic response. 58, 59, 239
SVR support vector regression. 89–92, 112
TasP treatment as prevention. 46, 50
TCID50 half maximum tissue culture infectious dose. 144, 145
TDR transmitted drug resistance. 114
TE treatment episode. 115
Th T helper. 34, 35
TMM thermodynamic mismatch model. 219–221, 223, 225–228
TN true negative. 83, 150
TNR true negative rate. 84
TP true positive. 83
TPR true positive rate. 84, 157
V1 variable loop 1. 43, 145, 152, 160, 161, 232
V2 variable loop 2. 43, 140, 145, 152, 160, 161, 232
V3 variable loop 3. 43, 44, 51, 52, 140–153, 155–162, 232
VH heavy chain variable. 164
VCF variant call format. 134
VL viral load. 45, 46, 49, 109, 115, 118, 130, 236
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